<HTML><HEAD>
<!-- This document was created from RTF source by rtftohtml version 3.8 -->
<TITLE>Observation Reporting</TITLE></HEAD>
<BODY BACKGROUND="" BGCOLOR="#FFFFFF" TEXT="#000000">

<H1>
References to other Chapters
</H1>
<A HREF="hl7.htm">Index HL7</A><br>
<A HREF="ch1.htm">Chapter 1: Introduction</A><br>
<A HREF="ch2.htm">Chapter 2: Control Query</A><br>
<A HREF="ch3.htm">Chapter 3: Patient Administration</A><br>
<A HREF="ch4.htm">Chapter 4: Order Entry</A><br>
<A HREF="ch5.htm">Chapter 5: Query</A><br>
<A HREF="ch6.htm">Chapter 6: Financial Management</A><br>
<A HREF="ch8.htm">Chapter 8: Master Files</A><br>
<A HREF="ch9.htm">Chapter 9: Medical Records/Information Management</A><br>
<A HREF="ch10.htm">Chapter 10: Scheduling</A><br>
<A HREF="ch11.htm">Chapter 11: Patient Referral</A><br>
<A HREF="ch12.htm">Chapter 12: Patient Care</A><br>
<A HREF="appa.htm">Appendix A: Data Definitin Tables</A><br>
<A HREF="appb.htm">Appendix B: Lower Layer Protocols</A><br>
<A HREF="appc.htm">Appendix C: Network Management</A><br>
<A HREF="appd.htm">Appendix D: Version 2.2 BNF Message Descriptions</A><br>
<A HREF="appe.htm">Appendix E: Glossary</A><br>



<H1>
Observation Reporting</H1>
<UL>
<LI><A HREF="#Heading1">7. </A>
<UL>
<LI><A HREF="#Heading2">7.1 INTRODUCTION AND OVERVIEW</A>
<UL>
<LI><A HREF="#Heading3">7.1.1 Glossary</A>
<UL>
<LI><A HREF="#Heading4">7.1.1.1 </A>
<LI><A HREF="#Heading5">7.1.1.2 </A>
<LI><A HREF="#Heading6">7.1.1.3 -</A>
<LI><A HREF="#Heading7">7.1.1.4 "</A>
<LI><A HREF="#Heading8">7.1.1.6 field:  . </A>
<LI><A HREF="#Heading9">7.1.1.7 repeated value.</A>
<LI><A HREF="#Heading10">7.1.1.8 </A>
</UL>
<LI><A HREF="#Heading11">7.1.2 Narrative reports as batteries with many OBX </A>
<LI><A HREF="#Heading12">7.1.3 Suffixes for defining observation IDs </A>
<UL>
<LI><A HREF="#Heading13">7.1.3.1 Diagnostic impressions (IMP)</A>
<LI><A HREF="#Heading14">7.1.3.2 Recommendations (REC)</A>
<LI><A HREF="#Heading15">7.1.3.3 Confirming procedure (CNP)</A>
<LI><A HREF="#Heading16">7.1.3.4 Procedure medication (MED)</A>
<LI><A HREF="#Heading17">7.1.3.5 Anatomic site (ANT)</A>
<LI><A HREF="#Heading18">7.1.3.6 Devices (DEV)</A>
<LI><A HREF="#Heading19">7.1.3.7 Gross or general description (GDT)</A>
<LI><A HREF="#Heading20">7.1.3.8 Secondary or microscopic description (MDT)</A>
<LI><A HREF="#Heading21">7.1.3.9 Technician comment (TCM)</A>
<LI><A HREF="#Heading22">7.1.3.10 Addendum note (ADT) </A>
<LI><A HREF="#Heading23">7.1.3.11 Diagnosis (problem) onset date-time (ITM) </A>
<LI><A HREF="#Heading24">7.1.3.12 Diagnosis (problem) resolution date-time (RTM) </A>
<LI><A HREF="#Heading25">7.1.3.13 Comparison study (CMS) </A>
<LI><A HREF="#Heading26">7.1.3.14 Comparison date-time (CMT) </A>
<LI><A HREF="#Heading27">7.1.3.15 Comparison results (CMR) </A>
<LI><A HREF="#Heading28">7.1.3.16 Comparison change (CMC) </A>
<LI><A HREF="#Heading29">7.1.3.17 Predicted (PRD) </A>
<LI><A HREF="#Heading30">7.1.3.18 Percent of predicted (PPR) </A>
<LI><A HREF="#Heading31">7.1.3.19 After drug observed (AFD) </A>
<LI><A HREF="#Heading32">7.1.3.20 Predicted value after drug (ADP) </A>
<LI><A HREF="#Heading33">7.1.3.21 Percent predicted after drug (APP) </A>
<LI><A HREF="#Heading34">7.1.3.22 Clinical observation codes</A>
</UL>
<LI><A HREF="#Heading35">7.1.4 Coding schemes</A>
</UL>
<LI><A HREF="#Heading36">7.2 MESSAGE DEFINITIONS</A>
<UL>
<LI><A HREF="#Heading37">7.2.1 ORU/ACK - unsolicited transmission (event R01)</A>
<LI><A HREF="#Heading38">7.2.2 QRY/ORF - query for results of observation (events R02, R04)  </A>
<UL>
<LI><A HREF="#Heading39">7.2.2.1 Query usage notes</A>
</UL>
</UL>
<LI><A HREF="#Heading40">7.3 SEGMENTS</A>
<UL>
<LI><A HREF="#Heading41">7.3.1 OBR - observation request segment</A>
<UL>
<LI><A HREF="#Heading42">7.3.1.1 Set ID - OBR   (SI)   00237</A>
<LI><A HREF="#Heading43">7.3.1.2 Placer order number  (EI)   00216</A>
<LI><A HREF="#Heading44">7.3.1.3 Filler order number  (EI)   00217</A>
<LI><A HREF="#Heading45">7.3.1.4 Universal service ID  (CE)   00238</A>
<LI><A HREF="#Heading46">7.3.1.5 Priority  (ID)   00239</A>
<LI><A HREF="#Heading47">7.3.1.6 Requested date/time  (TS)   00240</A>
<LI><A HREF="#Heading48">7.3.1.7 Observation date/time  (TS)   00241</A>
<LI><A HREF="#Heading49">7.3.1.8 Observation end date/time  (TS)   00242</A>
<LI><A HREF="#Heading50">7.3.1.9 Collection volume  (CQ)   00243</A>
<LI><A HREF="#Heading51">7.3.1.10 Collector identifier  (XCN)   00244</A>
<LI><A HREF="#Heading52">7.3.1.11 Specimen action code  (ID)   00245</A>
<LI><A HREF="#Heading53">7.3.1.12 Danger code  (CE)   00535</A>
<LI><A HREF="#Heading54">7.3.1.13 Relevant clinical information  (ST)   00247</A>
<LI><A HREF="#Heading55">7.3.1.14 Specimen received date/time  (TS)   00248</A>
<LI><A HREF="#Heading56">7.3.1.15 Specimen source  (CM)   00249</A>
<LI><A HREF="#Heading57">7.3.1.16 Ordering provider  (XCN)   00226</A>
<LI><A HREF="#Heading58">7.3.1.17 Order callback phone number  (XTN)   00250</A>
<LI><A HREF="#Heading59">7.3.1.18 Placer field #1  (ST)   00251</A>
<LI><A HREF="#Heading60">7.3.1.19 Placer field #2  (ST)   00252</A>
<LI><A HREF="#Heading61">7.3.1.20 Filler field #1  (ST)   00253</A>
<LI><A HREF="#Heading62">7.3.1.21 Filler field #2  (ST)   00254</A>
<LI><A HREF="#Heading63">7.3.1.22 Results rpt/status chng - date/time  (TS)   00255</A>
<LI><A HREF="#Heading64">7.3.1.23 Charge to practice  (CM)   00256</A>
<LI><A HREF="#Heading65">7.3.1.24 Diagnostic serv sect ID  (ID)   00257</A>
<LI><A HREF="#Heading66">7.3.1.25 Result status  (ID)   00258</A>
<LI><A HREF="#Heading67">7.3.1.26 Parent result  (CM)   00259</A>
<LI><A HREF="#Heading68">7.3.1.27 Quantity/timing  (TQ)   00221</A>
<LI><A HREF="#Heading69">7.3.1.28 Result copies to  (XCN)   00260</A>
<LI><A HREF="#Heading70">7.3.1.29 Parent   (CM)   00261</A>
<LI><A HREF="#Heading71">7.3.1.30 Transportation mode  (ID)   00262</A>
<LI><A HREF="#Heading72">7.3.1.31 Reason for study  (CE)   00263</A>
<LI><A HREF="#Heading73">7.3.1.32 Principal result interpreter  ( CM)   00264</A>
<LI><A HREF="#Heading74">7.3.1.33 Assistant result interpreter  ( CM)   00265</A>
<LI><A HREF="#Heading75">7.3.1.34 Technician  ( CM)   00266</A>
<LI><A HREF="#Heading76">7.3.1.35 Transcriptionist  ( CM)   00267</A>
<LI><A HREF="#Heading77">7.3.1.36 Scheduled - date/time  (TS)   00268</A>
<LI><A HREF="#Heading78">7.3.1.37 Number of sample containers  (NM)   01028</A>
<LI><A HREF="#Heading79">7.3.1.38 Transport logistics of collected sample  (CE)   01029</A>
<LI><A HREF="#Heading80">7.3.1.39 Collector's comment  (CE)   01030</A>
<LI><A HREF="#Heading81">7.3.1.40 Transport arrangement responsibility  (CE)   01031</A>
<LI><A HREF="#Heading82">7.3.1.41 Transport arranged  (ID)   01032</A>
<LI><A HREF="#Heading83">7.3.1.42 Escort required  (ID)   01033</A>
<LI><A HREF="#Heading84">7.3.1.43 Planned patient transport comment  (CE)   01034</A>
</UL>
<LI><A HREF="#Heading85">7.3.2 OBX - observation/result segment</A>
<UL>
<LI><A HREF="#Heading86">7.3.2.1 Set ID - observation simple  (SI)   00569</A>
<LI><A HREF="#Heading87">7.3.2.2 Value type  (ID)   00570</A>
<LI><A HREF="#Heading88">7.3.2.3 Observation identifier  (CE)   00571</A>
<LI><A HREF="#Heading89">7.3.2.4 Observation sub-ID  (ST)   00572</A>
<LI><A HREF="#Heading90">7.3.2.5 Observation value  (*)   00573</A>
<LI><A HREF="#Heading91">7.3.2.6 Units  (CE)   00574</A>
<UL>
<LI><A HREF="#Heading92">7.3.2.6.1 Identifying reporting units </A>
<UL>
<LI><A HREF="#Heading93">7.3.2.6.1.1 Background</A>
<LI><A HREF="#Heading94">7.3.2.6.1.2 ISO and ANSI customary units abbreviations </A>
<LI><A HREF="#Heading95">7.3.2.6.1.3 Local unit codes</A>
</UL>
</UL>
<LI><A HREF="#Heading96">7.3.2.7 References range  (ST)   00575 </A>
<LI><A HREF="#Heading97">7.3.2.8 Abnormal flags  (ID)   00576</A>
<LI><A HREF="#Heading98">7.3.2.9 Probability  (NM)   00577</A>
<LI><A HREF="#Heading99">7.3.2.10 Nature of abnormal test  (ID)   00578</A>
<LI><A HREF="#Heading100">7.3.2.11 Observ result status  (ID)   00579</A>
<LI><A HREF="#Heading101">7.3.2.12 Effective date last obs normal value  (TS)   00580</A>
<LI><A HREF="#Heading102">7.3.2.13 User defined access checks  (ST)   00581</A>
<LI><A HREF="#Heading103">7.3.2.14 Date-time of the observation  (TS)   00582</A>
<LI><A HREF="#Heading104">7.3.2.15 Producer's ID  (CE)   00583</A>
<LI><A HREF="#Heading105">7.3.2.16 Responsible observer  (XCN)   00584</A>
<LI><A HREF="#Heading106">7.3.2.17 Observation method  (CE)   00936</A>
</UL>
</UL>
<LI><A HREF="#Heading107">7.4 EXAMPLE TRANSACTIONS</A>
<UL>
<LI><A HREF="#Heading108">7.4.1 Query/response</A>
<LI><A HREF="#Heading109">7.4.2 Unsolicited</A>
<LI><A HREF="#Heading110">7.4.3 Example message</A>
<LI><A HREF="#Heading111">7.4.4 Example of narrative report messages</A>
<LI><A HREF="#Heading112">7.4.5 Reporting cultures and susceptibilities</A>
<UL>
<LI><A HREF="#Heading113">7.4.5.1 Culture battery/report representation</A>
<LI><A HREF="#Heading114">7.4.5.2 Susceptibility battery/report representation</A>
<LI><A HREF="#Heading115">7.4.5.3 Identification of the organism for a susceptibility battery</A>
</UL>
<LI><A HREF="#Heading116">7.4.6 Results reporting</A>
<LI><A HREF="#Heading117">7.4.7 Patient-specific clinical data with an order</A>
</UL>
<LI><A HREF="#Heading118">7.5 CLINICAL TRIALS</A>
<UL>
<LI><A HREF="#Heading119">7.5.1 Terminology and concepts </A>
<UL>
<LI><A HREF="#Heading120">7.5.1.1 </A>
<LI><A HREF="#Heading121">7.5.1.2 </A>
<UL>
<LI><A HREF="#Heading122">7.5.1.2.1 Example 1</A>
<LI><A HREF="#Heading123">7.5.1.2.2 Example 2</A>
<LI><A HREF="#Heading124">7.5.1.2.3 Example 3</A>
</UL>
<LI><A HREF="#Heading125">7.5.1.3 </A>
<UL>
<LI><A HREF="#Heading126">7.5.1.3.1 Schedule for a randomized cancer prevention trial</A>
<LI><A HREF="#Heading127">7.5.1.3.2 Schedule for a cancer chemotherapy trial</A>
<LI><A HREF="#Heading128">7.5.1.3.3 Schedule for a randomized pain medication trial</A>
</UL>
</UL>
</UL>
<LI><A HREF="#Heading129">7.6 CLINICAL TRIALS -</A>
<UL>
<LI><A HREF="#Heading130">7.6.1  CRM - clinical study registration message (events C01-C08)</A>
<LI><A HREF="#Heading131">7.6.2 CSU - unsolicited study data message (events C09-C12)</A>
<LI><A HREF="#Heading132">7.6.3 CM0, CM1, CM2 - clinical trials master file messages </A>
</UL>
<LI><A HREF="#Heading133">7.7 CLINICAL TRIALS - SEGMENT DEFINITIONS</A>
<UL>
<LI><A HREF="#Heading134">7.7.1 CSR - clinical study registration segment</A>
<UL>
<LI><A HREF="#Heading135">7.7.1.1 Sponsor study ID  (EI)   01035</A>
<LI><A HREF="#Heading136">7.7.1.2 Alternate study ID  (EI)   01036</A>
<LI><A HREF="#Heading137">7.7.1.3 Institution registering the patient  (CE)   01037</A>
<LI><A HREF="#Heading138">7.7.1.4 Sponsor patient ID  (CX)   01038</A>
<LI><A HREF="#Heading139">7.7.1.5 Alternate patient ID - CSR (CX)   01039</A>
<LI><A HREF="#Heading140">7.7.1.6 Date/time patient of patient study registration  (TS)   01040</A>
<LI><A HREF="#Heading141">7.7.1.7 Person performing study registration  (XCN)   01041</A>
<LI><A HREF="#Heading142">7.7.1.8 Study authorizing provider  (XCN)   01042</A>
<LI><A HREF="#Heading143">7.7.1.9 Date patient study consent signed  (TS)   01043</A>
<LI><A HREF="#Heading144">7.7.1.10 Patient study eligibility status  (CE)   01044</A>
<LI><A HREF="#Heading145">7.7.1.11 Study randomization date/time  (TS)   01045</A>
<LI><A HREF="#Heading146">7.7.1.12 Randomized study arm  (CE)   01046</A>
<LI><A HREF="#Heading147">7.7.1.13 Stratum for study randomization  (CE)   01047</A>
<LI><A HREF="#Heading148">7.7.1.14 Patient evaluability status  (CE)   01048</A>
<LI><A HREF="#Heading149">7.7.1.15 Date/time ended study  (TS)   01049</A>
<LI><A HREF="#Heading150">7.7.1.16 Reason ended study  (CE)   01050</A>
</UL>
<LI><A HREF="#Heading151">7.7.2 CSP - clinical study phase segment </A>
<UL>
<LI><A HREF="#Heading152">7.7.2.1 Study phase Identifier  (CE)   01051</A>
<LI><A HREF="#Heading153">7.7.2.2 Date/time study phase began  (TS)   01052</A>
<LI><A HREF="#Heading154">7.7.2.3 Date/time study phase ended  (TS)   01053</A>
<LI><A HREF="#Heading155">7.7.2.4 Study phase evaluability  (CE)   01054</A>
</UL>
<LI><A HREF="#Heading156">7.7.3 CSS - clinical study data schedule segment</A>
<UL>
<LI><A HREF="#Heading157">7.7.3.1 Study scheduled time point  (CE)   01055</A>
<LI><A HREF="#Heading158">7.7.3.2 Study scheduled patient time point  (TS)   01056</A>
<LI><A HREF="#Heading159">7.7.3.3 Study quality control codes  (CE)   01057</A>
</UL>
<LI><A HREF="#Heading160">7.7.4 CTI - clinical trial identification segment</A>
<UL>
<LI><A HREF="#Heading161">7.7.4.1 Sponsor study identifier  (EI)   01058</A>
<LI><A HREF="#Heading162">7.7.4.2 Study phase identifier  (CE)   01051</A>
<LI><A HREF="#Heading163">7.7.4.3 Study scheduled time point  (CE)   01055</A>
</UL>
<LI><A HREF="#Heading164">7.7.5 CM0  clinical study master segment</A>
<LI><A HREF="#Heading165">7.7.6 CM1  clinical study phase master segment</A>
<LI><A HREF="#Heading166">7.7.7 CM2  clinical study schedule master segment</A>
</UL>
<LI><A HREF="#Heading167">7.8 CLINICAL TRIALS - EXAMPLES</A>
<UL>
<LI><A HREF="#Heading168">7.8.1 CRM - message when patient registered on a clinical trial</A>
<LI><A HREF="#Heading169">7.8.2 CRM - message when patient begins a phase of a clinical trial</A>
<LI><A HREF="#Heading170">7.8.3 CSU - message reporting monthly patient data updates to the sponsor</A>
</UL>
<LI><A HREF="#Heading171">7.9 PRODUCT EXPERIENCE</A>
<UL>
<LI><A HREF="#Heading172">7.9.1 Terminology and concepts</A>
<UL>
<LI><A HREF="#Heading173">7.9.1.1 drug</A>
<LI><A HREF="#Heading335">7.9.1.2 medical device</A>
<LI><A HREF="#Heading174">7.9.1.3 product:</A>
<LI><A HREF="#Heading336">7.9.1.4 non-proprietary (generic) name</A>
<LI><A HREF="#Heading175">7.9.1.5 trade (brand) name:  </A>
<LI><A HREF="#Heading176">7.9.1.6 adverse event/adverse experience:  </A>
<LI><A HREF="#Heading177">7.9.1.7 adverse drug reaction:  </A>
<LI><A HREF="#Heading178">7.9.1.8 causation:  .</A>
<LI><A HREF="#Heading179">7.9.1.9 </A>
<LI><A HREF="#Heading180">7.9.1.10 regulatory agency</A>
<LI><A HREF="#Heading181">7.9.1.11 Product manufacturer:  .</A>
<LI><A HREF="#Heading182">7.9.1.12 Holder of marketing authorization (HMA):  .</A>
<LI><A HREF="#Heading183">7.9.1.13 Serious adverse product reaction:  an adverse product reaction which:</A>
<LI><A HREF="#Heading184">7.9.1.14 Expected adverse product reaction</A>
</UL>
</UL>
<LI><A HREF="#Heading185">7.10 PRODUCT EXPERIENCE - TRIGGER EVENTS </A>
<UL>
<LI><A HREF="#Heading186">7.10.1 PEX - product experience message (events P07, P08)</A>
<LI><A HREF="#Heading187">7.10.2 SUR - summary product experience report (event P09)</A>
</UL>
<LI><A HREF="#Heading188">7.11 PRODUCT EXPERIENCE - SEGMENTS DEFINITIONS</A>
<UL>
<LI><A HREF="#Heading189">7.11.1 PES - product experience sender segment</A>
<UL>
<LI><A HREF="#Heading190">7.11.1.1 Sender organization name  (XON)   01059</A>
<LI><A HREF="#Heading191">7.11.1.2 Sender individual name  (XCN)   01060</A>
<LI><A HREF="#Heading192">7.11.1.3 Sender address  (XAD)   01062</A>
<LI><A HREF="#Heading193">7.11.1.4 Sender telephone  (XTN)   01063</A>
<LI><A HREF="#Heading194">7.11.1.5 Sender event identifier  (EI)   01064</A>
<LI><A HREF="#Heading195">7.11.1.6 Sender sequence number  (NM)   01065</A>
<LI><A HREF="#Heading196">7.11.1.7 Sender event description  (FT)   01066</A>
<LI><A HREF="#Heading197">7.11.1.8 Sender comment  (FT)   01067</A>
<LI><A HREF="#Heading198">7.11.1.9 Sender aware date/time  (TS)</A>
<LI><A HREF="#Heading199">7.11.1.10 Event report date  (TS)   01069</A>
<LI><A HREF="#Heading200">7.11.1.11 Event report timing type  (ID)   01070</A>
<LI><A HREF="#Heading201">7.11.1.12 Event report source  (ID)   01071</A>
<LI><A HREF="#Heading202">7.11.1.13 Event reported to  (ID)   01072</A>
</UL>
<LI><A HREF="#Heading203">7.11.2 PEO - product experience observation segment</A>
<UL>
<LI><A HREF="#Heading204">7.11.2.1 Event identifiers used  (CE)   01073</A>
<LI><A HREF="#Heading205">7.11.2.2 Event symptom/diagnosis code  (CE)   01074</A>
<LI><A HREF="#Heading206">7.11.2.3 Event onset date/time  (TS)   01075</A>
<LI><A HREF="#Heading207">7.11.2.4 Event exacerbation date/time  (TS)   01076</A>
<LI><A HREF="#Heading208">7.11.2.5 Event improved date/time  (TS)   01077</A>
<LI><A HREF="#Heading209">7.11.2.6 Event ended data/time  (TS)   01078</A>
<LI><A HREF="#Heading210">7.11.2.7 Event location occurred address  (XAD)   01079</A>
<LI><A HREF="#Heading211">7.11.2.8 Event qualification  (ID)   01080</A>
<LI><A HREF="#Heading212">7.11.2.9 Event serious  (ID)   01081</A>
<LI><A HREF="#Heading213">7.11.2.10 Event expected  (ID)   01082</A>
<LI><A HREF="#Heading214">7.11.2.11 Event outcome  (ID)   01083</A>
<LI><A HREF="#Heading215">7.11.2.12 Patient outcome  (ID)   01084</A>
<LI><A HREF="#Heading216">7.11.2.13 Event description from others  (FT)   01085</A>
<LI><A HREF="#Heading217">7.11.2.14 Event description from original reporter  (FT)   01086</A>
<LI><A HREF="#Heading218">7.11.2.15 Event description from patient  (FT)   01087</A>
<LI><A HREF="#Heading219">7.11.2.16 Event description from practitioner  (FT)   01088</A>
<LI><A HREF="#Heading220">7.11.2.17 Event description from autopsy  (FT)   01089</A>
<LI><A HREF="#Heading221">7.11.2.18 Cause of death  (CE)   01090</A>
<LI><A HREF="#Heading222">7.11.2.19 Primary observer name  (XPN)   01091</A>
<LI><A HREF="#Heading223">7.11.2.20 Primary observer address  (XAD)   01092</A>
<LI><A HREF="#Heading224">7.11.2.21 Primary observer telephone  (XTN)   01093</A>
<LI><A HREF="#Heading225">7.11.2.22 Primary observer's qualification  (ID)   01094</A>
<LI><A HREF="#Heading226">7.11.2.23 Confirmation provided by  (ID)   01095</A>
<LI><A HREF="#Heading227">7.11.2.24 Primary observer aware date/time  (TS)   01096</A>
<LI><A HREF="#Heading228">7.11.2.25 Primary observer's identity may be divulged  (ID)   01097</A>
</UL>
<LI><A HREF="#Heading229">7.11.3 PCR - possible causal relationship segment</A>
<UL>
<LI><A HREF="#Heading230">7.11.3.1 Implicated product  (CE)   01098</A>
<LI><A HREF="#Heading231">7.11.3.2 Generic product  (IS)   01099</A>
<LI><A HREF="#Heading232">7.11.3.3 Product class  (CE)   01100</A>
<LI><A HREF="#Heading233">7.11.3.4 Total duration of therapy  (CQ)   01101</A>
<LI><A HREF="#Heading234">7.11.3.5 Product manufacture date  (DT)   01102</A>
<LI><A HREF="#Heading235">7.11.3.6 Product expiration date  (DT)   01103</A>
<LI><A HREF="#Heading236">7.11.3.7 Product implantation date  (DT)   01104</A>
<LI><A HREF="#Heading237">7.11.3.8 Product explantation date  (DT)   01105</A>
<LI><A HREF="#Heading238">7.11.3.9 Single use device  (IS)   01106</A>
<LI><A HREF="#Heading239">7.11.3.10 Indication for product use  (CE)   01107</A>
<LI><A HREF="#Heading240">7.11.3.11 Product problem  (IS)   01108</A>
<LI><A HREF="#Heading241">7.11.3.12 Product serial/lot number  (ST)   01109</A>
<LI><A HREF="#Heading242">7.11.3.13 Product available for inspection  (IS)   01110</A>
<LI><A HREF="#Heading243">7.11.3.14 Product evaluation performed  (CE)   01111</A>
<LI><A HREF="#Heading244">7.11.3.15 Product evaluation status  (CE)   01112</A>
<LI><A HREF="#Heading245">7.11.3.16 Product evaluation results  (CE)   01113</A>
<LI><A HREF="#Heading246">7.11.3.17 Evaluated product source  (ID)   01114</A>
<LI><A HREF="#Heading247">7.11.3.18 Date product returned to manufacturer  (TS)   01115</A>
<LI><A HREF="#Heading248">7.11.3.19 Device operator qualification  (ID)   01116</A>
<LI><A HREF="#Heading249">7.11.3.20 Relatedness assessment  (ID)   01117</A>
<LI><A HREF="#Heading250">7.11.3.21 Action taken in response to the event  (ID)   01118</A>
<LI><A HREF="#Heading251">7.11.3.22 Event causality observations  (ID)   01119</A>
<LI><A HREF="#Heading252">7.11.3.23 Indirect exposure mechanism  (ID)   01120</A>
</UL>
<LI><A HREF="#Heading253">7.11.4 PSH - product summary header segment </A>
<UL>
<LI><A HREF="#Heading254">7.11.4.1 Report type  (ST)   01233</A>
<LI><A HREF="#Heading255">7.11.4.2 Report form identifier  (ST)   01297</A>
<LI><A HREF="#Heading256">7.11.4.3 Report date  (TS)   01235</A>
<LI><A HREF="#Heading257">7.11.4.4 Report interval start date  (TS)   01236</A>
<LI><A HREF="#Heading258">7.11.4.5 Report interval end date  (TS)   01294</A>
<LI><A HREF="#Heading259">7.11.4.6 Quantity Manufactured  (CQ)   01238</A>
<LI><A HREF="#Heading260">7.11.4.7 Quantity Distributed  (CQ)   01239</A>
<LI><A HREF="#Heading261">7.11.4.8 Quantity distributed method  (ID)   01240</A>
<LI><A HREF="#Heading262">7.11.4.9 Quantity Distributed Comment  (FT)   01241</A>
<LI><A HREF="#Heading263">7.11.4.10 Quantity in use  (CQ)   01242</A>
<LI><A HREF="#Heading264">7.11.4.11 Quantity in use method  (ID)   01243</A>
<LI><A HREF="#Heading265">7.11.4.12 Quantity in use comment  (FT)   01244</A>
<LI><A HREF="#Heading266">7.11.4.13 No. of product experience reports filed by facility  (NM)   01245</A>
<LI><A HREF="#Heading267">7.11.4.14 No. of product experience reports filed by distributor  (NM)  01246</A>
</UL>
<LI><A HREF="#Heading268">7.11.5 PDC - product detail country segment</A>
<UL>
<LI><A HREF="#Heading269">7.11.5.1 Manufacturer/distributor  (XON)   01247</A>
<LI><A HREF="#Heading270">7.11.5.2 Country  (CE)   01248</A>
<LI><A HREF="#Heading271">7.11.5.3 Brand name  (ST)   01249</A>
<LI><A HREF="#Heading272">7.11.5.4 Device family name  (ST)   01250</A>
<LI><A HREF="#Heading273">7.11.5.5 Generic name  (CE)   01251</A>
<LI><A HREF="#Heading274">7.11.5.6 Model identifier  (ST)   01252</A>
<LI><A HREF="#Heading275">7.11.5.7 Catalogue identifier  (ST)   01253</A>
<LI><A HREF="#Heading276">7.11.5.8 Other identifier  (ST)   01254</A>
<LI><A HREF="#Heading277">7.11.5.9 Product code  (CE)   01255</A>
<LI><A HREF="#Heading278">7.11.5.10 Marketing basis  (ID)   01256</A>
<LI><A HREF="#Heading279">7.11.5.11 Marketing approval ID  (ST)   01257</A>
<LI><A HREF="#Heading280">7.11.5.12 Labeled shelf life  (CQ)   01258</A>
<LI><A HREF="#Heading281">7.11.5.13 Expected shelf life  (CQ)   01259</A>
<LI><A HREF="#Heading282">7.11.5.14 Date First Marked  (TS)   01260</A>
<LI><A HREF="#Heading283">7.11.5.15 Date Last Marked  (TS)   01261</A>
</UL>
<LI><A HREF="#Heading284">7.11.6 FAC - facility segment</A>
<UL>
<LI><A HREF="#Heading285">7.11.6.1 Facility ID  (EI)   01262</A>
<LI><A HREF="#Heading286">7.11.6.2 Facility type  (ID)   01263</A>
<LI><A HREF="#Heading287">7.11.6.3 Facility address  (XAD)   01264</A>
<LI><A HREF="#Heading288">7.11.6.4 Facility telecommunication  (XTN)   01265</A>
<LI><A HREF="#Heading289">7.11.6.5 Contact person  (XCN)   01266</A>
<LI><A HREF="#Heading290">7.11.6.6 Contact title  (ST)   01267</A>
<LI><A HREF="#Heading291">7.11.6.7 Contact address  (XAD)   01268</A>
<LI><A HREF="#Heading292">7.11.6.8 Contact telecommunication  (XTN)   01269</A>
<LI><A HREF="#Heading293">7.11.6.9 Signature authority  (XCN)   01270</A>
<LI><A HREF="#Heading294">7.11.6.10 Signature authority title  (ST)   01271</A>
<LI><A HREF="#Heading295">7.11.6.11 Signature authority address  (XAD)   01272</A>
<LI><A HREF="#Heading296">7.11.6.12 Signature authority telecommunication  (XTN)   01273</A>
</UL>
</UL>
<LI><A HREF="#Heading297">7.12 PRODUCT EXPERIENCE - EXAMPLE MESSAGES</A>
<LI><A HREF="#Heading298">7.13 PRODUCT EXPERIENCE - REFERENCES</A>
<LI><A HREF="#Heading299">7.14 WAVEFORM SUMMARY</A>
<LI><A HREF="#Heading300">7.15 WAVEFORM RESULT DATA TYPES</A>
<UL>
<LI><A HREF="#Heading301">7.15.1 NA - numeric array</A>
<LI><A HREF="#Heading302">7.15.2 MA - multiplexed array</A>
<LI><A HREF="#Heading303">7.15.3 CD - channel definition</A>
<UL>
<LI><A HREF="#Heading304">7.15.3.1 Channel identifier </A>
<LI><A HREF="#Heading305">7.15.3.2 Waveform source</A>
<LI><A HREF="#Heading306">7.15.3.3 Channel sensitivity and units (CM)</A>
<UL>
<LI><A HREF="#Heading307">7.15.3.3.1 Sensitivity (NM)</A>
<LI><A HREF="#Heading308">7.15.3.3.2 Units </A>
</UL>
<LI><A HREF="#Heading309">7.15.3.4 Channel calibration parameters (NM)</A>
<UL>
<LI><A HREF="#Heading310">7.15.3.4.1 Sensitivity correction factor</A>
<LI><A HREF="#Heading311">7.15.3.4.2 Baseline</A>
<LI><A HREF="#Heading312">7.15.3.4.3 Time skew </A>
</UL>
<LI><A HREF="#Heading313">7.15.3.5 Channel sampling frequency </A>
<LI><A HREF="#Heading314">7.15.3.6 Minimum and maximum data values (NM)</A>
</UL>
</UL>
<LI><A HREF="#Heading315">7.16 WAVEFORM SPECIFIC OBSERVATION ID SUFFIXES</A>
<UL>
<LI><A HREF="#Heading316">7.16.1 Timing information (TIM)</A>
<LI><A HREF="#Heading317">7.16.2 Channel definition data (CHN)</A>
<LI><A HREF="#Heading318">7.16.3 Waveform digital data (WAV)</A>
<LI><A HREF="#Heading319">7.16.4 Waveform annotation (ANO)</A>
</UL>
<LI><A HREF="#Heading320">7.17 COMBINING RULES FOR WAVEFORM OBX SEGMENTS</A>
<LI><A HREF="#Heading321">7.18 RESTRICTIONS ON VALUATION OF OBX SEGMENT FIELDS</A>
<UL>
<LI><A HREF="#Heading322">7.18.1 OBX segment - TIM category</A>
<LI><A HREF="#Heading323">7.18.2 OBX segment - CHN category</A>
<LI><A HREF="#Heading324">7.18.3 OBX segment - WAV category</A>
<LI><A HREF="#Heading325">7.18.4 ANO category OBX segment</A>
</UL>
<LI><A HREF="#Heading326">7.19 WAVEFORM RESPONSE TRIGGER EVENTS</A>
<UL>
<LI><A HREF="#Heading327">7.19.1 W01 - waveform result, unsolicited transmission of requested information </A>
<LI><A HREF="#Heading328">7.19.2 W02 - waveform result, response to query</A>
</UL>
<LI><A HREF="#Heading329">7.20 EXAMPLE MESSAGES FOR GENERIC WAVEFORM DATA</A>
<UL>
<LI><A HREF="#Heading330">7.20.1 Example 1: ":</A>
<LI><A HREF="#Heading331">7.20.2 Example 2: "</A>
<LI><A HREF="#Heading332">7.20.3 Example 3: ":</A>
<LI><A HREF="#Heading333">7.20.4 Example 4: ":</A>
</UL>
<LI><A HREF="#Heading334">7.21 OUTSTANDING ISSUES</A>
</UL>
</UL>
<hr size=4>
<h1>
7.	
</h1>

<h1>
<A NAME="Heading1">7. </A></h1>

<p><b>Observation
Reporting</b><br>
</p>
<TABLE><TR align="left">
<TD align="left">Chapter
Chair/Editor:</TD>
<TD align="left">Clement
J. McDonald, MD<br>Regenstrief Institute and Indiana University School of
Medicine</TD></TR>

<TR align="left">
<TD align="left">Chapter
Chair/Editor:</TD>
<TD align="left">Hans
Buitendijk<br>Shared Medical Systems</TD></TR><TR align="left">
<TD align="left">Editor:
Clinical Trials</TD>
<TD align="left">Susan
Rea Welch<br>M.D. Anderson Cancer Center</TD></TR>

<TR align="left">
<TD align="left">Editor:
Product Experience</TD>
<TD align="left">J.
Marc Overhage, MD<br>Regenstrief Institute and Indiana University School of
Medicine</TD></TR>

<TR align="left">
<TD align="left">Editor:
Product Experience</TD>
<TD align="left">Robert
Heiser<br>Eli Lilly and Company</TD></TR>

<TR align="left">
<TD align="left">Editor:
 Waveform Data</TD>
<TD align="left">Fritz
Friedhoff<br>SpaceLabs Medical</TD></TR>

<TR align="left">
<TD align="left">Editor:
Waveform Data</TD>
<TD align="left">Ernie
Jacobs, MD<br>Cleveland Clinic Foundation</TD></TR>

<TR align="left">
<TD align="left">Editor:
Waveform Data</TD>
<TD align="left">Wayne
Tracy<br>SpaceLabs Medical</TD></TR>

<TR align="left">
<TD align="left">Editor:
Waveform Data</TD>
<TD align="left">Terry
Lagerlund<br>Mayo Clinic</TD></TR></TABLE>
<h2>
<A NAME="Heading2">7.1 INTRODUCTION AND OVERVIEW</A></h2>

<p>This
chapter describes the transaction set required for sending structured
patient-oriented clinical data from one computer system to another.  A common
use of these transaction sets will be to transmit observations and results of
diagnostic studies from the producing system (e.g., clinical laboratory system,
EKG system) (the filler), to the ordering system (e.g., HIS order entry,
physician's office system) (the placer).  However, the transaction set is not
limited to such transactions.  Observations can be sent from producing systems
to archival medical record systems (not necessarily the order placer) and from
such medical record systems to other systems that were not part of the ordering
loop, e.g., an office practice system of the referring physician for inpatient
test results ordered by an inpatient surgeon.  This chapter also provides
mechanisms for registering clinical trials and methods for linking orders and
results to clinical trials and for reporting experiences with drugs and
devices.<br>
These transaction sets permit the transmission of any kind of clinical
observations including (but not limited to) clinical laboratory results, the
results of imaging studies (excluding the image), EKG pulmonary function
studies, measures of patient status and condition, vital signs, intake and
output, severity and/or frequency of symptoms, drug allergies, problem lists,
diagnostic lists, physician and nursing history, physicals, progress notes,
operative notes and so on.  These transaction sets carry information that is
reported as text, numeric or categorical values.  These messages do not carry
the images themselves. (See ACR NEMA Publication 300-1988<i> Digital Imaging
and Communications Standard</i>, for image standards, and ASTM E1467.91
<i>Standard specification for transferring digital neurophysiological data
between independent computer systems</i>, for transmitting EEG, EMG
tracings).<br>
An observation can be one of many data types.  The main ones are text, numbers
and codes.  This provides the flexibility needed to transmit observations that
are recorded as continuous values (e.g., glucose, diastolic blood pressure), as
categorical values, e.g., patient position (sitting, reclining or standing),
VDRL (reactive, weakly reactive or nonreactive), or as text. An entire History
and Physical could be transmitted as an observation whose value is one large
chunk of formatted text.<br>
This chapter provides mechanisms for transmitting <i>structured</i>,
record-oriented reports.  This means that individual observations are
transmitted as separate logical entities (objects), and within this entity,
separate fields are defined for identifying the observation, its values, its
units, normal ranges, etc., such that the receiving system can "understand,"
reorganize and/or react to the contents of these messages.  Structured reports
are to be distinguished from text-oriented reports which can also be
transmitted via HL7 using the UDM message described in Chapter 2.  The latter
are ASCII images of nonstandard printed reports intended for display to humans.
For practical purposes their contents are not understandable to the computer.
<br>
Observations may be transmitted in a solicited (in response to a query) or
unsolicited mode.  In the solicited mode, a user requests a set of observations
according to criteria transmitted by the user. The sending system responds with
existing data to satisfy the query (subject to access controls).  Queries do
not elicit new observations by the target system, they simply retrieve old
observations.  (See Chapter 2 for full discussion of the query
transmission.)<br>
The unsolicited mode is used primarily to transmit the values of new
observations. It is the mode used by producing services to return the values of
observations requested by an ordering system.  A laboratory system, for
example, would usually send the results of an AM electrolytes to the ordering
HIS via the unsolicited mode.  An intensive care system would send the blood
pressures to the same HIS by the same mode.  Calling such transactions
unsolicited may sound like a misnomer, but is not.  The placing service
solicits the producing service to make the observation.  It could also (through
a query) solicit the value of that observation after it has been made.
However, such an approach would demand continuous polling of the producing
system until the result was produced.  Using the unsolicited mode, the
producing service returns the value of an observation as soon as it is
available.  The unsolicited mode can also be used to transmit new results to a
system (e.g., an archival medical record system) that did not order the
observation.  The transactions that define these modes are more fully described
in Section 7.2, "MESSAGE DEFINITIONS."<br>
Observations are usually ordered and reported as sets (batteries) of many
separate observations. Physicians order electrolytes (consisting of sodium,
potassium, chloride, bicarbonate) or vitals (consisting of diastolic blood
pressure, systolic blood pressure, pulse, and temperature).  Moreover, tests
that we may think of as single entity, e.g., cardiac echo, usually yield
multiple separate measurements, e.g., left ventricular diameter, left atrial
diameter, etc.  Moreover, observations that are usually reported as text (e.g.
,the review of systems from the history and physical) can also be considered a
set of separately analyzable units (e.g., cardiac history, pulmonary history,
genito-urinary history, etc.).  We strongly suggest that all text clinical
reports be broken down into such separate analyzable entities and that these
individual entities be transmitted as separate OBX segments.  Because many
attributes of a set of observations taken at one time will be identical, one
OBR segment serves as a header for the report and carries the information that
applies to all of the individual observations in the set.  In the case of
ordered observations, the OBR segment is a "turn-around document" like the
manual request forms it replaces.  It carries information about the order to
the producing service; a copy of the OBR with additional fields completed is
returned with the observations to the requesting service.<br>
Not all observations are preceded by an order.  However, all observations
whether explicitly ordered or initiated without an order are reported with an
OBR segment as the report header.<br>
The major segments (OBR, OBX) defined in this chapter, their fields, and the
code tables have been defined in collaboration with ASTM E31.11 with the goal
of keeping HL7 observation transmission the same as ASTM E1238 in pursuit of
the goals of ANSI HISPP and the Message Standards Developers Subcommittee.
(Some sections of this chapter have been taken with permission directly from
the E1238-91 document and vice versa in pursuit of those goals).<br>
The OBR segment provides information that applies to all of the observations
that follow.  It includes a field that identifies a particular battery (or
panel or set) of observations (e.g., electrolytes, vital signs or Admission
H&amp;P).  For simplicity we will refer to the observation set as the battery.
The battery usually corresponds to the entity that is ordered or performed as a
unit.  (In the case of a query, observation sets may be a more arbitrary
collection of observations.)  The OBX segment provides information about a
single observation, and it includes a field that identifies that single
observation (e.g., potassium, diastolic blood pressure or admission diagnosis).
Both of these fields assume master tables that define coding systems (the
universe of valid identifying codes) for batteries and observations,
respectively.  These tables will usually be part of the producing and sending
services application and (usually) include many other useful pieces of
information about the observation or battery.  Segments for transmitting such
master file information between systems that produce and systems that use
clinical information are described in Chapter 8. <br>
This Standard does not require the use of a particular coding system to
identify either batteries or single observations  In the past, local
institutions tended to invent their own unique code systems for identifying
test and other clinical observations because standard codes were not available.
Such local code systems sufficed for transmitting information within the
institutions but presented high barriers to pooling data from many sources for
research or for building medical record systems. However, standard code systems
such as LOINC and SNOMED now exist for many of these purposes, and we strongly
encourage their use in observation reporting. These codes can be sent either as
the only code or they can be sent along with the local historic code as the
second code system in a CE code.  <br>
In past versions of the HL7 standard, Appendix A to Chapter 7 presented
suggestions for constructing clinical codes from existing procedure code
systems such as CPT4.  Appendix A is now part of the Implementation Guide and
contains LOINC codes for most laboratory tests and many common clinical
variables (e.g., vital signs, intake and output, cardiovascular measurements
and others).  The most recent version of the LOINC database, which includes
records for more than 7,000 observations and includes codes, names, synonyms
and other attributes (such as the molecular weights of chemical moieties) for
each observation, is available from the HL7 file server at
<b>http://dumccss.mc.duke.edu/standards/termcode/loinclab/loinc.html</b>.  The
Implementation Guide provides construction rules for many variables that are
not yet covered by LOINC. Codes for Neurophysiologic variables (EEG, EMG,
Evoked potentials) are provided in Appendix X2 of ASTM E1467. <br>
Some parts of this document (the discussion and tables defining units, the
discussion of the rules of mapping observations to OBX segments, and some of
the examples at the end of the chapter have been copied (with permission) from
ASTM E1238. <br>
As is true throughout this Standard, the emphasis should be on the abstract
messages, defined without regard to the encoding rules.  The example messages,
however, are based upon the HL7 encoding rules.
</p>

<h3>
<A NAME="Heading3">7.1.1 Glossary</A></h3>


<h4>
<A NAME="Heading4">7.1.1.1 </A></h4>


<h4>
<A NAME="Heading5">7.1.1.2 </A></h4>


<h4>
<A NAME="Heading6">7.1.1.3 -</A></h4>

<p>The
word battery is used in this specification synonymously with the word profile
or panel.  The individual observation elements within a battery may be
characteristic of a physiologic system (e.g., liver function tests), or many
different physiologic systems.  </p>
<h4>
</h4>

<h4>
<A NAME="Heading7">7.1.1.4 "</A></h4>

<h4>
7.1.1.5	segment (record):  a typed aggregate of fields (fields) describing one
complete aspect of a message.  For example, the information about one order is
sent as type of segment (OBR), the information related to an observation is
sent as another segment (OBX).</h4>
<p>The segment in a message is analogous to a record in a database, and in
previous versions of the Standard we used record in place of the word segment.
We have changed the nomenclature to be consistent with HL7 and other standards
organizations in this version. </p>

<h4>
<A NAME="Heading8">7.1.1.6 field:  one specific attribute of a segment, for example, patient diagnosis, which may contain aggregates of fields further refining the basic attribute. </A></h4>


<h4>
<A NAME="Heading9">7.1.1.7 repeated value:  some fields may contain many repeat fields.  For example, the diagnoses field may contain many different diagnoses.</A></h4>


<h4>
<A NAME="Heading10">7.1.1.8 </A></h4>


<h3>
<A NAME="Heading11">7.1.2 Narrative reports as batteries with many OBX </A></h3>

<p>Narrative
reports from services such as Radiology usually consist of a number of
subcomponents (e.g., a chest X-ray report may consist of a description, an
impression, and a recommendation).  Other studies, such as echocardiograms,
contain analogous components, as well as numeric observations (e.g., left
ventricular and diastolic diameter).  Surgical pathology reports may contain
information about multiple specimens and reports: the anatomic source, the
gross description, the microscopic description, and a diagnostic impression for
each specimen. <br>
The current Standard treats each component of a narrative report as a separate
"test" or observation.  Just as a CHEM12 is transmitted as an order segment
(OBR) plus 12 OBX segments, a chest X-ray would be transmitted as an order
(OBR) segment plus three OBX segments, one for the description, one for the
impression, and one for the recommendations.  Similarly, an EKG report would be
transmitted as an order segment (OBR), two OBX segments for the impression and
recommendation, and additional OBX segments for each EKG measurement, e.g. the
PR interval, QR interval, QRS axis, and so on.<br>
We have defined code suffixes for constructing observation IDs for the common
components of narrative reports (see <i>Figure 7-1</i>).  The observation
identifier for each such component is obtained by concatenating the observation
battery ID (the ID in <i>OBR-4-universal service ID</i> of the preceding OBR
from any coding system) with the appropriate suffix.  The observation ID for a
chest X-ray impression, for example, would be the chest X-ray observation ID
(if CPT4, it would be 71020), a subcomponent delimiter, and the suffix, IMP,
i.e., 71020&amp;IMP.  <br>
This same combining rule applies to other coding systems including local and
universal procedural codes (see Chapter 4).  For example, if a local code for
EKG was E793, and the locally agreed upon designation for that local code was
EKG, the impression would be identified as E793&amp;IMP^^99EKG.<br>
</p>
<TABLE BORDER><TR align="left">
<TD align="left"><b>Note:</b>
The "99EKG" in the 3rd component is included to indicate a local code.  The
EKG's description, in this case, would be E793&amp;GDT^^99EKG.</TD></TR></TABLE><p>Although
it is strongly discouraged, the sender and receiver may agree to allow the
omission of the observation ID component of a result segment when it is the
same as the observation ID of the preceding OBR.  In this case, only the
ampersand and the suffix would have to be sent, e.g., &amp;IMP or &amp;REC, in
<i>OBX-3-observation identifier</i> of a result segment.  The full code would
be assumed as the test identifier (recorded in the order segment) plus the
category identifier recorded in the observation segment.<br>
<center>Figure 7-1.  Observation ID suffices</center><br>
</p>
<TABLE BORDER><TR>
<TD >Coded
Results</TD>
<TD >Suffix</TD>
<TD >Type</TD></TR>

<TR align="left">
<TD align="left">Diagnostic
Impression</TD>
<TD >IMP</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Recommendation</TD>
<TD >REC</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Confirming
<strike>P</strike>rocedures</TD>
<TD >CNP</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Procedure
Medication</TD>
<TD >MED</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Anatomic
Site</TD>
<TD >ANT</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Device/Instrument</TD>
<TD >DEV</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Serial
# Device/Instrument</TD>
<TD >SER</TD>
<TD >ST</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left"><b>Bulk
Text Reports
</b></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Gross
Or General Description Of The Study</TD>
<TD >GDT</TD>
<TD >TX
or FT</TD></TR>

<TR align="left">
<TD align="left">Microscopic
Or Secondary Description</TD>
<TD >MDT</TD>
<TD >TX
or FT</TD></TR>

<TR align="left">
<TD align="left">Technician's
Comment</TD>
<TD >TCM</TD>
<TD >TX
or FT</TD></TR>

<TR align="left">
<TD align="left">Addendum
Note</TD>
<TD >ADT</TD>
<TD >TX
or FT</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left"><b>Other</b></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Diagnosis
Onset Date/Time</TD>
<TD >ITM</TD>
<TD >TS</TD></TR>

<TR align="left">
<TD align="left">Diagnosis
Resolution Date/Time</TD>
<TD >RTM</TD>
<TD >TS</TD></TR>

<TR align="left">
<TD align="left">Comparison
Study</TD>
<TD >CMS</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Comparison
Date/Time</TD>
<TD >CMT</TD>
<TD >TS</TD></TR>

<TR align="left">
<TD align="left">Comparison
Results</TD>
<TD >CMR</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Comparison
Change</TD>
<TD >CMC</TD>
<TD >CE</TD></TR>

<TR align="left">
<TD align="left">Predicted
Value</TD>
<TD >PRD</TD>
<TD >ST</TD></TR>

<TR align="left">
<TD align="left">Percent
Predicted</TD>
<TD >PPR</TD>
<TD >ST</TD></TR>

<TR align="left">
<TD align="left">After
Drug Observed</TD>
<TD >AFD</TD>
<TD >ST</TD></TR>

<TR align="left">
<TD align="left">Predicted
Value After Drug</TD>
<TD >ADP</TD>
<TD >ST</TD></TR>

<TR align="left">
<TD align="left">Percent
Predicted After Drug</TD>
<TD >APP</TD>
<TD >ST</TD></TR>

<TR align="left">
<TD align="left">Timing
Information</TD>
<TD >TIM</TD>
<TD >TS</TD></TR>

<TR align="left">
<TD align="left">Channel Definition Data</TD>
<TD >CHN</TD>
<TD >CD</TD></TR>

<TR align="left">
<TD align="left">Waveform Digital Data</TD>
<TD >WAS</TD>
<TD >NA or MA</TD></TR>

<TR align="left">
<TD align="left">Waveform
Annotation</TD>
<TD >ANO</TD>
<TD >CE</TD></TR>



</TABLE>
<h3>
<A NAME="Heading12">7.1.3 Suffixes for defining observation IDs for common components of narrative reports</A></h3>

<p>The
following subsections define each of the suffices except for the specialized
waveform suffices, which are defined in Section 7.16, "WAVEFORM SPECIFIC
OBSERVATION ID SUFFIXES."</p>

<h4>
<A NAME="Heading13">7.1.3.1 Diagnostic impressions (IMP)</A></h4>

<p>When
the suffix is IMP (<i>OBX-3-observation identifier</i>), the result is a
diagnosis or finding, stored as a CE data type.  Multiple result segments with
an IMP suffix can be used if there are multiple parts to the study and each
have an associated diagnosis (for example, the awake and sleep portion of an
EEG).  Each of these would have a different observation sub-ID.  Multiple
result segments with an IMP suffix can also be used if there are separate
diagnoses corresponding to separate anatomic sites; in this case, the site for
each diagnosis (each result segment with an IMP suffix) must be specified by an
immediately preceding result segment with a suffix of ANT (see Section 7.1.3.5,
"Anatomic site (ANT)"), which also has the same observation sub-ID.  When
multiple distinct diagnostic impressions are being reported, for example,
mitral valve prolapse and aortic stenosis, each distinct impression should be
sent in a separate OBX segment.  More than one code may be included within one
coded result segment, but only when such codes are modifiers of the principal
impression, e.g., to report additional detail about the finding, not to report
an entirely different finding.  In this case, the <i>OBX-5-observation
value</i> field may repeat, with each instance or repetition specifying one of
the related coded impressions.<br>
The coded data type for impressions does not mean that a reporting service must
actually code all such impressions.  The diagnostic impression can be sent as
dictated text, but the text should be sent in the second component of the CE
data type without a code to distinguish it from code, i.e. it should be
preceded by a component delimiter, e.g., <tt>^congestive heart failure</tt>.
<br>
When multiple separate text impressions are being reported, they should be
reported in separate OBX segments to indicate that they are distinct impressions.</p>

<h4>
<A NAME="Heading14">7.1.3.2 Recommendations (REC)</A></h4>

<p>When
the suffix is REC (<i>OBX-3-observation identifier</i>), the value is a CE
result, representing the reading physician's recommendations about repeat
testing, follow up or therapy.  For example, when an ambiguous lesion result is
seen on a mammogram, the reading physician might recommend a repeat mammogram
in six months, or a needle biopsy immediately.  The recommended procedures are
recorded as codes and/or text descriptions in the coded identifier structure.
<br>
If more than one follow up study is recommended, each such recommendation is
sent in a separate REC.</p>

<h4>
<A NAME="Heading15">7.1.3.3 Confirming procedure (CNP)</A></h4>

<p>The
confirming procedure OBX suffix identifies additional studies used to confirm
the diagnosis reported in the IMP OBX.  If, for example, electron microscopy
was done to confirm a surgical pathology diagnosis, the identifier for electron
microscopy <i>OBX-3-observation identifier</i> would be stored as the value
field of an observation ID with a confirming procedure suffix.  Confirming
procedures are most important in surgical pathology reports.  But they might
also be used by services such as endoscopy, to record the fact that a biopsy,
culture, etc., was taken during the procedure. If more than one confirming
procedure was used, each is sent in a separate result segment with observation
ID suffix CNP.</p>

<h4>
<A NAME="Heading16">7.1.3.4 Procedure medication (MED)</A></h4>

<p>A
coded result segment with a suffix of MED (<i>OBX-3-observation identifier</i>)
indicates that the segment contained information about medication given as part
of the procedure -- contrast medication, medication intended to invoke a
physiologic response (e.g., to be used in stress testing) or premedication.
When patients receive more than one procedure medication, each medication
should be reported in a separate OBX medication segment.  If the transmitting
system has codes available for medications, they would be recorded as the first
component of <i>OBX-3-observation identifier</i>.  The name and/or the dosages
could be included in the second component of <i>OBX-5-observation value</i>.
<br>
A coded result segment with a suffix of MED (procedure medication) may also be
used to define a medication administered during recording of digital waveform
data or other extended diagnostic procedure, e.g., exercise test.  These may be
displayed by the receiving system overlaid with the other events reported.  The
procedure medication is assumed to pertain to and be associated with the data
recorded at the time specified in <i>OBX-14-date/time of the observation</i>,
of the OBX segment labeled with MED, when present.
<a name="_Ref358356083"></a></p>

<h4>
<A NAME="Heading17">7.1.3.5 Anatomic site (ANT)</A></h4>

<p>Some
diagnostic studies include observations about more than one anatomic site
within one report.  If, for example, a patient had an appendectomy incidental
to gallbladder surgery, the pathologist's assessment of both specimens would
usually be included under a single specimen number in one report.  Each
distinct anatomic site would be reported as a separate OBX segment with a
suffix of ANT (<i>OBX-3-observation identifier</i>).  More than one coded
anatomic location may be included within a single OBX segment only when such
additional codes are used to construct an identity for a single site.  In this
case only, the <i>OBX-5-observation value</i> field may repeat, with each
instance or repetition specifying one of the related locations.  Each OBX
segment with an ANT suffix could be followed by one or more OBX segments with
an IMP or other suffix to transmit the diagnostic impression(s) associated with
the anatomic site. These impressions or recommendations would be associated
with a single anatomic site via a common observation ID.</p>

<h4>
<A NAME="Heading18">7.1.3.6 Devices (DEV)</A></h4>

<p>When
required, the instrument or device which generated an observation can be
transmitted as an additional result of the study.  In this case, the suffix of
<i>OBX-3-observation identifier</i> is DEV.  Examples include: an automated
instrument in the laboratory; an imaging device and model number in radiology;
or an automatic blood pressure machine on the ward.  The device is specified as
a coded entry in anticipation that these identifiers could be specified as
codes.  Initially, we expect that most of the information about devices will be
transmitted as text in the second component of the CE identifier.</p>

<h4>
<A NAME="Heading19">7.1.3.7 Gross or general description (GDT)</A></h4>

<p>The
general description suffix identifies the description component of a diagnostic
studies.  In the case of anatomic pathology, it applies to the macroscopic
(gross) description of the specimen.  If the description consists of multiple
paragraphs, the paragraphs should be separated by repeat delimiters so that the
receiving computer can display them as paragraphs.  It will not be necessary to
include a description segment for a report when the impression segment says it
all, e.g., for normal studies or studies such as EKG, whose reports are
traditionally terse. </p>

<h4>
<A NAME="Heading20">7.1.3.8 Secondary or microscopic description (MDT)</A></h4>

<p>For
most studies, a secondary description will not be needed.  In the case of
surgical pathology, however, the microscopic description is a separate part of
the report.  It describes the histology as seen through the microscope.  The
microscopic description will be sent in a segment with the suffix MDT in
<i>OBX-3-observation identifier</i>.  If the microscopic description consists
of multiple paragraphs, the paragraphs should be separated by repeat delimiters
so that the receiving computer can display them as paragraphs.</p>

<h4>
<A NAME="Heading21">7.1.3.9 Technician comment (TCM)</A></h4>

<p>This
is free text stored in a result segment whose <i>OBX-3-observation
identifier</i> has a suffix of TCM for technician comment.  It is used to
record information about technical performance of the procedure, usually
recorded by the technician.</p>

<h4>
<A NAME="Heading22">7.1.3.10 Addendum note (ADT) </A></h4>

<p>Use
to report information that is added as an addendum after the original dictation
and sent as a separate labeled section of the report.</p>

<h4>
<A NAME="Heading23">7.1.3.11 Diagnosis (problem) onset date-time (ITM) </A></h4>

<p>Use
to record the date-time that a problem was first perceived to exist. </p>

<h4>
<A NAME="Heading24">7.1.3.12 Diagnosis (problem) resolution date-time (RTM) </A></h4>

<p>Use
to record the date-time that a problem became inactive, i.e., the problem was
cured or remitted. </p>

<h4>
<A NAME="Heading25">7.1.3.13 Comparison study (CMS) </A></h4>

<p>When
the reader of a diagnostic report compares the results for the current study
with those of a previous study, this suffix allows them to report the nature of
the comparison study as a separate result, i.e., an OBX segment with a segment
whose observation ID has a suffix of CMS.  Ordinarily, this would not be
required because the observation ID in the other comparison OBX's would
identify the test, if any of the other comparison values were transmitted.</p>

<h4>
<A NAME="Heading26">7.1.3.14 Comparison date-time (CMT) </A></h4>

<p>When
the reader of a diagnostic procedure compares the current results with a
previous study, this suffix allows them to report the date-time of the previous
study (time optional) as a separate result within the current report.  </p>

<h4>
<A NAME="Heading27">7.1.3.15 Comparison results (CMR) </A></h4>

<p>When
the reader of a diagnostic procedure compares the current results with those of
a previous study on the same patient, this suffix allows them to report the
results (impression) of the previous study as a discrete result within the
current report.  </p>

<h4>
<A NAME="Heading28">7.1.3.16 Comparison change (CMC) </A></h4>

<p>When
a diagnostic service reports a comparison between the current and a previous
study, this suffix is used to report the degree of change (e.g., much worse,
worse, minimal worsening, no change, slightly better, better, much better,
returned to normal) as a separate result within the report. <br>
In current dictation, information about comparison is usually contained in the
descriptions of the study.  The provision of the comparison suffixes listed
above do not imply a <i>requirement</i> to send this information as separate
components.  The comparison variables are only meant to be enabling.  When a
system would like to transmit them as discrete report components, these
suffixes give them the option.</p>

<h4>
<A NAME="Heading29">7.1.3.17 Predicted (PRD) </A></h4>

<p>When
an observation has a predicted value as is the case for many spirometry tests,
this suffix identifies the predicted observation as distinguished from the
actual observation.  The AS4 code for forced vital capacity is 94010.1 (see the
HL7 Implementation Guide).  The predicted forced vital capacity would be
94010.1&amp;PRD.</p>

<h4>
<A NAME="Heading30">7.1.3.18 Percent of predicted (PPR) </A></h4>

<p>This
is a computed observation <tt>= (actual observation)/(predicted
observation.</tt>  For forced vital capacity the percent predicted would be
identified as 94010.1&amp;PPR.</p>

<h4>
<A NAME="Heading31">7.1.3.19 After drug observed (AFD) </A></h4>

<p>An
observation might be taken before and after a drug is given. This occurs
especially in Spirometry.  The predose observation is identified by the base
ID.  The post drug measure is identified by the AFD suffix.  Using the AS4 base
code for the forced vital capacity the post drug result would be identified by
94010.1&amp;AFD. </p>

<h4>
<A NAME="Heading32">7.1.3.20 Predicted value after drug (ADP) </A></h4>

<p>The
post drug predicted value is identified by the suffix, ADP.  Following the
pattern of the above example, it would be 94010.1&amp;ADP. </p>

<h4>
<A NAME="Heading33">7.1.3.21 Percent predicted after drug (APP) </A></h4>

<p>The
percent predicted after drug is identified by applying the suffix, APP to the
base code -- 94010.1&amp;APP if using the AS4 code for forced vital capacity.</p>

<h4>
<A NAME="Heading34">7.1.3.22 Clinical observation codes</A></h4>

<p>In
previous version of HL7, AS4 codes<a name="fnB0" href="#fn0">[1]</a> have been
recommended for identifying clinical observations.  The recently introduced
LOINC codes (See <i>Figure 7-2</i> for full information) may be more useful to
many users.  Code system information, including LOINC, has been moved from
Appendix 7A to the Implementation Guide.  



</p>

<h3>
<A NAME="Heading35">7.1.4 Coding schemes</A></h3>

<p>Various
fields of data type CE which are used in segments defined both in the current
chapter and other chapters, are used to transmit information about diagnoses,
observation results, procedures, health outcomes, and drugs administered.
<i>Figures 7-2</i> and <i>7-3</i> (which were located in Chapter 2 in previous
versions) list some common coding schemes for these types of information.  The
values in the second column of the table would be used in component 3 (and
optionally, component 6) of a CE field to identify the coding scheme used.

 </p>

<center>Figure 7-2.  Diagnostic coding schemes (from ASTM 1238-94 Table 3) 
</center>
<TABLE BORDER><TR>
<TH >Name</p>
<BR></TH>
<TH >Code</p>
<BR></TH>
<TH >Source</p>
<BR></TH></TR>

<TR align="left">
<TD align="left">American College of Radiology finding codes</TD>
<TD align="left">ACR</TD>
<TD align="left">Index
for Radiological Diagnosis Revised, 3rd Edition 1986, American College of Radiology, Reston, VA.</TD></TR>

<TR align="left">
<TD align="left">AS4 Neurophysiology Codes</TD>
<TD align="left">AS4E</TD>
<TD align="left">ASTM's
diagnostic codes and test result coding/grading systems for clinical
neurophysiology. See ASTM Specification E1467, Appendix 2.</TD></TR>

<TR align="left">
<TD align="left">CEN ECG diagnostic codes </TD>
<TD align="left">CE</TD>
<TD align="left">CEN
PT007. A quite comprehensive set of ECG diagnostic codes (abbreviations) and
descriptions published as a pre-standard by CEN TC251. Available from CEN TC251
secretariat, c/o Georges DeMoor, State University Hospital Gent, De Pintelaan
185-5K3, 9000 Gent, Belgium or Jos Willems, University of Gathuisberg, 49
Herestraat, 3000 Leuven, Belgium. </TD></TR>

<TR align="left">
<TD align="left">CLIP</TD>
<TD align="left">CLP</TD>
<TD align="left">Simon
Leeming, Beth Israel Hospital, Boston MA.  Codes for radiology reports.</TD></TR>

<TR align="left">
<TD align="left">EUCLIDES</TD>
<TD align="left">E</TD>
<TD align="left">Available
from Euclides Foundation International nv, Excelsiorlaan 4A, B-1930 Zaventem,
Belgium; Phone: 32 2 720 90 60.</TD></TR>

<TR align="left">
<TD align="left">Home Health Care</TD>
<TD align="left">HHC</TD>
<TD align="left">Home
Health Care Classification System; Virginia Saba, EdD, RN; Geogetown University
School of Nursing; Washington, DC.</TD></TR>

<TR align="left">
<TD align="left">ICD9</TD>
<TD align="left">I9</TD>
<TD align="left">World Health Publications, Albany, NY.</TD></TR>

<TR align="left">
<TD align="left">ICD9-CM</TD>
<TD align="left">I9C</TD>
<TD align="left">Commission on Professional and Hospital Activities, 1968 Green Rd., Ann Arbor, MI 48105.</TD></TR>

<TR align="left">
<TD align="left">ICD-10</TD>
<TD align="left">I10</TD>
<TD align="left">World Health Publications, Albany, NY.</TD></TR>

<TR align="left">
<TD align="left">International
Classification of Diseases for Oncology</TD>
<TD align="left">ICDO</TD>
<TD align="left">International
Classification of Diseases for Oncology, 2nd Edition.  World Health
Organization:  Geneva, Switzerland, 1990.  Order from:  College of American
Pathologists, 325 Waukegan Road, Northfield, IL, 60093-2750.  (847) 446-8800.</TD></TR>

<TR align="left">
<TD align="left">International
Classification of Sleep Disorders</TD>
<TD align="left">ICSD</TD>
<TD align="left">International
Classification of Sleep Disorders Diagnostic and Coding Manual, 1990, available
from American Sleep Disorders Association, 604 Second Street SW, Rochester, MN
55902</TD></TR>

<TR align="left">
<TD align="left">Local general code </TD>
<TD align="left">99zzz or L </TD>
<TD align="left">Locally
defined codes for purpose of sender or receiver.  Local codes can be identified
by L (for backward compatibility) or 99zzz (where z is an alphanumeric
character).</TD></TR>

<TR align="left">
<TD align="left">Local billing code </TD>
<TD align="left">LB</TD>
<TD align="left">Local
billing codes/names (with extensions if needed).</TD></TR>

<TR align="left">
<TD align="left">Omaha</TD>
<TD align="left">OHA</TD>
<TD align="left">Omaha
Visiting Nurse Association, Omaha, NB.</TD></TR>

<TR align="left">
<TD align="left">NANDA</TD>
<TD align="left">NDA</TD>
<TD align="left">North
American Nursing Diagnosis Association, Philadelphia, PA.</TD></TR>

<TR align="left">
<TD align="left">Read Classification</TD>
<TD align="left">RC</TD>
<TD align="left">The
Read Clinical Classification of Medicine, Park View Surgery, 26 Leicester Rd.,
Loughborough LE11 2AG (includes drug procedure and other codes, as well as
diagnostic codes).</TD></TR>

<TR align="left">
<TD align="left">Systemized
Nomenclature of Medicine (SNOMED) </TD>
<TD align="left">SNM</TD>
<TD align="left">Systemized
Nomenclature of Medicine, 2nd Edition 1984 Vols 1, 2, College of  American
Pathologists, Skokie, IL.</TD></TR>

<TR align="left">
<TD align="left">SNOMED International </TD>
<TD align="left">SNM3</TD>
<TD align="left">SNOMED International, 1993 Vols 1-4, College of  American Pathologists, Skokie, IL,
60077-1034..</TD></TR>

<TR align="left">
<TD align="left">SNOMED-DICOM Microglossary</TD>
<TD align="left">SDM</TD>
<TD align="left">College
of  American Pathologists, Skokie, IL, 60077-1034. (formerly designated as
99SDM).</TD></TR>

<TR align="left">
<TD align="left">Unified Medical Language</TD>
<TD align="left">UML</TD>
<TD align="left">National
Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894.</TD></TR></TABLE><p></p>

<center>Figure 7-3.  Procedure/observation/drug ID/health outcomes coding
systems  (From ASTM 1238-88 Table 5) 
</center>
<TABLE BORDER><TR>
<TH >Coding
System
</p>
<BR></TH>
<TH >Code</p>
<BR></TH>
<TH >Source/Description</p>
<BR></TH></TR>

<TR align="left">
<TD align="left">ASTM
E1238/ E1467 Universal</TD>
<TD align="left">AS4</TD>
<TD align="left">American
Society for Testing &amp; Materials and CPT4 (see Appendix X1 of Specification
E1238 and Appendix X2 of Specification E1467).</TD></TR>

<TR align="left">
<TD align="left">American
Type Culture Collection</TD>
<TD align="left">ATC</TD>
<TD align="left">Reference
cultures (microorganisms, tissue cultures, etc.), related biological materials
and associated data. American Type Culture Collection, 12301 Parklawn Dr,
Rockville MD, 20852. (301) 881-2600. http://www.atcc.org</TD></TR>

<TR align="left">
<TD align="left">CPT-4</TD>
<TD align="left">C4</TD>
<TD align="left">American
Medical Association, P.O. Box 10946, Chicago IL  60610.</TD></TR>

<TR align="left">
<TD align="left">CPT-5 </TD>
<TD align="left">C5</TD>
<TD align="left">(under
development - same contact as above)</TD></TR>

<TR align="left">
<TD align="left">CDC Surveillance</TD>
<TD align="left">CDS</TD>
<TD align="left">CDC
Surveillance Codes. For data unique to specific public health surveillance
requirements. Epidemiology Program Office, Centers for Disease Control and
Prevention, 1600 Clifton Rd, Atlanta, GA, 30333. (404) 639-3661.</TD></TR>

<TR align="left">
<TD align="left">DICOM
Class Label</TD>
<TD align="left">DCL</TD>
<TD align="left">From
the Message Standards Classes table of the SNOMED-DICOM-Microglossary. College
of American Pathologists, Skokie, IL, 60077-1034</TD></TR>

<TR align="left">
<TD align="left">DICOM
modality codes</TD>
<TD align="left">DCM</TD>
<TD align="left">Dean
Bidgood, MD; Duke University Medical Center, Durham NC. Digital Imaging and
Communications in Medicine (DICOM)  From NEMA Publications PS-3.1 - PS 3.12:
The ACR-NEMA DICOM Standard. National Electrical Manufacturers Association
(NEMA). Rosslyn, VA, 22209., 1992, 1993, 1995</TD></TR>

<TR align="left">
<TD align="left">DICOM
Query Label</TD>
<TD align="left">DQL</TD>
<TD align="left">HL7
Image Management Special Interest Group, Health Level Seven, Ann Arbor, MI.</TD></TR>

<TR align="left">
<TD align="left">Enzyme
Codes</TD>
<TD align="left">ENZC</TD>
<TD align="left">Enzyme
Committee of the International Union of Biochemistry and Molecular Biology.
Enzyme Nomenclature: Recommendations on the Nomenclature and Classification of
Enzyme-Catalysed Reactions. London: Academic Press, 1992.</TD></TR>

<TR align="left">
<TD align="left">EUCLIDES</TD>
<TD align="left">E</TD>
<TD align="left">AFP
codes.  Available from Euclides Foundation International nv, Excelsiorlaan 4A,
B-1930 Zaventem, Belgium; Phone: 32 2 720 90 60.</TD></TR>

<TR align="left">
<TD align="left">FDA
K10 </TD>
<TD align="left">FDK</TD>
<TD align="left">Dept.
of Health &amp; Human Services, Food &amp; Drug Administration, Rockville, MD
20857. (device &amp; analyte process codes).</TD></TR>

<TR align="left">
<TD align="left">HCFA
Procedure Codes</TD>
<TD align="left">HPC</TD>
<TD align="left">Under
development as replacement for ICD9 procedure codes. Due out 1997-1998.</TD></TR>

<TR align="left">
<TD align="left">UPIN</TD>
<TD align="left">UPIN</TD>
<TD align="left">Medicare/HCFA's
universal physician identification numbers, available from Health Care
Financing Administration, U.S. Dept. of Health and Human Services, Bureau of
Program Operations, 6325 Security Blvd., Meadows East Bldg., Room 300,
Baltimore, MD 21207</TD></TR>

<TR align="left">
<TD align="left">Health
Outcomes </TD>
<TD align="left">HI</TD>
<TD align="left">Health
Outcomes Institute codes for outcome variables available (with responses) from
Stratis Health (formerly Foundation for Health Care Evaluation and Health
Outcomes Institute), 2901 Metro Drive, Suite 400, Bloomington, MN, 55425-1525;
(612) 854-3306 (voice); (612) 853-8503 (fax); dziegen@winternet.com. See
examples in the Implementation Guide.</TD></TR>

<TR align="left">
<TD align="left">HIBCC</TD>
<TD align="left">HB</TD>
<TD align="left">Health
Industry Business Communications Council, 5110 N. 40th St., Ste 120, Phoenix,
AZ 85018.</TD></TR>

<TR align="left">
<TD align="left">Home
Health Care</TD>
<TD align="left">HHC</TD>
<TD align="left">Home
Health Care Classification System; Virginia Saba, EdD, RN; Georgetown
University School of Nursing; Washington, DC.</TD></TR>

<TR align="left">
<TD align="left">Logical
Observation Identifier Names and Codes (LOINC)</TD>
<TD align="left">LN</TD>
<TD align="left">Regenstrief
Institute, c/o Kathy Hutchins, 1001 West 10th Street RG-5, Indianapolis, IN
46202.  317/630-7433.   Also available via HL7 file server: FTP/Gopher
(www.mcis.duke.edu/ standards/ termcode/loinclab and
www.mcis.duke.edu/standards/termcode/loinclin) and World Wide Web (http://
www.mcis.duke.edu/ standards/termcode/ loincl.htm).   January 1997version has
identifiers, synonyms and cross-reference codes for reporting over  8,500
laboratory and related observations and 1,500 clinical measures.</TD></TR>

<TR align="left">
<TD align="left">ICCS</TD>
<TD align="left">ICS</TD>
<TD align="left">Commission
on Professional and Hospital Activities, 1968 Green Road, Ann Arbor, MI 48105.</TD></TR>

<TR align="left">
<TD align="left">ICD-9CM</TD>
<TD align="left">I9C</TD>
<TD align="left">Commission
on Professional and Hospital Activities, 1968 Green Road, Ann Arbor, MI 48105
(includes all procedures and diagnostic tests).</TD></TR>

<TR align="left">
<TD align="left">ICHPPC-2</TD>
<TD align="left">IC2</TD>
<TD align="left">International
Classification of Health Problems in Primary Care, Classification Committee of
World Organization of National Colleges, Academies and Academic Associations of
General Practitioners (WONCA), 3rd edition.  An adaptation of ICD9 intended for
use in General Medicine, Oxford University Press.</TD></TR>

<TR align="left">
<TD align="left">ISBT</TD>
<TD align="left">IBT</TD>
<TD align="left">International
Society of Blood Transfusion.  Blood Group Terminology 1990.  VOX Sanquines
1990 58(2):152-169. </TD></TR>

<TR align="left">
<TD align="left">IUPAC/IFCC
Property Codes </TD>
<TD align="left">IUC<br>
IUPP</TD>
<TD align="left">International
Union of Pure and Applied Chemistry/International Federation of Clinical
Chemistry. The Silver Book: Compendium of terminology and nomenclature of
properties in clinical laboratory sciences. Oxford: Blackwell Scientific
Publishers, 1995. Henrik Olesen, M.D., D.M.Sc., Chairperson,  Department of
Clinical Chemistry, KK76.4.2, Rigshospitalet, University Hospital of
Copenhagen, DK-2200, Copenhagen. http://inet.uni-c.dk/~qukb7642/</TD></TR>

<TR align="left">
<TD align="left">IUPAC/IFCC
Component Codes</TD>
<TD align="left">IUPC</TD>
<TD align="left">Codes
used by IUPAC/IFF to identify the component (analyte) measured. Contact Henrik
Olesen, as above for IUPP.</TD></TR>

<TR align="left">
<TD align="left">Japanese
Chemistry </TD>
<TD align="left">JC8</TD>
<TD align="left">Clinical
examination classification code.  Japan Association of Clinical Pathology.
Version 8, 1990.  A multiaxial code  including a subject code (e.g., Rubella =
5f395, identification code (e.g., virus ab IGG), a specimen code (e.g., serum
=023) and a method code (e.g., ELISA = 022)</TD></TR>

<TR align="left">
<TD align="left">Local</TD>
<TD align="left">99zzz
or L </TD>
<TD align="left">Locally
defined codes for purpose of sender or receiver.  If multiple local codes
exist, the format should be 99zzz, where z is an alphanumeric character.</TD></TR>

<TR align="left">
<TD align="left">Medicare</TD>
<TD align="left">MCR</TD>
<TD align="left">Medicare billing codes/names.</TD></TR>

<TR align="left">
<TD align="left">Medicaid</TD>
<TD align="left">MCD</TD>
<TD align="left">Medicaid billing codes/names.</TD></TR>

<TR align="left">
<TD align="left">Nursing
Interventions<br>
Classification</TD>
<TD align="left">NIC</TD>
<TD align="left">Iowa
Intervention Project, College of Nursing, University of Iowa, Iowa City, Iowa</TD></TR>

<TR align="left">
<TD align="left">National
Provider Identifier</TD>
<TD align="left">NPI</TD>
<TD align="left">Health
Care Finance Administration, US Dep't. of Health and Human Services, 7500
Security Blcd., Baltimore, MD 21244.</TD></TR>

<TR align="left">
<TD align="left">Omaha
System</TD>
<TD align="left">OHA</TD>
<TD align="left">Omaha
Visiting Nurse Association, Omaha, NB.</TD></TR>

<TR align="left">
<TD align="left">UCDS</TD>
<TD align="left">UC</TD>
<TD align="left">Uniform
Clinical Data Systems. Ms. Michael McMullan, Office of Peer Review Health Care
Finance Administration, The Meadows East Bldg., 6325 Security Blvd., Baltimore,
MD 21207; (301) 966 6851.</TD></TR>

<TR align="left">
<TD align="left">Universal
Product Code</TD>
<TD align="left">UPC</TD>
<TD align="left">The
Uniform Code Council.  8163 Old Yankee Road, Suite J, Dayton, OH  45458; (513)
435 3070</TD></TR>

<TR align="left">
<TD align="left">Euclides
Lab method codes </TD>
<TD align="left">E6</TD>
<TD align="left">Available
from Euclides Foundation International nv, Excelsiorlaan 4A, B-1930 Zaventem,
Belgium; Phone: 32 2 720 90 60.</TD></TR>

<TR align="left">
<TD align="left">Euclides Lab equipment codes </TD>
<TD align="left">E7</TD>
<TD align="left">Available
from Euclides Foundation International nv (see above)</TD></TR>

<TR align="left">
<TD align="left">SNOMED
topology codes (anatomic sites)</TD>
<TD align="left">SNT</TD>
<TD align="left">College
of American Pathologists, 5202 Old Orchard Road, Skokie, IL 60077-1034.</TD></TR>

<TR align="left">
<TD align="left">Euclides
 quantity codes </TD>
<TD align="left">E5</TD>
<TD align="left">Available
from Euclides Foundation International nv (see above)</TD></TR>

<TR align="left">
<TD align="left"><b>Drug
codes:
</b></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left">CDC
Vaccine Codes</TD>
<TD align="left">CVX</TD>
<TD align="left">National
Immunization Program, Centers for Disease Control and Prevention, 1660 Clifton
Road, Atlanta, GA, 30333</TD></TR>

<TR align="left">
<TD align="left">CDC
Vaccine Manufacturer Codes</TD>
<TD align="left">MVX</TD>
<TD align="left">As above, for CVX</TD></TR>

<TR align="left">
<TD align="left">CDC Methods/Instruments Codes</TD>
<TD align="left">CDCM</TD>
<TD align="left">Public
Health Practice Program Office, Centers for Disease Control and Prevention,
4770 Buford Highway, Atlanta, GA, 30421.  Also available via FTP:
ftp.cdc.gov/pub/laboratory _info/CLIA and Gopher:
gopher.cdc.gov:70/11/laboratory_info/CLIA</TD></TR>

<TR align="left">
<TD align="left">CDC Analyte Codes</TD>
<TD align="left">CDCA</TD>
<TD align="left">As above, for CDCM</TD></TR>

<TR align="left">
<TD align="left">First DataBank Drug Codes</TD>
<TD align="left">FDDC</TD>
<TD align="left">National
Drug Data File. Proprietary product of First DataBank, Inc. (800) 633-3453, or
http://www.firstdatabank.com.</TD></TR>

<TR align="left">
<TD align="left">First
DataBank Diagnostic Codes</TD>
<TD align="left">FDDX</TD>
<TD align="left">Used
for drug-diagnosis interaction checking. Proprietary product of First DataBank,
Inc. As above for FDDC.</TD></TR>

<TR align="left">
<TD align="left">Medispan
GPI</TD>
<TD align="left">MGPI</TD>
<TD align="left">Medispan
hHierarchical drug codes for identifying drugs down to manufacturer and pill
size.  Proprietary product of MediSpan, Inc.l 8425 Woodfield Crossing
Boulevard, Indianapolis, IN 46240. Tel: (800)428-4495.</TD></TR>

<TR align="left">
<TD align="left">Medispan
Diagnostic Codes</TD>
<TD align="left">MDDX</TD>
<TD align="left">Codes
Used for drug-diagnosis interaction checking. Proprietary product. Hierarchical
drug codes for identifying drugs down to manufacturer and pill size. MediSpan,
Inc.l 8425 Woodfield Crossing Boulevard, Indianapolis, IN 46240. Tel:
(800)428-4495.  WWW: http://www.espan.com/medispan/pages/ medhome.html  As
above for MGPI.</TD></TR>

<TR align="left">
<TD align="left">Medical
Economics Drug Codes</TD>
<TD align="left">MEDC</TD>
<TD align="left">Proprietary
Codes for identifying drugs. Proprietary product of Medical Economics Data,
Inc. (800) 223-0581.</TD></TR>

<TR align="left">
<TD align="left">Medical
Economics Diagnostic Codes</TD>
<TD align="left">MEDX</TD>
<TD align="left">Used
for drug-diagnosis interaction checking. Proprietary product of Medical
Economics Data, Inc. (800) 223-0581.</TD></TR>

<TR align="left">
<TD align="left">Chemical
abstract codes </TD>
<TD align="left">CAS</TD>
<TD align="left">These
include unique codes for each unique chemical, including all generic drugs.
The codes do not distinguish among different dosing forms.  When multiple
equivalent CAS numbers exist, use the first one listed in USAN. USAN 1990 and
the USP dictionary of drug names, William M. Heller, Ph.D., Executive Editor,
United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway,
Rockville, MD 20852.</TD></TR>

<TR align="left">
<TD align="left">National
drug codes </TD>
<TD align="left">NDC</TD>
<TD align="left">These
provide unique codes for each distinct drug, dosing form, manufacturer, and
packaging. (Available from the National Drug Code Directory, FDA, Rockville,
MD, and other sources.)</TD></TR>

<TR align="left">
<TD align="left">COSTART</TD>
<TD align="left">CST</TD>
<TD align="left">International
coding system for adverse drug reactions. In the USA, maintained by the FDA,
Rockville, MD.</TD></TR>

<TR align="left">
<TD align="left">Medical Dictionary for Drug Regulatory Affairs (MEDDRA)</TD>
<TD align="left">MEDR</TD>
<TD align="left">Dr.
Louise Wood, Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London
SW85NQ, UK   Tel: (44)0 171-273-0000 WWW:  http://www.open.gov.uk/mca/mcahome.htm</TD></TR>

<TR align="left">
<TD align="left">WHO rec# drug codes</TD>
<TD align="left">W1, W2 </TD>
<TD align="left">World
Health organization record number code. A unique sequential number is assigned
to each unique single component drug and to each multi-component drug.  Eight
digits are allotted to each such code, six to identify the active agent, and 2
to identify the salt, of single content drugs.  Six digits are assigned to each
unique combination of drugs in a dispensing unit.  The six digit code is
identified by W1, the 8 digit code by W2.</TD></TR>

<TR align="left">
<TD align="left">WHO
rec# code with ASTM extension</TD>
<TD align="left">W4</TD>
<TD align="left">With
ASTM extensions (see Implementation Guide), the WHO codes can be used to report
serum (and other) levels, patient compliance with drug usage instructions,
average daily doses and more (see Appendix X1 the Implementation Guide). </TD></TR>

<TR align="left">
<TD align="left">WHO ATC</TD>
<TD align="left">WC</TD>
<TD align="left">WHO's
ATC codes provide a hierarchical classification of drugs by therapeutic class.
They are linked to the record number codes listed above.</TD></TR>

<TR align="left">
<TD align="left">WHO
Adverse Reaction Terms</TD>
<TD align="left">ART</TD>
<TD align="left">WHO
Collaborating Centre for International Drug Monitoring, Box 26, S-751 03,
Uppsala, Sweden.</TD></TR>

<TR align="left">
<TD align="left"><b>Note:</b>
The Read and NLM (National Library of Medicine) codes in Table 3 also include
drugs.  A number of sources of unique drug names exist: British Approved Names
(BAN), French-approved nonproprietary names (DCF), and International
Nonproprietary name (INN).  These sources are now being reviewed.  Those that
also provide unique codes will be added to the registry of coding systems,
using the abbreviations given in parentheses.</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left"><b>Device code:</b></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left">MDNS</TD>
<TD align="left">UMD</TD>
<TD align="left">Universal
Medical Device Nomenclature System.  ECRI, 5200 Butler Pike, Plymouth Meeting,
PA  19462 USA.  Phone: 215-825-6000, Fax: 215-834-1275.</TD></TR><a name="_Ref358355969"></a><a name="_Ref358356635"></a><a name="_Ref373317168"></a><a name="_Ref373317330"></a></TABLE>
<h2>
<A NAME="Heading36">7.2 MESSAGE DEFINITIONS</A></h2>

<p>The
triggering events that follow are all served by the ORU (Observational report -
Unsolicited) or the ORF (Observational Report Response) messages in combination
with ACK and QRY.  Each triggering event is listed below, along with the
messages  exchanged, and the segments that comprise the messages.  The notation
used to describe the sequence, optionality, and repeating of segments is
described in Chapter 2, "Format for defining abstract messages."
</p>

<h3>
<A NAME="Heading37">7.2.1 ORU/ACK - unsolicited transmission of an observation message (event R01)</A></h3>

<p>With
the type (OBX) defined in this chapter, and the OBR defined in Chapter 4, one
can construct almost any clinical report as a three-level hierarchy, with the
PID segment defined in Chapter 3 at the upper level, an order record (OBR) at
the next level and one or more observation records (OBX) at the bottom.<br>
One result segment (OBX) is transmitted for each component of a  diagnostic
report, such as an EKG or obstetrical ultrasound or electrolyte battery. <br>
<tt><u>ORU					Observational Results (Unsolicited)	Chapter</u></tt><br>
MSH					Message Header	2<br>
{  <br>
   <br>
   [<br>
    PID				Patient Identification	3<br>
	  [PD1]			Additional Demographics	3<br>
      [{NTE}]			Notes and Comments	2<br>
    [PV1				Patient Visit	3<br>
      [PV2]]			Patient Visit - Additional Info	3<br>
   ]<br>
    {<br>
     [ORC]			Order common	4<br>
      OBR			Observations Report ID	7<br>
      {[NTE]}			Notes and comments	2<br>
        {<br>
         [OBX]		Observation/Result	7<br>
          {[NTE]}		Notes and comments	2<br>
        }   <br>
	{[CTI]}			Clinical Trial Identification	7<br>
     }   <br>
}   <br>
[DSC]				Continuation Pointer 	2<br>
 <br>
<tt><u>ACK					Acknowledgment	Chapter</u></tt><br>
MSH					Message header	2<br>
MSA					Message acknowledgment	2<br>
</p>
<TABLE BORDER><TR align="left">
<TD align="left"><b>Note:</b>
	The ORC is permitted but not required in this message.  Any information that
could be included in either the ORC or the OBR must be included in the OBR on
reporting.  Notice also that the ORU (and the QRY) messages accommodate reports
about many patients.  </TD></TR></TABLE><p>Many
report headers (OBR) may be sent beneath each patient segment, with many
separate observation segments (OBX) beneath each OBR.  Note segments (NTE) may
be inserted after any of the above segments.  The note segment applies to the
entity that immediately precedes it, i.e., the patient if it follows the PID
segment, the observation if it follows the OBR segment, and the individual
result if it follows the OBX segment. 
</p>

<h3>
<A NAME="Heading38">7.2.2 QRY/ORF - query for results of observation (events R02, R04)  </A></h3>

<p><tt><u>QRY
				Query	Chapter</u> </tt><br>
MSH					Message Header	2<br>
QRD					Query Definition	2<br>
QRF					Query Filter	2<br>
  <br>
<tt><u>ORF					Observational Report	Chapter</u></tt><br>
MSH					Message Header	2<br>
MSA					Message Acknowledgment	2<br>
QRD					Query Definition	2<br>
    [ QRF ]			Query Filter	2<br>
    { [ PID 			Patient ID	3<br>
        [{NTE}] ]		Notes and Comments	3<br>
{<br>
      [ ORC ]			Order common<br>
         OBR			Observation request	7<br>
         {[NTE]}		Notes and comments	2<br>
         {<br>
          [OBX]		Observation/Result	7<br>
            {[NTE]}	Notes and comments	2<br>
         }   <br>
        {[CTI]}		Clinical Trial Identification	7<br>
     } }  <br>
[DSC]				Continuation Pointer	2</p>

<h4>
<A NAME="Heading39">7.2.2.1 Query usage notes</A></h4>

<p>Display-oriented
results reporting is described in Chapter 2, Section 2.14.1, "Display vs.
record-oriented messages."  The QRD and QRF segments are defined in Chapter 2,
Section 2.24, "Messages Control Segments."  Event R05 is used for queries for
display results; event R06 is used in the unsolicited message for reporting
display results.<br>
The subject filters contained in the QRD and QRF segments are defined by local
agreement between the inquiring system and the ancillary system. <br>
The Set ID fields in the various segments (including PID) are used to count the
number of segments of one kind transmitted at one level of the hierarchy. <br>
The Query Result Level field of the QRD determines the amount of data
requested.  See Chapter 2, Section 2.24.4, "QRD - original style query
definition segment."
</p>

<h2>
<A NAME="Heading40">7.3 SEGMENTS</A></h2>

<p>The
full definitions of many segments required for reporting clinical observations
are included in other chapters.  The patient identifying segment (PID) is
provided in Chapter 3.  The NTE segment is in Chapter 2.  
</p>

<h3>
<A NAME="Heading41">7.3.1 OBR - observation request segment</A></h3>

<p>In
the reporting of clinical data, the OBR serves as the report header.  It
identifies the observation set represented by the following atomic
observations.  It includes the relevant ordering information when that applies.
It contains many of the attributes that usually apply to all of the included
observations.<br>
When a set of observations is ordered, the order message contains an OBR
segment.  However, observations can be collected and reported without an
antecedent order.  When observations are reported, the report message also
includes one or more OBR segments.  So, the OBR segment is like a turn-around
document.  Some fields in the OBR segment apply only to the ordering message
and some to the reporting message.  To those familiar with healthcare
procedures, these should be obvious from their names (e.g., transcriptionist or
principal result interpreter could only apply to the reporting phase).
However, we have also flagged them in <i>Figure 7-4</i> to indicate whether
placer, filler, or both may send data in a given field.<br>
<center> Figure 7-4.  OBR attributes</center><br>
</p>
<TABLE BORDER><TR>
<TD >SEQ</TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM
#</TD>
<TD >ELEMENT
NAME</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left">4</TD>
<TD align="left">SI</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00237</TD>
<TD >Set ID -  OBR</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">22</TD>
<TD align="left">EI</TD>
<TD>C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00216</TD>
<TD>Placer Order Number</TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">22</TD>
<TD align="left">EI</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00217</TD>
<TD >Filler
Order Number +</TD></TR>

<TR align="left">
<TD align="left">4</TD>
<TD align="left">200</TD>
<TD align="left">CE</TD>
<TD>R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00238</TD>
<TD>Universal Service ID</TD></TR>

<TR align="left">
<TD align="left">5</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00239</TD>
<TD >Priority</TD></TR>

<TR align="left">
<TD align="left">6</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00240</TD>
<TD>Requested Date/time</TD></TR>

<TR align="left">
<TD align="left">7</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00241</TD>
<TD >Observation
Date/Time #</TD></TR>

<TR align="left">
<TD align="left">8</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00242</TD>
<TD>Observation End Date/Time #</TD></TR>

<TR align="left">
<TD align="left">9</TD>
<TD align="left">20</TD>
<TD align="left">CQ</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00243</TD>
<TD >Collection
Volume *</TD></TR>

<TR align="left">
<TD align="left">10</TD>
<TD align="left">60</TD>
<TD align="left">XCN</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD>00244</TD>
<TD>Collector Identifier *</TD></TR>

<TR align="left">
<TD align="left">11</TD>
<TD align="left">1</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0065</TD>
<TD >00245</TD>
<TD >Specimen
Action Code *</TD></TR>

<TR align="left">
<TD align="left">12</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD>O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00246</TD>
<TD>Danger Code</TD></TR>

<TR align="left">
<TD align="left">13</TD>
<TD align="left">300</TD>
<TD align="left">ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00247</TD>
<TD >Relevant
Clinical Info.</TD></TR>

<TR align="left">
<TD align="left">14</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD>C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00248</TD>
<TD>Specimen Received Date/Time *</TD></TR>

<TR align="left">
<TD align="left">15</TD>
<TD align="left">300</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0070</TD>
<TD >00249</TD>
<TD >Specimen
Source *</TD></TR>

<TR align="left">
<TD align="left">16</TD>
<TD align="left">80</TD>
<TD align="left">XCN</TD>
<TD>O</TD>
<TD>Y</TD>
<TD><BR></TD>
<TD>00226</TD>
<TD>Ordering Provider</TD></TR>

<TR align="left">
<TD align="left">17</TD>
<TD align="left">40</TD>
<TD align="left">XTN</TD>
<TD >O</TD>
<TD >Y/2</TD>
<TD><BR></TD>
<TD >00250</TD>
<TD >Order
Callback Phone Number</TD></TR>

<TR align="left">
<TD align="left">18</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD>O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00251</TD>
<TD>Placer field 1</TD></TR>

<TR align="left">
<TD align="left">19</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00252</TD>
<TD >Placer
field 2</TD></TR>

<TR align="left">
<TD align="left">20</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD>O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00253</TD>
<TD>Filler Field 1 +</TD></TR>

<TR align="left">
<TD align="left">21</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00254</TD>
<TD >Filler
Field 2 +</TD></TR>

<TR align="left">
<TD align="left">22</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD>C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00255</TD>
<TD>Results Rpt/Status Chng - Date/Time +</TD></TR>

<TR align="left">
<TD align="left">23</TD>
<TD align="left">40</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00256</TD>
<TD >Charge
to Practice +</TD></TR>

<TR align="left">
<TD align="left">24</TD>
<TD align="left">10</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0074</TD>
<TD >00257</TD>
<TD >Diagnostic Serv Sect ID</TD></TR>

<TR align="left">
<TD align="left">25</TD>
<TD align="left">1</TD>
<TD align="left">ID</TD>
<TD >C</TD>
<TD><BR></TD>
<TD >0123</TD>
<TD >00258</TD>
<TD >Result
Status +</TD></TR>

<TR align="left">
<TD align="left">26</TD>
<TD align="left">400</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00259</TD>
<TD >Parent Result +</TD></TR>

<TR align="left">
<TD align="left">27</TD>
<TD align="left">200</TD>
<TD align="left">TQ</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00221</TD>
<TD >Quantity/Timing</TD></TR>

<TR align="left">
<TD align="left">28</TD>
<TD align="left">150</TD>
<TD align="left">XCN</TD>
<TD >O</TD>
<TD >Y/5</TD>
<TD><BR></TD>
<TD >00260</TD>
<TD >Result Copies To</TD></TR>

<TR align="left">
<TD align="left">29</TD>
<TD align="left">150</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00261</TD>
<TD >Parent *</TD></TR>

<TR align="left">
<TD align="left">30</TD>
<TD align="left">20</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0124</TD>
<TD >00262</TD>
<TD >Transportation Mode</TD></TR>

<TR align="left">
<TD align="left">31</TD>
<TD align="left">300</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00263</TD>
<TD >Reason for Study</TD></TR>

<TR align="left">
<TD align="left">32</TD>
<TD align="left">200</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00264</TD>
<TD >Principal
Result Interpreter +</TD></TR>

<TR align="left">
<TD align="left">33</TD>
<TD align="left">200</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00265</TD>
<TD >Assistant Result Interpreter + </TD></TR>

<TR align="left">
<TD align="left">34</TD>
<TD align="left">200</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00266</TD>
<TD >Technician +</TD></TR>

<TR align="left">
<TD align="left">35</TD>
<TD align="left">200</TD>
<TD align="left">CM</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00267</TD>
<TD >Transcriptionist
+</TD></TR>

<TR align="left">
<TD align="left">36</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00268</TD>
<TD >Scheduled Date/Time +</TD></TR>

<TR align="left">
<TD align="left">37</TD>
<TD align="left">4</TD>
<TD align="left">NM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01028</TD>
<TD >Number
of Sample Containers *</TD></TR>

<TR align="left">
<TD align="left">38</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01029</TD>
<TD >Transport
Logistics of Collected Sample *</TD></TR>

<TR align="left">
<TD align="left">39</TD>
<TD align="left">200</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01030</TD>
<TD >Collector's
Comment *</TD></TR>

<TR align="left">
<TD align="left">40</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01031</TD>
<TD >Transport
Arrangement Responsibility</TD></TR>

<TR align="left">
<TD align="left">41</TD>
<TD align="left">30</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0224</TD>
<TD >01032</TD>
<TD >Transport
Arranged</TD></TR>

<TR align="left">
<TD align="left">42</TD>
<TD align="left">1</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0225</TD>
<TD >01033</TD>
<TD >Escort Required</TD></TR>

<TR align="left">
<TD align="left">43</TD>
<TD align="left">200</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01034</TD>
<TD >Planned Patient Transport Comment</TD></TR></TABLE>

<p><br>
The complete description of these fields is provided below as well as  in Chapter 4.  <br>
7.3.1.0  OBR field definitions<br>
The daggered (+) items in this segment are not created by the placer known to
the filler, not the placer.  They are created by the filler and valued as
needed when the OBR segment is returned as part of a report.  Hence on a new
order sent to the filler, they are not valued.  There is an exception when the
filler initiates the order.  In that case, the filler order number is valued
and the placer order number may be blank. They are valued by the filler as
needed when the OBR segment is returned as part of a report.<br>
The starred (*) fields are only relevant when an observation is associated with
a specimen.  These are completed by the placer when the placer obtains the
specimen.  They are completed by the filler when the filler obtains the
specimen.  <br>
<i>OBR-7-observation date/time</i> and <i>OBR-8-observation end date/time</i>
(flagged with #) are the physiologically relevant times.  In the case of an
observation on a specimen, they represent the start and end of the specimen
collector.  In the case of an observation obtained directly from a subject
(e.g., BP, Chest X-ray), they represent the start and end time of the
observation.</p>

<h4>
<A NAME="Heading42">7.3.1.1 Set ID - OBR   (SI)   00237</A></h4>

<p>Definition:
 For the first order transmitted, the sequence number shall be 1; for the
second order, it shall be 2; and so on. </p>

<h4>
<A NAME="Heading43">7.3.1.2 Placer order number  (EI)   00216</A></h4>

<p><tt>Components:
 &lt;entity identifier (ST)&gt; ^ &lt;namespace ID (IS)&gt; ^ &lt;universal ID
(ST)&gt; ^ &lt;universal ID type (ID)&gt;</tt><br>
Definition:  This field is a case of the Entity Identifier data type (See
2.8.13, "EI - Entity identifier").  The first component is a string that
identifies an individual order (e.g., OBR).  A limit of fifteen (15) characters
is suggested but not required.  It is assigned by the place (ordering
application).  It identifies an order uniquely among all orders from a
particular ordering application.  The second through fourth components contain
the application ID of the placing application in the same form as the HD data
type (Section 2.8.18, "HD - Hierarchic designator").  The second component,
namespace ID, is a user-defined coded value that will be uniquely associated
with an application.  A limit of six (6) characters is suggested but not
required.  A given institution or group of intercommunicating institutions
should establish a unique list of applications that may be potential placers
and fillers and assign unique application IDs.  The components are separated by
component delimiters.<br>
There are three situations in which the true placer is somewhat arbitrary (and
thus not unique): <br>
a) 	in <i>ORC-1-order control</i> value of RO, following an RU replacement;<br>
b) 	in <i>ORC-1-order control</i> value of CH (child orders); and<br>
c) 	in <i>ORC-1-order control</i> value of SN (send number).<br>
See the Table Notes under <i>ORC-1-order control</i> for the details of how the
<i>ORC-2-placer order number</i> is assigned in these cases.<br>
A given institution or group of intercommunicating institutions should
establish a list of applications that may be potential placers and fillers of
orders and assign each a unique application ID.  The application ID list
becomes one of the institution's master dictionary lists that is documented in
Chapter 8.  Since third-party applications (those other than the placer and
filler of an order) can send and receive ORM and ORR messages, the placer
application ID in this field may not be the same as any sending and receiving
application on the network (as identified in the MSH segment).<br>
<i>ORC-2-placer order number</i> is the same as <i>OBR-2-placer order
number</i>.  If the placer order number is not present in the ORC, it must be
present in the associated OBR and vice versa.  If both fields, <i>ORC-2-placer
order number</i> and <i>OBR-2-placer order number,</i> are valued, they must
contain the same value.  When results are transmitted in an ORU message, an ORC
is not required, and the identifying placer order number <u>must</u> be present
in the OBR segments.<br>
These rules apply to the few other fields that are present in both ORC and OBR
for upward compatibility (e.g., quantity/timing, parent numbers, ordering
provider, and ordering call back numbers). </p>

<h4>
<A NAME="Heading44">7.3.1.3 Filler order number  (EI)   00217</A></h4>

<p><tt>Components:
 &lt;entity identifier (ST)&gt; ^ &lt;namespace ID (IS)&gt; ^ &lt;universal ID
(ST)&gt; ^ &lt;universal ID type (ID)&gt;</tt><br>
Definition:  This field is the order number associated with the filling
application.  It is a case of the Entity Identifier data type (Section 2.8.13,
"EI - Entity Identifier" ).  Its first component is a string that identifies an
order detail segment (e.g., OBR).  A limit of fifteen (15) characters is
suggested but not required.  It is assigned by the order filler (receiving)
application.  This string must uniquely identify the order (as specified in the
order detail segment) from other orders in a particular filling application
(e.g., clinical laboratory).  This uniqueness must persist over time.<br>
The second through fourth components contain the filler application ID, in the
form of the HD data type (see Section 2.8.18, "HD - hierarchic designator").
The second component is a user-defined coded value  that uniquely defines the
application from other applications on the network.  A limit of six (6)
characters is suggested but not required.  The second component of the filler
order number always identifies the actual filler of an order.<br>
A given institution or group of intercommunicating institutions should
establish a list of applications that may be potential placers and fillers of
orders and assign each a unique application ID.  The application ID list
becomes one of the institution's master dictionary lists that is documented in
Chapter 8.  Since third- party applications (those other than the placer and
filler of an order) can send and receive ORM and ORR messages, the filler
application ID in this field may not be the same as any sending and receiving
application on the network (as identified in the MSH segment).<br>
<i>ORC-3-filler order number</i> is the same as <i>OBR-3-filler order
number</i>.  If the filler order number is not present in the ORC, it must be
present in the associated OBR.  (This rule is the same for other identical
fields in the ORC and OBR and promotes upward and ASTM compatibility.)  This is
particularly important when results are transmitted in an ORU message.  In this
case, the ORC is not required and the identifying filler order number must be
present in the OBR segments. <br>
The <i>filler order number (OBR-3 or ORC-3)</i> also uniquely identifies an
order and its associated observations.  For example, suppose that an
institution collects observations from several ancillary applications into a
common database and this common database is queried by yet another application
for observations.  In this case, the filler order number and placer order
number transmitted by the common database application would be that of the
original filler and placer, respectively, rather than a new one assigned by the
common database application.  <br>
Similarly, if a third-party application, not the filler or placer, of an order
were authorized to modify the status of an order (say, cancel it), the
third-party application would send the filler an ORM message containing an ORC
segment with <i>ORC-1-order control</i> equal to "CA" and containing the
original placer order number and filler order number, rather than assign either
itself.</p>

<h4>
<A NAME="Heading45">7.3.1.4 Universal service ID  (CE)   00238</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^&lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field is the identifier code for the requested
observation/test/battery.  This can be based on local and/or "universal" codes.
We recommend the "universal" procedure identifier.  The structure of this CE
data type is described in the control section.</p>

<h4>
<A NAME="Heading46">7.3.1.5 Priority  (ID)   00239</A></h4>

<p>Definition:
 <b><i>This field has been retained for backward compatibility only</i></b>.
It is not used.  Previously priority (e.g., STAT, ASAP), but that information
is carried as the sixth component of <i>OBR-27-quantity/timing</i>.</p>

<h4>
<A NAME="Heading47">7.3.1.6 Requested date/time  (TS)   00240</A></h4>

<p>Definition:
 <b><i>This field has been retained for backward compatibility only</i></b>.
This is not used.  Previously requested date/time.  That information is now
carried in the fourth component of the <i>OBR-27-quantity/timing</i>.</p>

<h4>
<A NAME="Heading48">7.3.1.7 Observation date/time  (TS)   00241</A></h4>

<p>Definition:
 This field is the clinically relevant date/time of the observation.  In the
case of observations taken directly from a subject, it is the actual date and
time the observation was obtained.  In the case of a specimen-associated study,
this field shall represent the date and time the specimen was collected or
obtained.  (This is a results-only field except when the placer or a
third-party has already drawn the specimen.)  This field is conditionally
required. When the OBR is transmitted as part of a report message, the field
<b>must</b> be filled in. If it is transmitted as part of a request <b>and</b>
a sample has been sent along as part of the request, this field must be filled
in because this specimen time is the physiologically relevant date-time of the
observation.</p>

<h4>
<A NAME="Heading49">7.3.1.8 Observation end date/time  (TS)   00242</A></h4>

<p>Definition:
 This field is the end date and time of a study or timed specimen collection.
If an observation takes place over a substantial period of time, it will
indicate when the observation period ended.  For observations made at a point
in time, it will be null.  This is a results field except when the placer or a
party other than the filler has already drawn the specimen.</p>

<h4>
<A NAME="Heading50">7.3.1.9 Collection volume  (CQ)   00243</A></h4>

<p><tt>Components:
 &lt;quantity (NM)&gt; ^ &lt;units (CE)&gt;</tt><br>
<tt>Subcomponents of units: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt;
&amp; &lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier
(ST)&gt; &amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding
system (ST)&gt; </tt><br>
Definition:  For laboratory tests, the collection volume is the volume of a
specimen.  The default unit is ML.  Specifically, units should be expressed in
the ISO Standard unit abbreviations (ISO-2955,1977).  This is a results-only
field except when the placer or a party has already drawn the specimen.  (See
Chapter 7 for full details about units.)</p>

<h4>
<A NAME="Heading51">7.3.1.10 Collector identifier  (XCN)   00244</A></h4>

<p><tt>Components:
&lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type code (ID)&gt;
^ &lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID )&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  When a specimen is required for the study, this field will
identify the person, department, or facility that collected the specimen.
Either name or ID code, or both, may be present. </p>

<h4>
<A NAME="Heading52">7.3.1.11 Specimen action code  (ID)   00245</A></h4>

<p>Definition:
 This field is the action to be taken with respect to the specimens that
accompany or precede this order.  The purpose of this field is to further
qualify (when appropriate) the general action indicated by the order control
code contained in the accompanying ORC segment.  For example, when a new order
(ORC - "NW") is sent to the lab, this field would be used to tell the lab
whether or not to collect the specimen ("L" or "O").  Refer to <i>HL7 table
0065 - Specimen action code</i> for valid values.
</p>

<center>Table 0065 - Specimen action code
</center>
<TABLE BORDER><TR>
<TH >Value</p>
<BR></TH>
<TH >Description</p>
<BR></TH></TR>

<TR>
<TD >A</TD>
<TD >Add
ordered tests to the existing specimen</TD></TR>

<TR>
<TD >G</TD>
<TD >Generated
order; reflex order</TD></TR>

<TR>
<TD >L</TD>
<TD >Lab
to obtain specimen from patient</TD></TR>

<TR>
<TD >O</TD>
<TD >Specimen
obtained by service other than Lab</TD></TR>

<TR>
<TD >P</TD>
<TD >Pending
specimen; Order sent prior to delivery</TD></TR>

<TR>
<TD >R</TD>
<TD >Revised
order</TD></TR>

<TR>
<TD >S</TD>
<TD >Schedule
the tests specified below</TD></TR></TABLE>
<h4>
<A NAME="Heading53">7.3.1.12 Danger code  (CE)   00535</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field is the code and/or text indicating any known or
suspected patient or specimen hazards, e.g., patient with active tuberculosis
or blood from a hepatitis patient.  Either code and/or text may be absent.
However, the code is always placed in the first component position and any free
text in the second component.  Thus, free text without a code must be preceded
by a component delimiter. </p>

<h4>
<A NAME="Heading54">7.3.1.13 Relevant clinical information  (ST)   00247</A></h4>

<p>Definition:
 This field contains any additional clinical information about the patient or
specimen.  This field is used to report the suspected diagnosis and clinical
findings on requests for interpreted diagnostic studies.  Examples include
reporting the amount of inspired carbon dioxide for blood gasses, the point in
the menstrual cycle for cervical pap tests, and other conditions that influence
test interpretations.  For some orders this information may be sent on a more
structured form as a series of OBX segments (see Chapter 7) that immediately
follow the order segment. </p>

<h4>
<A NAME="Heading55">7.3.1.14 Specimen received date/time  (TS)   00248</A></h4>

<p>Definition:
 For observations requiring a specimen, the specimen received date/time is the
actual login time at the diagnostic service.  This field must contain a value
when the order is accompanied by a specimen, or when the observation required a
specimen <b>and</b> the message is a report.</p>

<h4>
<A NAME="Heading56">7.3.1.15 Specimen source  (CM)   00249</A></h4>

<p><tt>Components:
 &lt;specimen source name or code (CE)&gt; ^ &lt;additives (TX)&gt; ^
&lt;freetext (TX)&gt; ^ &lt;body site (CE)&gt; ^ &lt;site modifier (CE)&gt; ^
&lt;collection method modifier code (CE)&gt;</tt><br>
Subcomponents of specimen source name or doe: &lt;identifier (ST)&gt; &amp;
&lt;test (ST)&gt; &amp; &lt;name of coding system (ST)&gt; &amp; &lt;alternate
identifier (ST)&gt; &amp; &lt;alternate text (ST)&gt; &amp; &lt;name of
alternate coding system (ST)&gt; <br>
Subcomponents of body site: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt;
&amp; &lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier
(ST)&gt; &amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding
system (ST)&gt;<br>
Subcomponents of site modifier: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt;
&amp; &lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier
(ST)&gt; &amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding
system (ST)&gt;<br>
Subcomponents of collection method modifier code: &lt;identifier (ST)&gt; &amp;
&lt;test (ST)&gt; &amp; &lt;name of coding system (ST)&gt; &amp; &lt;alternate
identifier (ST)&gt; &amp; &lt;alternate text (ST)&gt; &amp; &lt;name of
alternate coding system (ST)&gt;<br>
Definition:  This field identifies the site where the specimen should be
obtained or where the service should be performed.  <br>
The first component contains the specimen source name or code (as a CE data
type component).  (Even in the case of observations whose name implies the
source, a source may be required, e.g., blood culture-heart blood.)  Refer
<i>to HL7 table 0070 - Source of specimen</i> for valid entries.<br>
The second component should include free text additives to the specimen such as
Heparin, EDTA, or Oxlate, when applicable.  <br>
The third is a free text component describing the method of collection when
that information is a part of the order.  When the method of collection is
logically an observation result, it should be included as a result segment.<br>
The fourth component specifies the body site from which the specimen was
obtained, and the fifth is the site modifier.  For example, the site could be
anticubital foss, and the site modifier "right."  The components of the CE
fields become subcomponents.  Refer to <i>HL7</i> <i>table  0163 -
Administrative site</i> for valid entries.</p>

<center>Table 0163 - Administrative site
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR align="left">
<TD align="left">BE</TD>
<TD align="left">Bilateral
Ears</TD>
<TD align="left">LVL</TD>
<TD align="left">Left
Vastus Lateralis</TD></TR>

<TR align="left">
<TD align="left">OU</TD>
<TD align="left">Bilateral
Eyes</TD>
<TD align="left">NB</TD>
<TD align="left">Nebulized</TD></TR>

<TR align="left">
<TD align="left">BN</TD>
<TD align="left">Bilateral
Nares</TD>
<TD align="left">PA</TD>
<TD align="left">Perianal</TD></TR>

<TR align="left">
<TD align="left">BU</TD>
<TD align="left">Buttock</TD>
<TD align="left">PERIN</TD>
<TD align="left">Perineal</TD></TR>

<TR align="left">
<TD align="left">CT</TD>
<TD align="left">Chest
Tube</TD>
<TD align="left">RA</TD>
<TD align="left">Right
Arm</TD></TR>

<TR align="left">
<TD align="left">LA</TD>
<TD align="left">Left
Arm</TD>
<TD align="left">RAC</TD>
<TD align="left">Right
Anterior Chest</TD></TR>

<TR align="left">
<TD align="left">LAC</TD>
<TD align="left">Left
Anterior Chest</TD>
<TD align="left">RACF</TD>
<TD align="left">Right
Antecubital Fossa</TD></TR>

<TR align="left">
<TD align="left">LACF</TD>
<TD align="left">Left
Antecubital Fossa</TD>
<TD align="left">RD</TD>
<TD align="left">Right
Deltoid</TD></TR>

<TR align="left">
<TD align="left">LD</TD>
<TD align="left">Left
Deltoid</TD>
<TD align="left">RE</TD>
<TD align="left">Right
Ear</TD></TR>

<TR align="left">
<TD align="left">LE</TD>
<TD align="left">Left
Ear</TD>
<TD align="left">REJ</TD>
<TD align="left">Right
External Jugular</TD></TR>

<TR align="left">
<TD align="left">LEJ</TD>
<TD align="left">Left
External Jugular </TD>
<TD align="left">OD</TD>
<TD align="left">Right
Eye</TD></TR>

<TR align="left">
<TD align="left">OS</TD>
<TD align="left">Left
Eye</TD>
<TD align="left">RF</TD>
<TD align="left">Right
Foot</TD></TR>

<TR align="left">
<TD align="left">LF</TD>
<TD align="left">Left
Foot</TD>
<TD align="left">RG</TD>
<TD align="left">Right
Gluteus Medius</TD></TR>

<TR align="left">
<TD align="left">LG</TD>
<TD align="left">Left
Gluteus Medius</TD>
<TD align="left">RH</TD>
<TD align="left">Right
Hand</TD></TR>

<TR align="left">
<TD align="left">LH</TD>
<TD align="left">Left
Hand</TD>
<TD align="left">RIJ</TD>
<TD align="left">Right
Internal Jugular</TD></TR>

<TR align="left">
<TD align="left">LIJ</TD>
<TD align="left">Left
Internal Jugular</TD>
<TD align="left">RLAQ</TD>
<TD align="left">Rt
Lower Abd Quadrant</TD></TR>

<TR align="left">
<TD align="left">LLAQ</TD>
<TD align="left">Left
Lower Abd Quadrant</TD>
<TD align="left">RLFA</TD>
<TD align="left">Right
Lower Forearm</TD></TR>

<TR align="left">
<TD align="left">LLFA</TD>
<TD align="left">Left
Lower Forearm</TD>
<TD align="left">RMFA</TD>
<TD align="left">Right
Mid Forearm</TD></TR>

<TR align="left">
<TD align="left">LMFA</TD>
<TD align="left">Left
Mid Forearm</TD>
<TD align="left">RN</TD>
<TD align="left">Right
Naris</TD></TR>

<TR align="left">
<TD align="left">LN</TD>
<TD align="left">Left
Naris</TD>
<TD align="left">RPC</TD>
<TD align="left">Right
Posterior Chest</TD></TR>

<TR align="left">
<TD align="left">LPC</TD>
<TD align="left">Left
Posterior Chest</TD>
<TD align="left">RSC</TD>
<TD align="left">Right
Subclavian</TD></TR>

<TR align="left">
<TD align="left">LSC</TD>
<TD align="left">Left
Subclavian</TD>
<TD align="left">RT</TD>
<TD align="left">Right
Thigh</TD></TR>

<TR align="left">
<TD align="left">LT</TD>
<TD align="left">Left
Thigh</TD>
<TD align="left">RUA</TD>
<TD align="left">Right
Upper Arm</TD></TR>

<TR align="left">
<TD align="left">LUA</TD>
<TD align="left">Left
Upper Arm</TD>
<TD align="left">RUAQ</TD>
<TD align="left">Right
Upper Abd Quadrant</TD></TR>

<TR align="left">
<TD align="left">LUAQ</p>
<BR></TD>
<TD align="left">Left
Upper Abd Quadrant</TD>
<TD align="left">RUFA</TD>
<TD align="left">Right
Upper Forearm</TD></TR>

<TR align="left">
<TD align="left">LUFA</TD>
<TD align="left">Left
Upper Forearm</TD>
<TD align="left">RVL</TD>
<TD align="left">Right
Vastus Lateralis</TD></TR>

<TR align="left">
<TD align="left">LVG</TD>
<TD align="left">Left
Ventragluteal</TD>
<TD align="left">RVG</TD>
<TD align="left">Right
Ventragluteal</TD></TR></TABLE><p>The
fifth component indicates whether the specimen is frozen as part of the
collection method.  Suggested values are F (Frozen); R (Refrigerated).  If the
component is blank, the specimen is assumed to be at room temperature.
</p>

<center>Table 0070 - Specimen source codes
</center>
<TABLE BORDER><TR align="left">
<TD align="left">Value</TD>
<TD align="left">Description</TD>
<TD align="left">Value</TD>
<TD align="left">Description</TD>
<TD align="left">Value</TD>
<TD align="left">Description</TD></TR>

<TR align="left">
<TD align="left">ABS</TD>
<TD align="left">Abscess</TD>
<TD align="left">FLU</TD>
<TD align="left">Body
fluid, unsp</TD>
<TD align="left">SER</TD>
<TD align="left">Serum</TD></TR>

<TR align="left">
<TD align="left">AMN</TD>
<TD align="left">Amniotic
fluid</TD>
<TD align="left">GAS</TD>
<TD align="left">Gas</TD>
<TD align="left">SKN</TD>
<TD align="left">Skin</TD></TR>

<TR align="left">
<TD align="left">ASP</TD>
<TD align="left">Aspirate</TD>
<TD align="left">GAST</TD>
<TD align="left">Gastric
fluid/contents</TD>
<TD align="left">SKM</TD>
<TD align="left">Skeletal
muscle</TD></TR>

<TR align="left">
<TD align="left">BPH</TD>
<TD align="left">Basophils</TD>
<TD align="left">GEN</TD>
<TD align="left">Genital</TD>
<TD align="left">SPRM</TD>
<TD align="left">Spermatozoa</TD></TR>

<TR align="left">
<TD align="left">BIFL</TD>
<TD align="left">Bile
fluid</TD>
<TD align="left">GENC</TD>
<TD align="left">Genital
cervix</TD>
<TD align="left">SPT</TD>
<TD align="left">Sputum</TD></TR>

<TR align="left">
<TD align="left">BLDA</TD>
<TD align="left">Blood
 arterial</TD>
<TD align="left">GENL</TD>
<TD align="left">Genital
lochia</TD>
<TD align="left">SPTC</TD>
<TD align="left">Sputum
- coughed</TD></TR>

<TR align="left">
<TD align="left">BBL</TD>
<TD align="left">Blood
bag</TD>
<TD align="left">GENV</TD>
<TD align="left">Genital
vaginal</TD>
<TD align="left">SPTT</TD>
<TD align="left">Sputum
- tracheal aspirate</TD></TR>

<TR align="left">
<TD align="left">BLDC</TD>
<TD align="left">Blood
 capillary</TD>
<TD align="left">HAR</TD>
<TD align="left">Hair</TD>
<TD align="left">STON</TD>
<TD align="left">Stone
(use CALC)</TD></TR>

<TR align="left">
<TD align="left">BPU</TD>
<TD align="left">Blood
product unit</TD>
<TD align="left">IHG</TD>
<TD align="left">Inhaled
Gas</TD>
<TD align="left">STL</TD>
<TD align="left">Stool
= Fecal</TD></TR>

<TR align="left">
<TD align="left">BLDV</TD>
<TD align="left">Blood
 venous</TD>
<TD align="left">IT</TD>
<TD align="left">Intubation
tube</TD>
<TD align="left">SWT</TD>
<TD align="left">Sweat</TD></TR>

<TR align="left">
<TD align="left">BON</TD>
<TD align="left">Bone</TD>
<TD align="left">ISLT</TD>
<TD align="left">Isolate</TD>
<TD align="left">SNV</TD>
<TD align="left">Synovial
fluid (Joint fluid)</TD></TR>

<TR align="left">
<TD align="left">BRTH</TD>
<TD align="left">Breath
(use EXHLD)</TD>
<TD align="left">LAM</TD>
<TD align="left">Lamella</TD>
<TD align="left">TEAR</TD>
<TD align="left">Tears</TD></TR>

<TR align="left">
<TD align="left">BRO</TD>
<TD align="left">Bronchial</TD>
<TD align="left">WBC</TD>
<TD align="left">Leukocytes</TD>
<TD align="left">THRT</TD>
<TD align="left">Throat</TD></TR>

<TR align="left">
<TD align="left">BRN</TD>
<TD align="left">Burn</TD>
<TD align="left">LN</TD>
<TD align="left">Line</TD>
<TD align="left">THRB</TD>
<TD align="left">Thrombocyte
(platelet)</TD></TR>

<TR align="left">
<TD align="left">CALC</TD>
<TD align="left">Calculus
(=Stone)</TD>
<TD align="left">LNA</TD>
<TD align="left">Line
arterial</TD>
<TD align="left">TISS</TD>
<TD align="left">Tissue</TD></TR>

<TR align="left">
<TD align="left">CDM</TD>
<TD align="left">Cardiac
muscle</TD>
<TD align="left">LNV</TD>
<TD align="left">Line
venous</TD>
<TD align="left">TISG</TD>
<TD align="left">Tissue
gall bladder</TD></TR>

<TR align="left">
<TD align="left">CNL</TD>
<TD align="left">Cannula</TD>
<TD align="left">LIQ</TD>
<TD align="left">Liquid
NOS</TD>
<TD align="left">TLGI</TD>
<TD align="left">Tissue
large intestine</TD></TR>

<TR align="left">
<TD align="left">CTP</TD>
<TD align="left">Catheter
tip</TD>
<TD align="left">LYM</TD>
<TD align="left">Lymphocytes</TD>
<TD align="left">TLNG</TD>
<TD align="left">Tissue
lung</TD></TR>

<TR align="left">
<TD align="left">CSF</TD>
<TD align="left">Cerebral
spinal fluid</TD>
<TD align="left">MAC</TD>
<TD align="left">Macrophages</TD>
<TD align="left">TISPL</TD>
<TD align="left">Tissue
placenta
</p>
<BR></TD></TR>

<TR align="left">
<TD align="left">CVM</TD>
<TD align="left">Cervical
mucus</TD>
<TD align="left">MAR</TD>
<TD align="left">Marrow</TD>
<TD align="left">TSMI</TD>
<TD align="left">Tissue
small intestine</TD></TR>

<TR align="left">
<TD align="left">CVX</TD>
<TD align="left">Cervix</TD>
<TD align="left">MEC</TD>
<TD align="left">Meconium</TD>
<TD align="left">TISU</TD>
<TD align="left">Tissue
ulcer</TD></TR>

<TR align="left">
<TD align="left">COL</TD>
<TD align="left">Colostrum</TD>
<TD align="left">MBLD</TD>
<TD align="left">Menstrual
blood</TD>
<TD align="left">TUB</TD>
<TD align="left">Tube
NOS</TD></TR>

<TR align="left">
<TD align="left">CBLD</TD>
<TD align="left">Cord
blood</TD>
<TD align="left">MLK</TD>
<TD align="left">Milk</TD>
<TD align="left">ULC</TD>
<TD align="left">Ulcer</TD></TR>

<TR align="left">
<TD align="left">CNJT</TD>
<TD align="left">Conjunctiva</TD>
<TD align="left">MILK</TD>
<TD align="left">Breast
milk</TD>
<TD align="left">UMB</TD>
<TD align="left">Umbilical
blood</TD></TR>

<TR align="left">
<TD align="left">CUR</TD>
<TD align="left">Curettage</TD>
<TD align="left">NAIL</TD>
<TD align="left">Nail</TD>
<TD align="left">UMED</TD>
<TD align="left">Unknown
medicine</TD></TR>

<TR align="left">
<TD align="left">CYST</TD>
<TD align="left">Cyst</TD>
<TD align="left">NOS</TD>
<TD align="left">Nose
(nasal passage)</TD>
<TD align="left">URTH</TD>
<TD align="left">Urethra</TD></TR>

<TR align="left">
<TD align="left">DIAF</TD>
<TD align="left">Dialysis
fluid</TD>
<TD align="left">ORH</TD>
<TD align="left">Other</TD>
<TD align="left">UR</TD>
<TD align="left">Urine</TD></TR>

<TR align="left">
<TD align="left">DOSE</TD>
<TD align="left">Dose
med or substance </TD>
<TD align="left">PAFL</TD>
<TD align="left">Pancreatic
fluid</TD>
<TD align="left">URC</TD>
<TD align="left">Urine
clean catch</TD></TR>

<TR align="left">
<TD align="left">DRN</TD>
<TD align="left">Drain</TD>
<TD align="left">PAT</TD>
<TD align="left">Patient</TD>
<TD align="left">URT</TD>
<TD align="left">Urine
catheter</TD></TR>

<TR align="left">
<TD align="left">DUFL</TD>
<TD align="left">Duodenal
fluid</TD>
<TD align="left">PRT</TD>
<TD align="left">Peritoneal
fluid /ascites</TD>
<TD align="left">URNS</TD>
<TD align="left">Urine
sediment</TD></TR>

<TR align="left">
<TD align="left">EAR</TD>
<TD align="left">Ear</TD>
<TD align="left">PLC</TD>
<TD align="left">Placenta</TD>
<TD align="left">USUB</TD>
<TD align="left">Unknown
substance</TD></TR>

<TR align="left">
<TD align="left">EARW</TD>
<TD align="left">Ear
wax (cerumen)</TD>
<TD align="left">PLAS</TD>
<TD align="left">Plasma</TD>
<TD align="left">VOM</TD>
<TD align="left">Vomitus</TD></TR>

<TR align="left">
<TD align="left">ELT</TD>
<TD align="left">Electrode</TD>
<TD align="left">PLB</TD>
<TD align="left">Plasma
bag</TD>
<TD align="left">BLD</TD>
<TD align="left">Whole
blood </TD></TR>

<TR align="left">
<TD align="left">ENDC</TD>
<TD align="left">Endocardium</TD>
<TD align="left">PLR</TD>
<TD align="left">Pleural
fluid (thoracentesis fld)</TD>
<TD align="left">BDY</TD>
<TD align="left">Whole
body</TD></TR>

<TR align="left">
<TD align="left">ENDM</TD>
<TD align="left">Endometrium</TD>
<TD align="left">PMN</TD>
<TD align="left">Polymorphonuclear
neutrophils</TD>
<TD align="left">WAT</TD>
<TD align="left">Water</TD></TR>

<TR align="left">
<TD align="left">EOS</TD>
<TD align="left">Eosinophils</TD>
<TD align="left">PPP</TD>
<TD align="left">Patelet
poor plasma</TD>
<TD align="left">WICK</TD>
<TD align="left">Wick</TD></TR>

<TR align="left">
<TD align="left">RBC</TD>
<TD align="left">Erythrocytes</TD>
<TD align="left">PRP</TD>
<TD align="left">Platelet
rich plasma</TD>
<TD align="left">WND</TD>
<TD align="left">Wound</TD></TR>

<TR align="left">
<TD align="left">EYE</TD>
<TD align="left">Eye</TD>
<TD align="left">PUS</TD>
<TD align="left">Pus</TD>
<TD align="left">WNDA</TD>
<TD align="left">Wound
abscess</TD></TR>

<TR align="left">
<TD align="left">EXHLD</TD>
<TD align="left">Exhaled
gas (=breath)</TD>
<TD align="left">RT</TD>
<TD align="left">Route
of medicine</TD>
<TD align="left">WNDE</TD>
<TD align="left">Wound
exudate</TD></TR>

<TR align="left">
<TD align="left">FIB</TD>
<TD align="left">Fibroblasts</TD>
<TD align="left">SAL</TD>
<TD align="left">Saliva</TD>
<TD align="left">WNDD</TD>
<TD align="left">Wound
drainage</TD></TR>

<TR align="left">
<TD align="left">FLT</TD>
<TD align="left">Filter</TD>
<TD align="left">SEM</TD>
<TD align="left">Seminal
fluid</TD>
<TD align="left">XXX</TD>
<TD align="left">To
be specified in another part of the message</TD></TR>

<TR align="left">
<TD align="left">FIST</TD>
<TD align="left">Fistula</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR></TABLE>
<h4>
<A NAME="Heading57">7.3.1.16 Ordering provider  (XCN)   00226</A></h4>

<p><tt>Components:
&lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type code(ID)&gt;
^ &lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID )&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  This field identifies the provider who ordered the test.  Either
the ID code or the name, or both, may be present.  This is the same as
<i>ORC-12-ordering provider</i>. </p>

<h4>
<A NAME="Heading58">7.3.1.17 Order callback phone number  (XTN)   00250</A></h4>

<p><tt>Components:
 [<b>N</b>NN] [(999)]999-9999 [X99999] [B99999] [C any text] ^
&lt;telecommunication use code (ID)&gt; ^ &lt;telecommunication equipment type
(ID)&gt; ^ &lt;email address (ST)&gt; ^ &lt;country code (NM)&gt; ^
&lt;area/city code (NM)&gt; ^ &lt;phone number (NM)&gt; ^ &lt;extension
(NM)&gt; ^ &lt;any text (ST)&gt;</tt><br>
Definition:  This field is the telephone number for reporting a status or a
result using the standard format with extension and/or beeper number when
applicable.</p>

<h4>
<A NAME="Heading59">7.3.1.18 Placer field #1  (ST)   00251</A></h4>

<p>Definition:
 This field is user field #1.  Text sent by the placer will be returned with
the results. </p>

<h4>
<A NAME="Heading60">7.3.1.19 Placer field #2  (ST)   00252</A></h4>

<p>Definition:
 This field is similar to placer field #1. </p>

<h4>
<A NAME="Heading61">7.3.1.20 Filler field #1  (ST)   00253</A></h4>

<p>Definition:
 This field is definable for any use by the filler (diagnostic service). </p>

<h4>
<A NAME="Heading62">7.3.1.21 Filler field #2  (ST)   00254</A></h4>

<p>Definition:
 This field is similar to filler field #1. </p>

<h4>
<A NAME="Heading63">7.3.1.22 Results rpt/status chng - date/time  (TS)   00255</A></h4>

<p>Definition:
 This field specifies the date/time results reported or status changed.  This
field is used to indicate the date and time that the results are composed into
a report and released, or that a status, as defined in <i>ORC-5-order
status</i>, is entered or changed.  (This is a results field only.)  When other
applications (such as office or clinical database applications) query the
laboratory application for untransmitted results, the information in this field
may be used to control processing on the communications link.  Usually, the
ordering service would want only those results for which the reporting
date/time is greater than the date/time the inquiring application last received
results. </p>

<h4>
<A NAME="Heading64">7.3.1.23 Charge to practice  (CM)   00256</A></h4>

<p><tt>Components:
 &lt;dollar amount (MO)&gt; ^ &lt;charge code (CE)&gt;</tt><br>
Subcomponents of dollar amount:  &lt;quantity (NM)&gt; &amp; &lt;denomination
(ID)&gt;<br>
Subcomponents of charge code: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt;
&amp; &lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier
(ST)&gt; &amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding
system (ST)&gt;<br>
Definition:  This field is the charge to the ordering entity for the studies
performed when applicable. The first component is a dollar amount when known by
the filler.  The second is a charge code when known by the filler (results
only). </p>

<h4>
<A NAME="Heading65">7.3.1.24 Diagnostic serv sect ID  (ID)   00257</A></h4>

<p>Definition:
 This field is the section of the diagnostic service where the observation was
performed.  If the study was performed by an outside service, the
identification of that service should be recorded here.  Refer to <i>HL7</i>
<i>table 0074 - Diagnostic service section ID</i> for valid entries. 
</p>

<center>Table 0074 - Diagnostic service section ID
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >AU</TD>
<TD >Audiology</TD>
<TD >OUS</TD>
<TD >OB
Ultrasound</TD></TR>

<TR>
<TD >BG</TD>
<TD >Blood
gases</TD>
<TD >OT</TD>
<TD >Occupational
Therapy</TD></TR>

<TR>
<TD >BLB</TD>
<TD >Blood
bank</TD>
<TD >OTH</TD>
<TD >Other</TD></TR>

<TR>
<TD >CUS</TD>
<TD >Cardiac
Ultrasound</TD>
<TD >OSL</TD>
<TD >Outside
Lab</TD></TR>

<TR>
<TD >CTH</TD>
<TD >Cardiac
catheterization</TD>
<TD >PHR</TD>
<TD >Pharmacy</TD></TR>

<TR>
<TD >CT</TD>
<TD >CAT
scan</TD>
<TD >PT</TD>
<TD >Physical
Therapy</TD></TR>

<TR>
<TD >CH</TD>
<TD >Chemistry</TD>
<TD >PHY</TD>
<TD >Physician
(Hx. Dx, admission note, etc.l)</TD></TR>

<TR>
<TD >CP</TD>
<TD >Cytopathology</TD>
<TD >PF</TD>
<TD >Pulmonary
function</TD></TR>

<TR>
<TD >EC</TD>
<TD >Electrocardiac
(e.g., EKG,  EEC, Holter)</TD>
<TD >RAD</TD>
<TD >Radiology</TD></TR>

<TR>
<TD >EN</TD>
<TD >Electroneuro
(EEG, EMG,EP,PSG)</TD>
<TD >RX</TD>
<TD >Radiograph</TD></TR>

<TR>
<TD >HM</TD>
<TD >Hematology</TD>
<TD >RUS</TD>
<TD >Radiology
ultrasound</TD></TR>

<TR>
<TD >ICU</TD>
<TD >Bedside
ICU Monitoring</TD>
<TD >RC</TD>
<TD >Respiratory
Care (therapy)</TD></TR>

<TR>
<TD >IMM</TD>
<TD >Immunology</TD>
<TD >RT</TD>
<TD >Radiation
therapy</TD></TR>

<TR>
<TD >LAB</TD>
<TD >Laboratory</TD>
<TD >SR</TD>
<TD >Serology</TD></TR>

<TR>
<TD >MB</TD>
<TD >Microbiology</TD>
<TD >SP</TD>
<TD >Surgical
Pathology</TD></TR>

<TR>
<TD >MCB</TD>
<TD >Mycobacteriology</TD>
<TD >TX</TD>
<TD >Toxicology</TD></TR>

<TR>
<TD >MYC</TD>
<TD >Mycology</TD>
<TD >VUS</TD>
<TD >Vascular
Ultrasound</TD></TR>

<TR>
<TD >NMS</TD>
<TD >Nuclear
medicine scan</TD>
<TD >VR</TD>
<TD >Virology</TD></TR>

<TR>
<TD >NMR</TD>
<TD >Nuclear
magnetic resonance</TD>
<TD >XRC</TD>
<TD >Cineradiograph</TD></TR>

<TR>
<TD >NRS</TD>
<TD >Nursing
service measures</TD>
<TD><BR></TD>
<TD><BR></TD></TR></TABLE>
<h4>
<A NAME="Heading66">7.3.1.25 Result status  (ID)   00258</A></h4>

<p>Definition:
 This field is the status of results for this order.  This conditional field is
required whenever the OBR is contained in a report message.  It is not required
as part of an initial order.<br>
There are two methods of sending status information.  If the status is that of
the entire order, use <i>ORC-15-order effective date/time</i> and
<i>ORC-5-order status</i>.  If the status pertains to the order detail segment,
use <i>OBR-25-result status</i> and <i>OBR-22-results report/status change -
date/time</i>.  If both are present, the OBR values override the ORC values.
<br>
This field would typically be used in a response to an order status query where
the level of detail requested does not include the OBX segments.  When the
individual status of each result is necessary, <i>OBX-11-observ result
status</i> may be used.  Refer to <i>HL7</i> <i>table 0123 - Result status</i>
for valid entries. 
</p>

<center>Table 0123 - Result status</center>
<TABLE BORDER><TR>
<TH >Value</p><BR></TH>
<TH >Description</p><BR></TH>
<TH >Value</p><BR></TH>
<TH >Description</p><BR></TH></TR>

<TR>
<TD >O</TD>
<TD >Order received; specimen not yet received</TD>
<TD >R</TD>
<TD >Results stored; not yet verified</TD></TR>

<TR>
<TD >I</TD>
<TD >No results available; specimen received, procedure incomplete</TD>
<TD >F</TD>
<TD >Final
results; results stored and verified.  Can only be changed with a corrected
result.</TD></TR>

<TR>
<TD >S</TD>
<TD >No results available; procedure scheduled, but not done</TD>
<TD >X</TD>
<TD >No results available; Order canceled.</TD></TR>

<TR>
<TD >A</TD>
<TD >Some, but not all, results available</TD>
<TD >Y</TD>
<TD >No order on record for this test.  (Used only on queries)</TD></TR>

<TR>
<TD >P</TD>
<TD >Preliminary:
A verified early result is available, final results not yet obtained</TD>
<TD >Z</TD>
<TD >No
record of this patient. (Used only on queries)</TD></TR>

<TR>
<TD >C</TD>
<TD >Correction to results</TD>
<TD><BR></TD>
<TD><BR></TD></TR></TABLE>
<h4>
<A NAME="Heading67">7.3.1.26 Parent result  (CM)   00259</A></h4>

<p><tt>Components:
 &lt;OBX-3-observation identifier of parent result (CE)&gt; ^ &lt;OBX-4-sub-ID
of parent result (ST)&gt; ^ &lt;part of OBX-5 observation result from parent
(TX) see discussion&gt;</tt><br>
Subcomponents of OBX-3-observation identifier or parent result: &lt;identifier
(ST)&gt; &amp; &lt;test (ST)&gt; &amp; &lt;name of coding system (ST)&gt; &amp;
&lt;alternate identifier (ST)&gt; &amp; &lt;alternate text (ST)&gt; &amp;
&lt;name of alternate coding system (ST)&gt;<br>
Definition:  This field is defined to make it available for other types of
linkages (e.g., toxicology).  This important information, together with the
information in <i>OBR-29-parent number,</i> uniquely identifies the parent
result's OBX segment related to this order.  The value of this OBX segment in
the parent result is the organism or chemical species about which this battery
reports.  For example, if the current battery is an antimicrobial
susceptibility, the parent result's identified OBX contains a result which
identifies the organism on which the susceptibility were run.  This indirect
linkage is preferred because the name of the organism in the parent result may
undergo several preliminary values prior to finalization.<br>
The third component may be used to record the name of the microorganism
identified by the parent result directly.  The organism in this case should be
identified exactly as it is in the parent culture.<br>
We emphasize that this field does not take the entire result field from the
parent.  It is meant only for the text name of the organism or chemical
subspecies identified.  This field is included only to provide a method for
linking back to the parent result for those systems which could not generate
unambiguous Observation IDs and sub-IDs.<br>
This field is present only when the parent result is identified by
<i>OBR-29-parent number</i> and the parent spawn child orders for each of many
results.  (See Chapter 7 for more details about this linkage.)<br>
A second mode of conveying this information is to use a standard observation
result segment (OBX).  If more than one organism is present, <i>OBX-4-subID</i>
is used to distinguish them.  In this case, the first OBX with subID N will
contain a value identifying the Nth microorganism, and each additional OBX with
subID N will contain susceptibility values for a given antimicrobial test on
this organism.</p>

<h4>
<A NAME="Heading68">7.3.1.27 Quantity/timing  (TQ)   00221</A></h4>

<p><tt>Components:
 &lt;quantity (CQ)&gt; ^ &lt;interval (CM)&gt; ^ &lt;duration&gt; ^ &lt;start
date/time (TS)&gt; ^ &lt;end date/time (TS)&gt; ^ &lt;priority (ID)&gt; ^
&lt;condition (ST)&gt; ^ &lt;text (TX)&gt; ^ &lt;conjunction (ID)&gt; ^
&lt;order sequencing&gt;</tt><br>
Definition: This field contains information about how many services to perform
at one service time and how often the service times are repeated, and to fix
duration of the request.  See Section 4.4, "Quantity/Timing (TQ) Definition."</p>

<h4>
<A NAME="Heading69">7.3.1.28 Result copies to  (XCN)   00260</A></h4>

<p><tt>Components:
&lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type code(ID)&gt;
^ &lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID )&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  This field is the people who are to receive copies of the results.
By local convention, either the ID number or the name may be absent.</p>

<h4>
<A NAME="Heading70">7.3.1.29 Parent   (CM)   00261</A></h4>

<p><tt>Components:
 &lt;parent's placer order number (EI)&gt; ^ &lt;parent's filler order number
(EI)&gt;</tt><br>
Subcomponents of parent's placer order number:  &lt;entity identifier (ST)&gt;
&amp; &lt;namespace ID (IS)&gt; &amp; &lt;universal ID (ST)&gt; &amp;
&lt;universal ID type (IS)&gt;<br>
Subcomponents of parent's filler order number:  &lt;entity identifier (ST)&gt;
&amp; &lt; &lt;namespace ID (IS)&gt; &amp; &lt;universal ID (ST)&gt; &amp;
&lt;universal ID type (IS)&gt;<br>
Definition:  This field is identical to <i>ORC-8-parent</i>.  This field
relates a child to its parent when a parent/child relationship exists.  For
example, observations that are spawned by previous observations, e.g.,
antimicrobial susceptibilities spawned by blood cultures, need to record the
parent (blood culture) filler order number here.  The parent/child mechanism is
described under the order control field notes (see Segment ORC field notes in
Section 4.3.1.1.1, "Table notes for order control codes of ORC."  It is
required when the order is a child.  <br>
Parent is a two-component field.  The first component contains the parent's
placer order number.  The second component is optional and contains the
parent's filler order number.  The components of the placer order number and
the filler order number are transmitted in subcomponents of the two components
of this field. </p>

<h4>
<A NAME="Heading71">7.3.1.30 Transportation mode  (ID)   00262</A></h4>

<p>Definition:
 This field identifies how (or whether) to transport a patient, when applicable.  Refer to <i>HL7</i> <i>table 0124 - Transportation mode</i> for valid codes.  
</p>

<center>Table 0124 - Transportation mode </center>
<TABLE BORDER><TR>
<TH >Value</TH>
<TH >Description</TH></TR>

<TR>
<TD >CART</TD>
<TD >Cart - patient travels on cart or gurney</TD></TR>

<TR>
<TD >PORT</TD>
<TD >The examining device goes to patient's location</TD></TR>

<TR>
<TD >WALK</TD>
<TD >Patient walks to diagnostic service</TD></TR>

<TR>
<TD >WHLC</TD>
<TD >Wheelchair</TD></TR></TABLE>
<h4>
<A NAME="Heading72">7.3.1.31 Reason for study  (CE)   00263</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field is the code or text using the conventions for coded
fields given in Chapter 2, Control/Query.  This is required for some studies to
obtain proper reimbursement. </p>

<h4>
<A NAME="Heading73">7.3.1.32 Principal result interpreter  ( CM)   00264</A></h4>

<p><tt>Components:
&lt;name (CN)&gt; ^ &lt;start date/time (TS)&gt; ^ &lt;end date/time (TS)&gt; ^
&lt;point of care (IS)&gt; ^ &lt;room (IS)&gt; ^ &lt;bed (IS)&gt; ^
&lt;facility (HD)&gt; ^ &lt;location status (IS)&gt; ^ &lt;patient location
type (IS)&gt; ^ &lt;building (IS)&gt; ^ &lt;floor (IS)&gt;</tt><br>
Subcomponents of name :  &lt;ID number (ST)&gt; &amp; &lt;family name (ST)&gt;
&amp; &lt;given name (ST)&gt; &amp; &lt;middle initial or name (ST)&gt; &amp;
&lt;suffix (e.g., JR. III) (ST)&gt; &amp; &lt;prefix (e.g., DR)&gt; &amp;
&lt;degree (e.g., MD) (ST)&gt; &amp; &lt;source table (IS)&gt; &amp;
&lt;assigning authority (HD)&gt;<br>
Subcomponents of facility:  &lt;namespace ID (IS)&gt; &amp; &lt;universal ID
(ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition: This field identifies the physician or other clinician who
interpreted the observation and is responsible for the report content.</p>

<h4>
<A NAME="Heading74">7.3.1.33 Assistant result interpreter  ( CM)   00265</A></h4>

<p><tt>Components:
&lt;name (CN)&gt; ^ &lt;start date/time (TS)&gt; ^ &lt;end date/time (TS)&gt; ^
&lt;point of care (IS)&gt; ^ &lt;room (IS)&gt; ^ &lt;bed (IS)&gt; ^
&lt;facility (HD)&gt; ^ &lt;location status (IS)&gt; ^ &lt;patient location
type (IS)&gt; ^ &lt;building (IS)&gt; ^ &lt;floor (IS)&gt;</tt><br>
Subcomponents of name :  &lt;ID number (ST)&gt; &amp; &lt;family name (ST)&gt;
&amp; &lt;given name (ST)&gt; &amp; &lt;middle initial or name (ST)&gt; &amp;
&lt;suffix (e.g., JR. III) (ST)&gt; &amp; &lt;prefix (e.g., DR)&gt; &amp;
&lt;degree (e.g., MD) (ST)&gt; &amp; &lt;source table (IS)&gt; &amp;
&lt;assigning authority (HD)&gt;<br>
Subcomponents of facility:  &lt;namespace ID (IS)&gt; &amp; &lt;universal ID
(ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  This field identifies the clinical observer who assisted with the
interpretation of this study.</p>

<h4>
<A NAME="Heading75">7.3.1.34 Technician  ( CM)   00266</A></h4>

<p><tt>Components:
&lt;name (CN)&gt; ^ &lt;start date/time (TS)&gt; ^ &lt;end date/time (TS)&gt; ^
&lt;point of care (IS)&gt; ^ &lt;room (IS)&gt; ^ &lt;bed (IS)&gt; ^
&lt;facility (HD)&gt; ^ &lt;location status (IS)&gt; ^ &lt;patient location
type (IS)&gt; ^ &lt;building (IS)&gt; ^ &lt;floor (IS)&gt;</tt><br>
Subcomponents of name :  &lt;ID number (ST)&gt; &amp; &lt;family name (ST)&gt;
&amp; &lt;given name (ST)&gt; &amp; &lt;middle initial or name (ST)&gt; &amp;
&lt;suffix (e.g., JR. III) (ST)&gt; &amp; &lt;prefix (e.g., DR)&gt; &amp;
&lt;degree (e.g., MD) (ST)&gt; &amp; &lt;source table (IS)&gt; &amp;
&lt;assigning authority (HD)&gt;<br>
Subcomponents of facility:  &lt;namespace ID (IS)&gt; &amp; &lt;universal ID
(ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  This field identifies the performing technician. </p>

<h4>
<A NAME="Heading76">7.3.1.35 Transcriptionist  ( CM)   00267</A></h4>

<p><tt>Components:
&lt;name (CN)&gt; ^ &lt;start date/time (TS)&gt; ^ &lt;end date/time (TS)&gt; ^
&lt;point of care (IS)&gt; ^ &lt;room (IS)&gt; ^ &lt;bed (IS)&gt; ^
&lt;facility (HD)&gt; ^ &lt;location status (IS)&gt; ^ &lt;patient location
type (IS)&gt; ^ &lt;building (IS)&gt; ^ &lt;floor (IS)&gt;</tt><br>
Subcomponents of name :  &lt;ID number (ST)&gt; &amp; &lt;family name (ST)&gt;
&amp; &lt;given name (ST)&gt; &amp; &lt;middle initial or name (ST)&gt; &amp;
&lt;suffix (e.g., JR. III) (ST)&gt; &amp; &lt;prefix (e.g., DR)&gt; &amp;
&lt;degree (e.g., MD) (ST)&gt; &amp; &lt;source table (IS)&gt; &amp;
&lt;assigning authority (HD)&gt;<br>
Subcomponents of facility:  &lt;namespace ID (IS)&gt; &amp; &lt;universal ID
(ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  This field identifies the report transcriber.  </p>

<h4>
<A NAME="Heading77">7.3.1.36 Scheduled - date/time  (TS)   00268</A></h4>

<p>Definition:
This field is the date/time the filler scheduled an observation, when
applicable (e.g., action code in <i>OBR-11-specimen action code</i>  = "S").
This is a result of a request to schedule a particular test and provides a way
to inform the Placer of the date/time a study is scheduled (result only). </p>

<h4>
<A NAME="Heading78">7.3.1.37 Number of sample containers  (NM)   01028</A></h4>

<p>Definition:
This field identifies the number of containers for a given sample.  For sample
receipt verification purposes; may be different from the total number of
samples which accompany the order.</p>

<h4>
<A NAME="Heading79">7.3.1.38 Transport logistics of collected sample  (CE)   01029</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field is the means by which a sample reaches the diagnostic
service provider.  This information is to aid the lab in scheduling or
interpretation of results.  Possible answers: routine transport van, public
postal service, etc.  If coded, requires a user-defined table.</p>

<h4>
<A NAME="Heading80">7.3.1.39 Collector's comment  (CE)   01030</A></h4>

<p><tt>Components:
&lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field is for reporting additional  comments related to the
sample. If coded, requires a user-defined table. If only free text is reported,
it is placed in the second component with a null in the first component, e.g.,
^difficult clotting after venepuncture and echymosis..</p>

<h4>
<A NAME="Heading81">7.3.1.40 Transport arrangement responsibility  (CE)   01031</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field is an indicator of who is responsible for arranging
transport to the planned diagnostic service.  Examples: Requester, Provider,
Patient. If coded, requires a user-defined table.</p>

<h4>
<A NAME="Heading82">7.3.1.41 Transport arranged  (ID)   01032</A></h4>

<p>Definition:
This field is an indicator of whether transport arrangements are known to have
been made.  <i>Refer to HL7 table 0224 - Transport arranged</i> for valid codes.
</p>

<center>Table 0224 - Transport arranged
</center>
<TABLE BORDER><TR>
<TH>Value</p><BR></TH>
<TH>Description</p><BR></TH></TR>

<TR>
<TH>A</p><BR></TH>
<TH>Arranged</p><BR></TH></TR>

<TR>
<TD>N</TD>
<TD>Not Arranged</TD></TR>

<TR>
<TH>U</TH>
<TH>Unknown</TH></TR></TABLE>
<h4>
<A NAME="Heading83">7.3.1.42 Escort required  (ID)   01033</A></h4>

<p>Definition:
 This field is an indicator that the patient needs to be escorted to the
diagnostic service department.  Note: The nature of the escort requirements
should be stated in the <i>OBR-43-planned patient</i> <i>transport comment</i>
field.  See <i>HL7 table 0225 - Escort required</i> for valid values.
</p>

<center>Table 0225 - Escort required</center>
<TABLE BORDER><TR>
<TH >Value</p><BR></TH>
<TH >Description</p><BR></TH></TR>

<TR>
<TH >R</p><BR></TH>
<TH >Required</p><BR></TH></TR>

<TR>
<TD >N</TD>
<TD >Not Required</TD></TR>

<TR>
<TH>U</TH>
<TH>Unknown</TH></TR>
</TABLE>
<h4>
<A NAME="Heading84">7.3.1.43 Planned patient transport comment  (CE)   01034</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field is the code or free text comments on special
requirements for the transport of the patient to the diagnostic service
department.  If coded, requires a user-defined table.
<a name="_Ref358356484"></a><a name="_Ref373545703"></a></p>

<h3>
<A NAME="Heading85">7.3.2 OBX - observation/result segment</A></h3>

<p>The
OBX segment is used to transmit a single observation or observation fragment.
It represents the smallest indivisible unit of a report.  Its structure is
summarized in <i>Figure 7-5.</i><br>
Its principal mission is to carry information about observations in report
messages.  But the OBX can also be part of an observation order (see Section
4.2, "Order Message Definitions").  In this case, the OBX carries clinical
information needed by the filler to interpret the observation the filler makes.
For example, an OBX is needed to report the inspired oxygen on an order for a
blood oxygen to a blood gas lab, or to report the menstrual phase information
which should be included on an order for a pap smear to a cytology lab.
Appendix 7A includes codes for identifying many of pieces of information needed
by observation producing services to properly interpret a test result.  OBX is
also found in other HL7 messages that need to include patient clinical
information.<br>
<center>Figure 7-5.  OBX attributes</center><br>
</p>
<TABLE BORDER><TR>
<TD >SEQ</TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left">10</TD>
<TD align="left">SI</TD>
<TD>O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD>00569</TD>
<TD>Set ID - OBX</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD>C</TD>
<TD><BR></TD>
<TD>0125</TD>
<TD>00570</TD>
<TD>Value Type</TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">590</TD>
<TD align="left">CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00571</TD>
<TD >Observation Identifier</TD></TR>

<TR align="left">
<TD align="left">4</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00572</TD>
<TD >Observation Sub-ID</TD></TR>

<TR align="left">
<TD align="left">5</TD>
<TD align="left">65536<a name="fnB1" href="#fn1">[2]</a><sup> </sup></TD>
<TD align="left">*</TD>
<TD >C</TD>
<TD >Y<a name="fnB2" href="#fn2">[3]</a></TD>
<TD><BR></TD>
<TD >00573</TD>
<TD >Observation Value</TD></TR>

<TR align="left">
<TD align="left">6</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00574</TD>
<TD >Units</TD></TR>

<TR align="left">
<TD align="left">7</TD>
<TD align="left">10</TD>
<TD align="left">ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00575</TD>
<TD >References Range</TD></TR>

<TR align="left">
<TD align="left">8</TD>
<TD align="left">5</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD >Y/5</TD>
<TD >0078</TD>
<TD >00576</TD>
<TD >Abnormal Flags</TD></TR>

<TR align="left">
<TD align="left">9</TD>
<TD align="left">5</TD>
<TD align="left">NM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00577</TD>
<TD >Probability</TD></TR>

<TR align="left">
<TD align="left">10</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD >Y</TD>
<TD >0080</TD>
<TD >00578</TD>
<TD >Nature of Abnormal Test</TD></TR>

<TR align="left">
<TD align="left">11</TD>
<TD align="left">1</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0085</TD>
<TD >00579</TD>
<TD >Observ Result Status</TD></TR>

<TR align="left">
<TD align="left">12</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00580</TD>
<TD >Date Last Obs Normal Values</TD></TR>

<TR align="left">
<TD align="left">13</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00581</TD>
<TD >User Defined Access Checks</TD></TR>

<TR align="left">
<TD align="left">14</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00582</TD>
<TD >Date/Time of the Observation</TD></TR>

<TR align="left">
<TD align="left">15</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00583</TD>
<TD >Producer's ID</TD></TR>

<TR align="left">
<TD align="left">16</TD>
<TD align="left">80</TD>
<TD align="left">XCN</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00584</TD>
<TD >Responsible Observer</TD></TR>

<TR align="left">
<TD align="left">17</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00936</TD>
<TD >Observation Method</TD></TR>
</TABLE>

<p>7.3.2.0  OBX field definitions</p>

<h4>
<A NAME="Heading86">7.3.2.1 Set ID - observation simple  (SI)   00569</A></h4>

<p>Definition:
This field contains the sequence number.  For compatibility with ASTM. </p>

<h4>
<A NAME="Heading87">7.3.2.2 Value type  (ID)   00570</A></h4>

<p>Definition:
 This field contains the format of the observation value in OBX.  It must be
valued if <i>OBX-11-Observation result status</i> is not valued with an `X".
If the value is CE then the result must be a coded entry.  When the value type
is TX or FT then the results are bulk text.  The valid values for the value
type of an observation are listed in <i>HL7 table 0125 - Value type</i>.<br>
The observation value must be represented according to the format for the data
type defined in Chapter 2, Section 2.8, "Data Types."  For example, a PN
consists of 6 components, separated by component delimiters. <br>
Although NM is a valid type, observations which are usually reported as numbers
will sometimes have the string (ST) data type because non-numeric characters
are often reported as part of the result, e.g., &gt;300 to indicate the result
was off-scale for the instrument.  In the example, "&gt;300", "&gt;" is a
symbol and the digits are considered a numeric value.  However, this usage of
the ST type should be discouraged since the SN (structured numeric) data type
now accommodates such reporting and, in addition, permits the receiving system
to interpret the magnitude.<br>
All HL7 data types are valid, and are included in Table 0125 except CM, CQ, SI,
and ID.  For a CM definition to have meaning, the specifics about the CM must
be included in the field definition.  <i>OBX-5-observation value</i> is a
general field definition that is influenced by the data type <i>OBX-3</i>, so
CMs are undefined in this context.   CQ is invalid because units for
<i>OBX-5-observation value</i> are always specified explicitly in an OBX
segment with <i>OBX-6 units</i>.  SI is invalid because it only applied to HL7
message segments, and ID because it requires a constant field definition.<br>
The RP value (reference pointer) must be used if the actual observation value
is not sent in OBX but exists somewhere else.  For example, if the observation
consists of an image (document or medical), the image itself cannot be sent in
OBX.  The sending system may in that case opt to send a reference pointer.  The
receiving system can use this reference pointer whenever it needs access to the
actual image through other interface standards, e.g., DICOM, or through
appropriate data base servers.<br>
<center>Table 0125 - Value type</center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >AD</TD>
<TD >Address</TD></TR>

<TR>
<TD >CE</TD>
<TD >Coded Entry</TD></TR>

<TR>
<TD >CF</TD>
<TD >Coded Element With Formatted Values</TD></TR>

<TR>
<TD >CK</TD>
<TD >Composite ID With Check Digit</TD></TR>

<TR>
<TD >CN</TD>
<TD >Composite ID And Name</TD></TR>

<TR>
<TD >CP</TD>
<TD >Composite Price</TD></TR>

<TR>
<TD >CX</TD>
<TD >Extended Composite ID With Check Digit</TD></TR>

<TR>
<TD >DT</TD>
<TD >Date</TD></TR>

<TR>
<TD >ED</TD>
<TD >Encapsulated Data</TD></TR>

<TR>
<TD >FT</TD>
<TD >Formatted Text (Display)</TD></TR>

<TR>
<TD >MO</TD>
<TD >Money</TD></TR>

<TR>
<TD >NM</TD>
<TD >Numeric</TD></TR>

<TR>
<TD >PN</TD>
<TD >Person Name</TD></TR>

<TR>
<TD >RP</TD>
<TD >Reference Pointer</TD></TR>

<TR>
<TD >SN</TD>
<TD >Structured Numeric</TD></TR>

<TR>
<TD >ST</TD>
<TD >String Data.</TD></TR>

<TR>
<TD >TM</TD>
<TD >Time</TD></TR>

<TR>
<TD >TN</TD>
<TD >Telephone Number</TD></TR>

<TR>
<TD >TS</TD>
<TD >Time
Stamp (Date &amp; Time)</TD></TR>

<TR>
<TD >TX</TD>
<TD >Text Data (Display)</TD></TR>

<TR>
<TD >XAD</TD>
<TD >Extended Address</TD></TR>

<TR>
<TD >XCN</TD>
<TD >Extended Composite Name And Number For Persons</TD></TR>

<TR>
<TD >XON</TD>
<TD >Extended Composite Name And Number For Organizations</TD></TR>

<TR>
<TD >XPN</TD>
<TD >Extended Person Number</TD></TR>

<TR>
<TD >XTN</TD>
<TD >Extended Telecommunications Number</TD></TR>
</TABLE>

<p>The
full definition of these data types is given in Chapter 2, Section 2.8, "Data
Types."  The structured numeric (SN) data type, new to version 2.3, provides
for reporting ranges (e.g., 3-5 or 10-20), titres (e.g., 1:10), and
out-of-range indicators (e.g., &gt;50) in a structured and computer
interpretable way. <br>
We allow the FT data type in the OBX segment but its use is discouraged.
Formatted text usually implies a meaningful structure e.g., a list of three
independent diagnoses reported on different lines.  But ideally, the structure
in three independent diagnostic statements would be reported as three separate
OBX segments.<br>
TX should <b>not</b> be used except to send large amounts of text.  In the TX
data type, the repeat delimiter can only be used to identify paragraph breaks.
Use ST to send short, and possibly encodable, text strings.</p>

<h4>
<A NAME="Heading88">7.3.2.3 Observation identifier  (CE)   00571</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains a unique identifier for the observation. The
format is that of the Coded Element (CE).  Example: 93000.3^P-R interval^A34.
<br>
In most systems the identifier will <b>point</b> to a master observation table
that will provide other attributes of the observation that may be used by the
receiving system to process the observations it receives.  A set of message
segments for transmitting such master observation tables is described in
Chapter 8.  The relation of an observation ID to a master observation table is
analogous to the relationship between a charge code (in a billing record) and
the charge master.<br>
When local codes are used as the first identifier in this field we strongly
encourage sending a universal identifier as well to permit receivers to
equivalence results from different providers of the same service (e.g., a
hospital lab and commercial lab that provides serum potassium to a nursing
home).  One possible <b>universal</b> identifier is LOINC codes for laboratory
and clinical measurements (see <i>Figure 7-3</i> and the HL7 www list server);
see Section 7.15, "WAVEFORM RESULT DATA TYPES," and Appendix X2 of ASTM E1467
for neurophysiology tests.</p>

<h4>
<A NAME="Heading89">7.3.2.4 Observation sub-ID  (ST)   00572</A></h4>

<p>Definition:
 This field is used to distinguish between multiple OBX segments with the same
observation ID organized under one OBR.  For example, a chest X-ray report
might include three separate diagnostic impressions.  The standard requires
three OBX segments, one for each impression.  By putting a 1 in the Sub-ID of
the first of these OBX segments, 2 in the second, and 3 in the third, we can
uniquely identify each OBX segment for editing or replacement.<br>
The sub-identifier is also used to group related components in reports such as
surgical pathology.  It is traditional for surgical pathology reports to
include all the tissues taken from one surgical procedure in one report.
Consider, for example, a single surgical pathology report that describes the
examination of gallbladder and appendix tissue.  This report would be
transmitted roughly as shown in <i>Figure 7-6</i>.<br>
<center>Figure 7-6.  Example of sub-identifier usage </center><br>
OBR|1|||88304&amp;SURG PATH REPORT...<br>
OBX|1|CE|88304&amp;ANT|1|T57000^GALLBLADDER^SNM...<br>
OBX|2|TX|88304&amp;GDT|1|THIS IS A NORMAL GALLBLADDER...<br>
OBX|3|TX|88304&amp;MDT|1|MICROSCOPIC EXAM SHOWS HISTOLOGICALLY <br>
	NORMAL GALLBLADDER TISSUE...<br>
OBX|4|CE|88304&amp;IMP|1|M-00100^NML^SNM...<br>
OBX|5|CE|88304&amp;ANT|2|T66000^APPENDIX^SNM...<br>
OBX|6|TX|88304&amp;GDT|2|THIS IS A RED, INFLAMED, SWOLLEN, BOGGY APPENDIX...<br>
OBX|7|TX|88304&amp;MDT|2|INFILTRATION WITH MANY PMN's - INDICATING INFLAMATORY
CHANGE...<br>
OBX|8|CE|88304&amp;IMP|2|M-40000^INFLAMMATION NOS^SNM...<br>
The example in <i>Figure 7-6</i> has two segments for each component of the
report, one for each of the two tissues.  Thus, there are two 88304&amp;ANT
segments; there are two 88304&amp;GDT segments, and there are two 88304&amp;MDT
segments.  Segments that apply to the gallbladder all have the sub-identifier
1.  Segments that apply to the appendix all have sub-identifier 2.  <br>
The observation sub ID has other grouping uses.  It can be used to organize the
reporting of some kinds of fluid intakes and outputs.  For example, when intake
occurs through multiple intravenous lines, a number of separate observations
(OBX segments), the intake volume, the type of intake (Blood, D5W, Plasma,
etc.), the site of the IV line, etc. may be needed for each intravenous line,
each requiring a separate OBX segment.  If more than one IV line is running, we
can logically link all of the OBX segments that pertain to the first IV line by
assigning them an observation sub ID of 1.  We can do the same with the second
IV line by assigning them a sub ID 2 and so on.  The same would apply to the
outputs of surgical drains when there are multiple such drains.<br>
The use of the sub ID to distinguish repeating OBXs for the same observation ID
is really a special case of using the sub ID to group, as can be seen if we
picture the OBX segments in <i>Figure 7-6</i> as part of a table where the rows
correspond to a particular species of observation and the cells correspond to
the sub ID numbers that would be associated with each corresponding OBX.<br>
</p>
<TABLE BORDER><TR align="left">
<TD align="left">Distinct Observations</TD>
<TD >88304&amp;ANT</TD>
<TD >88304&amp;GDT</TD>
<TD >80304&amp;MDT</TD>
<TD >80304&amp;IMP</TD></TR>

<TR align="left">
<TD align="left">Sub ID 1st Group</TD>
<TD >1</TD>
<TD >1</TD>
<TD >1</TD>
<TD >1</TD></TR>

<TR align="left">
<TD align="left">Sub ID 2nd Group</TD>
<TD >2</TD>
<TD >2</TD>
<TD >2</TD>
<TD >2</TD></TR></TABLE><p>The
use of Sub IDs to group results is equivalent to defining a table, and the use
of sub IDs to distinguish repeats is just a special case, represented by one
column in this table.<br>
However, this approach introduces ambiguities if we have a set of repeating
observations within a group, e.g., if the appendix observations include two
impressions as in the 8th and 9th OBXs shown in <i>Figure 7-7.</i>  This really
represents the existence of a row nested within a single cell of the table
given above.</p>

<center>Figure 7-7.  Example of sub-identifier usage</center>
<p>OBX|1|CE|880304&amp;ANT|1|T57000^GALLBLADDER^SNM...<br>
OBX|2|TX|880304&amp;GDT|1|THIS IS A NORMAL GALL BLADDER...<br>
OBX|3|TX|880304&amp;MDT|1|MICROSCOPIC EXAMINATION SHOWS HISTOLOGICALLY <br>
	NORMAL GALLBLADDER TISSUE...<br>
OBX|4|CE|880304&amp;IMP|1|M-00100^NML^SNM...<br>
OBX|5|CE|880304&amp;ANT|2|T57000^APPENDIX^SNM...<br>
OBX|6|TX|880304&amp;GDT|2|THIS IS A RED, INFLAMED APPENDIX...<br>
OBX|7|TX|880304&amp;MDT|2|INFLAMMATION WITH MANY PUS CELLS-ACUTE
INFLAMMATION...<br>
OBX|8|CE|880304&amp;IMP|2|M-40000^INFLAMMATION NOS^SNM...<br>
OBX|9|CE|880304&amp;IMP|2|M-30280^FECALITH^SNM...</p>
<blockquote>The text under<i> OBX-5-observation value</i> provides guidance
about dealing with two OBXs with the same observation ID and observation sub
IDs.  They are sent and replaced as a unit.  However, some systems will take
this to mean that the set of OBXs are to be combined into one composite
observation in the receiving system.  We suggest the use of a dot and a string
(similar to the Dewey Decimal system) when users wish to distinguish each of
the repeats within one type, or results within a cell for editing and
correction purposes.  Using this system, <i>Figure 7-7</i> would become
<i>7-8</i>.  If there are cases where such nesting occurs at even deeper
levels, this approach could be extended.</blockquote>
<center>Figure 7-8.  Example of sub-identifier usage</center>
<p>OBX|1|CE|880304&amp;ANT|1|T57000^GALLBLADDER^SNM...<br>
OBX|2|TX|880304&amp;GDT|1|THIS IS A NORMAL GALL BLADDER...<br>
OBX|3|TX|880304&amp;MDT|1|MICROSCOPIC EXAMINATION SHOWS HISTOLOGICALLY <br>
	NORMAL GALLBLADDER TISSUE...<br>
OBX|4|CE|880304&amp;IMP|1|M-00100^NML^SNM...<br>
OBX|5|CE|880304&amp;ANT|2|T57000^APPENDIX^SNM...<br>
OBX|6|TX|880304&amp;GDT|2|THIS IS A RED, INFLAMED APPENDIX...<br>
OBX|7|TX|880304&amp;MDT|2|INFLAMMATION WITH MANY PUS CELLS-ACUTE
INFLAMMATION...<br>
OBX|8|CE|880304&amp;IMP|2.1|M-40000^INFLAMMATION NOS^SNM...<br>
OBX|9|CE|880304&amp;IMP|2.2|M-30280^FECALITH^SNM...<br>
Use a null or 1 when there is no need for multiples.<br>
If the observation includes a number of OBXs with the same value for the
observation ID OBX-3, then one must use different values for the sub-ID.  This
is in fact the case of the repeats depicted in Figure 7-8, but without any need
to group sets of OBXs.  Three such OBXs could be distinguished by using sub-IDs
1,2,e; alternatively, sub-IDs 1.1, 1.2, 1.3 could be used, as shown in
<i>Figure 7-8</i>.  <i>Figure 7-9</i> shows and example of an
electrocardiograph chest radiograph report with three diagnostic impressions,
using 1,2,3 in the sub-ID field to distinguish the three separate results.<br>
<center>Figure 7-9  Example of  Sub-ID used to distinguish three independent
results with the same observation ID</center><br>
OBX|1|CE|8601-7^EKG IMPRESSION ^LN|1|^atrial fibrillation|. . .<br>
OBX|2|CE|8601-7^EKG IMPRESSION ^LN|2|^OLD SEPTAL MYOCARDIAL INFARCT| . . .<br>
OBX|3|CE|8601-7^EKG IMPRESSION ^LN|3|^poor R wave progression|. . .</p>

<h4>
<A NAME="Heading90">7.3.2.5 Observation value  (*)   00573</A></h4>

<p>Definition:
 This field contains the value observed by the observation producer.
<i>OBX-2-value type</i> contains the data type for this field according to
which observation value is formatted.  It is not a required field because some
systems will report only the normalcy/abnormalcy (<i>OBX-8</i>), especially in
product experience reporting.<br>
Representation <br>
This field contains the value of <i>OBX-3-observation identifier</i> of the
same segment.  Depending upon the observation, the data type may be a number
(e.g., a respiratory rate), a coded answer (e.g., a pathology impression
recorded as SNOMED), or a date/time (the date/time that a unit of blood is sent
to the ward).  An observation value is always represented as the data type
specified in <i>OBX-2-value type</i> of the same segment.  Whether numeric or
short text, the answer shall be recorded in ASCII text.<br>
Reporting logically independent observations<br>
The main sections of dictated reports, such as radiologic studies or history
and physicals, are reported as separate OBX segments.  In addition, each
logically independent observation should be reported in a separate OBX segment,
i.e. one OBX segment should not contain the <b>result</b> of more than one
logically independent observation.  This requirement is included to assure that
the contents of <i>OBX-6-units</i>, <i>OBX-8-abnormal flags</i>, and
<i>OBX-9-probability</i> can be interpreted unambiguously.  The electrolytes
and vital signs batteries, for example, would each be reported as four separate
OBX segments.  Two diagnostic impressions, e.g., congestive heart failure and
pneumonia, would also be reported as two separate OBX segments whether reported
as part of a discharge summary or chest X-ray report.  Similarly, two bacterial
organisms isolated in a single bacterial culture would be reported as two
separate OBX segments.  <br>
Though two independent diagnostic <b>statements</b> cannot be reported in one
OBX segment, multiple categorical responses are allowed (usually as CE data
types separated by repeat delimiters), so long as they are fragments
(modifiers) that together construct one diagnostic statement.  Right upper lobe
(recorded as one code) and pneumonia (recorded as another code), for example,
could be both reported in one OBX segment.  Such multiple "values" would be
separated by repeat delimiters.<br>
Multiple OBX segments with the same observation ID and Sub ID<br>
In some systems, a single observation may include <b>fragments</b> of more than
one data type.  The most common example is a numeric result followed by coded
comments (CE).  In this case, the logical observation can be sent in more than
one OBX segment.  For example, one segment of numeric or string data type for
the numeric result and another segment of CE data type for coded comments.  If
the producer was reporting multiple coded comments they would all be sent in
one OBX segment separated by repeat delimiters because they all modified a
single logical observation.  Multiple OBX segments with the same observation ID
and sub ID should always be sent in sequence with the most significant OBX
segment (the one that has the normal flag/units and or reference range and
status flag) first.  The value of <i>OBX-6 through 12</i> should be null in any
following OBX segments with the same <i>  OBX-3-observation identifier</i> and
<i>OBX-4-observation sub-ID</i>.  For the purpose of replacement or deletion,
multiple OBX segments with the same observation ID and sub ID are treated as a
unit.  If any are replaced or deleted, they all are replaced.<br>
Coded values <br>
When an OBX segment contains values of CE data types, the observations are
stored as a combination of codes and/or text.  In Section 7.4.4, "Example of
narrative report messages," examples of results that are represented as CE data
types are shown in the first and second OBX segments of OBR 1 and the first and
second OBX segments of OBR 2.  The observation may be an observation battery ID
(for recommended studies), a diagnostic code or finding (for a diagnostic
impression), or an anatomic site for a pathology report, or any of the other
kinds of coded results.<br>
It is not necessary to always encode the information stored within a coded
observation.  For example, a chest X-ray impression could be transmitted as
pure text even though it has a CE data type.  In this case, the test must be
recorded as the second component of the <b>result code,</b> e.g., <br>
OBX|1|CE|71020&amp;IMP|1|^CONGESTIVE HEART FAILURE.<br>
However, separate impressions, recommendations, etc., even if recorded as pure
text, should be recorded in separate result segments.  That is, congestive
heart failure and pneumonia should not be sent as:<br>
OBX|1|CE|71020&amp;IMP|1|^CONGESTIVE HEART FAILURE AND PNEUMONIA|<br>
but as:<br>
OBX|1|CE|71020&amp;IMP|1|^CONGESTIVE HEART FAILURE| <br>
OBX|2|CE|71020&amp;IMP|2|^PNEUMONIA|.  <br>
Even better would be fully-coded results that include computer understandable
codes (component 1) instead of, or in addition to, the text description
(component 2).  One may include multiple values in a CE value and these can be
mixtures of code and text, but only when they are needed to construct one
diagnosis, impression, or concept.  When text follows codes as an independent
value it would be taken as a modifier or addenda to the codes.  E.g.,<br>
OBX|1|CE|710120&amp;IMP^CXR|1|428.0^CONGESTIVE HEART FAILURE^I9C~^MASSIVE
HEART</p>
<blockquote>The text in component 2 should be an accurate description of the
code in component 1.  Likewise, if used, the text in component 5 should be an
accurate description of the code in component 4.</blockquote>
<h4>
<A NAME="Heading91">7.3.2.6 Units  (CE)   00574</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains the units that have a data type of CE.  The
default coding system for the units codes consists of the ISO+ abbreviation for
a single case unit (ISO 2955-83) plus extensions, that do not collide with ISO
abbreviations (see introductory section to this chapter).  We designate this
coding system as ISO+.  Both the ISO unit's abbreviations and the extensions
are defined in Section 7.3.2.6.1.2, "ISO and ANSI customary units
abbreviations," and listed in <i>Figure 7-13</i>.  The ISO+ abbreviations
<i>are</i> the codes for the default coding system.  Consequently, when ISO+
units are being used, only ISO+ abbreviations need be sent, and the contents of
the units field will be backward compatible to HL7 Version. 2.1.  
<a name="_Ref371148501"></a></p>

<h5>
<A NAME="Heading92">7.3.2.6.1 Identifying reporting units </A></h5>


<h6>
<A NAME="Heading93">7.3.2.6.1.1 Background</A></h6>

<p>When
an observation's value is measured on a continuous scale, one must report the
measurement units within the units field of the OBX segment.  Since in HL7
Version 2.2 of the specification, all fields that report units are of data type
CE.  The default coding system for the units codes consists of the ISO
abbreviation for a single case unit (ISO 2955-83) plus extensions that do not
collide with ISO abbreviations.  We designate this coding system as ISO+ (see
<i>Figure 7-13</i>).  Both the ISO unit's abbreviations and the extensions are
defined in Section 7.3.2.6.1.2, "ISO and ANSI customary units abbreviations."
The ISO+ abbreviations <i>are</i> the codes for the default coding system.
Consequently, when ISO+ units are being used, only ISO+ abbreviations need be
sent, and the contents of the units field will be backward compatible to HL7
Version 2.1 and ASTM 1238-88.<br>
We strongly encourage observation producers to use ISO+ abbreviated units
exclusively, but permit the use of other code systems, including US customary
units (ANSI X3.50) and locally defined codes where necessary.  Local units are
designated <b>L</b> or 99zzz where z is an alpha numeric character (see
<i>Figures 7-2</i> and <i>73</i>).  ANSI X3.50 -1986 provides an excellent
description of these standards, as well as a table of single case abbreviations
for US customary units such as foot or gallon.<br>
We had originally intended to include the ANSI X3.50 - 1986 US customary units
in the default ISO+ coding system.  However, there are overlaps between ISO's
abbreviations and the abbreviations for US customary units.  For example,
<b>ft</b> is the abbreviation for foot in US customary units and for femtotesla
in ISO; <b>pt</b> is the abbreviation for pint in US customary and for
picotesla in ISO.  (Be aware that the ANSI document also differs from the ISO
document regarding the abbreviation of a few ISO units, as well.)   In order to
avoid potential ambiguity, we have defined another coding system, designated
ANS+.  It includes the US customary units (e.g., feet, pounds) and <b>ISO</b>
abbreviations defined in ANSI X3.50-1986, as well as other non-metric units
listed in <i>Figure 7-13</i> and the ISO combinations of these units.  Be aware
that a few of the ANSI <b>ISO</b> unit abbreviations differ from their
abbreviations in ISO (see note at bottom of <i>Figure 7-13</i>).  <br>
Because the ANS+ specification includes both <b>ISO</b> and US customary units,
as well as miscellaneous non-metric units, some of the abbreviations are
ambiguous.  Although there should be little confusion, in the context of a
particular observation, this ambiguity is a good reason for avoiding ANS+ unit
codes when possible.<br>
When ANS+ units codes (abbreviations) are being transmitted, <b>ANS</b>+ must
be included in the third (sixth) component of the field.  If the units of
distance were transmitted as meters (ISO+) it would be transmitted as <b>m</b>
because ISO+ is the default coding system for units.  However, if transmitted
in the US customary units of feet, the units would be transmitted as
<b>ft^^ANS+.</b>  When required, the full text of the units can be sent as the
second component in keeping with the CE data type conventions. <br>
Both ISO and ANSI also provide a set of mixed case abbreviations, but these
abbreviations cannot be translated to single case without loss of meaning, and
should not be used in this specification whose content is required to be case
insensitive.
<a name="_Ref373545500"></a></p>

<h6>
<A NAME="Heading94">7.3.2.6.1.2 ISO and ANSI customary units abbreviations </A></h6>

<p>ISO
builds its units from seven base dimensions measured as meters, kilograms,
seconds, amperes, kelvins, moles and candelas (see <i>Figure 7-10</i>).  Other
units can be derived from these by adding a prefix to change the scale and/or
by creating an algebraic combination of two or more base or derived units.
However, some derived units have acquired their own abbreviations (see
<i>Figure 7-10</i>).  Abbreviations for U.S. customary units are given in
<i>Figure 7-11</i>.<br>
The ISO rules, well explained in ANSI X3.50, provide a way to create units of
different scales by adding <b>multiplier</b> prefixes.  These prefixes can be
expressed as <b>words</b> or abbreviations.  In this Standard we are only
concerned with the abbreviations.<br>
<center>Figure 7-10.  ISO single case units abbreviations</center><br>
</p>
<TABLE BORDER><TR>
<TD >Units</TD>
<TD >Abbreviation</TD>
<TD >Units</TD>
<TD >Abbreviation</TD>
<TD >Units</TD>
<TD >Abbreviation</TD></TR>

<TR>
<TD >Base units code/abbreviations</TD></TR>

<TR align="left">
<TD align="left">ampere</TD>
<TD align="left">a</TD>
<TD align="left">kelvin</TD>
<TD align="left">k</TD>
<TD align="left">meter</TD>
<TD align="left">m</TD></TR>

<TR align="left">
<TD align="left">candela</TD>
<TD align="left">cd</TD>
<TD align="left">kilogram</TD>
<TD align="left">kg</TD>
<TD align="left">mole</TD>
<TD align="left">mol</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">second</TD>
<TD align="left">s</TD></TR>

<TR>
<TD >Derived units with specified name and abbreviation</TD></TR>

<TR align="left">
<TD align="left">coulomb</TD>
<TD align="left">c</TD>
<TD align="left">hour</TD>
<TD align="left">hr</TD>
<TD align="left">pascal</TD>
<TD align="left">pal</TD></TR>

<TR align="left">
<TD align="left">day</TD>
<TD align="left">d</TD>
<TD align="left">joule</TD>
<TD align="left">j</TD>
<TD align="left">volt</TD>
<TD align="left">v</TD></TR>

<TR align="left">
<TD align="left">degree Celsius</TD>
<TD align="left">cel</TD>
<TD align="left">minute (ti)</TD>
<TD align="left">min</TD>
<TD align="left">watt</TD>
<TD align="left">w</TD></TR>

<TR align="left">
<TD align="left">farad</TD>
<TD align="left">f</TD>
<TD align="left">newton</TD>
<TD align="left">n</TD>
<TD align="left">weber</TD>
<TD align="left">wb</TD></TR>

<TR align="left">
<TD align="left">hertz</TD>
<TD align="left">hz</TD>
<TD align="left">ohm</TD>
<TD align="left">ohm</TD>
<TD align="left">year</TD>
<TD align="left">ann</TD></TR>

<TR>
<TD>Other units</TD></TR>

<TR align="left">
<TD align="left">atomic mass unit</TD>
<TD align="left">u</TD>
<TD align="left">grey</TD>
<TD align="left">gy</TD>
<TD align="left">minute of arc</TD>
<TD align="left">mnt</TD></TR>

<TR align="left">
<TD align="left">bel</TD>
<TD align="left">b</TD>
<TD align="left">henry</TD>
<TD align="left">h</TD>
<TD align="left">radian</TD>
<TD align="left">rad</TD></TR>

<TR align="left">
<TD align="left">decibel</TD>
<TD align="left">db</TD>
<TD align="left">liter</TD>
<TD align="left">l</TD>
<TD align="left">siemens</TD>
<TD align="left">sie</TD></TR>

<TR align="left">
<TD align="left">degree</TD>
<TD align="left">deg</TD>
<TD align="left">lumen</TD>
<TD align="left">lm</TD>
<TD align="left">steradian</TD>
<TD align="left">sr</TD></TR>

<TR align="left">
<TD align="left">gram</TD>
<TD align="left">g</TD>
<TD align="left">lux</TD>
<TD align="left">lx</TD>
<TD align="left">tesla</TD>
<TD align="left">t</TD></TR>

<TR>
<TD >See ISA 2955-1983 for full set</TD></TR>
</TABLE>
<p>
The ISO abbreviations for multiplier prefixes are given in <i>Figure 7-12</i>.
Prefixes ranging from 10<sup>-24</sup> (1/billion billionth) to 10<sup>24</sup>
(a billion billion) are available.  The single case abbreviation for kilo
(x1000) is <b>k</b>.  A unit consisting of 1000 seconds would be abbreviated as
<b>ks</b>, 1000 grams as <b>kg</b>, 1000 meters as <b>km</b>, and so on.  Some
prefixes share the abbreviation of a base unit.  Farad and femto, for example,
(10<sup>-18</sup>) both have the abbreviation of <b>f</b>.  To avoid confusion,
ISO forbids the use of solitary prefixes. It also deprecates the use of two
prefixes in one complex unit. Thus, <b>f</b> always means farad, <b>ff</b>
would mean 1 million billionth of a farad.  Compound prefixes are not
allowed.<br>
A unit can be raised to an exponential power.  Positive exponents are
represented by a number immediately following a unit's abbreviation, i.e., a
square meter would be denoted by m2.  Negative exponents are signified by a
negative number following the base unit, e.g., <b>1/m<sup>2</sup></b> would be
represented <b>as m-2</b>  Fractional exponents are expressed by a numeric
fraction in parentheses: the square root of a meter would be expressed as
m(1/2). The multiplication of units is signified by a period (.) between the
units, e.g., meters X seconds would be denoted <b>m.s</b>.  Notice that spaces
are not permitted.  Division is signified by a slash (/) between two units,
e.g. meters per second would be denoted as <b>m/s</b>.  Algebraic combinations
of ISO unit abbreviations constructed by dividing, multiplying, or
exponentiating base ISO units, are also valid ISO abbreviations units.
Exponentiation has precedence over multiplication or division. For example,
microvolts squared per hertz (a unit of spectral power) would be denoted
<b>uv2/hz</b> and evaluated as uv <sup>2</sup>/hz<sub>  </sub>while microvolts
per square root of hertz (a unit of spectral amplitude) would be denoted
uv/hz(1/2) and evaluated as uv/hz<sup>&#189;</sup>.  If more than one division
operator is included in the expression the associations should be parenthesized
to avoid any ambiguity, but the best approach is to convert a/(b/c) to a.c/b or
a.c.b-1 to simplify the expression.<br>
<center>Figure 7-11.  ANSI+ unit codes for some U.S. customary
units</center><br>
</p>
<TABLE BORDER><TR>
<TD >Units</TD>
<TD >Abbreviation</TD>
<TD >Units</TD>
<TD >Abbreviation</TD>
<TD >Units</TD>
<TD >Abbreviation</TD></TR>

<TR>
<TD >LENGTH</TD>
<TD><BR></TD>
<TD >VOLUME</TD>
<TD><BR></TD>
<TD >TIME</TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">inch</TD>
<TD align="left">in</TD>
<TD align="left">cubic foot</TD>
<TD align="left">cft</TD>
<TD align="left">year</TD>
<TD align="left">yr</TD></TR>

<TR align="left">
<TD align="left">foot</TD>
<TD align="left">ft</TD>
<TD align="left">cubic inch</TD>
<TD align="left">cin</TD>
<TD align="left">month</TD>
<TD align="left">mo</TD></TR>

<TR align="left">
<TD align="left">mile (statute)</TD>
<TD align="left">mi</TD>
<TD align="left">cubic yard</TD>
<TD align="left">cyd</TD>
<TD align="left">week</TD>
<TD align="left">wk</TD></TR>

<TR align="left">
<TD align="left">nautical mile</TD>
<TD align="left">nmi</TD>
<TD align="left">tablespoon</TD>
<TD align="left">tbs</TD>
<TD align="left">day</TD>
<TD align="left">d</TD></TR>

<TR align="left">
<TD align="left">rod</TD>
<TD align="left">rod</TD>
<TD align="left">teaspoon</TD>
<TD align="left">tsp</TD>
<TD align="left">hour</TD>
<TD align="left">hr</TD></TR>

<TR align="left">
<TD align="left">yard</TD>
<TD align="left">yd</TD>
<TD align="left">pint</TD>
<TD align="left">pt</TD>
<TD align="left">minute</TD>
<TD align="left">min</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">quart</TD>
<TD align="left">qt</TD>
<TD align="left">second</TD>
<TD align="left">sec</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">gallon</TD>
<TD align="left">gal</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">ounce (fluid)</TD>
<TD align="left">foz</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR>
<TD >AREA</TD>
<TD><BR></TD>
<TD >MASS</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">square foot</TD>
<TD align="left">sqf</TD>
<TD align="left">dram</TD>
<TD align="left">dr</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left">square inch</TD>
<TD align="left">sin</TD>
<TD align="left">grain</TD>
<TD align="left">gr (avoir)</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left">square yard</TD>
<TD align="left">syd</TD>
<TD align="left">ounce (weight)</TD>
<TD align="left">oz</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">pound</TD>
<TD align="left">lb</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR>
<TD>Other ANSI units, derived units, and miscellaneous</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">**British thermal unit</TD>
<TD align="left">btu</TD>
<TD align="left">**degrees fahrenheit</TD>
<TD align="left">degf</TD>
<TD align="left">**millirad</TD>
<TD align="left">mrad</TD></TR>

<TR align="left">
<TD align="left">cubic feet/minute</TD>
<TD align="left">cft/min</TD>
<TD align="left">**feet/minute</TD>
<TD align="left">ft/min</TD>
<TD align="left">**RAD</TD>
<TD align="left">rad</TD></TR>

<TR align="left">
<TD align="left">Note:
the abbreviations for conventional U.S. units of time are the same as ISO,
except for year.  ISO = ANN, AMSI = yr.  The metric units in X3.50 are the same
as ISO, except for: pascal ("pa" in ANSI, "pal" in ISO); ANSI uses "min" for
both time and arc while ISO uses "mnt" for minutes of arc; and in ISA seconds
are abbreviated "s", in ANSI, "sec". </TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left">This list is not exhaustive.  Refer to ANSI X3.50-1986, Table 1, for other metric
and standard U.S. units.</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left">**Non-metric units not explicitly listed in ANSI</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR></TABLE><p><center>Figure
7-12.  Single case ISO abbreviations for multiplier prefixes</center><br>
</p>
<TABLE BORDER><TR>
<TD >Prefix</TD>
<TD><BR></TD>
<TD >Code</TD>
<TD >Prefix</TD>
<TD><BR></TD>
<TD >Code</TD></TR>

<TR align="left">
<TD align="left">yotta*</TD>
<TD align="left">10<sup>24</sup></TD>
<TD align="left">ya</TD>
<TD align="left">yocto</TD>
<TD align="left">10<sup>-24</sup></TD>
<TD align="left">y</TD></TR>

<TR align="left">
<TD align="left">zetta*</TD>
<TD align="left">10<sup>21</sup></TD>
<TD align="left">za</TD>
<TD align="left">zepto</TD>
<TD align="left">10<sup>-21</sup></TD>
<TD align="left">z</TD></TR>

<TR align="left">
<TD align="left">exa</TD>
<TD align="left">10<sup>18</sup></TD>
<TD align="left">ex</TD>
<TD align="left">atto</TD>
<TD align="left">10<sup>-18</sup></TD>
<TD align="left">a</TD></TR>

<TR align="left">
<TD align="left">peta</TD>
<TD align="left">10<sup>15</sup></TD>
<TD align="left">pe</TD>
<TD align="left">femto</TD>
<TD align="left">10<sup>-15</sup></TD>
<TD align="left">f</TD></TR>

<TR align="left">
<TD align="left">tera</TD>
<TD align="left">10<sup>12</sup></TD>
<TD align="left">t</TD>
<TD align="left">pico</TD>
<TD align="left">10<sup>-12</sup></TD>
<TD align="left">p</TD></TR>

<TR align="left">
<TD align="left">giga</TD>
<TD align="left">10<sup>9</sup></TD>
<TD align="left">g</TD>
<TD align="left">nano</TD>
<TD align="left">10<sup>-9</sup></TD>
<TD align="left">n</TD></TR>

<TR align="left">
<TD align="left">mega</TD>
<TD align="left">10<sup>6</sup></TD>
<TD align="left">ma</TD>
<TD align="left">micro</TD>
<TD align="left">10<sup>-6</sup></TD>
<TD align="left">u</TD></TR>

<TR align="left">
<TD align="left">kilo</TD>
<TD align="left">10<sup>3</sup></TD>
<TD align="left">k</TD>
<TD align="left">milli</TD>
<TD align="left">10<sup>-3</sup></TD>
<TD align="left">m</TD></TR>

<TR align="left">
<TD align="left">hecto</TD>
<TD align="left">10<sup>2</sup></TD>
<TD align="left">h</TD>
<TD align="left">centi</TD>
<TD align="left">10<sup>-2</sup></TD>
<TD align="left">c</TD></TR>

<TR align="left">
<TD align="left">deca</TD>
<TD align="left">10<sup>1</sup></TD>
<TD align="left">da</TD>
<TD align="left">deci</TD>
<TD align="left">10<sup>-1</sup></TD>
<TD align="left">d</TD></TR>

<TR align="left">
<TD align="left">*These abbreviations are not defined in the ISO specification for single case
abbreviations.</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR></TABLE><p><i>Figure
7-13</i> lists the abbreviations for common ISO derived units.  It also
includes standard unit abbreviations for common units, e.g., Milliequivalents,
and international units, mm(Hg), and for counting per which we denote by a
division sign, a denominator, but no numerator, e.g., /c, that are not part of
the above referenced ISO standards.  We have extended the units table to better
accommodate drug routes and physiologic measures, and otherwise fill in gaps in
Version 2.2.<br>
We have generally followed the IUPAC 1995 Silver Book<sup>2</sup> in the
definitions of units. However, IUPAC specifies standards for reporting or
displaying units and employs 8-bit data sets to distinguish them. This Standard
is concerned with the <i>transmission </i>of patient information. Therefore, we
have restricted ourselves to case insensitive alphabetic characters and a few
special characters (e.g., ".", "/", "( ", ") ","*", and "_" ) to avoid any
possible confusion in the transmission.  Therefore, we use ISO 2955-1983
(Information processing -- representation of SI and other units in systems with
limited character sets) and ANSI X3.50-1986 (Representations for U.S.
customary, SI, and other units to be used in systems with limited character
sets) case insensitive units abbreviations where they are defined. This means
that in some cases, IUPAC abbreviations have different abbreviations in ISO+
even when the IUPAC abbreviations use only standard alphabetic characters.  For
example, <b>Pascal</b> is abbreviated <b>Pa</b> in IUPAC but <b>PAL</b> in ISO+
(following ISO 2955) because <b>Pa</b> in a case insensitive context also means
<b>Picoampere</b>.  However, the requirements for transmission do not preclude
usage of IUPAC standards for presentation on paper or video display reports to
end users. <br>
All unit abbreviations are case insensitive. One could write milliliters as ML,
ml, or mL. In this table we have used lower case for all of the abbreviations
except for the letter <b>L</b> which we represent in upper case so that readers
will not confuse it with the numeral one (1). This is just a change in
presentation, not a change in the Standard. <b> </b>Systems should continue to
send the codes as upper or lower case as they always have.<br>
<center>Figure 7-13.  Common ISO derived units and *ISO extensions</center><br>
</p>
<TABLE BORDER><TR>
<TH ><b>Code/Abbr.</b></p><BR></TH>
<TH ><b>Name</b></p><BR></TH></TR>

<TR align="left">
<TD align="left">/(arb_u)</TD>
<TD align="left">*1 / arbitrary unit</TD></TR>

<TR align="left">
<TD align="left">/iu</TD>
<TD align="left">*1 / international unit</TD></TR>

<TR align="left">
<TD align="left">/kg</TD>
<TD align="left">*1 / kilogram</TD></TR>

<TR align="left">
<TD align="left">/L</TD>
<TD align="left">
1 / liter</TD></TR>

<TR align="left">
<TD align="left">1/mL</TD>
<TD align="left">*1 / milliliter </TD></TR>

<TR align="left">
<TD align="left">10.L/min</TD>
<TD align="left">*10
x liter / minute</TD></TR>

<TR align="left">
<TD align="left">10.L /(min.m2)</TD>
<TD align="left">*10 x (liter / minute) / meter<sup>2</sup> = liter / (minute &#215;
meter<sup>2</sup>)</TD></TR>

<TR align="left">
<TD align="left">10*3/mm3</TD>
<TD align="left">*10<sup>3</sup>/ cubic millimeter (e.g., white blood cell count)</TD></TR>

<TR align="left">
<TD align="left">10*3/L</TD>
<TD align="left">*10<sup>3</sup>/ Liter</TD></TR>

<TR align="left">
<TD align="left">10*3/mL</TD>
<TD align="left">*10<sup>3</sup>/ milliliter</TD></TR>

<TR align="left">
<TD align="left">10*6/mm3</TD>
<TD align="left">*10<sup>6</sup>/ millimeter<sup>3</sup></TD></TR>

<TR align="left">
<TD align="left">10*6/L</TD>
<TD align="left">*10<sup>6</sup>/ Liter</TD></TR>

<TR align="left">
<TD align="left">10*6/mL</TD>
<TD align="left">*10<sup>6</sup>/ milliliter</TD></TR>

<TR align="left">
<TD align="left">10*9/mm3</TD>
<TD align="left">*10<sup>9</sup>/ millimeter<sup>3
</sup></TD></TR>

<TR align="left">
<TD align="left">10*9/L</TD>
<TD align="left">*10<sup>9</sup>/ Liter</TD></TR>

<TR align="left">
<TD align="left">10*9/mL</TD>
<TD align="left">*10<sup>9</sup>/ milliliter</TD></TR>

<TR align="left">
<TD align="left">10*12/L</TD>
<TD align="left">*10<sup>12</sup>/ Liter</TD></TR>

<TR align="left">
<TD align="left">10*3(rbc)</TD>
<TD align="left">*1000 red blood cells<sup>[dagger]</sup></TD></TR>

<TR align="left">
<TD align="left">a/m</TD>
<TD align="left">Ampere per meter</TD></TR>

<TR align="left">
<TD align="left">(arb_u)</TD>
<TD align="left">*Arbitrary unit</TD></TR>

<TR align="left">
<TD align="left">bar</TD>
<TD align="left">Bar (pressure; 1 bar = 100 kilopascals)</TD></TR>

<TR align="left">
<TD align="left">/min</TD>
<TD align="left">Beats Per Minute</TD></TR>

<TR align="left">
<TD align="left">bq</TD>
<TD align="left">Becquerel</TD></TR>

<TR align="left">
<TD align="left">(bdsk_u)</TD>
<TD align="left">*Bodansky Units</TD></TR>

<TR align="left">
<TD align="left">(bsa)</TD>
<TD align="left">*Body surface area</TD></TR>

<TR align="left">
<TD align="left">(cal)</TD>
<TD align="left">*Calorie</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left">*Catalytic Fraction</TD></TR>

<TR align="left">
<TD align="left">/L</TD>
<TD align="left">Cells / Liter</TD></TR>

<TR align="left">
<TD align="left">cm</TD>
<TD align="left"> Centimeter</TD></TR>

<TR align="left">
<TD align="left">cm_h20</TD>
<TD align="left">* Centimeters of water =H<sub>2</sub>0 (pressure)</TD></TR>

<TR align="left">
<TD align="left">cm_h20.s/L</TD>
<TD align="left">Centimeters H<sub>2</sub>0 / (liter / second) = (centimeters H<sub>2</sub>0
&#215; second) / liter (e.g., mean pulmonary resistance)</TD></TR>

<TR align="left">
<TD align="left">cm_h20/(s.m)</TD>
<TD align="left">(Centimeters H<sub>2</sub>0 / second) / meter = centimeters H<sub>2</sub>0 /
(second &#215; meter) (e.g., pulmonary pressure time product)</TD></TR>

<TR align="left">
<TD align="left">(cfu)</TD>
<TD align="left">*Colony
Forming Units</TD></TR>

<TR align="left">
<TD align="left">m3/s</TD>
<TD align="left">Cubic meter per second</TD></TR>

<TR align="left">
<TD align="left">d</TD>
<TD align="left">Day</TD></TR>

<TR align="left">
<TD align="left">db</TD>
<TD align="left">Decibels </TD></TR>

<TR align="left">
<TD align="left">dba</TD>
<TD align="left">*Decibels a Scale</TD></TR>

<TR align="left">
<TD align="left">cel</TD>
<TD align="left">Degrees Celsius</TD></TR>

<TR align="left">
<TD align="left">deg</TD>
<TD align="left">Degrees of Angle</TD></TR>

<TR align="left">
<TD align="left">(drop)</TD>
<TD align="left">Drop</TD></TR>

<TR align="left">
<TD align="left">10.un.s/cm5</TD>
<TD align="left">
Dyne &#215; Second / centimeter<sup>5</sup>  (1 dyne =  10 micronewton = 10 un)
(e.g., systemic vascular resistance) </TD></TR>

<TR align="left">
<TD align="left">10.un.s/(cm5.m2)</TD>
<TD align="left">
((Dyne &#215; second) / centimeter<sup>5</sup>) / meter<sup>2</sup>  = (Dyne
&#215; second) / (centimeter<sup>5</sup> &#215; meter<sup>2</sup>)     (1 dyne
= 10 micronewton = 10 un) (e.g., systemic vascular resistance/body surface area)</TD></TR>

<TR align="left">
<TD align="left">ev</TD>
<TD align="left">Electron volts (1 electron volt = 160.217 zeptojoules)</TD></TR>

<TR align="left">
<TD align="left">eq</TD>
<TD align="left">Equivalent</TD></TR>

<TR align="left">
<TD align="left">f</TD>
<TD align="left">Farad (capacitance)</TD></TR>

<TR align="left">
<TD align="left">fg</TD>
<TD align="left">Femtogram</TD></TR>

<TR align="left">
<TD align="left">fL</TD>
<TD align="left">Femtoliter</TD></TR>

<TR align="left">
<TD align="left">fmol</TD>
<TD align="left">Femtomole</TD></TR>

<TR align="left">
<TD align="left">/mL</TD>
<TD align="left">*Fibers / milliliter</TD></TR>

<TR align="left">
<TD align="left">g</TD>
<TD align="left">Gram</TD></TR>

<TR align="left">
<TD align="left"><sub>g/d</sub></TD>
<TD align="left">*Gram/ Day</TD></TR>

<TR align="left">
<TD align="left">g/dL</TD>
<TD align="left">Gram / Deciliter</TD></TR>

<TR align="left">
<TD align="left">g/hr</TD>
<TD align="left">Gram / Hour</TD></TR>

<TR align="left">
<TD align="left">g/(8.hr)</TD>
<TD align="left">*Gram
/ 8 Hour Shift</TD></TR>

<TR align="left">
<TD align="left">g/kg</TD>
<TD align="left">Gram / Kilogram (e.g., mass dose of medication per body weight)</TD></TR>

<TR align="left">
<TD align="left">g/(kg.d)</TD>
<TD align="left">(Gram / Kilogram) / Day = gram / (kilogram &#215; day) (e.g., mass dose of
medication per body weight per day)</TD></TR>

<TR align="left">
<TD align="left">g/(kg.hr)</TD>
<TD align="left">(Gram / Kilogram) / Hour = gram / (kilogram &#215; hour)<sub> </sub>(e.g., mass
dose of medication per body weight per hour)</TD></TR>

<TR align="left">
<TD align="left">g/(8.kg.hr)</TD>
<TD align="left">(Gram / Kilogram) /8 Hour Shift = gram / (kilogram &#215; 8 hour shift)<sub>
</sub>(e.g., mass dose of medication per body weight per 8 hour shift)</TD></TR>

<TR align="left">
<TD align="left">g/(kg.min)</TD>
<TD align="left">
(Gram / Kilogram) / Minute = gram / (kilogram &#215; minute<sub>) </sub>(e.g.,
mass dose of medication per body weight per minute)</TD></TR>

<TR align="left">
<TD align="left">g/L</TD>
<TD align="left">Gram / Liter</TD></TR>

<TR align="left">
<TD align="left">g/m2</TD>
<TD align="left">Gram / Meter<sup>2</sup> <br>
(e.g., mass does of medication per body surface area)</TD></TR>

<TR align="left">
<TD align="left">g/min</TD>
<TD align="left">Gram / Minute</TD></TR>

<TR align="left">
<TD align="left">g.m/(hb)</TD>
<TD align="left">
Gram &#215; meter / heart beat <br>
(e.g., ventricular stroke work)</TD></TR>

<TR align="left">
<TD align="left">g.m/((hb).m2)</TD>
<TD align="left">
(Gram &#215; meter/ heartbeat) / meter<sup>2</sup> = (gram &#215; meter) /
(heartbeat &#215; meter<sup>2</sup>) <br>
(e.g., ventricular stroke work/body surface area,  ventricular stroke work index)</TD></TR>

<TR align="left">
<TD align="left">g(creat)</TD>
<TD align="left">*Gram creatinine</TD></TR>

<TR align="left">
<TD align="left">g(hgb)</TD>
<TD align="left">*Gram hemoglobin</TD></TR>

<TR align="left">
<TD align="left">g.m</TD>
<TD align="left">Gram meter</TD></TR>

<TR align="left">
<TD align="left">g(tot_nit)</TD>
<TD align="left">*Gram total nitrogen</TD></TR>

<TR align="left">
<TD align="left">g(tot_prot)</TD>
<TD align="left">*Gram total protein</TD></TR>

<TR align="left">
<TD align="left">g(wet_tis)</TD>
<TD align="left">*Gram wet weight tissue</TD></TR>

<TR align="left">
<TD align="left">gy</TD>
<TD align="left">Grey (absorbed radiation dose)</TD></TR>

<TR align="left">
<TD align="left">hL</TD>
<TD align="left">Hectaliter = 10<sup>2</sup> liter</TD></TR>

<TR align="left">
<TD align="left">h</TD>
<TD align="left">Henry</TD></TR>

<TR align="left">
<TD align="left">in</TD>
<TD align="left">Inches</TD></TR>

<TR align="left">
<TD align="left">in_hg</TD>
<TD align="left">Inches of Mercury (=Hg)</TD></TR>

<TR align="left">
<TD align="left">iu</TD>
<TD align="left">*International Unit</TD></TR>

<TR align="left">
<TD align="left">iu/d</TD>
<TD align="left">*International Unit / Day</TD></TR>

<TR align="left">
<TD align="left">iu/hr</TD>
<TD align="left">*International Unit / Hour</TD></TR>

<TR align="left">
<TD align="left">iu/kg</TD>
<TD align="left">International Unit / Kilogram</TD></TR>

<TR align="left">
<TD align="left">iu/L</TD>
<TD align="left">*International Unit / Liter</TD></TR>

<TR align="left">
<TD align="left">iu/mL</TD>
<TD align="left">*International Unit / Milliliter</TD></TR>

<TR align="left">
<TD align="left">iu/min</TD>
<TD align="left">*International Unit / Minute</TD></TR>

<TR align="left">
<TD align="left">j/L</TD>
<TD align="left">Joule/liter <br>(e.g., work of breathing)</TD></TR>

<TR align="left">
<TD align="left">kat</TD>
<TD align="left">*Katal</TD></TR>

<TR align="left">
<TD align="left">kat/kg</TD>
<TD align="left">*Katal / Kilogram</TD></TR>

<TR align="left">
<TD align="left">kat/L</TD>
<TD align="left">*Katal / Liter</TD></TR>

<TR align="left">
<TD align="left">k/watt</TD>
<TD align="left">Kelvin per watt</TD></TR>

<TR align="left">
<TD align="left">(kcal)</TD>
<TD align="left">Kilocalorie (1 kcal = 6.693 kilojoule)</TD></TR>

<TR align="left">
<TD align="left">(kcal)/d</TD>
<TD align="left">*Kilocalorie/ Day</TD></TR>

<TR align="left">
<TD align="left">(kcal)/hr</TD>
<TD align="left">*Kilocalorie / Hour</TD></TR>

<TR align="left">
<TD align="left">(kcal)/(8.hr)</TD>
<TD align="left">*Kilocalorie / 8 Hours Shift</TD></TR>

<TR align="left">
<TD align="left">kg</TD>
<TD align="left">Kilogram</TD></TR>

<TR align="left">
<TD align="left">kg(body_wt)</TD>
<TD align="left">* kilogram body weight</TD></TR>

<TR align="left">
<TD align="left">kg/m3</TD>
<TD align="left">Kilogram per cubic meter</TD></TR>

<TR align="left">
<TD align="left">kh/h</TD>
<TD align="left">Kilogram per hour</TD></TR>

<TR align="left">
<TD align="left">kg/L</TD>
<TD align="left">Kilogram / liter</TD></TR>

<TR align="left">
<TD align="left">kg/min</TD>
<TD align="left">Kilogram per minute</TD></TR>

<TR align="left">
<TD align="left">kg/mol</TD>
<TD align="left">Kilogram / mole</TD></TR>

<TR align="left">
<TD align="left">kg/s</TD>
<TD align="left">Kilogram / second</TD></TR>

<TR align="left">
<TD align="left">kg/(s.m2)</TD>
<TD align="left">(Kilogram / second)/ meter<sup>2</sup> = kilogram / (second &#215;
meter<sup>2</sup>)</TD></TR>

<TR align="left">
<TD align="left">kg/ms</TD>
<TD align="left">Kilogram per square meter</TD></TR>

<TR align="left">
<TD align="left">kg.m/s</TD>
<TD align="left">Kilogram meter per second</TD></TR>

<TR align="left">
<TD align="left">kpa</TD>
<TD align="left">Kilopascal (1 mmHg = 0.1333 kilopascals)</TD></TR>

<TR align="left">
<TD align="left">ks</TD>
<TD align="left">Kilosecond</TD></TR>

<TR align="left">
<TD align="left">(ka_u)</TD>
<TD align="left">King-Armstrong Unit</TD></TR>

<TR align="left">
<TD align="left">(knk_u)</TD>
<TD align="left">*Kunkel Units</TD></TR>

<TR align="left">
<TD align="left">L</TD>
<TD align="left">Liter</TD></TR>

<TR align="left">
<TD align="left">L/d</TD>
<TD align="left">*Liter / Day</TD></TR>

<TR align="left">
<TD align="left">L/hr</TD>
<TD align="left">Liter / hour</TD></TR>

<TR align="left">
<TD align="left">L/(8.hr)</TD>
<TD align="left">*Liter / 8 hour shift</TD></TR>

<TR align="left">
<TD align="left">L/kg</TD>
<TD align="left">Liter / kilogram</TD></TR>

<TR align="left">
<TD align="left">L/min</TD>
<TD align="left">Liter / minute</TD></TR>

<TR align="left">
<TD align="left">L/(min.m2)</TD>
<TD align="left">(Liter / minute) / meter<sup>2</sup> = liter / (minute &#215;
meter<sup>2</sup>) <br>(e.g., cardiac output/body surface area = cardiac index)</TD></TR>

<TR align="left">
<TD align="left">L/s</TD>
<TD align="left">Liter / second <br>(e.g., peak expiratory flow)</TD></TR>

<TR align="left">
<TD align="left">L.s</TD>
<TD align="left">Liter / second / second<sup>2</sup>  = liter &#215; second</TD></TR>

<TR align="left">
<TD align="left">lm</TD>
<TD align="left">Lumen</TD></TR>

<TR align="left">
<TD align="left">lm/m2</TD>
<TD align="left">Lumen / Meter<sup>2</sup></TD></TR>

<TR align="left">
<TD align="left">(mclg_u)</TD>
<TD align="left">*MacLagan Units</TD></TR>

<TR align="left">
<TD align="left">mas</TD>
<TD align="left">Megasecond</TD></TR>

<TR align="left">
<TD align="left">m</TD>
<TD align="left">Meter</TD></TR>

<TR align="left">
<TD align="left">m2</TD>
<TD align="left">Meter<sup>2</sup> <br>(e.g., body surface area)</TD></TR>

<TR align="left">
<TD align="left">m/s</TD>
<TD align="left">Meter / Second</TD></TR>

<TR align="left">
<TD align="left">m/s2</TD>
<TD align="left">Meter / Second<sup>2</sup></TD></TR>

<TR align="left">
<TD align="left">ueq</TD>
<TD align="left">*Microequivalents</TD></TR>

<TR align="left">
<TD align="left">ug</TD>
<TD align="left">Microgram</TD></TR>

<TR align="left">
<TD align="left">ug/d</TD>
<TD align="left">Microgram / Day</TD></TR>

<TR align="left">
<TD align="left">ug/dL</TD>
<TD align="left">Microgram / Deciliter</TD></TR>

<TR align="left">
<TD align="left">ug/g</TD>
<TD align="left">Microgram / Gram</TD></TR>

<TR align="left">
<TD align="left">ug/hr</TD>
<TD align="left">*Microgram / Hour</TD></TR>

<TR align="left">
<TD align="left">ug(8hr)</TD>
<TD align="left">Microgram / 8 Hour Shift</TD></TR>

<TR align="left">
<TD align="left">ug/kg</TD>
<TD align="left">Microgram / Kilogram</TD></TR>

<TR align="left">
<TD align="left">mg/(kg.d)</TD>
<TD align="left">
(Microgram / Kilogram) /Day = microgram / (kilogram &#215; day) (e.g., mass
dose of medication per patient body weight per day)</TD></TR>

<TR align="left">
<TD align="left">mg/(kg.hr)</TD>
<TD align="left">
(Microgram / Kilogram) / Hour = microgram / (kilogram &#215; hours) (e.g., mass
dose of medication per patient body weight per hour)</TD></TR>

<TR align="left">
<TD align="left">mg/(8.hr.kg)</TD>
<TD align="left">
(Microgram / Kilogram) / 8 hour shift  = microgram / (kilogram &#215; 8 hour
shift) <br>
(e.g., mass dose of medication  per patient body weight per 8 hour shift)</TD></TR>

<TR align="left">
<TD align="left">mg/(kg.min)</TD>
<TD align="left">
(Microgram / Kilogram) / Minute  = microgram / (kilogram &#215; minute) <br>
(e.g., mass dose of medication per patient body weight per minute)</TD></TR>

<TR align="left">
<TD align="left">ug/L</TD>
<TD align="left">Microgram / Liter</TD></TR>

<TR align="left">
<TD align="left">ug/m2</TD>
<TD align="left">Microgram / Meter<sup>2</sup> (e.g., mass dose of medication per patient body
surface area)</TD></TR>

<TR align="left">
<TD align="left">ug/min</TD>
<TD align="left">Microgram / Minute</TD></TR>

<TR align="left">
<TD align="left">uiu</TD>
<TD align="left">*Micro international unit </TD></TR>

<TR align="left">
<TD align="left">ukat</TD>
<TD align="left">*Microkatel</TD></TR>

<TR align="left">
<TD align="left">um</TD>
<TD align="left">Micrometer (Micron)</TD></TR>

<TR align="left">
<TD align="left">umol</TD>
<TD align="left">Micromole     </TD></TR>

<TR align="left">
<TD align="left">umol/d</TD>
<TD align="left">Micromole / Day</TD></TR>

<TR align="left">
<TD align="left">umol/L</TD>
<TD align="left">Micromole / Liter</TD></TR>

<TR align="left">
<TD align="left">umol/min</TD>
<TD align="left">Micromole / Minute</TD></TR>

<TR align="left">
<TD align="left">us</TD>
<TD align="left">Microsecond</TD></TR>

<TR align="left">
<TD align="left">uv</TD>
<TD align="left">Microvolt</TD></TR>

<TR align="left">
<TD align="left">mbar</TD>
<TD align="left">Millibar (1 millibar = 100 pascals)</TD></TR>

<TR align="left">
<TD align="left">mbar.s/L</TD>
<TD align="left">Millibar / (liter / second) =(millibar &#215; second) / liter (e.g., expiratory
resistance)</TD></TR>

<TR align="left">
<TD align="left">meq</TD>
<TD align="left">*Milliequivalent</TD></TR>

<TR align="left">
<TD align="left">meq/d</TD>
<TD align="left">*Milliequivalent / Day</TD></TR>

<TR align="left">
<TD align="left">meq/hr</TD>
<TD align="left">*Milliequivalent / Hour</TD></TR>

<TR align="left">
<TD align="left">meq/(8.hr)</TD>
<TD align="left">Milliequivalent / 8 Hour Shift</TD></TR>

<TR align="left">
<TD align="left">meq/kg</TD>
<TD align="left">
Milliequivalent / Kilogram (e.g., dose of medication in milliequivalents per
patient body weight)</TD></TR>

<TR align="left">
<TD align="left">meq/(kg.d)</TD>
<TD align="left">
(Milliequivalents / Kilogram) / Day = milliequivalents / (kilogram &#215; day)
(e.g., dose of medication in milliequivalents per patient body weight per day)</TD></TR>

<TR align="left">
<TD align="left">meq/(kg.hr)</TD>
<TD align="left">
(Milliequivalents / Kilogram) / Hour  = milliequivalents / (kilogram &#215;
hour) (e.g., dose of medication in milliequivalents per patient body weight per
hour)</TD></TR>

<TR align="left">
<TD align="left">meq/(8.hr.kg)</TD>
<TD align="left">
(Milliequivalents / Kilogram) / 8 Hour Shift  = milliequivalents / (kilogram
&#215; 8 hour shift) (e.g., dose of medication  in milliequivalents per patient
body weight per 8 hour shift)</TD></TR>

<TR align="left">
<TD align="left">meq/(kg.min)</TD>
<TD align="left">
(Milliequivalents / Kilogram) / Minute  = milliequivalents / (kilogram &#215;
minute) (e.g., dose of medication  in milliequivalents per patient body weight
per minute)</TD></TR>

<TR align="left">
<TD align="left">meq/L</TD>
<TD align="left">Milliequivalent / Liter</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left">
Milliequivalent / Meter<sup>2</sup> (e.g., dose of medication in
milliequivalents per patient body surface area)</TD></TR>

<TR align="left">
<TD align="left">meq/min</TD>
<TD align="left">Milliequivalent / Minute</TD></TR>

<TR align="left">
<TD align="left">mg</TD>
<TD align="left">Milligram</TD></TR>

<TR align="left">
<TD align="left">mg/m3</TD>
<TD align="left">Milligram / Meter<sup>3</sup></TD></TR>

<TR align="left">
<TD align="left">mg/d</TD>
<TD align="left">Milligram / Day</TD></TR>

<TR align="left">
<TD align="left">mg/dL</TD>
<TD align="left">Milligram / Deciliter</TD></TR>

<TR align="left">
<TD align="left">mg/hr</TD>
<TD align="left">Milligram / Hour</TD></TR>

<TR align="left">
<TD align="left">mg/(8.hr)</TD>
<TD align="left">Milligram / 8 Hour shift</TD></TR>

<TR align="left">
<TD align="left">mg/kg</TD>
<TD align="left">Milligram / Kilogram</TD></TR>

<TR align="left">
<TD align="left">mg/(kg.d)</TD>
<TD align="left">
(Milligram / Kilogram) / Day = milligram / (kilogram &#215; day) (e.g., mass
dose of medication per patient body weight per day)</TD></TR>

<TR align="left">
<TD align="left">mg/(kg.hr)</TD>
<TD align="left">
(Milligram / Kilogram) / Hour  = milligram/ (kilogram &#215; hour) (e.g., mass
dose of medication per patient body weight per hour)</TD></TR>

<TR align="left">
<TD align="left">mg/(8.hr.kg)</TD>
<TD align="left">
(Milligram / Kilogram) /8 Hour Shift = milligram / (kilogram &#215; 8 hour
shift) (e.g., mass dose of medication per patient body weight per 8 hour shift)</TD></TR>

<TR align="left">
<TD align="left">mg/(kg.min)</TD>
<TD align="left">
(Milligram / Kilogram) / Minute  = milligram / (kilogram &#215; minute) (e.g.,
mass dose of medication per patient body weight per hour)</TD></TR>

<TR align="left">
<TD align="left">mg/L</TD>
<TD align="left">Milligram / Liter</TD></TR>

<TR align="left">
<TD align="left">mg/m2</TD>
<TD align="left">
Milligram / Meter<sup>2</sup> (e.g., mass dose of medication per patient body
surface area)</TD></TR>

<TR align="left">
<TD align="left">mg/min</TD>
<TD align="left">Milligram / Minute</TD></TR>

<TR align="left">
<TD align="left">mL</TD>
<TD align="left">Milliliter</TD></TR>

<TR align="left">
<TD align="left">mL/cm_h20</TD>
<TD align="left">Milliliter / Centimeters of Water (H<sub>2</sub>0) (e.g., dynamic lung
compliance)</TD></TR>

<TR align="left">
<TD align="left">mL/d</TD>
<TD align="left">*Milliliter / Day</TD></TR>

<TR align="left">
<TD align="left">mL/(hb)</TD>
<TD align="left">
Milliliter / Heart Beat (e.g., stroke volume)</TD></TR>

<TR align="left">
<TD align="left">mL/((hb).m2)</TD>
<TD align="left">
(Milliliter / Heart Beat) / Meter<sup>2</sup> = Milliliter / (Heart Beat &#215;
Meter<sup>2</sup>) (e.g., ventricular stroke volume index)</TD></TR>

<TR align="left">
<TD align="left">mL/hr</TD>
<TD align="left">*Milliliter / Hour</TD></TR>

<TR align="left">
<TD align="left">mL/(8.hr)</TD>
<TD align="left">*Milliliter
/ 8 Hour Shift</TD></TR>

<TR align="left">
<TD align="left">mL/kg</TD>
<TD align="left">Milliliter / Kilogram  (e.g., volume dose of medication or treatment per
patient body weight)</TD></TR>

<TR align="left">
<TD align="left">mL/(kg.d)</TD>
<TD align="left">
(Milliliter / Kilogram) / Day  = milliliter / (kilogram &#215; day) (e.g.,
volume dose of medication or treatment per patient body weight per day)</TD></TR>

<TR align="left">
<TD align="left">mL/(kg.hr)</TD>
<TD align="left">
(Milliliter / Kilogram) / Hour = milliliter / (kilogram &#215; hour) (e.g.,
volume dose of medication or treatment per patient body weight per hour)</TD></TR>

<TR align="left">
<TD align="left">mL/(8.hr.kg)</TD>
<TD align="left">
(Milliliter / Kilogram) / 8 Hour Shift = milliliter / (kilogram &#215; 8 hour
shift) (e.g., volume dose of medication or treatment per body weight per 8 hour
shift)</TD></TR>

<TR align="left">
<TD align="left">mL/(kg.min)</TD>
<TD align="left">
(Milliliter / Kilogram) / Minute = milliliter / (kilogram &#215; minute) (e.g.,
volume dose of medication or treatment per patient body weight per minute)</TD></TR>

<TR align="left">
<TD align="left">mL/m2</TD>
<TD align="left">
Milliliter / Meter<sup>2</sup> (e.g., volume of medication or other treatment
per patient body surface area)</TD></TR>

<TR align="left">
<TD align="left">mL/mbar</TD>
<TD align="left">
Milliliter / Millibar (e.g., dynamic lung compliance)</TD></TR>

<TR align="left">
<TD align="left">mL/min</TD>
<TD align="left">
Milliliter / Minute</TD></TR>

<TR align="left">
<TD align="left">mL/(min.m2)</TD>
<TD align="left">
(Milliliter / Minute) / Meter<sup>2</sup>  = milliliter / (minute &#215;
meter<sup>2</sup>) (e.g., milliliters of prescribed infusion per body surface
area; oxygen consumption index)</TD></TR>

<TR align="left">
<TD align="left">mL/s</TD>
<TD align="left">Milliliter / Second</TD></TR>

<TR align="left">
<TD align="left">mm</TD>
<TD align="left">Millimeter</TD></TR>

<TR align="left">
<TD align="left">mm(hg)</TD>
<TD align="left">*Millimeter (HG) (1 mm Hg = 133.322 kilopascals)</TD></TR>

<TR align="left">
<TD align="left">mm/hr</TD>
<TD align="left">Millimeter/ Hour</TD></TR>

<TR align="left">
<TD align="left">mmol/kg</TD>
<TD align="left">Millimole / Kilogram  (e.g., molar dose of medication per patient body weight)</TD></TR>

<TR align="left">
<TD align="left">mmol/(kg.d)</TD>
<TD align="left">(Millimole / Kilogram) / Day = millimole / (kilogram &#215; day) (e.g., molar
dose of medication per patient body weight per day)</TD></TR>

<TR align="left">
<TD align="left">mmol/(kg.hr)</TD>
<TD align="left">
(Millimole / Kilogram) / Hour = millimole / (kilogram &#215; hour) (e.g., molar
dose of medication per patient body weight per hour)</TD></TR>

<TR align="left">
<TD align="left">mmol/(8.hr.kg)</TD>
<TD align="left">
(Millimole / Kilogram) / 8 Hour Shift = millimole / (kilogram &#215; 8 hour
shift) (e.g., molar dose of medication  per patient body weight per 8 hour shift)</TD></TR>

<TR align="left">
<TD align="left">mmol/(kg.min)</TD>
<TD align="left">
(Millimole / Kilogram) / Minute = millimole / (kilogram &#215; minute) (e.g.,
molar dose of medication per patient body weight per minute)</TD></TR>

<TR align="left">
<TD align="left">mmol/L</TD>
<TD align="left">Millimole / Liter</TD></TR>

<TR align="left">
<TD align="left">mmol/hr</TD>
<TD align="left">Millimole / Hour</TD></TR>

<TR align="left">
<TD align="left">mmol/(8hr)</TD>
<TD align="left">Millimole / 8 Hour Shift</TD></TR>

<TR align="left">
<TD align="left">mmol/min</TD>
<TD align="left">Millimole / Minute</TD></TR>

<TR align="left">
<TD align="left">mmol/m2</TD>
<TD align="left">Millimole / Meter<sup>2</sup> (e.g., molar dose of medication per patient body
surface area)</TD></TR>

<TR align="left">
<TD align="left">mosm/L</TD>
<TD align="left">*Milliosmole / Liter</TD></TR>

<TR align="left">
<TD align="left">ms</TD>
<TD align="left">Milliseconds</TD></TR>

<TR align="left">
<TD align="left">mv</TD>
<TD align="left">Millivolts</TD></TR>

<TR align="left">
<TD align="left">miu/mL</TD>
<TD align="left">*Milliunit / Milliliter</TD></TR>

<TR align="left">
<TD align="left">mol/m3</TD>
<TD align="left">Mole per cubic meter</TD></TR>

<TR align="left">
<TD align="left">mol/kg</TD>
<TD align="left">Mole / Kilogram</TD></TR>

<TR align="left">
<TD align="left">mol/(kg.s)</TD>
<TD align="left">(Mole / Kilogram) / Second = mole / (kilogram &#215; second)</TD></TR>

<TR align="left">
<TD align="left">mol/L</TD>
<TD align="left">Mole / Liter</TD></TR>

<TR align="left">
<TD align="left">mol/s</TD>
<TD align="left">Mole / Second</TD></TR>

<TR align="left">
<TD align="left">ng</TD>
<TD align="left">Nanogram</TD></TR>

<TR align="left">
<TD align="left">ng/d</TD>
<TD align="left">Nanogram / Day</TD></TR>

<TR align="left">
<TD align="left">ng/hr</TD>
<TD align="left">*Nanogram
/ Hour</TD></TR>

<TR align="left">
<TD align="left">ng/(8.hr)</TD>
<TD align="left">Nanogram / 8 Hour shift</TD></TR>

<TR align="left">
<TD align="left">ng/L</TD>
<TD align="left">Nanogram / Liter</TD></TR>

<TR align="left">
<TD align="left">ng/kg</TD>
<TD align="left">Nanogram / Kilogram (e.g., mass dose of medication  per patient body weight)</TD></TR>

<TR align="left">
<TD align="left">ng/(kg.d)</TD>
<TD align="left">
(Nanogram / Kilogram) / Day = nanogram / (kilogram &#215; day) (e.g., mass dose
of medication per patient body weight per day)</TD></TR>

<TR align="left">
<TD align="left">ng/(kg.hr)</TD>
<TD align="left">
(Nanogram / Kilogram) / Hour = nanogram / (kilogram &#215; hour) (e.g., mass
dose of medication per patient body weight per hour)</TD></TR>

<TR align="left">
<TD align="left">ng/(8.hr.kg)</TD>
<TD align="left">
(Nanogram / Kilogram) / 8 Hour Shift = nanogram / (kilogram &#215; 8 hour
shift) (e.g., mass dose of medication per patient body weight per 8 hour shift)</TD></TR>

<TR align="left">
<TD align="left">ng/(kg.min)</TD>
<TD align="left">
(Nanogram / Kilogram) / Minute = nanogram / (kilogram &#215; minute) (e.g.,
mass dose of medication  per patient body weight per minute)</TD></TR>

<TR align="left">
<TD align="left">ng/m2</TD>
<TD align="left">
Nanogram / Meter<sup>2</sup> (e.g., mass dose of medication per patient body
surface area)</TD></TR>

<TR align="left">
<TD align="left">ng/mL</TD>
<TD align="left">Nanogram / Milliliter</TD></TR>

<TR align="left">
<TD align="left">ng/min</TD>
<TD align="left">*Nanogram / Minute</TD></TR>

<TR align="left">
<TD align="left">ng/s</TD>
<TD align="left">*Nanogram / Second</TD></TR>

<TR align="left">
<TD align="left">nkat</TD>
<TD align="left">*Nanokatel</TD></TR>

<TR align="left">
<TD align="left">nm</TD>
<TD align="left">Nanometer</TD></TR>

<TR align="left">
<TD align="left">nmol/s</TD>
<TD align="left">Nanomole / Second</TD></TR>

<TR align="left">
<TD align="left">ns</TD>
<TD align="left">Nanosecond</TD></TR>

<TR align="left">
<TD align="left">n</TD>
<TD align="left">Newton (force)</TD></TR>

<TR align="left">
<TD align="left">n.s</TD>
<TD align="left">Newton second</TD></TR>

<TR align="left">
<TD align="left">(od)</TD>
<TD align="left">*O.D. (optical density)</TD></TR>

<TR align="left">
<TD align="left">ohm</TD>
<TD align="left">Ohm (electrical resistance)</TD></TR>

<TR align="left">
<TD align="left">ohm.m</TD>
<TD align="left">Ohm meter</TD></TR>

<TR align="left">
<TD align="left">osmol</TD>
<TD align="left">Osmole</TD></TR>

<TR align="left">
<TD align="left">osmol/kg</TD>
<TD align="left">Osmole per kilogram</TD></TR>

<TR align="left">
<TD align="left">osmol/L</TD>
<TD align="left">Osmole per liter</TD></TR>

<TR align="left">
<TD align="left">/m3</TD>
<TD align="left">*Particles / Meter<sup>3
</sup></TD></TR>

<TR align="left">
<TD align="left">/L</TD>
<TD align="left">*Particles / Liter</TD></TR>

<TR align="left">
<TD align="left">/(tot)</TD>
<TD align="left">*Particles / Total Count</TD></TR>

<TR align="left">
<TD align="left">(ppb)</TD>
<TD align="left">*Parts Per Billion</TD></TR>

<TR align="left">
<TD align="left">(ppm)</TD>
<TD align="left">*Parts Per Million</TD></TR>

<TR align="left">
<TD align="left">(ppth)</TD>
<TD align="left">Parts per thousand</TD></TR>

<TR align="left">
<TD align="left">(ppt)</TD>
<TD align="left">Parts per trillion (10^12)</TD></TR>

<TR align="left">
<TD align="left">pal</TD>
<TD align="left">Pascal (pressure)</TD></TR>

<TR align="left">
<TD align="left">/(hpf)</TD>
<TD align="left">*Per High Power Field</TD></TR>

<TR align="left">
<TD align="left">(ph)</TD>
<TD align="left">*pH</TD></TR>

<TR align="left">
<TD align="left">pa</TD>
<TD align="left">Picoampere</TD></TR>

<TR align="left">
<TD align="left">pg</TD>
<TD align="left">Picogram</TD></TR>

<TR align="left">
<TD align="left">pg/L</TD>
<TD align="left">Picogram / Liter</TD></TR>

<TR align="left">
<TD align="left">pg/mL</TD>
<TD align="left">Picogram / Milliliter</TD></TR>

<TR align="left">
<TD align="left">pkat</TD>
<TD align="left">*Picokatel</TD></TR>

<TR align="left">
<TD align="left">pm</TD>
<TD align="left">Picometer</TD></TR>

<TR align="left">
<TD align="left">pmol</TD>
<TD align="left">*Picomole</TD></TR>

<TR align="left">
<TD align="left">ps</TD>
<TD align="left">Picosecond</TD></TR>

<TR align="left">
<TD align="left">pt</TD>
<TD align="left">Picotesla</TD></TR>

<TR align="left">
<TD align="left">(pu)</TD>
<TD align="left">*P.U.</TD></TR>

<TR align="left">
<TD align="left">%</TD>
<TD align="left">Percent</TD></TR>

<TR align="left">
<TD align="left">dm2/s2</TD>
<TD align="left">
Rem (roentgen equivalent man) = 10<sup>-2</sup> meter<sup>2 </sup>/
second<sup>2</sup> = decimeter<sup>2</sup> / second<sup>2</sup> Dose of
ionizing radiation equivalent to 1 rad of x-ray or gamma ray) [From Dorland's
Medical Dictionary]</TD></TR>

<TR align="left">
<TD align="left">sec</TD>
<TD align="left">
Seconds of arc</TD></TR>

<TR align="left">
<TD align="left">sie</TD>
<TD align="left">Siemens (electrical conductance)</TD></TR>

<TR align="left">
<TD align="left">sv</TD>
<TD align="left">Sievert</TD></TR>

<TR align="left">
<TD align="left">m2/s</TD>
<TD align="left">Square meter / second</TD></TR>

<TR align="left">
<TD align="left">cm2/s</TD>
<TD align="left">Square centimeter / second</TD></TR>

<TR align="left">
<TD align="left">t</TD>
<TD align="left">Tesla (magnetic flux density)</TD></TR>

<TR align="left">
<TD align="left">(td_u)</TD>
<TD align="left">Todd Unit</TD></TR>

<TR align="left">
<TD align="left">v</TD>
<TD align="left">Volt (electric potential difference)</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left">Volume Fraction</TD></TR>

<TR align="left">
<TD align="left">wb</TD>
<TD align="left">Weber (magnetic flux)</TD></TR>

<TR align="left">
<TD align="left">*Starred
items are not genuine ISO, but do not conflict.<br>
[dagger]This approach to units is discouraged by IUPAC. We leave them solely
for backward compatibility</TD>
<TD align="left"><BR></TD></TR></TABLE>
<h6>
<A NAME="Heading95">7.3.2.6.1.3 Local unit codes</A></h6>

<p>Local
codes can be used for the units by indicating the code source of <b>99zzz</b>
in the third component (where 99zzz is an alpha-numeric string).  In the case
of local codes, the text name of the codes or the description of the units
should also be transmitted (in the second component), so that the receiving
system can compare the results with results for the same measurement sent by
another service (refer to Chapter 2, Section 2.8, "Data Types").  An "L" should
be stored in the third component to indicate that the code is locally defined.
More specialized local code designations, as specified in the CE data type
definition, can also be employed.</p>

<h4>
<A NAME="Heading96">7.3.2.7 References range  (ST)   00575 </A></h4>

<p>Components:
 for numeric values in the format:<br>
a)	lower limit-upper limit	(when both lower and upper limits are defined, e.g.,
for potassium 3.5 - 4.5)<br>
b)	&gt; lower limit		(if no upper limit, e.g., &gt;10)<br>
c)	&lt; upper limit		(if no lower limit, e.g., &lt;15)<br>
alphabetical values: the normal value may be reported in this location<br>
Definition:  When the observation quantifies the amount of a toxic substance,
then the upper limit of the range identifies the toxic limit.  If the
observation quantifies a drug, the lower limits identify the lower therapeutic
bounds and the upper limits represent the upper therapeutic bounds above which
toxic side effects are common.</p>

<h4>
<A NAME="Heading97">7.3.2.8 Abnormal flags  (ID)   00576</A></h4>

<p>Definition:
 This field contains a table lookup indicating the normalcy status of the
result.  We strongly recommend sending this value when applicable.  If the
observation is an antimicrobial susceptibility,  the interpretation codes are:
S=susceptible; R=resistant; I=intermediate; MS=moderately susceptible; VS=very
susceptible. (See ASTM 1238 - review for more details).  Refer to <i>HL7</i>
<i>table 0078 - Abnormal flags</i> for valid entries. <br>
When the laboratory can discern the normal status of a textual report, such as
chest X-ray reports or microbiologic culture, these should be reported as N
when normal and A when abnormal.  Multiple codes, e.g., abnormal and worse,
would be separated by a repeat delimiter, e.g., A~W. <br>
<center>Table 0078  Abnormal flags</center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >L</TD>
<TD >Below low normal</TD></TR>

<TR>
<TD >H</TD>
<TD >Above high normal</TD></TR>

<TR>
<TD >LL</TD>
<TD >Below lower panic limits</TD></TR>

<TR>
<TD >HH</TD>
<TD >Above upper panic limits</TD></TR>

<TR>
<TD >&lt;</TD>
<TD >Below absolute low-off instrument scale</TD></TR>

<TR>
<TD >&gt;</TD>
<TD >Above absolute high-off instrument scale</TD></TR>

<TR>
<TD >N</TD>
<TD >Normal (applies to non-numeric results)</TD></TR>

<TR>
<TD >A</TD>
<TD >Abnormal (applies to non-numeric results)</TD></TR>

<TR>
<TD >AA</TD>
<TD >Very abnormal (applies to non-numeric units, analogous to panic limits for numeric
units)</TD></TR>

<TR>
<TD >null</TD>
<TD >No range defined, or normal ranges don't apply</TD></TR>

<TR>
<TD >U</TD>
<TD >Significant change up</TD></TR>

<TR>
<TD >D</TD>
<TD >Significant change down</TD></TR>

<TR>
<TD >B</TD>
<TD >Better-use when direction not relevant</TD></TR>

<TR>
<TD >W</TD>
<TD >Worse-use when direction not relevant</TD></TR>

<TR>
<TD >For microbiology susceptibilities only:</TD>
<TD><BR></TD></TR>

<TR>
<TD >S</TD>
<TD >Susceptible</TD></TR>

<TR>
<TD >R</TD>
<TD >Resistant</TD></TR>

<TR>
<TD >I</TD>
<TD >Intermediate</TD></TR>

<TR>
<TD >MS</TD>
<TD >Moderately
susceptible</TD></TR>

<TR>
<TD >VS</TD>
<TD >Very
susceptible</TD></TR></TABLE><p>Results
may also be reported in <b>shorthand</b> by reporting the normalcy status
without specifying the exact numeric value of the result. Such shorthand is
quite common in clinical notes, where physicians will simply say that <b>the
glucose result was normal.</b>  Such shorthand reporting is also seen in drug
experience reporting. In such cases, the result can be reported in the OBX by
reporting the normalcy code in <i>OBX-8-abnormal flags</i> without specifying
any value in <i>OBX-5-observation value.</i></p>

<h4>
<A NAME="Heading98">7.3.2.9 Probability  (NM)   00577</A></h4>

<p>Definition:
 This field contains the probability of a result being true for results with
categorical values.  It mainly applies to discrete coded results.  It is a
decimal number represented as an ASCII string that must be between 0 and 1,
inclusive. </p>

<h4>
<A NAME="Heading99">7.3.2.10 Nature of abnormal test  (ID)   00578</A></h4>

<p>Definition:
 This field contains the nature of the abnormal test.  Refer to <i>HL7 table
0080 - Nature of abnormal testing</i> for valid values.  As many of the codes
as apply may be included, separated by repeat delimiters. For example, normal
values based on age, sex, and race would be codes as A~S~R.<br>
<center>Table 0080  Nature of abnormal testing </center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >A</TD>
<TD >An
age-based population</TD></TR>

<TR>
<TD >N</TD>
<TD >None - generic normal range</TD></TR>

<TR>
<TD >R</TD>
<TD >A race-based population</TD></TR>

<TR>
<TD >S</TD>
<TD >A sex-based population</TD></TR></TABLE>
<h4>
<A NAME="Heading100">7.3.2.11 Observ result status  (ID)   00579</A></h4>

<p>Definition:
 This field contains the observation result status.  Refer to<i> HL7 table 0085
- Observation result status</i> for valid values. This field reflects the
current completion status of the results for one Observation Identifier.<br>
It is a required field.  Previous versions of HL7 stated this implicitly by
defining a default value of "F." Code <b>F</b> indicates that the result has
been verified to be correct and final.  Code <b>W</b> indicates that the result
has been verified to be wrong (incorrect); a replacement (corrected) result may
be transmitted later.  Code <b>C</b> indicates that data contained in the
<i>OBX-5-observation value</i> field are to replace previously transmitted
(verified and) final result data with the same observation ID (including
suffix, if applicable) and observation sub-ID usually because the previous
results were wrong.  Code <b>D</b> indicates that data previously transmitted
in a result segment with the same observation ID (including suffix) and
observation sub-ID should be deleted.  When changing or deleting a result,
multiple OBX segments with the same observation ID and observation sub-ID are
replaced or deleted as a unit.  Normal progression of results through
intermediate (e.g., `gram positive cocci') to final (e.g., `staphylococcus
aureus') should not be transmitted as <b>C</b> (correction); they should be
transmitted as <b>P</b> or <b>S</b> (depending upon the specific case) until
they are final.<br>
<center>Table 0085 - Observation result status codes interpretation</center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >C</TD>
<TD >Record coming over is a correction and thus replaces a final result</TD></TR>

<TR>
<TD >D</TD>
<TD >Deletes the OBX record</TD></TR>

<TR>
<TD >F</TD>
<TD >Final results;  Can only be changed with a corrected result.</TD></TR>

<TR>
<TD >I</TD>
<TD >Specimen in lab; results pending</TD></TR>

<TR>
<TD >P</TD>
<TD >Preliminary results</TD></TR>

<TR>
<TD >R</TD>
<TD >Results entered -- not verified</TD></TR>

<TR>
<TD >S</TD>
<TD >Partial results</TD></TR>

<TR>
<TD >X</TD>
<TD >Results cannot be obtained for this observation</TD></TR>

<TR>
<TD >U</TD>
<TD >Results
status change to Final.  without retransmitting results already sent as
`preliminary.'  E.g., radiology changes status from preliminary to final</TD></TR>

<TR>
<TD >W</TD>
<TD >Post
original as wrong, e.g., transmitted for wrong patient</TD></TR></TABLE>
<h4>
<A NAME="Heading101">7.3.2.12 Effective date last obs normal value  (TS)   00580</A></h4>

<p>Definition:
 This field contains the changes in the observation methods that would make
values obtained from the old method not comparable with those obtained from the
new method.<br>
Null if there are no normals or units.  If present, a change in this date
compared to date-time recorded, the receiving system's test dictionary should
trigger a manual review of the results to determine whether the new observation
ID should be assigned a new ID in the local system to distinguish the new
results from the old. </p>

<h4>
<A NAME="Heading102">7.3.2.13 User defined access checks  (ST)   00581</A></h4>

<p>Definition:
 This field permits the producer to record results-dependent codes for
classifying the observation at the receiving system.  This field should be
needed only rarely, because most classifications are fixed attributes of the
observation ID and can be defined in the associated observation master file
(see description in Chapter 8). <br>
However, there are a few cases when such controls vary with the value of the
observation in a complex way that the receiving system would not want to
re-calculate.  An example is an antimicrobial susceptibility result. Some
systems prefer to display only the susceptibility results of inexpensive
antimicrobials depending upon the organism, the source of the specimen and the
patient's allergy status.  The sending service wants to send all of the
susceptibilities so that certain privileged users (e.g., Infectious Disease
specialists) can review all of the results but nonprivileged users would see
only the "preferred" antimicrobials to which the organism was susceptible.  We
expect that other cases also occur.</p>

<h4>
<A NAME="Heading103">7.3.2.14 Date-time of the observation  (TS)   00582</A></h4>

<p>Definition:
 This field is required in two circumstances.  The first is when the
observations reported beneath one report header (OBR) have different dates.
This could occur in the case of queries, timed test sequences, or clearance
studies where one measurement within a battery may have a different time than
another measurement. <br>
It is also needed in the case of OBX segments that are being sent by the placer
to the filler, in which case the date of the observation being transmitted is
likely to have no relation to the date of the requested observation.  In
France, requesting services routinely send a set of the last observations along
with the request for a new set of observations.  The date of these observations
is important to the filler laboratories.<br>
In all cases, the observation date-time is the physiologically relevant
date-time or the closest approximation to that date-time.  In the case of tests
performed on specimens, the relevant date-time is the specimen's collection
date-time.  In the case of observations taken directly on the patient (e.g.,
X-ray images, history and physical), the observation date-time is the date-time
that the observation was performed. </p>

<h4>
<A NAME="Heading104">7.3.2.15 Producer's ID  (CE)   00583</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains a unique identifier of the responsible
producing service.  It should be reported explicitly when the test results are
produced at outside laboratories, for example.  When this field is null, the
receiving system assumes that the observations were produced by the sending
organization.  This information supports CLIA regulations in the US.  The code
for producer ID is recorded as a CE data type.  In the US, the Medicare number
of the producing service is suggested as the identifier.</p>

<h4>
<A NAME="Heading105">7.3.2.16 Responsible observer  (XCN)   00584</A></h4>

<p><tt>Components:
 &lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type (ID)&gt;
^&lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID)&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility ID (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  When required, this field contains the identifier of the
individual directly responsible for the observation (i.e., the person who
either performed or verified it).  In a nursing service, the observer is
usually the professional who performed the observation (e.g., took the blood
pressure).  In a laboratory, the observer is the technician who performed or
verified the analysis.  The code for the observer is recorded as a CE data
type.  If the code is sent as a local code, it should be unique and unambiguous
when combined with <i>OBX-15-producer ID</i>.</p>

<h4>
<A NAME="Heading106">7.3.2.17 Observation method  (CE)   00936</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
This optional field can be used to transmit the method or procedure by which an
observation was obtained when the sending system wishes to distinguish among
one measurement obtained by different methods and the distinction is not
implicit in the test ID.  Chemistry laboratories do not usually distinguish
between two different methods used to measure a given serum constituent (e.g.,
serum potassium) as part of the test name.  See the LOINC Users Manual<a
name="fnB2" href="#fn2">[4]</a> for a more complete discussion of these
distinctions.  If an observation producing service wanted to report the method
used to obtain a particular observation, and the method was NOT embedded in the
test name, they can use this field.<br>
The Centers for Disease Control and Prevention (CDC) Method Code (CDCM) (see
<i>Figure 7-3</i>) is one candidate code system for reporting
methods/instruments.  EUCLIDES method codes are another. User-defined tables
are an alternative.
</p>

<h2>
<A NAME="Heading107">7.4 EXAMPLE TRANSACTIONS</A></h2>


<h3>
<A NAME="Heading108">7.4.1 Query/response</A></h3>

<p>The
following is a query of the EKG system for the data for a particular patient
number 0123456-1 for reports that have been modified or created since 1/1/88.
The response ends with a continuation pointer.  A continuation query follows,
in reply to which a continuation response is sent.<br>
Query (QRY)<br>
MSH|^~\&amp;|CBD||EKG||||QRY^R02|CDB22222|P&lt;cr&gt;   <br>
QRD|198904180943|R|I|Q4412|||10|RD|0123456-1|RES&lt;cr&gt;   <br>
QRF|EKG||198801010000&lt;cr&gt;<br>
Response<br>
MSH|^~\&amp;|EKG||CDB||||ORF^R04|X981672|P&lt;cr&gt;   <br>
MSA|AA|CDB22222|P&lt;cr&gt;   <br>
QRD|198904180943|R|I|Q4412|||10|RD|0123456-1|RES&lt;cr&gt;   <br>
QRF|EKG||198804010000&lt;cr&gt;   <br>
PID|1|0123456-1||ROBERTSON^JOHN^H|||||||9821111&lt;cr&gt;   <br>
OBR|1|43215^OE|98765^EKG|93000^EKG
REPORT|R|198801111000|198801111330|||RMT||||<br>
	... 1988011 11330|?|P030||||||198801120930||||||88-126666|A111|<br>
	... VIRANYI ^ANDREW&lt;cr&gt;   <br>
OBX|1|ST|8897-1^QRS COMPLEX:^LN||91|/MIN|60-100||||F&lt;cr&gt;   <br>
OBX|2|ST|8894-8^P WAVE:^LN|||/MIN|60-100||||F&lt;cr&gt;   <br>
OBX|3|ST|8625-6^P-R INTERVAL:^LN||0|/MSEC|1.06-.10||||F&lt;cr&gt;   <br>
OBX|4|ST|8633-0^QRS DURATION:^LN||368|/MSEC|.18-.22||||F&lt;cr&gt;   <br>
               ...   <br>
               ...   <br>
               ...   <br>
OBX|8|CE|8601-7^EKG IMPRESSION:^LN|1|^ATRIAL FIBRILATION||||||F&lt;cr&gt;   <br>
OBX|9|CE|8601-7^EKG IMPRESSION:^LN|2|^ST DEPRESSION||||||F&lt;cr&gt;
OBX|109|FT||93000&amp;ADT^EKG COMMENT||\.in+4\\.ti-4\ 1. When compared with EKG
of<br>
	... 31-oct-88 ventricular rate has increased by 30 bpm.\.sp\\.ti-4\ <br>
	... 2. Criteria for Lateral infarct are no longer present.|||||F&lt;cr&gt;
<br>
OBR|2|43217^OE|98767^EKG|93000^EKG
REPORT||198810311004|198810311004||||?|||198810311004|?|P030||||||198810311744||||||<br>
	... 88-126689|A122|BREAL|WILLIAM&lt;cr&gt;   <br>
               ...   <br>
               ...   <br>
               ...   <br>
DSC|1896X22;0123456-1&lt;cr&gt;   <br>
Continuation query<br>
MSH|^~\&amp;|CDB||EKG||||QRY^R02|CDB22289|P&lt;cr&gt;   <br>
QRD|198904180943|R|I|Q4412|||10|RD|0123456-1|RES&lt;cr&gt;   <br>
QRF|EKG||1988040100000&lt;cr&gt;   <br>
DSC|1896X22;0123456-1&lt;cr&gt;   <br>
Continuation response   <br>
MSH|^~\&amp;|EKG||CDB||||ORF^R04|X981672|P&lt;cr&gt;   <br>
MSA|AA|CDB22289|P&lt;cr&gt;   <br>
QRD|198904180943|R|I|Q4412|||10|RD|0123456-1RES&lt;cr&gt;   <br>
QRF|EKG||198804010000&lt;cr&gt;   <br>
PID||0123456-1||ROBERTSON^JOHN^H|||||||9821111&lt;cr&gt;   <br>
OBR| ...   <br>
     ...   <br>
     ...   
</p>

<h3>
<A NAME="Heading109">7.4.2 Unsolicited</A></h3>

<p>The
following is an unsolicited transmission of radiology data. <br>
MSH|^~\&amp;|XRAY||CDB||||ORU^R01|K172|P&lt;cr&gt;   <br>
PID|1|0123456-1||ROBERTSON^JOHN^H|||||||9821111&lt;cr&gt;   <br>
OBR|1|X89-1501^OE|78912^RD|71020^CHEST XRAY AP &amp;
LATERAL|R|198703291530|19873290800|||JBM|N &lt;cr&gt;<br>
OBX|1|CE|71020&amp;IMP^RADIOLOGIST'S IMPRESSION|4||^MASS LEFT LOWER
LOBE|1||A||F&lt;cr&gt;  <br>
OBX|2|CE|71020&amp;IMP|2|^INFILTRATE RIGHT LOWER LOBE|||A||F&lt;cr&gt;<br>
OBX|3|CE|71020&amp;IMP|3|^HEART SIZE NORMAL|||N||F&lt;cr&gt;<br>
OBX|4|FT|71020&amp;GDT|1|circular density (2 x 2 cm) is seen in the posterior
segment of<br>
	... the LLL.  A second, less well-defined infiltrated circulation density
is<br>
	... seen in the R mid lung field and appears to cross the minor
fissure#||||||F&lt;cr&gt;<br>
OBX|5|CE|71020&amp;REC||71020^Follow up CXR 1 month||30-45||||F&lt;cr&gt; 
</p>

<h3>
<A NAME="Heading110">7.4.3 Example message</A></h3>

<p>Laboratory
message:  electrolytes, CBC, sed rate, blood cultures and susceptibilities <br>
MSH|...<br>
PID|...<br>
Electrolytes:<br>
OBR|1|870930010^OE|CM3562^LAB|80004^ELECTROLYTES|R|198703281530|198703290800|||<br>
	401-0^INTERN^JOE^^^^MD^L|N|||||SER|^SMITH^RICHARD^W.^^^DR.|(319)377-4400|<br>
	This is requestor field #1. Requestor field #2|Diag.serv.field #1.|<br>
	Diag.serv.field #2.|198703311400|||F&lt;cr&gt; <br>
OBX|1|ST|84295^NA||150|mmol/l|136-148|H||A|F|19850301&lt;cr&gt; <br>
OBX|2|ST|84132^K+||4.5|mmol/l|3.5-5|N||N|F|19850301&lt;cr&gt; <br>
OBX|3|ST|82435^CL||102|mmol/l|94-105|N||N|F|19850301&lt;cr&gt; <br>
OBX|4|ST|82374^CO2||27|mmol/l|24-31|N||N|F|19850301&lt;cr&gt; <br>
CBC:<br>
OBR|2|870930011^OE|HEM3268^LAB|85022^CBC|R|198703281530|198703290800|||401-0
^<br>
	INTERN^JOE^^^^MD^L|N||||BLD|^SMITH^RICHARD^W.^^^DR.|(319)377-4400|This is<br>
	requestor field #1.|This is Requestor field #2.|This is lab field #1.|Lab<br>
	field #2.|198703311400|||F&lt;cr&gt; <br>
OBX|1|ST|718-7^HEMOGLOBIN:^LN||13.4|GM/DL|14-18|N||S|F|19860522&lt;cr&gt; <br>
OBX|2|ST|4544-3^HEMOATOCRIT:^LN||40.3|%|42-52|L||S|F|19860522&lt;cr&gt; <br>
OBX|3|ST|789-8^ERYTHROCYTES:^LN||4.56|10*6/ml|4.7-6.1|L||S|F|19860522&lt;cr&gt;
<br>
OBX|4|ST|787-2^ERYTHROCYTE MEAN CORPUSCULAR VOLUME:^LN <br>
   ||88|fl|80-94|N||S|F|19860522&lt;cr&gt; <br>
OBX|5|ST|785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN:^LN  <br>
   ||29.5|pg|27-31|N||N|F|19860522&lt;cr&gt; <br>
OBX|6|ST|786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION:^LN <br>
   ||33|%|33-37|N||N|F|19860522&lt;cr&gt; <br>
OBX|7|ST|6690-2^LEUKOCYTES:^LN||10.7|10*3/ml|4.8-10.8|N||N|F|19860522&lt;cr&gt;
<br>
OBX|8|ST|764-1^NEUTROPHILS BAND FORM/100 LEUKOCYTES:^LN||2|%||||F&lt;cr&gt; <br>
OBX|9|ST|769-0^NEUTROPHILS SEGMENTED/100 LEUKOCYTES:^LN||67|%||||F&lt;cr&gt;
<br>
OBX|10|ST|736-9^LYMPHOCYTES/100 LEUKOCYTES:^LN||29|%||||F&lt;cr&gt; <br>
OBX|11|ST|5905-5^MONOCYTES/100 LEUKOCYTES:^LN||1|%||||F&lt;cr&gt; <br>
OBX|12|ST|713-8^EOSINOPHILS/100 LEUKOCYTES:^LN||2|%||||F&lt;cr&gt;  <br>
Sed rate:<br>
OBR|3|870930011^OE|HEM3269^LAB|4537-7^ERYTHROCYTE SEDIMENTATION RATE:^LN <br>
   |R|198703281530|198703290800|||<br>
	401-0^INTERN^JOE^^^^MD^L|N||||BLD|^SMITH^RICHARD^W.^^^DR.|(319)377-4400|<br>
	This is requestor field #1.|This is Requestor field #2.|This is lab field<br>
	#1.|Lab field #2.|198703311400|||F&lt;cr&gt; <br>
OBX|1|ST|4537-7^ERYTHROCYTE SEDIMENTATION RATE:^LN| <br>
   |7|MM/HR|0-10|N||S|F|19860522|E|1|1792|27&lt;cr&gt; <br>
Parent micro result, identifies organism<br>
OBR|4|2740X^OE|BC376^MIC|87040^Blood culture|R|198703280600|198703290800|||<br>
	99-2^JONES&amp;COLLECTOR|N|Hepatitis risk||198703290830|Bld|<br>
	4010^INTERN^JOE^^^^MD^L|X3472|Requestor field 1|Requestor field 2|<br>
	Producer's field 1|Producer's field 2|198703301000|35.00|MB|F|&lt;cr&gt;<br>
OBX|1|CE|600-7^MICROORGANISM IDENTIFIED:^LN|1|^E Coli|||A||F&lt;cr&gt;<br>
OBX|2|CE|600-7^MICROORGANISM IDENTIFIED:^LN|2|^S Aureus|||A||F&lt;cr&gt;<br>
Child micro result, gives antimicrobials susceptibilities for organism
identified in first OBX of parent<br>
OBR|5|2740X^OE|BC402^MIC|87186^Antibiotic MIC|R|198703281230 <br>
   |198703290800||||G|Hepatitis Risk||198703290830|Bld<br>
   |401.0^INTERN^JOE^^^^MD^L|X3472|||||198703310900|40.00 <br>
   |MB|F|87040^1|||2740X&amp;OE^BC376&amp;MIC&lt;cr&gt;<br>
OBX|1|ST|28-1^AMIPICILLIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|2|ST|60-4^CARBENICILLIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;16|ug/ml||S|||F&lt;cr&gt;<br>
OBX|3|ST|267-5^GENTAMICIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|4|ST|496-0^TETRACYCLINE:SUSC:PT:ISLT:QN:MIC^LN||&lt;1|ug/ml||S|||F&lt;cr&gt;<br>
OBX|5|ST|408-5^PIPERACILLIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;8|ug/ml||S|||F&lt;cr&gt;<br>
OBX|6|ST|145-3^CEFUROXIME:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|7|ST|161-0^CEPHALOTHIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;8|ug/ml||S|||F&lt;cr&gt;<br>
OBX|8|ST|20-8^AMOXICILLIN+CLAVULANATE:SUSC:PT:ISLT:QN:MIC^LN <br>
   ||&lt;4|ug/ml||S|||F&lt;cr&gt;<br>
OBX|9|ST|173-5^CHLORAMPHENICOL:SUSC:PT:ISLT:QN:MIC^LN||&lt;4|ug/ml||S|||F&lt;cr&gt;<br>
OBX|10|ST|508-2^TOBRAMYCIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|11|ST|12-5^AMAKACIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;4|ug/ml||S|||F&lt;cr&gt;<br>
OBX|12|ST|516-5^TRIMETHOPRIM+SULFMOETHOXAZOLE:SUSC:PT:ISLT:QN:MIC^LN| <br>
   |&lt;2/38|ug/ml||S|||F&lt;cr&gt;<br>
OBX|13|ST|76-0^CEFAZOLIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|14|ST|116-4^CEFOXITIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|15|ST|140-4^CEFTRIAXONE:SUSC:PT:ISLT:QN:MIC^LN||&lt;4|ug/ml||S|||F&lt;cr&gt;<br>
OBX|16|ST|133-9^CEFTAZIDIME:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|17|ST|185-9^CIPROFLOXACIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;1|ug/ml||S|||F&lt;cr&gt;<br>
Second micro child result, gives susceptibilities or organism identified by
Second OBX of parent<br>
OBR|6|2740X^OE|BC403^MIC|87186^Antibiotic
MIC|R|198703281230|198703290800||||G|<br>
	Hepatitis risk||198703290830|Bld|401.0^INTERN^JOE^^^^MD^L|X3472|||||<br>
	198703310900|40.00|MB|F|87040^2|||2740X&amp;OE^BC376&amp;MIC&lt;cr&gt;<br>
OBX|1|ST|28-1^AMPICILLIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;8|ug/ml||R|||F&lt;cr&gt;<br>
OBX|2|ST|193-3^CLINDAMYCIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;.25|ug/ml||S|||F&lt;cr&gt;<br>
OBX|3|ST|267-5^GENTAMICIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;1|ug/ml||S|||F&lt;cr&gt;<br>
OBX|4|ST|233-7^ERYTHROMYCIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;.5|ug/ml||S|||F&lt;cr&gt;<br>
OBX|5|ST|383-0^OXACILLIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;.5|ug/ml||S|||F&lt;cr&gt;<br>
OBX|6|ST|524-9^VANCOMYCIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|7|ST|6932-8^PENICILLIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;8|ug/ml||R|||F&lt;cr&gt;<br>
OBX|8|ST|161-0^CEPHALOTHIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;2|ug/ml||S|||F&lt;cr&gt;<br>
OBX|9|ST|173-5^CHLORAMPHENICOL:SUSC:PT:ISLT:QN:MIC^LN||&lt;4|ug/ml||S|||F&lt;cr&gt;<br>
OBX|10|ST|12-5^AMIKACIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;16|ug/ml||S|||F&lt;cr&gt;<br>
OBX|11|ST|185-9^CIPROFLOXACIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;1|ug/ml||S|||F&lt;cr&gt;<br>
OBX|12|ST|428-3^RIFAMPIN:SUSC:PT:ISLT:QN:MIC^LN||&lt;1|ug/ml||S|||F&lt;cr&gt;
<a name="_Ref358356342"></a><a name="_Ref373545099"></a></p>

<h3>
<A NAME="Heading111">7.4.4 Example of narrative report messages</A></h3>

<p>This
example of the body of reports shows the following observation from what are
usually free text reports.  The text within these examples that begins with
**-- and ends with --** are explanatory comments, not a formal part of the
message.  The following outline shows the segments that are included in this
example message.<br>
a)	patient identifying record (PID)<br>
b)	EKG order record (OBR)<br>
c)	EKG coded result record (OBX)<br>
d)	EKG result records (OBX):<br>
1)	ventricular rate<br>
2)	atrial rate<br>
3)	QRS width<br>
4)	PR interval<br>
e)	order record for chest x-ray (OBR)<br>
f)	two diagnostic impressions for CXR (OBX)<br>
g)	description record for CXR (OBX)<br>
h)	a recommendation record for CXR (OBX)<br>
i)	an order record for surgical pathology (OBR)<br>
j)	a gross description record for pathology showing use of anatomy fields
(OBX)<br>
k)	a microscopic description record for pathology (OBX)<br>
l)	vital signs request (OBR)<br>
m)	six vital signs (OBX)<br>
n)	part of the physical history (OBR &amp; OBX)<br>
o)	end record<br>
MSH|...<br>
PID|...<br>
**--Order record for EKG--**<br>
OBR|1|P8753^OE|EK5230^EKG|93000^EKG|R|198703281530|198703290800|||401<br>
0^INTERN^JOE^^^^MD^L|N &lt;cr&gt;<br>
**--Two interpretation records for EKG--**<br>
**--[In this case, the result observation ID assumes the observation code in
the order<br>
record.]--**<br>
OBX|1|CE|&amp;IMP|1|^Sinus bradycardia|||A|||F &lt;cr&gt;<br>
OBX|2|CE|&amp;IMP|2|^Occasional PVCs|||A|||F &lt;cr&gt;<br>
**--Four numeric results for EKG--**<br>
**--[The AS4 code is an extension of the CPT4 code (93000) for EKG plus
extension .1,<br>
.2, etc., as detailed in the Implementation Guide.]--**<br>
OBX|3|ST|8897-1^QRS COMPLEX:NRAT:PT:CARDIAC VENTRICLES:QN:EKG^LN| <br>
   |80|/min|60-100||||F &lt;cr&gt;<br>
OBX|4|ST|8894-8^P WAVE:NRAT:PT:CARDIAC ATRIA:QN:^LN||80|/min<br>
   |60-100||||F &lt;cr&gt;<br>
OBX|5|ST|8633-0^QRS DURATION:TIM:PT:HEART:QN:EKG^LN||.08|msec<br>
   |.06-.10||||F &lt;cr&gt;<br>
OBX|6|ST|8625-6^P-R INTERVAL:TIM:OT:HEART:QN:EKG^LN||.22|msec<br>
   |.18-.22||||F &lt;cr&gt;<br>
**--Order record for CXR--**<br>
OBR|2|P8754^OE|XR1501^XR|71020^Chest X-ray AP &amp;
Lateral|R|198703281530|198703290800|||<br>
   401-0^INTERN^JOE^^^^MD^L|N &lt;cr&gt;<br>
**--Two CXR diagnostic impressions--**<br>
OBX|1|CE|71020&amp;IMP^Radiologist's<br>
Impression|1|.61^RUL^ACR~.212^Bronchopneumonia^ACR|||A|||F&lt;cr&gt;<br>
OBX|2|CE|71020&amp;IMP|2|51.71^Congestive heart
failure^ACR|||A|||F&lt;cr&gt;<br>
**--CXR Description with continuation records--**<br>
OBX|3|TX|71020&amp;GDT||Infiltrate probably representing bronchopneumonia in
the right<br>
lower lobe.  Also pulmonary venous congestion cardiomegaly and cephalization,
indicating early congestive heart failure.&lt;cr&gt;<br>
**--Recommendations about CXR report to follow up one month with a repeat
CXR--**<br>
OBX|4|CE|71020&amp;REC||71020^Followup CXR 1 month^AS4||||||F&lt;cr&gt; <br>
**--Order record for pathology report--**<br>
OBR|3|P8755^OE|SP89-739^SP|88304^Surgical Path<br>
Report|R|198703281530|198703290800|||401-0^INTERN^JOE^^^^MD^L|N&lt;cr&gt;<br>
OBX|1|CE|&amp;ANT|1|Y0480-912001^orbital region^SNM||||||F&lt;cr&gt;<br>
**--Gross description record (with overflow) for pathology--**<br>
OBX|2|TX|&amp;GDT^GrossSpecimenDescription|1|The specimen is received in four
containers.  The first is labeled with the patient's name and consists of three
fragments of reddish-brown tissue each of which measures 2 mm in greatest
dimension.  They are wrapped in tissue paper and submitted in toto in a single
cassette| &lt;cr&gt;<br>
**--Microscopic description record for pathology--**<br>
OBX|3|TX|&amp;MDT^MicroscopicDescription|1|A|Sections of the first specimen
received for frozen section diagnosis reveal thick walled, ramifying vessels
lined by a single layer of flattened endothelial cells.  The thick smooth
muscle walls exhibit no malignant cytologic features nor do the endothelial
lining cells.  Within the same specimen are also found fragments of fibrous
connective tissue, bone, and nerve which are histologically
unremarkable||||||F&lt;cr&gt;<br>
**--Vital signs--**<br>
OBR|4|P8756^OE|N2345^NR|3000.02^VITAL
SIGNS|R|198703281530|198703290800|||401-0^INTERN^JOE^^^^MD^L|N&lt;cr&gt;<br>
OBX|1|ST|8462-4^INTRAVASCULAR
DIASTOLIC:PRES:^LN||90|mm(hg)|60-90||||F&lt;cr&gt;<br>
OBX|2|ST|8479-8^INTRAVASCULAR SYSTOLIC:PRES:^LN||120|mm(hg)<br>
   |100-160||||F&lt;cr&gt;<br>
OBX|3|ST|8478-0^INTRAVASCULAR
MEAN:PRES:^LN||100|mm(hg)|80-120|N|||F&lt;cr&gt;<br>
OBX|4|ST|8867-4^HEART BEAT:NRAT:^LN||74|/min|60-100|N|||F&lt;cr&gt;<br>
OBX|5|ST|8357-6^BLOOD PRESSURE METHOD:^LN||MANUAL BY CUFF||||||F&lt;cr&gt;<br>
OBX|6|ST|8886-4^HEART RATE METHOD:^LN||MANUAL BY PALP||||||F&lt;cr&gt;<br>
**--Part of the patient's history--** <br>
OBR|5|P8568^OE|HX2230^CLN||2000^HISTORY|R|198703281530|198703290800|401<br>
0^INTERN^JOE^^^^MD^L|N&lt;cr&gt;<br>
OBX|1|CE|8661-1^CHIEF COMPLAINT:^LN|| ... &lt;cr&gt;<br>
OBX|2|ST|8674-4^HISTORY SOURCE:^LN||PATIENT||||||F&lt;cr&gt;<br>
OBX|3|TX|8684-3^PRESENT ILLNESS:^LN||SUDDEN ONSET OF CHEST PAIN. 2 DAYS,<br>
   PTA ASSOCIATED WITH NAUSEA, VOMITING &amp; SOB.  NO RELIEF WITH ANTACIDS <br>
   OR NTG. NO OTHER SX. NOT PREVIOUSLY ILL.||||||F&lt;cr&gt;<br>
	.<br>
	.<br>
and so on.
</p>

<h3>
<A NAME="Heading112">7.4.5 Reporting cultures and susceptibilities</A></h3>


<h4>
<A NAME="Heading113">7.4.5.1 Culture battery/report representation</A></h4>

<p>Organisms
and other observations/tests are reported using multiple OBX segments.  The
granularity expected for HL7culture reports is one observation per organism.<br>
All OBX segments which have the same observation ID and sub-ID are part of a
single observation.<br>
Each organism in a culture battery is assigned a unique <i>OBX-4-observation
sub-ID </i>(and is therefore a separate observation).  The organism name is
given in <i>OBX-5-observation value </i>(results).  It is recommended, but not
required, that the organism name may change over time, but the corresponding
observation sub-ID never changes.  (The observation ID will be identical for
all organisms reported.)<br>
Recommended:<br>
OBX||CE|organism^413^L|1|^E. Coli||||||F &lt;cr&gt;<br>
OBX||CE|organism^413^L|2|^S. Aureus||||||F &lt;cr&gt;<br>
Not recommended:<br>
OBX||CE|organism1^413^L|1|^E. Coli||||||F &lt;cr&gt;<br>
OBX||CE|organism2^413^L|1|^S. Aureus||||||F &lt;cr&gt;</p>

<h4>
<A NAME="Heading114">7.4.5.2 Susceptibility battery/report representation</A></h4>

<p>Each
antimicrobial should be reported as a separate (OBX) observation where the
Observation ID is a code for the antimicrobial.  (OBXs for non-antimicrobials
observations and related information may be present in the same battery.)<br>
MIC and disk diffusion (Kirby Bauer) susceptibility results can be combined in
the same OBX segment.  An OBX can contain an MIC value (in <i>OBX-5-observation
value</i> (results)) and <i>OBX-8-abnormal flag</i> that indicates whether the
organism is sensitive, resistant, or intermediate (see <i>HL7 table 0078-
Abnormal flags</i> under<i> </i>abnormal flag fields).<br>
Or, an OBX can contain a disk diffusion result string (e.g., <b>sensitive</b>)
in the Observation Results field and the disk diffusion interpretation in
<i>OBX-8-abnormal flags</i> (e.g., <b>S</b>).<br>
A susceptibility battery may only contain results corresponding to a single
organism that has been previously reported in a culture battery.</p>

<h4>
<A NAME="Heading115">7.4.5.3 Identification of the organism for a susceptibility battery</A></h4>

<p>The
following is the preferred, but not required method of organizing data about
antimicrobial susceptibility.<br>
A susceptibility battery may only contain results corresponding to a single
organism that has been previously reported in a culture battery.<br>
A susceptibility battery is always a child order to a culture battery.
<i>OBR-29-parent number</i> (parent's filler order number) in the
susceptibility OBR is equal to <i>OBR-3-filler order number</i> in the parent
culture OBR and is used to link the two batteries logically.<br>
The susceptibility battery also contains a linkage back to a particular
organism in the culture battery.  <i>OBR-26-parent result</i> of the
susceptibility OBR contains two components--<i>OBX-3-observation identifier</i>
(code only) and <i>OBX-4-observation sub-ID</i> of the OBX in the culture
battery which contains the organism name.<br>
The identity of an organism/isolate is expected to be refined over time.  When
an organism identification changes, the parent culture battery can be resent
without resending the child susceptibility battery.<br>
The case may occur where a susceptibility battery is reported on an organism
which has not yet been identified.  In this case, it is required that a
placeholder OBX for the organism name be reported in the corresponding culture
battery so that <i>OBR-26-parent result</i> in the susceptibility OBR will
point to a valid organism OBX in the culture battery.  Transmission of an
organism OBX (in the culture battery) with the Sub-ID field valued must precede
the susceptibility battery which uses the identical Sub-ID in <i>OBR-26-parent
result</i>.<br>
Discussion and examples:<br>
Order micro results (blood culture)<br>
MSH|^~\&amp;|LAB1||DESTINATION||19910127105114||ORU^R03|LAB1003929<br>
PID|||900329493||PETRSN~DAVID|||927<br>
PV1||I|<br>
ORC|NW|<br>
OBR||A485388^OE|H29847^LAB1|BLOOD CULTURE|||<br>
Result for culture<br>
ORC|RE...<br>
OBR||A485388^OE|H29847^LAB1|BLOOD CULTURE||...<br>
OBX||FT|SDES^SOURCE||BLOOD-RAPID||||||F &lt;cr&gt;<br>
OBX||FT|EXAM^MICROSCOPIC||GRAM POSITIVE COCCI IN GROUPS||||||F &lt;cr&gt;<br>
OBX||FT|ORGANISM^IDENTIFIER|1|ISOLATE 1||||||F &lt;cr&gt;<br>
Result for susceptibility<br>
ORC|RE...<br>
OBR||A485388^OE|H29848^LAB1|BT1^SUSCEPTIBILITY BATTERY|||||MC|to field<br>
	... 26|ORGANISM^1|||A485388&amp;OE^H29847&amp;LAB1|<br>
OBX||CE|ACAPEN^PENICILLIN||0.5|R|||||F &lt;cr&gt;<br>
OBX||CE|ACHNAF^NAICILLIN||1|R|||||F &lt;cr&gt;<br>
OBX||CE|ACHCCLI^CLINDAMYCIN||&lt;=0.1|S|||||F &lt;cr&gt;<br>
Result for Culture ID<br>
ORC|RE...<br>
OBR||A485388^OE|H29847^LAB1|BLOOD CULTURE||...<br>
OBX||FT|ORGANISM^IDENTIFIER|1|STAPH EPI||||||F &lt;cr&gt;<br>
New result for culture ID<br>
ORC|RE...<br>
OBR||A485388^OE|H29847^LAB1|BLOOD CULTURE||...<br>
OBX||FT|ORGANISM^IDENTIFIER|1|STAPH EPI SERO TYPE 3||||||F &lt;cr&gt;<br>
Assumptions<br>
1.	All OBXs in the parent order must employ the same coding scheme.<br>
2.	The Sub-ID of the parent OBXs (result) cannot change.
</p>

<h3>
<A NAME="Heading116">7.4.6 Results reporting</A></h3>

<p>Suppose
an order has been placed to the EKG system for three EKGs to be performed on
successive days.  These results can be reported in various ways.<br>
1.	The EKG application needs to communicate to anyone the results of the 1st
EKG:<br>
ORU message:<br>
MSH|...<br>
PID|...<br>
OBR|||89-551^EKG|93000^EKG REPORT|...         // 1ST child OBR.<br>
OBX||ST|93000.1^VENTRICULAR RATE (EKG)|...<br>
OBX||ST|93000.2^...<br>
	...<br>
	...<br>
OBX||FT|93000.14^EKG COMMENT|...<br>
OBR|...                                        // other observation segments to
follow<br>
*	Notice that this report is without reference to the original order.<br>
*	No ORC is required because the identifying Fillers Order Number (and other
ORC fields) are carried in the OBR segment.<br>
2.	The EKG application needs to communicate to anyone the original order
information, the details of the child orders, the fact of the child spin off,
and the results of all three EKGs:<br>
ORU message:<br>
MSH|...<br>
PID|...<br>
ORC|PA|A226677^OE|89-450^EKG|...           // original order's ORC.<br>
OBR||||93000^EKG REPORT|...         // original order segment<br>
ORC|CH|A226677^OE|89-451^EKG&lt;cr&gt;           // 1st child ORC.<br>
OBR||||93000^EKG REPORT|...         // 1st EKG child OBR.<br>
OBX||ST...                          // 1st EKG report<br>
OBX||ST...<br>
	...<br>
OBX||FT...<br>
ORC|CH|A226677^OE|89-452^EKG&lt;cr&gt;           // 2nd child ORC.<br>
OBR||||93000^EKG REPORT|...         // 2nd EKG child OBR.<br>
OBX||ST...                          // 2nd EKG report<br>
OBX||ST...<br>
	...<br>
OBX||FT...<br>
ORC|CH|A226677^OE|89-453^EKG&lt;cr&gt;           // 3rd child ORC.<br>
OBR||||93000^EKG REPORT|...         // 3rd EKG child OBR.<br>
OBX||ST...                          // 3rd EKG report<br>
OBX||ST...<br>
	...<br>
OBX||FT...<br>
    ...                             // Other parts of message might follow.<br>
In this case, we are transmitting the information about the fact of child spin
off, the original order and the results all at the same time.  Thus, this form
of the ORU message reports not only the results of an order, but all of its
associated ordering information including the original OBR for three EKGs that
was replaced by three separate OBR EKG segments.
</p>

<h3>
<A NAME="Heading117">7.4.7 Patient-specific clinical data with an order</A></h3>

<p>Reporting
body weight and height with a creatinine clearance.<br>
MSH|...<br>
PID|...<br>
ORC|NW|...                          // New order.<br>
OBR||P42^PC||2164-2^CREATININE RENAL CLEARANCE:VRAT:24H:UR:QN^LN|...<br>
OBX||ST|3141-9^BODY WEIGHT:MASS:^LN||62|kg&lt;cr&gt;<br>
OBX||ST|3137-7^BODY HEIGHT:LEN:^LN||190|cm&lt;cr&gt;<br>
ORC|NW|...                          // Next order.
</p>

<h2>
<A NAME="Heading118">7.5 CLINICAL TRIALS</A></h2>

<p>Academic
medical institutions, academic research coordinating centers, and
industry-based research organizations often have computer systems that support
registration, compliance and safety monitoring, and outcomes analysis for
clinical trials.  Patients on these trials may receive their treatment and
evaluation at one research facility or at many different medical facilities.
Clinical trials systems could message other applications that a patient is
registered on a clinical trial.  Several functional examples follow:  (1)  Some
of the data required to monitor or analyze outcomes on the trial are generated
in other medical computer systems, such as pharmacy, laboratory, or clinical
applications.  These applications may tag patients on clinical trials so that
data may be sent back to the clinical trials system.  (2)  Order entry systems
could also use patient registration information:  They could display standard
order sets for the protocol or particular treatment/evaluation phases of a
complex protocol.  They could pass the clinical trials status on to service
provider applications to initiate a results report to the clinical trials
system.  It could also be passed to billing applications that may use
specialized procedures for research-related costs.  (3)  Nursing and pharmacy
systems can use information on patients' clinical trials status for care plans
or dispensing authorization (auxiliary to the physician's prescription),
respectively.  There could be many other uses of this message since a patient's
involvement on a clinical trial affects all concurrent medical care.<br>
To meet monitoring and analysis requirements, patient registration, treatment,
diagnostic, and study summary data are reported to study sponsors like
pharmaceutical or medical device companies, regulatory agencies, and data
management centers for collaborative studies.  Automated procedures must be
used to transfer these voluminous data among the participant computer systems
in a cost-efficient and timely manner.  The following additions to HL7 aim to
specify standard messaging transactions to automate such reporting as well as
to enable communication of clinical trials registration data to relevant
medical applications as described above.<br>
The objectives of the clinical trials messages and segments are to identify
that patients are registered on clinical trials, have entered a study-specific
phase of treatment or evaluation, or to indicate the study protocol's data
schedule.  Messages include OBR (Section 4.5.1, ""OBR - observation request
segment"), OBX (Section 7.3.2, "OBX - observation/result segment"), RXA
(Section 4.8.14, "RXA - pharmacy /treatment administration segment"), and RXR
(Section 4.8.3, "RXR - pharmacy/treatment order segment") segments to report
observations or drug administration that are relevant to the study.  In
addition to study-related clinical data, OBX segments may contain the results
of study variables according to master code tables such as the Health Outcomes
Variables (HL7 Implementation Guide).  There are also master segments to
describe the clinical trial, its treatment phases, and its scheduled date-time
points for message recipients.  These are analogous to the Test/Observation
Master Segments (Chapter 8), with the trials, phases, or scheduled time points
treated as the OMx treats observation identifiers.
</p>

<h3>
<A NAME="Heading119">7.5.1 Terminology and concepts </A></h3>


<h4>
<A NAME="Heading120">7.5.1.1 </A></h4>

<a name="_Ref358356535"></a>
<h4>
<A NAME="Heading121">7.5.1.2 </A></h4>

<p>The
phase structure serves several purposes in the clinical trials messages.  Other
computer systems may need to know that the patient has begun a phase with a
particular treatment regimen or diagnostic schedule, such as the pharmacy or
order entry systems.  When reporting study data, observations and variables
often describe particular phase instances.  For example, each course of
treatment may have its own values for the same set of observations or
variables.  Phase instances may also have distinct data schedules that need to
be linked to submitted data.<br>
Several examples follow with each line depicting a phase.</p>

<h5>
<A NAME="Heading122">7.5.1.2.1 Example 1</A></h5>

<p>Alternating
treatment plus observation intervals:<br>
   __________&gt;  _________&gt;  _________&gt;  _________&gt;   ...<br>
          Rx A          Rx B        Rx A        Rx B                  </p>

<h5>
<A NAME="Heading123">7.5.1.2.2 Example 2</A></h5>

<p>Random
assignment to two courses each of treatment A or B, all responding patients to
treatment C, continue with observation and a diagnostic regimen after all
treatment phases are completed.  Treatment phases include the evaluation
component for that course of treatment: <br>
     <br>
  ___________&gt; __________     <br>
  Rx A Crs 1   Rx A Crs 2                           <br>
                         \&gt; __________&gt;  __________&gt; _______<br>
                         /  Rx C Crs 1   Rx C Crs 2    <br>
  Observe   <br>
  ___________&gt; __________/<br>
  Rx B Crs 1   Rx B Crs 2              </p>

<h5>
<A NAME="Heading124">7.5.1.2.3 Example 3</A></h5>

<p>Random
assignment to placebo or treatment A, both taken daily and evaluated
monthly.<br>
  ___________&gt; __________&gt; __________&gt; __________&gt;  . . . <br>
    Month 1      Month 2     Month 3     Month 4
<a name="_Ref358356562"></a></p>

<h4>
<A NAME="Heading125">7.5.1.3 </A></h4>

<p>The
data schedule will be keyed by time points relative to the study.  Some data
may be due prior to and at the conclusion of the study and/or one or more of
its phases.  Some are interim within the study or its phases depending on
protocol events such as administration of treatment, arbitrary time intervals
instated to make and record assessments, or some clinical milestone such as
relapse of disease.  Often, multiple data parameters are scheduled at the same
time point.  Several examples follow:</p>

<h5>
<A NAME="Heading126">7.5.1.3.1 Schedule for a randomized cancer prevention trial</A></h5>

<TABLE><TR>
<TD >Treatment
1st - 3rd Years</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left">Reg</TD>
<TD align="left">Rand</TD>
<TD align="left">Months</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >3</TD>
<TD >6</TD>
<TD >9</TD>
<TD >12</TD>
<TD >18</TD>
<TD >24</TD>
<TD >30</TD>
<TD >36</TD>
<TD >42</TD>
<TD >48</TD>
<TD >54</TD>
<TD >60</TD>
<TD >66</TD>
<TD >72</TD>
<TD >78</TD>
<TD >84</TD></TR>

<TR align="left">
<TD align="left">Disease
Staging</TD>
<TD >X</TD>
<TD><BR></TD>
<TD ></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">H
&amp; P</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Assess
Adverse Events and Outcome Variables</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Chest
PAL X-ray</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">CBC,
Diff, Plt</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">SMA 12</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Cholesterol
and Triglyceride</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Electrolytes</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Plasma
Retinoic Acid</TD>
<TD >X</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Cotinine Level (nonsmokers)</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR></TABLE>
<h5>
<A NAME="Heading127">7.5.1.3.2 Schedule for a cancer chemotherapy trial</A></h5>

<TABLE><TR>
<TD><BR></TD>
<TD >Prestudy</TD>
<TD >Prior to Each Cycle</TD>
<TD >During Cycle</TD>
<TD >Every 3 Cycles</TD>
<TD >End Study</TD></TR>

<TR align="left">
<TD align="left">Informed Consent</TD>
<TD >X</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">H &amp; P Neurologic</TD>
<TD >X1</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Vital
Signs</TD>
<TD >X1</TD>
<TD><BR></TD>
<TD >X2</TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Disease Staging</TD>
<TD >X</TD>
<TD >X3</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">ECG</TD>
<TD >X1</TD>
<TD><BR></TD>
<TD >X4</TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Radiology*</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD >X5</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Chest
X-ray</TD>
<TD >X</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Bone
Marrow Bx.</TD>
<TD >X6</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">HCG</TD>
<TD >X1</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Assess
Adverse Events</TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">CBC, Diff, Plt</TD>
<TD >X1</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X7</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">UA, PT, PTT</TD>
<TD >X1</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">SMA12,
Mg, CEA</TD>
<TD >X1</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR></TABLE><p>1
Within 3 days prior to start of infusion.<br>
2	At 0,10,30, and 60 minutes after start of drug administration and one-half
hour after test drug infusion ends for cycles 1 and 2.  For subsequent cycles
at 0 and 10 minutes after start of drug administration, and at the end of
infusion.<br>
3	Record tumor measurements at the end of every cycle if assessable clinically
by physical examination or with simple X-ray.<br>
4	Continuous ECG monitoring during infusion if necessary, due to bradycardia
(&lt;50 beats/min) or other significant cardiac findings.<br>
5	When measurable disease requires complex radiologic studies such as CT or
radionuclide scans.<br>
6	To be done at baseline (if clinically indicated) at the option of the
investigator and also during study if patient has prolonged myelosuppression
(WBC&lt;2000 cells/mm3&gt;14 days).<br>
7	Blood counts will be done twice weekly during cycles 1 and 2, then weekly.<br>
*	Radionuclide scan and X-ray of the bones, CT scans of the chest, pelvis, and
brain only when clinically indicated.</p>

<h5>
<A NAME="Heading128">7.5.1.3.3 Schedule for a randomized pain medication trial</A></h5>

<TABLE><TR align="left">
<TD align="left"><BR></TD>
<TD align="left">Day 1<br>Before RX</TD>
<TD align="left">Day 1<br>After RX</TD>
<TD align="left"><br>Daily</TD>
<TD align="left"><br>Day 30</TD></TR>

<TR align="left">
<TD align="left">H&amp; P</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Creat,
Bili, SGOT</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Urinalysis</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Pain
Diagnosis</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Opioid Dose Strand</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Non-opiod
Analgesic</TD>
<TD><BR></TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Medications
for Side Effects</TD>
<TD><BR></TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Phone Report:  Pain and Side Effects</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD>
<TD><BR></TD></TR>

<TR align="left">
<TD align="left">Visual
Analog Scales</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD>
<TD >X</TD></TR>

<TR align="left">
<TD align="left">Pain Evaluation Form</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >X</TD></TR></TABLE>
<h2>
<A NAME="Heading129">7.6 CLINICAL TRIALS - TRIGGER EVENTS AND MESSAGE DEFINITIONS</A></h2>

<p>The
event type will be carried in the message header segment.
</p>

<h3>
<A NAME="Heading130">7.6.1  CRM - clinical study registration message (events C01-C08)</A></h3>

<p>The
data are entered in a clinical trials or other patient data system and
broadcast to other facility systems such as order entry, pharmacy, accounting,
and nursing systems.  They can be transmitted in batch mode or broadcast to
outside-facility computer systems, including diagnostic and patient management
systems.  It is assumed that proper routing and security mechanisms are in
place.<br>
</p>
<TABLE><TR>
<TD ><b>Event</b></TD>
<TD ><b>Description</b></TD></TR>

<TR>
<TD >C01</TD>
<TD >Register a patient on a clinical trial</TD></TR>

<TR>
<TD >C02</TD>
<TD >Cancel a patient registration on clinical trial(for clerical mistakes since an
intended registration should not be canceled)</TD></TR>

<TR>
<TD >C03</TD>
<TD >Correct/update registration information</TD></TR>

<TR>
<TD >C04</TD>
<TD >Patient has gone off a clinical trial</TD></TR>

<TR>
<TD >C05</TD>
<TD >Patient enters phase of clinical trial</TD></TR>

<TR>
<TD >C06</TD>
<TD >Cancel patient entering a phase (clerical mistake)</TD></TR>

<TR>
<TD >C07</TD>
<TD >Correct/update phase information</TD></TR>

<TR>
<TD >C08</TD>
<TD >Patient has gone off phase of clinical trial</TD></TR></TABLE><p><br>
<tt><u>CRM				Clinical Study Registration Message	Chapter</u></tt><br>
MSH				Message Header	2<br>
{PID				Patient Identification	3<br>
  [PV1]			Patient Visit	3<br>
  CSR			Clinical Study Registration	7<br>
   {[CSP]}		Clinical Study Phase	7<br>
}
</p>

<h3>
<A NAME="Heading131">7.6.2 CSU - unsolicited study data message (events C09-C12)</A></h3>

<p>Data
are entered in the clinical trials system or may reside in laboratory,
pathology, radiology, pharmacy and/or other clinical applications.  Most
clinical trials data - clinical observations and study variables - will be
communicated in OBR and OBX segments.  The CSR, CSP, and CSS segments will
identify the specific association these OBR and OBX have to the clinical trial.
Data can be broadcast or transmitted in batch mode to study sponsors or the
data management center for collaborative studies.<br>
</p>
<TABLE><TR>
<TD ><b>Event</b></TD>
<TD ><b>Description</b></TD></TR>

<TR>
<TD >C09</TD>
<TD >Automated
time intervals for reporting, like monthly</TD></TR>

<TR>
<TD >C10</TD>
<TD >Patient completes the clinical trial</TD></TR>

<TR>
<TD >C11</TD>
<TD >Patient completes a phase of the clinical trial</TD></TR>

<TR>
<TD >C12</TD>
<TD >Update/correction
of patient order/result information</TD></TR></TABLE><p><br>
<tt><u>CSU				Unsolicited Study Data Message	Chapter</u></tt><br>
<tt>MSH				Message Header	2</tt><br>
{<br>
 PID				Patient Identification	3<br>
 [PD1]			Additional Demographics	3<br>
 [{NTE}]			Notes and comments	2<br>
 [PV1			Patient Visit	3<br>
  [PV2]			Patient Visit - Additional Info	3<br>
 ] <br>
 CSR				Clinical Study Registration	7<br>
 {[CSP]			Clinical Study Phase	7<br>
    {[CSS]		Clinical Study Data Schedule	7<br>
      {[[ORC]		Common Order 	4<br>
          OBR		Observation Battery	7<br>
          {OBX}	Observation Results	7<br>
       }]<br>
       {[ORC]		Common Order	4<br>
          {RXA	Pharmacy Administration	4	<br>
           RXR	Pharmacy Route	4<br>
           }<br>
           }<br>
         }<br>
      }<br>
     }   
</p>

<h3>
<A NAME="Heading132">7.6.3 CM0, CM1, CM2 - clinical trials master file messages </A></h3>

<p>The master file definition segments are defined in Chapter 8.
</p>

<h2>
<A NAME="Heading133">7.7 CLINICAL TRIALS - SEGMENT DEFINITIONS</A></h2>


<h3>
<A NAME="Heading134">7.7.1 CSR - clinical study registration segment</A></h3>

<p>The
CSR segment will contain fundamental administrative and regulatory information
required to document a patient's enrollment on a clinical trial.  This segment
is all that is required if one needs to message another system that an
enrollment has taken place, i.e., from clinical trials to pharmacy, accounting,
or order entry systems.  The CSR segment may also be used to identify that OBR,
OBX, RXA, and RXR segments that follow represent data applicable to the
identified study.<br>
<center>Figure 7-14.  CSR attributes</center><br>
</p>
<TABLE BORDER><TR>
<TH >SEQ</TH>
<TH >LEN</TH>
<TH >DT</TH>
<TH >OPT</TH>
<TH >RP/#</TH>
<TH >TBL#</TH>
<TH >ITEM#</TH>
<TH >ELEMENT NAME</TH></TR>

<TR>
<TD >1</TD>
<TD >60</TD>
<TD >EI</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01035</TD>
<TD >Sponsor Study ID</TD></TR>

<TR>
<TD >2</TD>
<TD >60</TD>
<TD >EI</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01036</TD>
<TD >Alternate
Study ID</TD></TR>

<TR>
<TD >3</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01037</TD>
<TD >Institution Registering the Patient</TD></TR>

<TR>
<TD >4</TD>
<TD >30</TD>
<TD >CX</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01038</TD>
<TD >Sponsor
Patient ID  </TD></TR>

<TR>
<TD >5</TD>
<TD >30</TD>
<TD >CX</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01039</TD>
<TD >Alternate Patient ID - CSR</TD></TR>

<TR>
<TD >6</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01040</TD>
<TD >Date/Time
Of Patient Study Registration</TD></TR>

<TR>
<TD >7</TD>
<TD >60</TD>
<TD >XCN</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01041</TD>
<TD >Person Performing Study Registration</TD></TR>

<TR>
<TD >8</TD>
<TD >60</TD>
<TD >XCN</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01042</TD>
<TD >Study Authorizing Provider </TD></TR>

<TR>
<TD >9</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01043</TD>
<TD >Date/time Patient Study Consent Signed</TD></TR>

<TR>
<TD >10</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01044</TD>
<TD >Patient Study Eligibility Status</TD></TR>

<TR>
<TD >11</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD >Y/3</TD>
<TD><BR></TD>
<TD >01045</TD>
<TD >Study Randomization Date/time</TD></TR>

<TR>
<TD >12</TD>
<TD >200</TD>
<TD >CE</TD>
<TD >O</TD>
<TD >Y/3</TD>
<TD><BR></TD>
<TD >01046</TD>
<TD >Randomized Study Arm</TD></TR>

<TR>
<TD >13</TD>
<TD >200</TD>
<TD >CE</TD>
<TD >O</TD>
<TD >Y/3</TD>
<TD><BR></TD>
<TD >01047</TD>
<TD >Stratum for Study Randomization</TD></TR>

<TR>
<TD >14</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01048</TD>
<TD >Patient Evaluability Status</TD></TR>

<TR>
<TD >15</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01049</TD>
<TD >Date/time
Ended Study</TD></TR>

<TR>
<TD >16</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01050</TD>
<TD >Reason
Ended Study</TD></TR></TABLE><p>7.7.1.0
  CSR field definitions</p>

<h4>
<A NAME="Heading135">7.7.1.1 Sponsor study ID  (EI)   01035</A></h4>

<p><tt>Components:
 &lt;entity identifier (ST)&gt; ^ &lt;namespace ID (IS)&gt; ^ &lt;universal ID
(ST)&gt; ^ &lt;universal ID type (ID). </tt><br>
Definition:  The field contains the universal identifier for the clinical
trial.  Since many clinical trials are collaborative and multi-centered, and
since one goal of these standards is to promote automated data exchange among
sites, the primary identifier should come from the sponsor.  The coding system
component may reference the sponsor.  Example:<br>
T93-0807^NCI (where NCI refers to the National Cancer Institute).</p>

<h4>
<A NAME="Heading136">7.7.1.2 Alternate study ID  (EI)   01036</A></h4>

<p><tt>Components:
 &lt;entity identifier (ST)&gt; ^ &lt;namespace ID (IS)&gt; ^ &lt;universal ID
(ST)&gt; ^ &lt;universal ID type (ID)&gt;</tt><br>
Definition:  This field contains an alternate identifier that may be used as
agreed upon by messaging parties.  For example, the sending application may
code its internal study number here.</p>

<h4>
<A NAME="Heading137">7.7.1.3 Institution registering the patient  (CE)   01037</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field distinguishes the institution where registration
occurred.  The legal approval to give patients access to a trial lies with the
Internal Review Board for the institution. Universal healthcare provider
facility codes should be used when they exist.  Currently coding systems must
be devised by users.</p>

<h4>
<A NAME="Heading138">7.7.1.4 Sponsor patient ID  (CX)   01038</A></h4>

<p><tt>Components:
 &lt;ID (ST)&gt; ^ &lt;check digit (ST)&gt; ^ &lt;code identifying the check
digit scheme employed (ID)&gt; ^ &lt; assigning authority (HD)&gt; ^
&lt;identifier type code (IS)&gt; ^ &lt; assigning facility (HD)&gt;</tt><br>
Subcomponets of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility: &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;<br>
Definition:  This field contains the main patient identification for the study.
The sponsor patient ID allows automation of records on patients treated at
various institutions.  The sponsor patient ID should be unique for each patient
participating on the study identified in <i>CSR-1-sponsor study ID</i>.</p>

<h4>
<A NAME="Heading139">7.7.1.5 Alternate patient ID - CSR (CX)   01039</A></h4>

<p><tt>Components:
 &lt;ID (ST)&gt; ^ &lt;check digit (ST)&gt; ^ &lt;code identifying the check
digit scheme employed (ID)&gt; ^ &lt; assigning authority (HD)  )&gt; ^
&lt;identifier type code (IS)&gt; ^ &lt; assigning facility (HD)&gt;</tt><br>
Subcomponets of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility: &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;<br>
Definition:  This field may be the sending application's patient
identification.  Coding conventions may be used as agreed upon by users.</p>

<h4>
<A NAME="Heading140">7.7.1.6 Date/time patient of patient study registration  (TS)   01040</A></h4>

<p>Definition:
 This field contains the date of the patient registration is mandatory.  The
time component is optional.  The time stamp for a registration may be useful.
For example, patients may be randomized at the pharmacy according to the order
in which they were registered.</p>

<h4>
<A NAME="Heading141">7.7.1.7 Person performing study registration  (XCN)   01041</A></h4>

<p><tt>Components:
 &lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type (ID)&gt;
^&lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID)&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility ID (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  This field contains the healthcare facility employee who actually
phoned, submitted a form, or interactively registered the patient on the
clinical trial.  This is generally done under authorization from the attending
physician or a principal or collaborating investigator.</p>

<h4>
<A NAME="Heading142">7.7.1.8 Study authorizing provider  (XCN)   01042</A></h4>

<p><tt>Components:
 &lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type (ID)&gt;
^&lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID)&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility ID (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition:  This field contains the healthcare provider, generally the
attending physician, who is accountable that the patient is eligible for the
trial and has signed an informed consent.  National standard healthcare
provider codes should be used when they exist.  This field is required for the
patient registration trigger event (C01).</p>

<h4>
<A NAME="Heading143">7.7.1.9 Date patient study consent signed  (TS)   01043</A></h4>

<p>Definition:
 This field contains the consent form signing date is collected to provide a
checkpoint that the consent form was obtained.  Since many trials involve
unapproved drugs and other treatment modalities, the consent form is highly
important to document and store.  This field is required for the patient
registration trigger event (C01).  The time component is optional.</p>

<h4>
<A NAME="Heading144">7.7.1.10 Patient study eligibility status  (CE)   01044</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field indicates whether the patient was an appropriate
candidate for the trial.  It is important for quality control and data
analysis.  The code set will vary among clinical trials.  An example answer set
is:  <b><i>Yes, No, By Approval, Not Assessed, Unknown</i></b>.  This field is
required for the patient registration trigger event (C01).</p>

<h4>
<A NAME="Heading145">7.7.1.11 Study randomization date/time  (TS)   01045</A></h4>

<p>Definition:
 This field contains the date the patient was randomized.  The time component
is optional.  Up to three randomizations are supported.  Sequential
randomizations are listed in chronologic order.</p>

<h4>
<A NAME="Heading146">7.7.1.12 Randomized study arm  (CE)   01046</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains codes that must be developed by users.  The
blind treatment assignment may be communicated as a dummy text:  <b>^blind</b>
or if a coded treatment assignment must also be communicated<b>:
1^blind^local_code</b>.  If more than one randomization occurs, the second and
third repetitions will correspond to the second and third repetitions of
<i>CSR-11-study randomization date/time</i>, if they exist.</p>

<h4>
<A NAME="Heading147">7.7.1.13 Stratum for study randomization  (CE)   01047</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  Many studies have stratified randomization schemas.  The strata
codes must be developed for each clinical trial.  This field is important for
statistical analysis of the study results. The second and third repetitions
will correspond to the second and third repetitions of <i>CSR-11-study
randomization date/time</i> and <i>CSR-12-randomized study arm</i>, if they
exist.</p>

<h4>
<A NAME="Heading148">7.7.1.14 Patient evaluability status  (CE)   01048</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field categorizes the inclusion of this patient's data for
various analyses.  The patient's data may be evaluable for analysis of adverse
events but not for outcomes.  Or it may be evaluable for some outcomes and not
others.  The coding systems will vary among trials.  This field is required for
the off-study trigger event (C04).</p>

<h4>
<A NAME="Heading149">7.7.1.15 Date/time ended study  (TS)   01049</A></h4>

<p>Definition:
 This field contains the date the patient completes or is otherwise removed
from the study.  This field is required for the off-study event (C04).  The
time component is optional.</p>

<h4>
<A NAME="Heading150">7.7.1.16 Reason ended study  (CE)   01050</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This information is important for quality control and data
analysis.  The coding systems will vary among trials.  An example answer set
is:  <b>Adverse Events, Completed Trial, Death, Drug Resistance, Intercurrent
Illness, Lost to Follow up, No Response to Therapy, Noncompliance, Progression
of Disease, Protocol Violation, Refused Further Therapy</b>.  This field is
required for the off-study trigger event (C04).
</p>

<h3>
<A NAME="Heading151">7.7.2 CSP - clinical study phase segment </A></h3>

<p>The
CSP segment contains information on a patient's status for a particular phase
of the study.  This segment is optional and is useful when a study has
different evaluation intervals within it.  (See Section 7.5.1.2, "phase of a
clinical trial.")  The CSP segment is implemented on a study-specific basis for
messaging purposes.  The fact that the patient has entered a phase of the study
that represents a certain treatment approach may need to be messaged to other
systems, like pharmacy, nursing, or order entry.  It is also important to
sponsors and data management centers for tracking patient progress through the
study and monitoring the data schedule defined for each phase.  It may subsume
OBR and OBX segments that follow it to indicate that these data describe the
phase.<br>
<center>Figure 7-15.  CSP attributes</center><br>
</p>
<TABLE BORDER><TR>
<TH >SEQ</TH>
<TH >LEN</TH>
<TH >DT</TH>
<TH >OPT</TH>
<TH >RP/#</TH>
<TH >TBL#</TH>
<TH >ITEM#</TH>
<TH >ELEMENT NAME</TH></TR>

<TR>
<TD >1</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01051</TD>
<TD >Study Phase Identifier</TD></TR>

<TR>
<TD >2</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01052</TD>
<TD >Date/time Study Phase Began</TD></TR>

<TR>
<TD >3</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01053</TD>
<TD >Date/time Study Phase Ended</TD></TR>

<TR>
<TD >4</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01054</TD>
<TD >Study Phase Evaluability</TD></TR></TABLE>

<p>7.7.2.0  CSP  field definitions</p>

<h4>
<A NAME="Heading152">7.7.2.1 Study phase Identifier  (CE)   01051</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field identifies the phase of the study that a patient has
entered.  The set of codes will generally be developed for each clinical trial,
although there are patterns that trials in particular disease or prevention
categories may follow.  The phase structure will be based on data collation and
reporting needs for the study.  It is an operational structure and need not be
discussed in the clinical trial protocol documentation or even made known to
patient care or data collection personnel.  The coding system will usually be
developed by the sponsor for multicentered clinical trials to standardize the
receipt of automated data.  Local codes could be added if an additional local
message is desired.  Otherwise, local coding conventions will be used.
Example:  <tt>2^Init Rx, Crs 1^NCI T93-0807 Phases</tt></p>

<h4>
<A NAME="Heading153">7.7.2.2 Date/time study phase began  (TS)   01052</A></h4>

<p>Definition:
 This field contains the date the patient began this phase interval.  The time
is optional.</p>

<h4>
<A NAME="Heading154">7.7.2.3 Date/time study phase ended  (TS)   01053</A></h4>

<p>Definition:
 This field contains the date the patient ended this phase interval.</p>

<h4>
<A NAME="Heading155">7.7.2.4 Study phase evaluability  (CE)   01054</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains the disposition of the patient's data for this
phase interval for quality control and data analysis purposes.  The set of
codes will vary across clinical trials.  An example answer set:  <b>Complete,
Adverse Events Only, Outcome Only, None, Unknown</b>.
</p>

<h3>
<A NAME="Heading156">7.7.3 CSS - clinical study data schedule segment</A></h3>

<p>The
Clinical Study Data Schedule (CSS) segment is optional depending on whether
messaging of study data needs to be linked to the scheduled data time points
for the study.  (See Section 7.5.1.3, "data schedule.")  The CSS segment
enables communication of data schedules and adherence that ranges from the
basic to the elaborate.  Use of the segment must be planned for each
implementation.  Each CSS segment will subsume observation and drug
administration segments that follow, indicating that they satisfy this
scheduled time point.  <br>
<center>Figure 7-16.  CSS attributes</center><br>
</p>
<TABLE BORDER><TR align="left">
<TH align="left">SEQ</TH>
<TH align="left">LEN</TH>
<TH align="left">DT</TH>
<TH align="left">OPT</TH>
<TH align="left">RP/#</TH>
<TH align="left">TBL#</TH>
<TH align="left">ITEM#</TH>
<TH align="left">ELEMENT NAME</TH></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD align="left">R</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">01055</TD>
<TD align="left">Study Scheduled Time Point</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD align="left">O</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">01056</TD>
<TD align="left">Study Scheduled Patient Time Point </TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD align="left">O</TD>
<TD align="left">Y/3</TD>
<TD align="left"><BR></TD>
<TD align="left">01057</TD>
<TD align="left">Study
Quality Control Codes</TD></TR></TABLE><p>7.7.3.0
 CSS field definitions</p>

<h4>
<A NAME="Heading157">7.7.3.1 Study scheduled time point  (CE)   01055</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains the time point for which some instance of data
for the clinical trial was scheduled.  The time point may be expressed in any
coded format.  Some examples of time point values are: <b>Prestudy,
Pretreatment, 4 times/day, Weekly, Every 3 days, Every course, At Relapse, At
Off Study,</b>  Alternatively, frequency values from Section 4.4.2, "Interval
component (CM)," (the Interval component of the TQ Timing/Quantity data type
could be used.)  Time point naming conventions and usage must be specified by
implementors.</p>

<h4>
<A NAME="Heading158">7.7.3.2 Study scheduled patient time point  (TS)   01056</A></h4>

<p>Definition:
 This field contains the date/time that the scheduled time point should occur
for this patient.  The date/time may be used for a reference in reviewing the
actual dates on which scheduled items that follow in OBR segments occur for the
patient.  The time component is optional. </p>

<h4>
<A NAME="Heading159">7.7.3.3 Study quality control codes  (CE)   01057</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  In clinical settings, the <b>actual</b> date of a treatment or
procedure may vary considerably from the <b>due</b> date.  Various coding
systems may be used to evaluate the adherence to the schedule or acceptability
of the data.  Coding systems will vary among trials.
</p>

<h3>
<A NAME="Heading160">7.7.4 CTI - clinical trial identification segment</A></h3>

<p>The
CTI segment is an optional segment that contains information to identify the
clinical trial, phase and time point with which an order or result is
associated.</p>

<center>Figure 7-17.  CTI attributes
</center>
<TABLE BORDER><TR align="left">
<TD align="left">SEQ</TD>
<TD align="left">LEN</TD>
<TD align="left">DT</TD>
<TD align="left">OPT</TD>
<TD align="left">RP/#</TD>
<TD align="left">TBL#</TD>
<TD align="left">ITEM#</TD>
<TD align="left">ELEMENT NAME</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left">60</TD>
<TD align="left">EI</TD>
<TD align="left">R</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">01058</TD>
<TD align="left">Sponsor Study Identifier</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD align="left">C</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">01051</TD>
<TD align="left">Study Phase Identifier</TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD align="left">O</TD>
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">01055</TD>
<TD align="left">Study Scheduled Time Point</TD></TR></TABLE>

<p>7.7.4.0 CTI field definitions</p>

<h4>
<A NAME="Heading161">7.7.4.1 Sponsor study identifier  (EI)   01058</A></h4>

<p><tt>Components:
 &lt;entity identifier (ST)&gt; ^ &lt;namespace ID (IS)&gt; ^ &lt;universal ID
(ST)&gt; ^ &lt;universal ID type (ID)&gt;</tt><br>
Definition: This field contains  the universal identifier for the clinical
trial.  The coding system is as described in <i>CSR-1-study ID</i>.</p>

<h4>
<A NAME="Heading162">7.7.4.2 Study phase identifier  (CE)   01051</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition: This field identifies the phase of the study that a patient has
entered.  See <i>CSP-1-study phase ID</i> for details of coding systems.</p>

<h4>
<A NAME="Heading163">7.7.4.3 Study scheduled time point  (CE)   01055</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field identifies a time point in the clinical trial phase.
<i> CTI-2-study phase identifier</i> must be valued if <i>CTI-3-study scheduled
time point</i> is valued.  Should correspond to <i>CSS-1-scheduled time
point</i>.
</p>

<h3>
<A NAME="Heading164">7.7.5 CM0  clinical study master segment</A></h3>

<p>The
clinical study master segment (CMO) is described in Chapter 8.
</p>

<h3>
<A NAME="Heading165">7.7.6 CM1  clinical study phase master segment</A></h3>

<p>The
clinical study phase master segment (CMI) is described in Chapter 8.
</p>

<h3>
<A NAME="Heading166">7.7.7 CM2  clinical study schedule master segment</A></h3>

<p>The
clinical study schedule master segment is described in Chapter 8.
</p>

<h2>
<A NAME="Heading167">7.8 CLINICAL TRIALS - EXAMPLES</A></h2>


<h3>
<A NAME="Heading168">7.8.1 CRM - message when patient registered on a clinical trial</A></h3>

<p>MSH|^~\&amp;|PDMS|MDACC|ORDER
ENTRY|MDACC|||CRM^C01 &lt;cr&gt;<br>
CMO|1|DM90-004^Didemnin Small Cell Lung^MDACC||<br>     Phase II Study of
Didemnin in Early Stage Small Cell Lung Cancer|<br>     31^Smith^Joan
^^^^MD^MDACC|19941001|12|19941013 &lt;cr&gt;<br>
PID|1||223892||King^Sally^Brown||19530117 &lt;cr&gt;<br>
CSR|1|DM94-004^MDACC||MDACC|3||19941013||342^^^^^^^PDMS|
<br>.....1005^^^^^^^MDACC| 19941013|Y^Meets All Requirements^PDMS &lt;cr&gt;
</p>

<h3>
<A NAME="Heading169">7.8.2 CRM - message when patient begins a phase of a clinical trial</A></h3>

<p>MSH|^~\&amp;|PDMS|MDACC|PHARM|MDACC|||CRM^C05
&lt;cr&gt;<br>
CMO|1|ID91-025^MDACC||Double Blind, Multicenter Study of 13-Cis
<br>.....Retinoic Acid to Prevent Secondary Primary Tumors^MDACC|
<br>.....863^McDougall^Lester^^^^MD^MDACC|19940701|312|19941227 &lt;cr&gt;<br>
CM1|1|2^Treatment^PDMS|Daily Drug/Placebo Treatment|3^YEARS &lt;cr&gt;<br>
PID|1||352352||West^Mary^L.||19230213 &lt;cr&gt;<br>
CSR||ID91-025^MDACC||MDACC|301||19941005|||||19941201|2^blind^PDMS|<br>
12^Smoker,Stage II,&lt;60^PDMS &lt;cr&gt;<br>
CSP||2^Treatment^PDMS|19941201 &lt;cr&gt;
</p>

<h3>
<A NAME="Heading170">7.8.3 CSU - message reporting monthly patient data updates to the sponsor</A></h3>

<p>MSH|^~\&amp;|PDMS|MDACC|CTMS|NCI|||CSU^C09
&lt;cr&gt;<br>
CMO|1|T93-0800^NCI|ID93-030^Ph I Study of Oral Fostriecin^MDACC|<br>
|235^Alexander^Susan^B.^^^MD^MDACC|19940801|14|19941205|^Sam Smith
&lt;cr&gt;<br>
CM2|1|^Prestudy^NCI|Prestudy Eligibility and Baseline Clinical Params|<br>
^CBC~^SMA12~^Pathology~^Elig.checklist~^Prestudy Form~^<br>     Imaging
procedures as indicated &lt;cr&gt;<br>
CM2|2|^Course Completion^NCI|Course Completion Toxicity and Response
.....Evaluation|Adverse Events Form~^Course Completion Form~^CEA &lt;cr&gt;<br>
</p>
<TABLE><TR align="left">
<TD align="left">PID|1|235925||J^F^M||19350616
&lt;cr&gt;</TD>
<TD align="left">[note:
anonymous]</TD></TR></TABLE><p>CSR||T93-080^NCI|ID93-030^^MDACC|MDACC|14||19941205
&lt;cr&gt;<br>
CSS||^Prestudy|19941204|C^compliant^NCI &lt;cr&gt;<br>
OBR|1|||3^EligibilChecklist^StudyFormsList|||19941205 &lt;cr&gt;<br>
OBX|1|CE|ELIG1^Elig Crit 1^NCI|Text Elig Crit 1|Y &lt;cr&gt;<br>
OBX|2|CE|ELIG2^Elig Crit 2^NCI||Y &lt;cr&gt; <br>
OBR|2|||4^Prestudy Form^StudyFormsList|||19941205 &lt;cr&gt;<br>
OBX|1|CE|QOL^Quality of Life^NCI||2&amp;3&amp;2&amp;4&amp;2^SPITZER
&lt;cr&gt;<br>
OBX|2|CE|PRICHEM^Prior Chemo^NCI||Yes &lt;cr&gt;<br>
OBX|3|CE|PRIBIOL^Prior Biologics^NCI||No &lt;cr&gt;<br>
OBX|4|NM|NUMREM^Number Prior Remissions^NCI||2 &lt;cr&gt;<br>
OBR|3|||88304^SURG PATH REPORT|||19940101 &lt;cr&gt;<br>
OBX|1|CE|88304&amp;ANT|1|9999^PANCREAS^SNM &lt;cr&gt;<br>
OBX|2|CE|88304&amp;IMP|2|9999^ADENOCARCINOMA^SNM &lt;cr&gt;<br>
OBR|4|||85022^CBC|||199412050800 &lt;cr&gt;<br>
OBX|1|ST|718-7^HEMOGLOBIN:^LN||13.4|GM/DL|14-18|N||S|F|19860522&lt;cr&gt;[cbc
values]OBX|2|ST|4544-3^HEMATOCRIT:^LN||40.3|%|42-52|L||S|F|19860522 &lt;cr&gt;
OBX|3|ST|789-8^ERYTHROCYTES:^LN||4.56|10*6/ml|4.7-6.1|L||S|F|19860522
&lt;cr&gt; OBX|4|ST|787-22^ERYTHROCYTE MEAN CORPUSCULAR VOLUME:^LN||88|fl
|80-94|N||S|F|19860522 &lt;cr&gt; OBX|5|ST|785-6^ERYTHROCYTE MEAN CORPUSCULAR
HEMOGLOBIN:^LN||29.5|pg   |27-31|N||N|F|19860522 &lt;cr&gt;
OBX|6|ST|786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION:^LN|
|33|%|33-37|N||N|F|19860522 &lt;cr&gt;
OBX|7|ST|6690-2^LEUKOCYTES:^LN||10.7|10*3/ml|4.8-10.8|N||N|F|19860522
&lt;cr&gt; <br>
OBX|8|ST|764-1^NEUTROPHILS BAND FORM/100 LEUKOCYTES:^LN||2|%||||F &lt;cr&gt;
<br>
OBX|9|ST|769-0^NEUTROPHILS SEGMENTED/100 LEUKOCYTES:^LN||67|%||||F &lt;cr&gt;
<br>
OBX|10|ST|736-9^LYMPHOCYTES/100 LEUKOCYTES:^LN||29|%||||F &lt;cr&gt; <br>
OBX|11|ST|5905-5^MONOCYTES/100 LEUKOCYTES:^LN||1|%||||F &lt;cr&gt; <br>
OBX|12|ST|713-8^EOSINOPHILS/100 LEUKOCYTES:^LN||2|%||||F &lt;cr&gt; <br>
OBR|5|||80004^ELECTROLYTES|||199412050800 &lt;cr&gt;<br>
OBX|1|ST|2947-0^SODIUM:^LN||150|mmol/l|136-148|H||A|F|19850301 &lt;cr&gt;<br>
OBX|2|ST|2823-3^POTASSIUM:^LN||4.5|mmol/l|3.5-5|N||N|F|19850301 &lt;cr&gt;
[electrolytes
values]OBX|3|ST|2069-3^CHLORIDE:^LN||102|mmol/l|94-105|N||N|F|19850301
&lt;cr&gt; OBX|4|ST|2028-9^CARBON DIOXIDE.TOTAL:^LN||27|mmol/l|24-31|N||N|F
|19850301&lt;cr&gt; CSP|1|^Course 1|19941205|19950120|Y^Toxicity and
Response^NCI &lt;cr&gt;CSS|1|^Course Completion|19950120|
&lt;cr&gt;OBR|1|||2039-6^CARCINOEMBRYONIC AG:^LN|||19941008 &lt;cr&gt;
OBX|1|NM|2039-6^CARCINOEMBRYONIC AG:^LN||15.2|IU &lt;cr&gt;OBR|2|||10^Course
Completion Form^StudyPhaseFormsList|||19950120 &lt;cr&gt;<br>
OBX|1|CE|CRSRESP^Course Response^NCI||4^Partial Response &lt;cr&gt;<br>
OBX|2|NM|DRUGDISP^Capsules Dispensed^NCI||60 &lt;cr&gt;<br>
OBX|3|NM|DRUGRETN^Capsules Returned^NCI||5 &lt;cr&gt;<br>
OBX|4|ID|DXCOMP^Diagnostic Tests Compliance^NCI||Y &lt;cr&gt;<br>
OBX|5|CE|PERSTAT^Performance Status^NCI||3^ZUBRODS &lt;cr&gt;<br>
</p>
<TABLE><TR align="left">
<TD align="left">OBR|3|||9999^Adverse
Events &lt;cr&gt;<br>
OBX|1|CE|9999&amp;EVENT|1|45^Vomiting^NCI &lt;cr&gt;<br>
OBX|2|DT|9999&amp;ONSET|1|19941215 &lt;cr&gt;<br>
OBX|3|DT|9999&amp;RESOLUTION|1|19941217 &lt;cr&gt;</TD>
<TD align="left">[Note:
Needs to maintain compatibility with ongoing product experience message efforts.]</TD></TR>

<TR align="left">
<TD align="left">OBX|4|ID|9999&amp;GRADE|1|M^MODERATE
&lt;cr&gt;<br>
OBX|5|ID|9999&amp;RELATION_TO_RX|1|L^LIKELY &lt;cr&gt;<br>
OBX|6|CE|9999&amp;EVENT|2|303^Dyspnea^NCI &lt;cr&gt;<br>
OBX|7|DT|9999&amp;ONSET|2|19941231 &lt;cr&gt;<br>
OBX|8|DT|9999&amp;RESOLUTION|2 &lt;cr&gt;<br>
OBX|9|ID|9999&amp;GRADE|2|MI^MILD &lt;cr&gt;<br>
OBX|10|ID|9999&amp;RELATION_TO_RX|2|U^UNLIKELY &lt;cr&gt;</TD>
<TD align="left">[Note2:
There are other possible OBX suffixes defined by FDA: APEX/ NADIR, ACTION,
THERAPY, OUTCOME, RECHALLENGE.]</TD></TR></TABLE><h2>
	
</h2>

<h2>
<A NAME="Heading171">7.9 PRODUCT EXPERIENCE</A></h2>

<p>Patients
experience symptoms, manifest signs or develop diseases or syndromes while
exposed to medical devices and/or drugs.  Evidence suggests that some of these
symptoms, signs, diseases or syndromes may develop as a consequence of the
products used.  Examples include the development of clear cell adenocarcinoma
of the vagina in the daughters of mothers treated with diethylstilbestrol
during pregnancy and gastrointestinal bleeding in patients treated with
non-steroidal anti-inflammatory drugs.  While it is difficult to prove
causality, strong evidence exists in many cases.  <br>
It is important to document such experiences during the development and testing
of products to identify potential adverse effects but also during routine use
of the product to identify serious adverse effects which occur infrequently.
The latter is the realm of pharmacoepidemiology and post-marketing
surveillance.<br>
Adverse events are important for product manufacturers as signal generating
hypotheses concerning drug kinetics or dynamics, often in special populations
of patients.  Adverse events are important for regulators in ensuring that
manufacturers protect the public health in assessments of risk and benefits,
including special populations, and that they promptly and thoroughly
investigate individual events and clusters of events.  Adverse events are
especially important for practitioners and patients who always deal with a
special population of one individual who may be having an event and a
practitioner seeking information about related events seen with the same or
similar products.  <br>
Reporting has usually focused on <i>serious</i> and <i>unexpected</i> events.
Serious, if defined unambiguously, focuses attention on those events of most
importance to the patient and practitioner. Expected events are those which
prior experience has demonstrated to be probabilistically linked to the product
and are generally included in product labeling.<br>
Because of the risks associated with the uses of drugs and medical devices, a
system of surveillance has been established in most developed countries.  With
globalization of the marketplace, the need to share this information across
national boundaries has increased.  Currently most reporting is performed using
a series of  forms, including CIOMS, yellow cards, the FDA's 1639 and MedWatch
forms and the Japanese form, which are sent:<br>
*	from identified reporting sources to regulatory bodies<br>
*	from identified reporting sources to product manufacturers<br>
*	between regulatory bodies<br>
*	within product manufacturers<br>
*	within regulatory bodies<br>
*	from product manufacturers to regulatory bodies<br>
*	from regulatory bodies to the WHO Collaborative Drug Surveillance Center</p>

<center>Figure 7-18. - Flow of  product experience information</center>
<p>
<b><A href="CH701.gif">Click here for Picture </A></b><br>
Regardless of who originates a drug experience report, documentation of the
experience eventually reaches the regulatory agencies. The manufacturer is
mandated to alert the regulatory agency.<br>
Electronic interchange of these data would reduce errors, decrease costs and
speed communications.


</p>

<h3>
<A NAME="Heading172">7.9.1 Terminology and concepts</A></h3>


<h4>
<A NAME="Heading173">7.9.1.1 drug</A></h4>
any chemical compound that may be used on or administered to humans or animals as an aid in the diagnosis, 
treatment or prevention of disease or other abnormal condition, for the relief of pain or suffering, or to control or improve 
any physiologic condition (Dorland's Illustrated Medical Dictionary 27th edition).



<h4>
<A NAME="Heading335">7.9.1.2 medical device</A></h4>
something contrived for or used in the diagnosis (vascular catheters), treatment (thermotherapy units) or prevention 
of  disease or other abnormal condition, for the relief of pain or suffering or to control or improve any physiologic condition,  
including instrumentation and implanted devices (prosthetic cardiac valves, pacemakers, hip prostheses)



<h4>
<A NAME="Heading174">7.9.1.3 product: </A></h4>
a drug or medical device.

<h4>
<A NAME="Heading336">7.9.1.4 non-proprietary (generic) name:</a></h4>
drug name that is not protected by a
trademark, usually descriptive of its chemical structure; sometimes called a
public name.  In the US, most generic drug names are assigned by the US Adopted
Name Council (USAN). Other generic names in common use are the National
Formulary (NF) and the US Pharmacopoeia (USP) names.  Figure 7-3 lists other
available drug coding systems.<br>


<h4>
<A NAME="Heading175">7.9.1.5 trade (brand) name: </A></h4>
proprietary names that are registered to protect the name for the sole use of the manufacturer holding the trademark. 


<h4>
<A NAME="Heading176">7.9.1.6 adverse event/adverse experience:  </A></h4>

*	Pre-marketing: Any untoward medical occurrence in a patient or clinical
investigation subject administered a pharmaceutical product and which does not
necessarily have a causal relationship with this treatment.<br>
*	Post-marketing/European Union: Any undesirable experience occurring to a
patient treated with a pharmaceutical product whether or not considered related
to the medicinal product.<br>
*	Post-marketing/US: Any adverse event associated with the use of a drug in
humans, whether or not considered drug related, including the following: An
adverse event occurring in the course of the use of a drug product in
professional practice; an adverse event occurring from drug overdose; an
adverse event occurring from drug withdrawal; and any failure of expected
pharmacologic action.<br>
*	WHO: Any untoward medical occurrence that may present during treatment with a
pharmaceutical product but which does not necessarily have a causal
relationship with this product.</p>

<h4>
<A NAME="Heading177">7.9.1.7 adverse drug reaction:  </A></h4>

*	Pre-marketing: All noxious and unintended responses to a medicinal product
related to any dose.<br>
*	Post-marketing/WHO: A response to a drug which is noxious and unintended, and
which occurs at doses normally used in man for prophylaxis, diagnosis, or
therapy of disease or for the modification of physiologic function<br>
*	Post-marketing/European Union: A reaction which is harmful and unintended and
which occurs at doses normally used in man for the prophylaxis, diagnosis, or
treatment of disease or the modification of physiological function.<br>
*	Post-marketing/US: Any undesirable effect reasonably associated with the use
of the drug, that may occur as part of the pharmacological action of the drug
or may be unpredictable.</p>

<h4>
<A NAME="Heading178">7.9.1.8 causation:  an exposure which truly does increase or decrease the probability of a certain outcome.</A></h4>


<h4>
<A NAME="Heading179">7.9.1.9 </A></h4>


<h4>
<A NAME="Heading180">7.9.1.10 regulatory agency: </A></h4>
many geopolitical entities have established agencies/authority responsible for regulating products used in health care.  The agencies are collectively referred to as regulatory agencies. 


<h4>
<A NAME="Heading181">7.9.1.11 Product manufacturer: </A></h4>
the organization which is responsible for the manufacture of a product.  This will usually be the entity which holds the marketing authorization for the product.


<h4>
<A NAME="Heading182">7.9.1.12 Holder of marketing authorization (HMA):  the organization which holds the authority to market a product.  This will often be the organization which manufactures the product.</A></h4>


<h4>
<A NAME="Heading183">7.9.1.13 Serious adverse product reaction: </A></h4>
an adverse product reaction which: 

<p>*
is fatal (results in death)<br>
*	is life threatening<br>
*	requires hospitalization or prolongation of a hospitalization<br>
*	results in persistent or significant disability/incapacity<br>
*	results in a congenital anomaly/birth defect.<br>
Medical and scientific judgment should be exercised in deciding whether
expedited reporting is appropriate in other situations, such as important
medical events that may not be immediately life threatening or result in
hospitalization but may jeopardize the patient or may require intervention to
prevent one of the other outcomes listed in the definition above.  These should
also be considered serious.</p>

<h4>
<A NAME="Heading184">7.9.1.14 Expected adverse product reaction: </A></h4>
expected events are those which prior experience has demonstrated to be probabilistically 
linked to the product and are generally included in product labeling. 

<p>Pre-marketing:
An adverse reaction, the nature or severity of which is not consistent with the
applicable product information (e.g., Investigator's Brochure for an unapproved
investigational product).<br>
Post-marketing/European Union: This relates to an adverse reaction which is not
mentioned in any EC summary of product characteristics (SPC).  In the absence
of any European SPC, an international document prepared by the marketing
authorization holder containing all relevant safety information which the
marketing authorization holder considers should be listed for the medicinal
product in all countries where the medicinal product is marketed (Care Data
Sheet).<br>
Post-marketing/US current: Unexpected means an adverse drug experience that is
not listed in the current labeling for the drug product and includes an event
that may be symptomatically and pathophysiologically related to an event listed
in the labeling but differs from the event because of greater severity or
specificity.<br>
Post-marketing/US (proposed): The applicant's core safety data sheet shall be a
document prepared by the applicant that contains all relevant safety
information, including adverse drug experiences, which the applicant believes
should e listed for the drug in all countries where the drug is marketed.  It
may be used by the applicant as the reference document by which an adverse drug
experience is judged to be expected or unexpected for purposes of this
post-marketing periodic report.<br>
Post-marketing/WHO: An adverse reaction, the nature or severity of which is not
consistent with domestic labeling or market authorization, or expected from
characteristics of the drug.
</p>

<h2>
<A NAME="Heading185">7.10 PRODUCT EXPERIENCE - TRIGGER EVENTS AND MESSAGE DEFINITIONS</A></h2>

<p>The
message header segment will care one of three event types at <i>MSH-9-message
type</i>.<br>
</p>
<TABLE><TR align="left">
<TD align="left"><u>Event</u></TD>
<TD align="left"><u>Description</u></TD></TR>

<TR align="left">
<TD align="left">P07</TD>
<TD align="left">PEX
- Unsolicited initial individual product experience report</TD></TR>

<TR align="left">
<TD align="left">P08</TD>
<TD align="left">PEX
- Unsolicited update individual product experience report</TD></TR>

<TR align="left">
<TD align="left">P09</TD>
<TD align="left">SUR
- Summary product experience report</TD></TR></TABLE>
<h3>
<A NAME="Heading186">7.10.1 PEX - product experience message (events P07, P08)</A></h3>

<p>The
primary application of this message is to transfer information related to an
adverse event occurring while a patient was exposed to a product.<br>
<tt><u>PEX 					Product Experience Message	Chapter</u></tt><br>
MSH					Message Header	2<br>
EVN					Event Type	3<br>
PID					Patient Identification	3<br>
[PD1]				Additional Demographics	3<br>
[{NTE}]				Notes and comments	2<br>
 [PV1				Patient Visit	3<br>
 [PV2]]				Patient Visit - Additional Info	3<br>
{ PES				Product Experience Sender	7<br>
 { PEO				Product Experience Observation	7<br>
  { PCR				Potential Causal Relationship	7<br>
  [ RXE				Pharmacy/Treatment Encoded Order	4<br>
  [{RXR}]			Pharmacy/Treatment Route	4<br>
  ]<br>
  [{RXA				Pharmacy/Treatment Administration	4<br>
    [RXR]			Pharmacy/Treatment Route	4<br>
  }]<br>
  [{PRB}]			Detail problem segment	12<br>
  [{OBX}]			Observation/Result Segment	7<br>
  [{NTE}]			Notes and comments	2<br>
  [NK1				Associated parties segment	2<br>
  [RXE				Pharmacy/Treatment Encoded Order	4<br>
  [{RXR}]			Pharmacy/Treatment Route	4<br>
  ]<br>
  [{RXA				Pharmacy/Treatment Administration	4<br>
  [RXR]				Pharmacy/Treatment Route	4<br>
 }]<br>
[{PRB}]				Detail Problem Segment	12<br>
  [{OBX}]			Observation/Results Segment	7<br>
]<br>
[{CSR				Clinical study registration	7<br>
[{CSP}]				Clinical study phase segment	7<br>
}]<br>
}}}<br>
The PID segment provides the patient identification information including
institutional identification numbers, date of birth and in the case of patients
who die, information about their death.  Patients are frequently identified
only by their initials which can be represented in the PID segment, e.g. the
initials JMO would appear as J^M^O in the name field of the PID segment.  The
EVN segment identifies the type of transaction that is being sent -- primarily
it specifies who the sender is and implies which information is expected to be
included in the message.  A message sent from a healthcare provider, for
example, might contain minimal information, while a message from a
pharmaceutical manufacturer might contain nearly complete information.<br>
The PES or Product Experience Sender segment provides information about the
message sender and its knowledge of the event.  The heart of the product
experience message is the product experience observation  (PEO) segment and the
PCR segments clustered under it.  The PEO segment identifies a clinical event
and the PCR segments identify products which are potentially causally related
to the event.  There may be more than one product which is potentially related
to the event so multiple PCR segments can be included.  RXE and RXR segments
can be repeated and provide information about the products the patient was
exposed to at the time of the event (typically excluding those used to treat
the event).  Details about the administration of the products identified in the
PCR segments should be described with RXE and RXR segments. Repeated  PRB
segments provide information about diagnoses which represent comorbid
conditions. The repeated OBX segments are used to send patient observations
such as height, weight, last menstrual period, and laboratory results.
Analytical commentary can be included in the NTE segment. This commentary will
typically be the sender's analysis of the event and the potentially causally
related products.  Finally, the CSR and CSP segments can optionally be included
if the event occurred during a formal clinical trial in order to describe the
trial.<br>
When a product experience relates to an exposure which occurred indirectly
(transmammary or transplacentally for example), the individual experiencing the
adverse effect -- the fetus or child -- would be described in the PID segment
and the individual via which they are exposed in the NK1 segment.  The first
set of  RXE segments would typically indicate the drugs which to which the
fetus or child was exposed.  Additional codes for the route are defined in this
Appendix to allow the suspected routes of exposure to be represented.  The
second set of RXE/RXR segment - those clustered under the NK1 segment - would
represent the route by which the mother or father were exposed to the drug.
Early spontaneous abortion would normally be treated as an adverse effect on
the mother rather than on the fetus, and the PID would refer to the mother.
The second set of PRB/OBX segments reflects the problems/observations
associated with the individual via which they were exposed.<br>
Each message contains information about a single case including one patient
(PID), at least one sender (PES), one or more events (PEO) and one or more
suspected products (PCR and RXE/RXA) for a minimal message. The structure of
the message allows actual administration information to be sent in the RXA if
known; if administration information is unavailable, or the adverse reaction
cannot be related to a single administration event, the RXE segment can be used
to send prescription level information. Additional information may be included
based on availability and regulatory requirements.<br>
The MSH segment specifies the character set (<i>MSH-18</i>) and the language
(<i>MSH-19</i>) used in the PEX message.<br>
The PEX message is designed to accommodate required reporting of adverse
product events to the responsible regulatory agencies.  In the United States,
the paper version of this report is Medwatch.</p>

<h3>
<A NAME="Heading187">7.10.2 SUR - summary product experience report (event P09)</A></h3>

<blockquote>Sending
summary reports related to products constitutes a P09
event.</blockquote><p><tt><u>SUR				Summary Product Experience Report
Chapter</u></tt><br>
<tt>MSH				Message Header	2</tt><br>
{<br>
  FAC			Facility 	7<br>
   {PSH			Product Summary Header	7<br>
    PDC			Product Detail Country	7<br>
   }<br>
  PSH			Product Summary Header	7<br>
   {FAC			Facility	7<br>
    PDC			Product Detail Country	7<br>
    NTE			Notes (for PCR)	2<br>
   }<br>
   ED			Encapsulated Data	2<br>
}</p>
<blockquote>The Summary Product Experience Report message can be divided into
two separate parts.  Part 1 consists of a Facility segment which identifies the
reporting organization, a Product Summary Header segment which provides summary
information about the products and manufacturers, and a Product Detail Country
segment which provides country specific product identification and marketing
information.  Part 2 consists of a repeating series of segments.  These
segments could be used to represent data about each model of a medical device
(Part 2 of FDA Form 3417, for example).  The Product Summary Header segment
provides manufacturer's data, under which repeating sets of Facility segments
(representing multiple manufacturing sites), a Product Detail Country segment
(representing marketing and product identification data) and the Note segment
(for other commentary) may follow.  Finally, the Encapsulated Data (ED) segment
can be used to transmit images of documents, including any of the MIME
(Multimedia Internet Mail Extension) support formats such as JPEG, GIF, and FAX.
Regulatory agencies require a variety of reports that are centered on the
product, not on a single patient.  Some of these reports request information
just about the product, and some request information about the product combined
with a summary of the product experience reports on that product.  These are
used by regulatory agencies to provide totals against which they can verify
that they have received and processed all of the relevant reports, and to
calculate denominators for computing event rates.  If manufacturers begin to
transmit these reports electronically and regulatory agencies in turn
electronically confirm the receipt of such reports, the need for some of these
summary reports will decline.
The SUR message provides a mechanism for sending a variety of different summary
reports.  In the United States, the Medical Device Reporting Annual
Certification and the Medical Device Reporting Baseline Report are examples of
such reports.  Below, we use these two medical device reports to illustrate how
one would map the contents of this kind of report to the SUR message.
Manufacturers are required to submit a Baseline Report (FDA Form 3417 of
October, 1995 (when a device is first released.  The focus of this report is a
single product.  The first part requests information about the manufacturer of
the product (Questions 2a through 2g), e.g., the firm's name, street address,
city, country, type of firm (e.g., manufacturer, distributor, both); the
manufacturer's contact (Questions 3a through 3g). e.g., title, street address,
city, state, phone number, and whether the firm is an organization of a foreign
manufacturer.  Most of this information can be transmitted as fields within the
FAC (Facility segment - the first  segment in the SUR message following the
MSH).  Question 1 (which asks the type of baseline report - initial or annual
update) and Question 7 (the date of the report) are reported in the PSH
(Product Summary Header) segment that follows the FAC segment in the SUR
message.  The second part of the Baseline Report form also includes information
about the device name (Question 2), generic name (Question 3), device model
number (Question 4), device catalogue number (Question 5), other device
identifier (Question 6), product code (Question 7), and device family (Question
8), related device information (Question 9), the basis for marketing the device
(Question 10), device life (Question 11), the date the device was first
marketed (Question 12), the date the device ceased being marketed (Question
13), whether the device was the subject of a 522 study (Question 14), and the
number of devices manufactured, distributed, and in current use (Question 15).
All of these questions with the exception of #9 are represented in the PDC
segment.  Questions 16a and 16b are represented by nested PSH segments.
The Medical Device Reporting Annual Certification form consists of two parts.
Part 12 transmits information describing the firm submitting the report
(Questions 2a through 2h) and the individual who completed the report
(Questions 3a through 3g).  These questions are represented in the FAC segment.
Question 1 (period covered by the certification) corresponds to the PSH
segment.  Part 2, Question 3, which details one or more individual devices, can
be transmitted in the repeating FAC and PSH segments.  <i>Figure 7-19</i>
summarizes the mapping between questions on these two FDA forms and the SUR
message.</blockquote>
<center>Figure 7-19.  Mapping of FDA medical device reports to SUR message
</center>
<TABLE BORDER><TR>
<TD ><b>Baseline
Report
</b></TD>
<TD ><b>Annual
Certification
</b></TD>
<TD ><b>SUR</b></TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">MSH</TD></TR>

<TR align="left">
<TD align="left">Part
1<br>Questions 2a-2g, 3a-3g</TD>
<TD align="left">Part
1<br>Questions 2,3</TD>
<TD align="left">{
 FAC</TD></TR>

<TR align="left">
<TD align="left">Part
1 <br>Questions 1, 7</TD>
<TD align="left">Part
1<br>Question 1</TD>
<TD align="left">
  {PSH</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">
    PDC</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">
  }</TD></TR>

<TR align="left">
<TD align="left">Part
2<br>Questions 16a, 16b</TD>
<TD align="left">Part
2<br>Question 3</TD>
<TD align="left">
  PSH</TD></TR>

<TR align="left">
<TD align="left">Part
2<br>Questions 1a, 1b</TD>
<TD align="left">Part
2<br>Question 3</TD>
<TD align="left">
 {  FAC</TD></TR>

<TR align="left">
<TD align="left">Part
2<br>Questions 2-15</TD>
<TD align="left"><BR></TD>
<TD align="left">
     PDC</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">
     NTE</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">
 }</TD></TR>

<TR align="left">
<TD align="left">Part
2<br>Alternative transmission method - image file rather than text</TD>
<TD align="left"><BR></TD>
<TD align="left">ED</TD></TR>

<TR align="left">
<TD align="left"><BR></TD>
<TD align="left"><BR></TD>
<TD align="left">}</TD></TR>
</TABLE>
<h2>
<A NAME="Heading188">7.11 PRODUCT EXPERIENCE - SEGMENTS DEFINITIONS</A></h2>


<h3>
<A NAME="Heading189">7.11.1 PES - product experience sender segment</A></h3>

<p><center>Figure
7-20.  PES attributes</center><br>
</p>
<TABLE BORDER><TR>
<TD >SEQ</TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR>
<TD >1</TD>
<TD >80</TD>
<TD >XON</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01059</TD>
<TD >Sender
Organization Name</TD></TR>

<TR>
<TD >2</TD>
<TD >60</TD>
<TD >XCN</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01060</TD>
<TD >Sender Individual Name</TD></TR>

<TR>
<TD >3</TD>
<TD >200</TD>
<TD >XAD</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01062</TD>
<TD >Sender
Address</TD></TR>

<TR>
<TD >4</TD>
<TD >44</TD>
<TD >XTN</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01063</TD>
<TD >Sender Telephone</TD></TR>

<TR>
<TD >5</TD>
<TD >75</TD>
<TD >EI</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01064</TD>
<TD >Sender
Event Identifier</TD></TR>

<TR>
<TD >6</TD>
<TD >2</TD>
<TD >NM</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01065</TD>
<TD >Sender Sequence Number</TD></TR>

<TR>
<TD >7</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01066</TD>
<TD >Sender
Event Description</TD></TR>

<TR>
<TD >8</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01067</TD>
<TD >Sender Comment</TD></TR>

<TR>
<TD >9</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01068</TD>
<TD >Sender
Aware Date/Time</TD></TR>

<TR>
<TD >10</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01069</TD>
<TD >Event Report Date</TD></TR>

<TR>
<TD >11</TD>
<TD >3</TD>
<TD >ID</TD>
<TD >O</TD>
<TD >Y/2</TD>
<TD >0234</TD>
<TD >01070</TD>
<TD >Event
Report Timing/Type</TD></TR>

<TR>
<TD >12</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0235</TD>
<TD >01071</TD>
<TD >Event Report Source</TD></TR>

<TR>
<TD >13</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD >Y</TD>
<TD >0236</TD>
<TD >01072</TD>
<TD >Event
Reported To</TD></TR></TABLE><p>7.11.1.0
  PES - field definitions</p>

<h4>
<A NAME="Heading190">7.11.1.1 Sender organization name  (XON)   01059</A></h4>

<p><tt>Components:
 &lt;organization name (ST)&gt; ^ &lt;organization name type code (IS)&gt; ^
&lt;ID Number (NM)&gt; ^ &lt;check digit (NM)&gt; ^ &lt;code identifying the
check digit scheme employed (ID)&gt; ^ &lt;assigning authority  (HD)&gt; ^
&lt;identifier type code (IS)&gt; ^ &lt;assigning facility ID (HD)&gt; </tt><br>
Subcomponents of assigning authority: &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility: &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;<br>
Definition:  This field contains the name of the organization sending the
message.  Coded lists of manufacturers such as that from the World Health
Organization database might be used in the component of the coded name to
identify the source code type.  If sent from an individual, this field may not
be sent.</p>

<h4>
<A NAME="Heading191">7.11.1.2 Sender individual name  (XCN)   01060</A></h4>

<p><tt>Components:
 &lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type (ID)&gt;
^&lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID)&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility ID (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Definition: This field contains the name of the contact individual.  If sent by
an organization, the individuals in the organization who serve as primary
contact points correspondence regarding this event.</p>

<h4>
<A NAME="Heading192">7.11.1.3 Sender address  (XAD)   01062</A></h4>

<p><tt>Components:
 &lt;street address (ST)&gt; ^ &lt;other designation (ST)&gt; ^ &lt;city
(ST)&gt; ^ &lt;state or province (ST)&gt; ^ &lt;zip or postal code(ST)&gt; ^
&lt;country (ID)&gt; ^ &lt; address type (ID)&gt;<b> </b>^ &lt;other geographic
designation (ST)&gt; ^<b> </b>&lt;county/parish code (IS)&gt; ^ &lt;census
tract (IS)&gt;</tt><br>
Definition:  This field contains the postal address of the message sender to
which correspondence regarding the experience being reported should be directed.</p>

<h4>
<A NAME="Heading193">7.11.1.4 Sender telephone  (XTN)   01063</A></h4>

<p><tt>Components:
 [NNN] [(999)]999-9999 [X99999] [B99999] [C any text] ^ &lt;telecommunication
use code (ID)&gt; ^ &lt;telecommunication equipment type (ID)&gt; ^ &lt;email
address (ST)&gt; ^ &lt;country code (NM)&gt; ^ &lt;area/city code (NM)&gt; ^
phone number (NM)&gt; ^ &lt;extension (NM)&gt; ^ &lt;any text (ST)&gt;</tt><br>
Definition:  This field contains the telephone number of the message sender to
which telephone communications regarding the experience being reported should
be directed.  An electronic mail address can be specified in this field.</p>

<h4>
<A NAME="Heading194">7.11.1.5 Sender event identifier  (EI)   01064</A></h4>

<p><tt>Components:
&lt;entity identifier (ST)&gt; ^ &lt;namespace ID (IS)&gt; ^ &lt;universal ID
(ST)&gt; ^ &lt;universal ID type (ID)&gt;</tt><br>
Definition:  The first component of this field contains the product
manufacturer's unique alphanumeric identifier for this specific event.  This
identifier will be used on all subsequent communications regarding this event.
For events reported to the FDA, the identifier is: the FDA assigned
manufacturer or distributor number; a hyphen; the 4-digit year; a hyphen; and a
consecutive 5-digit sequence number for each report filled by the sender that
year.  For example, the event identifier for the third event reported in 1996
by a manufacturer whose FDA-assigned registration number is 1234567 would be
1234567-1993-3.  Organizations without an FDA-assigned registration number
should use 0000000 until assigned a number.  Reports from other facilities
should use the 10-digit HCFA number left padded with zeros in place of the
FDA-assigned registration number.  The second through fourth components are
defined in exactly the same way as the three components of the hierarchic
designator (HD) data type (Section 2.8.18, "HD - hierarchic designator").</p>

<h4>
<A NAME="Heading195">7.11.1.6 Sender sequence number  (NM)   01065</A></h4>

<p>Definition:
 This field contains sequentially assigned integer values which distinguish
messages which share the same sender event identification element.  0 for
initial report, 1 for second, and so on.</p>

<h4>
<A NAME="Heading196">7.11.1.7 Sender event description  (FT)   01066</A></h4>

<p>Definition:
 This field contains the summary narrative text description of the event that
occurred written by the sender, which may include a description of the nature
of the event, how the product was involved, any environmental conditions that
may have influenced the event, and patient follow-up or required treatment.
Note that laboratory results can be encoded as OBX segments rather then
including them in the narrative.  By representing clinical information in OBX
segments rather than in the narrative, these data become much more useful and
flexible.</p>

<h4>
<A NAME="Heading197">7.11.1.8 Sender comment  (FT)   01067</A></h4>

<p>Definition:
 This field contains the text commentary regarding the report being made, such
as disclaimers, which is not necessarily part of the report.</p>

<h4>
<A NAME="Heading198">7.11.1.9 Sender aware date/time  (TS)</A></h4>

<p>Definition:
This field identifies the date the sender became aware of the event.</p>

<h4>
<A NAME="Heading199">7.11.1.10 Event report date  (TS)   01069</A></h4>

<p>Definition:
This field contains the date the message was originally sent to the regulatory
agency.</p>

<h4>
<A NAME="Heading200">7.11.1.11 Event report timing type  (ID)   01070</A></h4>

<p>Definition:
 This field contains the timing type of report as required by regulatory
agency.  Refer to<i> HL7 table 0234 - Report timing</i> for valid values.</p>

<center>Table 0234 - Report timing
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >CO</TD>
<TD >Correction</TD></TR>

<TR>
<TD >AD</TD>
<TD >Additional information</TD></TR>

<TR>
<TD >RQ</TD>
<TD >Requested information</TD></TR>

<TR>
<TD >DE</TD>
<TD >Device evaluation</TD></TR>

<TR>
<TD >PD</TD>
<TD >Periodic</TD></TR>

<TR>
<TD >3D</TD>
<TD >3 day report</TD></TR>

<TR>
<TD >7D</TD>
<TD >7 day report</TD></TR>

<TR>
<TD >10D</TD>
<TD >10 day report</TD></TR>

<TR>
<TD >15D</TD>
<TD >15 day report</TD></TR>

<TR>
<TD >30D</TD>
<TD >30 day report</TD></TR></TABLE>
<h4>
<A NAME="Heading201">7.11.1.12 Event report source  (ID)   01071</A></h4>

<p>Definition:
 This field identifies the source from which the sender learned about the
event.  Multiple sources may be reported by repeating the element.<br>
If the source of the report is a clinical trial, the CSR and CSP segments can
be included to define the study.  Refer to <i>HL7 table 0235 - Report
source</i> for valid values.</p>

<center>Table 0235 - Report source
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >C</TD>
<TD >Clinical trial</TD></TR>

<TR>
<TD >L</TD>
<TD >Literature</TD></TR>

<TR>
<TD >H</TD>
<TD >Health professional</TD></TR>

<TR>
<TD >R</TD>
<TD >Regulatory agency</TD></TR>

<TR>
<TD >D</TD>
<TD >Database/registry/poison control center</TD></TR>

<TR>
<TD >N</TD>
<TD >Non-healthcare professional</TD></TR>

<TR>
<TD >P</TD>
<TD >Patient</TD></TR>

<TR>
<TD >M</TD>
<TD >Manufacturer/marketing authority holder</TD></TR>

<TR>
<TD >E</TD>
<TD >Distributor</TD></TR>

<TR>
<TD >O</TD>
<TD >Other</TD></TR></TABLE>
<h4>
<A NAME="Heading202">7.11.1.13 Event reported to  (ID)   01072</A></h4>

<p>Definition:
 This field indicates all the entities to whom the entity submitting the report
has reported the event.  Repeat the element if the report was submitted to more
than one entity.  Refer to <i>HL7 table 0236 - Event reported to</i> for valid
values.<br>
<center>Table 0236 - Event reported to</center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >M</TD>
<TD >Manufacturer</TD></TR>

<TR>
<TD >L</TD>
<TD >Local facility/user facility</TD></TR>

<TR>
<TD >R</TD>
<TD >Regulatory agency</TD></TR>

<TR>
<TD >D</TD>
<TD >Distributor</TD></TR></TABLE>
<h3>
<A NAME="Heading203">7.11.2 PEO - product experience observation segment</A></h3>

<p>Details
related to a particular clinical experience or event are embodied in the PEO
segment.  This segment can be used to characterize an event which might be
attributed to a product to which the patient was exposed.   Products with a
possible causal relationship to the observed experience are described in the
following PCR (possible causal relationship) segments.  The message format was
designed to be robust and includes many optional elements which may not be
required for a particular regulatory purpose but allow a complete
representation of the drug experience if needed.<br>
A PEX message can contain multiple PEO segments if the patient experienced more
than one event but must contain at least one PEO segment.</p>

<center>Figure 7-21.  PEO attributes
</center>
<TABLE BORDER><TR>
<TD >SEQ</TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPTC</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM #</TD>
<TD >ELEMENT NAME</TD></TR>

<TR>
<TD >1</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01073</TD>
<TD >Event Identifiers Used</TD></TR>

<TR>
<TD >2</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01074</TD>
<TD >Event
Symptom/Diagnosis Code</TD></TR>

<TR>
<TD >3</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01075</TD>
<TD >Event Onset Date/Time</TD></TR>

<TR>
<TD >4</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01076</TD>
<TD >Event
Exacerbation Date/Time</TD></TR>

<TR>
<TD >5</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01077</TD>
<TD >Event Improved Date/Time</TD></TR>

<TR>
<TD >6</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01078</TD>
<TD >Event
Ended Data/Time</TD></TR>

<TR>
<TD >7</TD>
<TD >106</TD>
<TD >XAD</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01079</p>
<BR></TD>
<TD >Event Location Occurred Address</TD></TR>

<TR>
<TD >8</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD >Y</TD>
<TD >0237</TD>
<TD >01080</TD>
<TD >Event
Qualification</TD></TR>

<TR>
<TD >9</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0238</TD>
<TD >01081</TD>
<TD >Event Serious</TD></TR>

<TR>
<TD >10</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0239</TD>
<TD >01082</TD>
<TD >Event Expected</TD></TR>

<TR>
<TD >11</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD >Y</TD>
<TD >0240</TD>
<TD >01083</TD>
<TD >Event Outcome</TD></TR>

<TR>
<TD >12</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0241</TD>
<TD >01084</TD>
<TD >Patient Outcome</TD></TR>

<TR>
<TD >13</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01085</TD>
<TD >Event
Description From Others</TD></TR>

<TR>
<TD >14</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01086</TD>
<TD >Event From Original Reporter</TD></TR>

<TR>
<TD >15</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01087</TD>
<TD >Event Description From Patient</TD></TR>

<TR>
<TD >16</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01088</TD>
<TD >Event Description From Practitioner</TD></TR>

<TR>
<TD >17</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01089</TD>
<TD >Event Description From Autopsy</TD></TR>

<TR>
<TD >18</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01090</TD>
<TD >Cause Of Death</TD></TR>

<TR>
<TD >19</TD>
<TD >46</TD>
<TD >XPN</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01091</TD>
<TD >Primary Observer Name</TD></TR>

<TR>
<TD >20</TD>
<TD >106</TD>
<TD >XAD</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01092</TD>
<TD >Primary
Observer Address</TD></TR>

<TR>
<TD >21</TD>
<TD >40</TD>
<TD >XTN</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01093</TD>
<TD >Primary
Observer Telephone</TD></TR>

<TR>
<TD >22</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0242</TD>
<TD >01094</TD>
<TD >Primary Observer's Qualification</TD></TR>

<TR>
<TD >23</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0242</TD>
<TD >01095</TD>
<TD >Confirmation Provided By</TD></TR>

<TR>
<TD >24</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01096</TD>
<TD >Primary Observer Aware Date/Time</TD></TR>

<TR>
<TD >25</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0243</TD>
<TD >01097</TD>
<TD >Primary
Observer's identity May Be Divulged</TD></TR></TABLE><p>7.11.2.0
  PEO  field definitions</p>

<h4>
<A NAME="Heading204">7.11.2.1 Event identifiers used  (CE)   01073</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field may be used to transmit the event identifier used by
other entities for this event.   The entry would typically contain a unique
alphanumeric identifier assigned by an entity with the text component null or
repeating the unique alphanumeric identifier followed by the organization's
identifier.  An event identifier might be GB1234^GB1234^PharmaGiant for example.</p>

<h4>
<A NAME="Heading205">7.11.2.2 Event symptom/diagnosis code  (CE)   01074</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition: This field is the coded diagnosis or problem description which
best describes the event.  A text representation of the coded item should
routinely be included.  MEDDRA and WHO-ART are examples of appropriate coding
schemes, as are the patient and device codes included in the FDA Center for
Devices and Radiologic Health's coding manual for Form 3500A.</p>

<h4>
<A NAME="Heading206">7.11.2.3 Event onset date/time  (TS)   01075</A></h4>

<p>Definition:
 This field contains a report or best estimate of the date/time of onset of the
event  The date/time can be recorded to any level of precision it is known
(hour, day, month, year).</p>

<h4>
<A NAME="Heading207">7.11.2.4 Event exacerbation date/time  (TS)   01076</A></h4>

<p>Definition:
 This field identifies the best estimate of the date/time the event was
exacerbated.</p>

<h4>
<A NAME="Heading208">7.11.2.5 Event improved date/time  (TS)   01077</A></h4>

<p>Definition:
 This field identifies the best estimate of the date/time the event improved.</p>

<h4>
<A NAME="Heading209">7.11.2.6 Event ended data/time  (TS)   01078</A></h4>

<p>Definition:
 This field identifies the best estimate of the date/time the event resolved.</p>

<h4>
<A NAME="Heading210">7.11.2.7 Event location occurred address  (XAD)   01079</A></h4>

<p><tt>Components:
 &lt;street address (ST)&gt; ^ &lt;other designation (ST)&gt; ^ &lt;city
(ST)&gt; ^ &lt;state or province (ST)&gt; ^ &lt;zip or postal code(ST)&gt; ^
&lt;country (ID)&gt; ^ &lt; address type (ID)&gt;<b> </b>^ &lt;other geographic
designation (ST)&gt; ^<b> </b>&lt;county/parish code (IS)&gt; ^ &lt;census
tract (IS)&gt;</tt><br>
Definition:  This field identifies the location at which the event started.
Often this will specify only the country in which the event started.</p>

<h4>
<A NAME="Heading211">7.11.2.8 Event qualification  (ID)   01080</A></h4>

<p>Definition:
This field is contains a classification of the type of product experience this
event is considered to represent.  Refer to <i>HL7 table 0237 - Event
qualification</i> for valid values.</p>

<center>Table 0237 - Event qualification
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >I</TD>
<TD >Interaction</TD></TR>

<TR>
<TD >O</TD>
<TD >Overdose</TD></TR>

<TR>
<TD >A</TD>
<TD >Abuse</TD></TR>

<TR>
<TD >M</TD>
<TD >Misuse</TD></TR>

<TR>
<TD >D</TD>
<TD >Dependency</TD></TR>

<TR>
<TD >L</TD>
<TD >Lack of expect therapeutic effect</TD></TR>

<TR>
<TD >W</TD>
<TD >Drug withdrawal</TD></TR>

<TR>
<TD >B</TD>
<TD >Unexpected
beneficial effect</TD></TR></TABLE><p>Unexpected
beneficial effects would not often be reported but are required by certain
countries.</p>

<h4>
<A NAME="Heading212">7.11.2.9 Event serious  (ID)   01081</A></h4>

<p>Definition:
 This field indicates whether the event was judged as serious.  If the event
did not meet the criteria for seriousness but the sender judges the event
significant on other grounds, the event can be identified as significant
[<i>but not serious</i>].  Refer to <i>HL7 table 0238 - Event seriousness</i>
for valid values.</p>

<center>Table 0238 - Event seriousness
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >Y</TD>
<TD >Yes</TD></TR>

<TR>
<TD >S</TD>
<TD >Significant</TD></TR>

<TR>
<TD >N</TD>
<TD >No</TD></TR></TABLE>
<h4>
<A NAME="Heading213">7.11.2.10 Event expected  (ID)   01082</A></h4>

<p>Definition:
 This field indicates whether the observed event was expected or unexpected as
judged.  Refer to <i>HL7 table 0239 - Event expected</i> for valid values.</p>

<center>Table 0239 - Event expected
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >Y</TD>
<TD >Yes</TD></TR>

<TR>
<TD >N</TD>
<TD >No</TD></TR>

<TR>
<TD >U</TD>
<TD >Unknown</TD></TR></TABLE>
<h4>
<A NAME="Heading214">7.11.2.11 Event outcome  (ID)   01083</A></h4>

<p>Definition:
This field identifies the consequence of the <u>event</u> on the patient.  If
the consequence of the event is not understood or not available, the patient
outcome element may be used although neither is required.  May be repeated if
more than one is appropriate.  Refer to <i>HL7 table 0240 - Event
consequences</i> for valid values.</p>

<center>Table 0240 - Event consequence
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >D</TD>
<TD >Death</TD></TR>

<TR>
<TD >L</TD>
<TD >Life threatening</TD></TR>

<TR>
<TD >H</TD>
<TD >Caused hospitalized </TD></TR>

<TR>
<TD >P</TD>
<TD >Prolonged hospitalization</TD></TR>

<TR>
<TD >C</TD>
<TD >Congenital anomaly/birth defect</TD></TR>

<TR>
<TD >I</TD>
<TD >Incapacity which is significant, persistent or permanent</TD></TR>

<TR>
<TD >J</TD>
<TD >Disability which is significant, persistent or permanent</TD></TR>

<TR>
<TD >R</TD>
<TD >Required intervention to prevent permanent impairment/damage</TD></TR>

<TR>
<TD >O</TD>
<TD >Other</TD></TR></TABLE>
<h4>
<A NAME="Heading215">7.11.2.12 Patient outcome  (ID)   01084</A></h4>

<p>When
an event specific outcome is not available, the patient outcome element may be
used to represent the patient's overall outcome if that information is known.
Refer to <i>HL7 table 0241 - Patient outcome</i> for valid values.<br>
<center>Table 0241 - Patient outcome</center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >D</TD>
<TD >Died</TD></TR>

<TR>
<TD >R</TD>
<TD >Recovering</TD></TR>

<TR>
<TD >N</TD>
<TD >Not
recovering/unchanged</TD></TR>

<TR>
<TD >W</TD>
<TD >Worsening</TD></TR>

<TR>
<TD >S</TD>
<TD >Sequelae</TD></TR>

<TR>
<TD >F</TD>
<TD >Fully
recovered</TD></TR>

<TR>
<TD >U</TD>
<TD >Unknown</TD></TR></TABLE>
<h4>
<A NAME="Heading216">7.11.2.13 Event description from others  (FT)   01085</A></h4>

<p>Definition:
 This field contains a summary narrative text description of the event that
occurred written by the sender.  Note that laboratory results can be encoded as
OBX segments rather then including them in the narrative.  By representing
clinical information in OBX segments rather than in the narrative, these data
become much more useful and flexible.</p>

<h4>
<A NAME="Heading217">7.11.2.14 Event description from original reporter  (FT)   01086</A></h4>

<p>Definition:
 This field contains a summary narrative text description of the event provided
by the original reporter.  Note that laboratory results can be encoded as OBX
segments rather then including them in the narrative.</p>

<h4>
<A NAME="Heading218">7.11.2.15 Event description from patient  (FT)   01087</A></h4>

<p>Definition:
 This field contains a summary narrative text description of the event obtained
directly from the patient.  Note that laboratory results can be encoded as OBX
segments rather then including them in the narrative, which will allow the data
to be more readily represented and manipulated.</p>

<h4>
<A NAME="Heading219">7.11.2.16 Event description from practitioner  (FT)   01088</A></h4>

<p>Definition:
 This field contains a summary narrative text description of the event provided
by the practitioner most familiar with the event.  Note that laboratory results
can be encoded as OBX segments rather then including them in the narrative.</p>

<h4>
<A NAME="Heading220">7.11.2.17 Event description from autopsy  (FT)   01089</A></h4>

<p>Definition:
 This field contains a summary narrative text description of the autopsy
results.  Note that laboratory results can be encoded as OBX segments rather
then including them in the narrative.</p>

<h4>
<A NAME="Heading221">7.11.2.18 Cause of death  (CE)   01090</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field identifies the coded cause of death.  May be repeated
as necessary to list multiple contributing causes.  A text description can be
included by including text but no code or coding system.  For example, if the
cause of death is to be determined at autopsy but results are not yet
available, the cause of death element could be ^Pending autopsy^.  The
date/time of death can be sent in the PID and the autopsy results sent in the
event description from autopsy element of the PEO segment.  </p>

<h4>
<A NAME="Heading222">7.11.2.19 Primary observer name  (XPN)   01091</A></h4>

<p><tt>Components:
 &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^ &lt;middle initial or
name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^ &lt;prefix (e.g., DR)
(ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^<b> </b>&lt;name type code (ID)
&gt;</tt><br>
Definition:  This field identifies the name of the person who initially
described the event.  </p>

<h4>
<A NAME="Heading223">7.11.2.20 Primary observer address  (XAD)   01092</A></h4>

<p><tt>Components:
 &lt;street address (ST)&gt; ^ &lt;other designation (ST)&gt; ^ &lt;city
(ST)&gt; ^ &lt;state or province (ST)&gt; ^ &lt;zip or postal code(ST)&gt; ^
&lt;country (ID)&gt; ^ &lt; address type (ID)&gt;<b> </b>^ &lt;other geographic
designation (ST)&gt; ^<b> </b>&lt;county/parish code (IS)&gt; ^ &lt;census
tract (IS)&gt;</tt><br>
Definition:  This field identifies the address of the person who initially
described the event.</p>

<h4>
<A NAME="Heading224">7.11.2.21 Primary observer telephone  (XTN)   01093</A></h4>

<p><tt>Components:
 [NNN] [(999)]999-9999 [X99999] [B99999] [C any text] ^ &lt;telecommunication
use code (ID)&gt; ^ &lt;telecommunication equipment type (ID)&gt; ^ &lt;email
address (ST)&gt; ^ &lt;country code (NM)&gt; ^ &lt;area/city code (NM)&gt; ^
phone number (NM)&gt; ^ &lt;extension (NM)&gt; ^ &lt;any text (ST)&gt;</tt><br>
Definition:  This field identifies the telephone number of the person who
initially described the event.</p>

<h4>
<A NAME="Heading225">7.11.2.22 Primary observer's qualification  (ID)   01094</A></h4>

<p>Definition:
 This field contains the qualification of the primary observer which may assist
in assessing the validity of the observations.  Refer to<i> HL7 table 0242 -
Primary observer's qualification</i> for valid values.</p>

<center>Table 0242 - Primary observer's qualification
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >P</TD>
<TD >Physician (osteopath, homeopath)</TD></TR>

<TR>
<TD >R</TD>
<TD >Pharmacist</TD></TR>

<TR>
<TD >M</TD>
<TD >Mid-level professional (nurse, nurse practitioner, physician's assistant)</TD></TR>

<TR>
<TD >H</TD>
<TD >Other health professional</TD></TR>

<TR>
<TD >C</TD>
<TD >Health care consumer/patient</TD></TR>

<TR>
<TD >L</TD>
<TD >Lawyer/attorney</TD></TR>

<TR>
<TD >O</TD>
<TD >Other non-health professional</TD></TR></TABLE>
<h4>
<A NAME="Heading226">7.11.2.23 Confirmation provided by  (ID)   01095</A></h4>

<p>Definition:
 This field contains the qualification of the health professional who confirmed
the observation if the primary observer was not a health professional.  Refer
to <i>HL7 table 0242 - Primary observer's</i> <i>qualification</i> for valid
values.  </p>

<h4>
<A NAME="Heading227">7.11.2.24 Primary observer aware date/time  (TS)   01096</A></h4>

<p>Definition:
 This field identifies the date/time the primary observer became aware of event.</p>

<h4>
<A NAME="Heading228">7.11.2.25 Primary observer's identity may be divulged  (ID)   01097</A></h4>

<p>Definition:
Indicates whether or not the primary observer, if known to the sender, grants
permission to disclose his or her identity to the product manufacturer for the
purpose of further investigating the event.  If the element is absent, the
assumption should be made that permission is not granted.  Refer to<i> HL7
table 0243 - Identity may be divulged</i> for valid values.</p>

<center>Table 0243 - Identity may be divulged
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >Y</TD>
<TD >Yes</TD></TR>

<TR>
<TD >N</TD>
<TD >No</TD></TR>

<TR>
<TD >NA</TD>
<TD >Not applicable</TD></TR></TABLE>
<h3>
<A NAME="Heading229">7.11.3 PCR - possible causal relationship segment</A></h3>

<p>The
PCR segment is used to communicate a potential or suspected relationship
between a product (drug or device) or test and an event with detrimental effect
on a patient.  This segment identifies a potential causal relationship between
the product identified in this segment and the event identified in the PEO
segment.<br>
More than one PCR segment can be included in the message if more than one
product is possibly causally related to the event.</p>

<center>Figure 7-22.  PCR attributes
</center>
<TABLE BORDER><TR>
<TD >SEQ</p>
<BR></TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR>
<TD >1</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01098</TD>
<TD >Implicated Product</TD></TR>

<TR>
<TD >2</TD>
<TD >1</TD>
<TD >IS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0239</TD>
<TD >01099</TD>
<TD >Generic
Product</TD></TR>

<TR>
<TD >3</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01100</TD>
<TD >Product Class</TD></TR>

<TR>
<TD >4</TD>
<TD >8</TD>
<TD >CQ</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01101</TD>
<TD >Total
Duration Of Therapy</TD></TR>

<TR>
<TD >5</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01102</TD>
<TD >Product Manufacture Date</TD></TR>

<TR>
<TD >6</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01103</TD>
<TD >Product
Expiration Date</TD></TR>

<TR>
<TD >7</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01104</TD>
<TD >Product Implantation Date</TD></TR>

<TR>
<TD >8</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01105</TD>
<TD >Product
Explantation Date</TD></TR>

<TR>
<TD >9</TD>
<TD >8</TD>
<TD >IS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0239</TD>
<TD >01106</TD>
<TD >Single Use Device</TD></TR>

<TR>
<TD >10</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01107</TD>
<TD >Indication
For Product Use</TD></TR>

<TR>
<TD >11</TD>
<TD >8</TD>
<TD >IS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0239</TD>
<TD >01108</TD>
<TD >Product Problem</TD></TR>

<TR>
<TD >12</TD>
<TD >30</TD>
<TD >ST</TD>
<TD >O</TD>
<TD >Y/3</TD>
<TD><BR></TD>
<TD >01109</TD>
<TD >Product
Serial/Lot Number</TD></TR>

<TR>
<TD >13</TD>
<TD >1</TD>
<TD >IS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0239</TD>
<TD >01110</TD>
<TD >Product Available For Inspection</TD></TR>

<TR>
<TD >14</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01111</TD>
<TD >Product
Evaluation Performed</TD></TR>

<TR>
<TD >15</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0247</TD>
<TD >01112</TD>
<TD >Product Evaluation Status</TD></TR>

<TR>
<TD >16</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01113</TD>
<TD >Product
Evaluation Results</TD></TR>

<TR>
<TD >17</TD>
<TD >8</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0248</TD>
<TD >01114</TD>
<TD >Evaluated Product Source</TD></TR>

<TR>
<TD >18</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01115</TD>
<TD >Date
Product Returned To Manufacturer</TD></TR>

<TR>
<TD >19</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0242</TD>
<TD >01116</TD>
<TD >Device Operator Qualifications</TD></TR>

<TR>
<TD >20</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0250</TD>
<TD >01117</TD>
<TD >Relatedness Assessment</TD></TR>

<TR>
<TD >21</TD>
<TD >2</TD>
<TD >ID</TD>
<TD >O</TD>
<TD >Y/6</TD>
<TD >0251</TD>
<TD >01118</TD>
<TD >Action Taken In Response To The Event</TD></TR>

<TR>
<TD >22</TD>
<TD >2</TD>
<TD >ID</TD>
<TD >O</TD>
<TD >Y/6</TD>
<TD >0232</TD>
<TD >01119</TD>
<TD >Event Causality Observations</TD></TR>

<TR>
<TD >23</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD >Y/3</TD>
<TD >0253</TD>
<TD >01120</TD>
<TD >Indirect Exposure Mechanism</TD></TR></TABLE>

<p>
7.11.3.0 PCR field definitions</p>

<h4>
<A NAME="Heading230">7.11.3.1 Implicated product  (CE)   01098</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains the coded identity of the product (drug,
device, etc.) which is possibly causally related to the event.  Includes the
product identity number such as NDC,  model or catalogue numbers.  If a coded
value is not available for the product a text description can be included as
the second component of the CE data.  See Chapter 2 for a listing of some
recognized coding systems for drugs and devices.</p>

<h4>
<A NAME="Heading231">7.11.3.2 Generic product  (IS)   01099</A></h4>

<p>Definition:
 This field indicates whether the product used was a generic or a branded
product.  Refer to <i>user-defined  table 0239 - Event expected </i> for
suggested values.</p>

<h4>
<A NAME="Heading232">7.11.3.3 Product class  (CE)   01100</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition: This field contains the coded classification of the implicated
product. For drugs, this would usually be the drug class - calcium channel
blocking agents for nifedipine for example.  For other products it would be the
generic type of device, e.g., urinary catheter, cardiac pacemaker.  If a coded
value is not available for the class, a text description can be included.</p>

<h4>
<A NAME="Heading233">7.11.3.4 Total duration of therapy  (CQ)   01101</A></h4>

<p><tt>Components:
 &lt;quantity (NM)&gt; ^ &lt;units (CE)&gt;</tt><br>
Subcomponents of units: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt; &amp;
&lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier (ST)&gt;
&amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding system
(ST)&gt;<br>
Definition:  This field represents the total duration of therapy with product
listed.  The treatment at the current dose and schedule are indicted in the
quantity timing attribute of the RXE segment but the patient may have been
treated for some time previously at a different dose or on a different
schedule.  The quantity in the second component of the CQ should be a time
quantity.</p>

<h4>
<A NAME="Heading234">7.11.3.5 Product manufacture date  (DT)   01102</A></h4>

<p>Definition:  This field indicates the date the product was manufactured.</p>

<h4>
<A NAME="Heading235">7.11.3.6 Product expiration date  (DT)   01103</A></h4>

<p>Definition:  This field contains the expiration date indicated on the product packaging.</p>

<h4>
<A NAME="Heading236">7.11.3.7 Product implantation date  (DT)   01104</A></h4>

<p>Definition:
 If an implantable medical device, this field identifies the date device was
implanted.</p>

<h4>
<A NAME="Heading237">7.11.3.8 Product explantation date  (DT)   01105</A></h4>

<p>Definition:
 If an implantable medical device and it was removed, the field identifies the
date it was removed.</p>

<h4>
<A NAME="Heading238">7.11.3.9 Single use device  (IS)   01106</A></h4>

<p>Definition:
 This field indicates whether the product was designed for a single use.  Refer
to <i>user-defined  table 0239 - Event expected</i> for suggested values.</p>

<h4>
<A NAME="Heading239">7.11.3.10 Indication for product use  (CE)   01107</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains coded representation of the problem or
diagnosis for which the product was used.  See Chapter 2 for some coding
systems which might be chosen to transmit diagnoses or problems.</p>

<h4>
<A NAME="Heading240">7.11.3.11 Product problem  (IS)   01108</A></h4>

<p>Definition:
 A product problem would exist if a product malfunction could lead to death or
serious injury.  Refer to <i>user-defined  table 0239 - Event expected</i> for
suggested values.</p>

<h4>
<A NAME="Heading241">7.11.3.12 Product serial/lot number  (ST)   01109</A></h4>

<p>Definition:
This field is an alphanumeric descriptor which identifies the specific item or
lot of drug.  This descriptor would normally be obtained from the package
labeling or item itself.</p>

<h4>
<A NAME="Heading242">7.11.3.13 Product available for inspection  (IS)   01110</A></h4>

<p>Definition:
 This field indicates that the product is available for analysis.  Refer to
<i>user-defined table 0239 -Event expected</i> for suggested values.  If the
product was returned to the manufacturer, this would be indicated by including
the date it was returned in the date product returned to manufacturer element.</p>

<h4>
<A NAME="Heading243">7.11.3.14 Product evaluation performed  (CE)   01111</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field indicates the type of product evaluation performed.
The evaluation codes listed in SubPart B of the Coding Manual for FDA Form
3500A, "Type of Evaluation Performed" may be used.  If no codes are available,
text may be sent in the second component of the field.</p>

<h4>
<A NAME="Heading244">7.11.3.15 Product evaluation status  (CE)   01112</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field identifies the status of product evaluation.  Subpart A
Item H.3 of the Coding Manual for FDA Form 3500A may also be used.  If no codes
are available, text may be sent in the second component of the field.  Refer to
<i>HL7 table 0247 - Status of evaluation</i> for valid values.</p>

<center>Table 0247 - Status of evaluation
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >Y</TD>
<TD >Evaluation completed</TD></TR>

<TR>
<TD >P</TD>
<TD >Evaluation in progress</TD></TR>

<TR>
<TD >K</TD>
<TD >Problem already known, no evaluation necessary</TD></TR>

<TR>
<TD >X</TD>
<TD >Product not made by company</TD></TR>

<TR>
<TD >A</TD>
<TD >Evaluation anticipated, but not yet begun</TD></TR>

<TR>
<TD >D</TD>
<TD >Product discarded -- unable to follow up</TD></TR>

<TR>
<TD >C</TD>
<TD >Product received in condition which made analysis impossible</TD></TR>

<TR>
<TD >I</TD>
<TD >Product remains implanted -- unable to follow up</TD></TR>

<TR>
<TD >U</TD>
<TD >Product unavailable for follow up investigation</TD></TR>

<TR>
<TD >Q</TD>
<TD >Product
under quarantine -- unable to follow up</TD></TR>

<TR>
<TD >R</TD>
<TD >Product
under recall/corrective action</TD></TR>

<TR>
<TD >O</TD>
<TD >Other</TD></TR></TABLE>
<h4>
<A NAME="Heading245">7.11.3.16 Product evaluation results  (CE)   01113</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt><br>
Definition:  This field contains the results of the product evaluation.</p>

<h4>
<A NAME="Heading246">7.11.3.17 Evaluated product source  (ID)   01114</A></h4>

<p>Definition:
 This field contains the source of the product evaluated.  Refer to <i>HL7
table 0248 - Product source</i> for valid values.<br>
<center>Table 0248 - Product source</center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >A</TD>
<TD >Actual product involved in incident was evaluated</TD></TR>

<TR>
<TD >L</TD>
<TD >A product from the same lot as the actual product involved was evaluated</TD></TR>

<TR>
<TD >R</TD>
<TD >A product from a reserve sample was evaluated</TD></TR>

<TR>
<TD >N</TD>
<TD >A product from a controlled/non-related inventory was evaluated</TD></TR></TABLE>
<h4>
<A NAME="Heading247">7.11.3.18 Date product returned to manufacturer  (TS)   01115</A></h4>

<p>Definition:
 If the product was returned to the manufacturer, this field contains the date
it was returned may be reported.</p>

<h4>
<A NAME="Heading248">7.11.3.19 Device operator qualification  (ID)   01116</A></h4>

<p>Definition:
 This field identifies the qualification of the person operating the device
when the event occurred.  Refer to <i>HL7 table 0242 - Primary observers
qualification</i> for valid values.</p>

<h4>
<A NAME="Heading249">7.11.3.20 Relatedness assessment  (ID)   01117</A></h4>

<p>Definition:
 This field represents the assessment of relatedness of the product to the
event.  Refer to <i>HL7 table 0250 - Relatedness assessment</i> for valid
values.</p>

<center>Table 0250 - Relatedness assessment</center>

<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >H</TD>
<TD >Highly probable</TD></TR>

<TR>
<TD >M</TD>
<TD >Moderately probable</TD></TR>

<TR>
<TD >S</TD>
<TD >Somewhat probable</TD></TR>

<TR>
<TD >I</TD>
<TD >Improbable</TD></TR>

<TR>
<TD >N</TD>
<TD >Not related</TD></TR></TABLE>
<h4>
<A NAME="Heading250">7.11.3.21 Action taken in response to the event  (ID)   01118</A></h4>

<p>Definition:
 This field indicates the action taken as a result of the event.  Segment may
repeat if multiple categories of evidence are relevant.  Refer to<i> HL7 table
0251 - Action taken in response to the event</i> for valid values.</p>

<center>Table 0251 - Action taken in response to the event
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >WP</TD>
<TD >Product withdrawn permanently</TD></TR>

<TR>
<TD >WT</TD>
<TD >Product withdrawn temporarily</TD></TR>

<TR>
<TD >DR</TD>
<TD >Product dose or frequency of use reduced</TD></TR>

<TR>
<TD >DI</TD>
<TD >Product dose or frequency of use increased</TD></TR>

<TR>
<TD >OT</TD>
<TD >Other</TD></TR>

<TR>
<TD >N</TD>
<TD >None</TD></TR></TABLE>
<h4>
<A NAME="Heading251">7.11.3.22 Event causality observations  (ID)   01119</A></h4>

<p>Definition:
 This field contains observations made about the event which may bear on
causality.  Refer to <i>HL7 table 0252 - Causality observations</i> for valid
values.  Segment may repeat if multiple categories of evidence are relevant.<br>
<center>Table 0252 - Causality observations</center><br>
</p>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >AW</TD>
<TD >Abatement of event after product withdrawn</TD></TR>

<TR>
<TD >BE</TD>
<TD >Event recurred after product reintroduced</TD></TR>

<TR>
<TD >LI</TD>
<TD >Literature reports association of product with event</TD></TR>

<TR>
<TD >IN</TD>
<TD >Event occurred after product introduced</TD></TR>

<TR>
<TD >EX</TD>
<TD >Alternative explanations for the event available</TD></TR>

<TR>
<TD >PL</TD>
<TD >Effect observed when patient receives placebo</TD></TR>

<TR>
<TD >TC</TD>
<TD >Toxic levels of product documented in blood or body fluids</TD></TR>

<TR>
<TD >DR</TD>
<TD >Dose response observed</TD></TR>

<TR>
<TD >SE</TD>
<TD >Similar events in past for this patient</TD></TR>

<TR>
<TD >OE</TD>
<TD >Occurrence of event was confirmed by objective evidence</TD></TR>

<TR>
<TD >OT</TD>
<TD >Other</TD></TR></TABLE>
<h4>
<A NAME="Heading252">7.11.3.23 Indirect exposure mechanism  (ID)   01120</A></h4>

<p>Definition:
 The patient identified in the PID segment, who experienced the event, might
have been exposed to the potential causal product via an intermediary, e.g., a
child might be exposed to a product through the placenta or in breast milk, or
a transfusion recipient might be exposed via a blood product.  If this is the
case, the mechanism of product transmission is identified in this field, using
the valid values in <i>HL7 table 0253 - Indirect exposure mechanism</i>.  If
this field is populated, the identity of the person through whom the product
was transmitted is contained in NK1 and RXE segments which follow.</p>

<center>Table 0253 - Indirect exposure mechanism
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >B</TD>
<TD >Breast milk</TD></TR>

<TR>
<TD >P</TD>
<TD >Transplacental</TD></TR>

<TR>
<TD >F</TD>
<TD >Father</TD></TR>

<TR>
<TD >X</TD>
<TD >Blood product</TD></TR>

<TR>
<TD >O</TD>
<TD >Other</TD></TR></TABLE>
<h3>
<A NAME="Heading253">7.11.4 PSH - product summary header segment </A></h3>


<center>Figure 7-23.  PSH attributes
</center>
<TABLE BORDER><TR>
<TD >SEQ</TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR>
<TD >1</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01233</TD>
<TD >Report
Type</TD></TR>

<TR>
<TD >2</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01297</TD>
<TD >Report Form Identifier</TD></TR>

<TR>
<TD >3</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01235</TD>
<TD >Report Date</TD></TR>

<TR>
<TD >4</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01236</TD>
<TD >Report Interval Start Date</TD></TR>

<TR>
<TD >5</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01294</TD>
<TD >Report Interval End Date</TD></TR>

<TR>
<TD >6</TD>
<TD >12</TD>
<TD >CQ</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01238</TD>
<TD >Quantity Manufactured</TD></TR>

<TR>
<TD >7</TD>
<TD >12</TD>
<TD >CQ</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01239</TD>
<TD >Quantity Distributed</TD></TR>

<TR>
<TD >8</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0329</TD>
<TD >01240</TD>
<TD >Quantity Distributed Method</TD></TR>

<TR>
<TD >9</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01241</TD>
<TD >Quantity Distributed Comment</TD></TR>

<TR>
<TD >10</TD>
<TD >12</TD>
<TD >CQ</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01242</TD>
<TD >Quantity in Use</TD></TR>

<TR>
<TD >11</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0329</TD>
<TD >01243</TD>
<TD >Quantity in Use Method</TD></TR>

<TR>
<TD >12</TD>
<TD >600</TD>
<TD >FT</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01244</TD>
<TD >Quantity in Use Comment</TD></TR>

<TR>
<TD >13</TD>
<TD >2</TD>
<TD >NM</TD>
<TD >O</TD>
<TD >Y/8</TD>
<TD><BR></TD>
<TD >01245</TD>
<TD >Number of Product Experience Reports Filed by Facility</TD></TR>

<TR>
<TD >14</TD>
<TD >2</TD>
<TD >NM</TD>
<TD >O</TD>
<TD >Y/8</TD>
<TD><BR></TD>
<TD >01246</TD>
<TD >Number
of Product Experience Reports Filed by Distributor</TD></TR></TABLE><p>7.11.4.0
  PSH field definitions</p>

<h4>
<A NAME="Heading254">7.11.4.1 Report type  (ST)   01233</A></h4>

<blockquote>Definition:
 This field contains the name, title, or other description of the report.
Typically, the field will include the agency name (e.g., FDA), agency component
if applicable (e.g., CDRH) and the report type (e.g., Medical Device Reporting
Baseline Report).</blockquote>
<h4>
<A NAME="Heading255">7.11.4.2 Report form identifier  (ST)   01297</A></h4>

<blockquote>Definition:
 This field contains the form descriptor which describes the report.
Typically, the field will include the agency name (e.g., FDA), agency component
if applicable (e.g., CDRH) and the form number (e.g., 3417).</blockquote>
<h4>
<A NAME="Heading256">7.11.4.3 Report date  (TS)   01235</A></h4>

<blockquote>Definition:
 This field contains the date as assigned by the sender.</blockquote>
<h4>
<A NAME="Heading257">7.11.4.4 Report interval start date  (TS)   01236</A></h4>

<blockquote>Definition:
 This field contains the date which marks the beginning of the time interval
covered by the current report.</blockquote>
<h4>
<A NAME="Heading258">7.11.4.5 Report interval end date  (TS)   01294</A></h4>

<blockquote>Definition:
 This field contains the date which marks the inclusive end of the time
interval covered by the current report.</blockquote>
<h4>
<A NAME="Heading259">7.11.4.6 Quantity Manufactured  (CQ)   01238</A></h4>

<p><tt>Components:
 &lt;quantity (NM)&gt; ^ &lt;units (CE)&gt;</tt><br>
Subcomponents of units: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt; &amp;
&lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier (ST)&gt;
&amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding system
(ST)&gt;</p>
<blockquote>Definition:  This field is used to send the number of units of the
product manufactured during the reporting interval.  The second component can
be used to specify the units for the quantity.</blockquote>
<h4>
<A NAME="Heading260">7.11.4.7 Quantity Distributed  (CQ)   01239</A></h4>

<p><tt>Components:
 &lt;quantity (NM)&gt; ^ &lt;units (CE)&gt;</tt><br>
Subcomponents of units: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt; &amp;
&lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier (ST)&gt;
&amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding system
(ST)&gt;</p>
<blockquote>Definition:  This field is used to send the number of units of the
product which were distributed during the reporting interval.  The second
component can be used to specify the units for the quantity.</blockquote>
<h4>
<A NAME="Heading261">7.11.4.8 Quantity distributed method  (ID)   01240</A></h4>

<blockquote>Definition:
 This field is used for measuring the quantity distributed.  An explanation of
the method used for estimation can be included in <i>PSH-9-quantity distributed
comment</i>.  Refer to<i> HL7 table 0329 - Quantity</i> <i> method</i> for
valid values.</blockquote>
<center>Table 0329 - Quantity method
</center>
<TABLE BORDER>
<TR>
<TH >Value</TH>
<TH >Description</TH></TR>

<TR>
<TD >A</TD>
<TD >Actual count</TD></TR>

<TR>
<TD >E</TD>
<TD >Estimated (see comment_</TD></TR></TABLE>
<h4>
<A NAME="Heading262">7.11.4.9 Quantity Distributed Comment  (FT)   01241</A></h4>

<blockquote>Definition:
 This field is used for any explanatory text needed but in particular should
provide a description of the estimation method used.  If referring to the
description used in a previous report, the comment should include the product
identifier and data of that report.</blockquote>
<h4>
<A NAME="Heading263">7.11.4.10 Quantity in use  (CQ)   01242</A></h4>

<p><tt>Components:
 &lt;quantity (NM)&gt; ^ &lt;units (CE)&gt;</tt><br>
Subcomponents of units: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt; &amp;
&lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier (ST)&gt;
&amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding system
(ST)&gt;</p>
<blockquote>Definition:  This field is used to send the number of units of the
product which were in use during the reporting interval.  The second component
can be used to specify the units for the quantity.</blockquote>
<h4>
<A NAME="Heading264">7.11.4.11 Quantity in use method  (ID)   01243</A></h4>

<blockquote>Definition:
 This field contains the method used for measuring the quantity in use.  An
explanation of the method used for estimation can be included in
<i>PSH-12-quantity in use comment</i>.  Refer to <i>HL7 table 0329</i> <i>-
Quantity method</i> for valid values.</blockquote>
<h4>
<A NAME="Heading265">7.11.4.12 Quantity in use comment  (FT)   01244</A></h4>

<blockquote>Definition:
 This field can be used for any explanatory text needed but in particular
should provide a description of the estimation method used.  If referring to
the description used in a previous report, the comment should include the
product identifier and data of the report.  </blockquote>
<h4>
<A NAME="Heading266">7.11.4.13 Number of product experience reports filed by facility  (NM)   01245</A></h4>

<blockquote>Definition:
 The field contains the number of product experience reports filed by facility.</blockquote>
<h4>
<A NAME="Heading267">7.11.4.14 Number of product experience reports filed by distributor  (NM)  01246</A></h4>

<blockquote>Definition:
 This field contains the number of product experience reports filed by
distributor.</blockquote>
<h3>
<A NAME="Heading268">7.11.5 PDC - product detail country segment</A></h3>


<center>Figure 7-24.  PDC attributes
</center>
<TABLE BORDER><TR>
<TD >SEQ</TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR>
<TD >1</TD>
<TD >80</TD>
<TD >XON</TD>
<TD >R</TD>
<TD ><BR></TD>
<TD ><BR></TD>
<TD >01247</TD>
<TD >Manufacturer/Distributor</TD></TR>

<TR>
<TD >2</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01248</TD>
<TD >Country</TD></TR>

<TR>
<TD >3</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01249</TD>
<TD >Brand
Name</TD></TR>

<TR>
<TD >4</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01250</TD>
<TD >Device Family Name</TD></TR>

<TR>
<TD >5</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01251</TD>
<TD >Generic
Name</TD></TR>

<TR>
<TD >6</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01252</TD>
<TD >Model Identifier</TD></TR>

<TR>
<TD >7</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01253</TD>
<TD >Catalogue
Identifier</TD></TR>

<TR>
<TD >8</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD >Y</p>
<BR></TD>
<TD><BR></TD>
<TD >01254</TD>
<TD >Other Identifier</TD></TR>

<TR>
<TD >9</TD>
<TD >60</TD>
<TD >CE</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01255</TD>
<TD >Product
Code</TD></TR>

<TR>
<TD >10</TD>
<TD >4</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0330</TD>
<TD >01256</TD>
<TD >Marketing Basis</TD></TR>

<TR>
<TD >11</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01257</TD>
<TD >Marketing Approval ID</TD></TR>

<TR>
<TD >12</TD>
<TD >12</TD>
<TD >CQ</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01258</TD>
<TD >Labeled Shelf Life</TD></TR>

<TR>
<TD >13</TD>
<TD >12</TD>
<TD >CQ</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01259</TD>
<TD >Expected Shelf Life</TD></TR>

<TR>
<TD >14</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01260</TD>
<TD >Date
First Marked</TD></TR>

<TR>
<TD >15</TD>
<TD >26</TD>
<TD >TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01261</TD>
<TD >Date Last Marked</TD></TR></TABLE><p>7.11.5.0
  PDC field definitions</p>

<h4>
<A NAME="Heading269">7.11.5.1 Manufacturer/distributor  (XON)   01247</A></h4>

<p><tt>Components:
 &lt;organization name (ST)&gt; ^ &lt;organization name type code (IS)&gt;
^&lt;ID Number (NM)&gt; ^ &lt;check digit (NM)&gt; ^ &lt;code identifying the
check digit scheme employed (ID)&gt; ^ &lt;assigning authority  (HD)&gt; ^
&lt;identifier type code (IS)&gt; ^ &lt;assigning facility ID (HD)&gt; </tt><br>
Subcomponents of assigning authority: &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility: &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; * &lt;universal ID type (ID)&gt;</p>
<blockquote>Definition:  This field contains the identity of the
manufacturer/distributor.</blockquote>
<h4>
<A NAME="Heading270">7.11.5.2 Country  (CE)   01248</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt></p>
<blockquote>Definition:  This field contains the country to which this product
detail is relevant.  ISO 3166 provides a list of country codes that may be used.</blockquote>
<h4>
<A NAME="Heading271">7.11.5.3 Brand name  (ST)   01249</A></h4>

<blockquote>Definition:
 This field contains the name under which the product is marketed by this
manufacturer.</blockquote>
<h4>
<A NAME="Heading272">7.11.5.4 Device family name  (ST)   01250</A></h4>

<blockquote>Definition:
 This field contains the name used by the manufacturer to describe the family
of products to which this product belongs.</blockquote>
<h4>
<A NAME="Heading273">7.11.5.5 Generic name  (CE)   01251</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt></p>
<blockquote>Definition:  This field contains the name generically used to
identify the product.</blockquote>
<h4>
<A NAME="Heading274">7.11.5.6 Model identifier  (ST)   01252</A></h4>

<blockquote>Definition:
 This field contains the manufacturer's model identifier for the product.</blockquote>
<h4>
<A NAME="Heading275">7.11.5.7 Catalogue identifier  (ST)   01253</A></h4>

<blockquote>Definition:
 This field contains the manufacturer's catalogue identifier for the product.</blockquote>
<h4>
<A NAME="Heading276">7.11.5.8 Other identifier  (ST)   01254</A></h4>

<blockquote>Definition:
 This field contains any other identifier used to for the product.</blockquote>
<h4>
<A NAME="Heading277">7.11.5.9 Product code  (CE)   01255</A></h4>

<p><tt>Components:
 &lt;identifier (ST)&gt; ^ &lt;text (ST)&gt; ^ &lt;name of coding system
(ST)&gt; ^ &lt;alternate identifier (ST)&gt; ^ &lt;alternate text (ST)&gt; ^
&lt;name of alternate coding system (ST)&gt;</tt></p>
<blockquote>Definition:  This field contains the product code from an external
coding system such as that used by the CDRH at the FDA.</blockquote>
<h4>
<A NAME="Heading278">7.11.5.10 Marketing basis  (ID)   01256</A></h4>

<blockquote>Definition:
 This field contains the basis for marketing approval.  Refer to <i>HL7 table
0330 - Marketing</i> <i>basis</i> for valid values.  </blockquote>
<center>Table 0330 - Marketing basis
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >510K</TD>
<TD >510(K)</TD></TR>

<TR>
<TD >510E</TD>
<TD >510(K) exempt</TD></TR>

<TR>
<TD >PMA</TD>
<TD >Premarketing
authorization</TD></TR>

<TR>
<TD >PRE</TD>
<TD >Preamendment</TD></TR>

<TR>
<TD >TXN</TD>
<TD >Transitional</TD></TR>

<TR>
<TD >522S</TD>
<TD >Post marketing study (522)</TD></TR></TABLE>
<h4>
<A NAME="Heading279">7.11.5.11 Marketing approval ID  (ST)   01257</A></h4>

<blockquote>Definition:
 This field contains the designation or description of the marketing basis.</blockquote>
<h4>
<A NAME="Heading280">7.11.5.12 Labeled shelf life  (CQ)   01258</A></h4>

<p><tt>Components:
 &lt;quantity (NM)&gt; ^ &lt;units (CE)&gt;</tt><br>
Subcomponents of units: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt; &amp;
&lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier (ST)&gt;
&amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding system
(ST)&gt;</p>
<blockquote>Definition:  This field contains the shelf life of the product as
labeled.  This will usually be in months or years.  If there is no shelf life
indicated in the product labeling, this field will be empty.</blockquote>
<h4>
<A NAME="Heading281">7.11.5.13 Expected shelf life  (CQ)   01259</A></h4>

<p><tt>Components:
 &lt;quantity (NM)&gt; ^ &lt;units (CE)&gt;</tt><br>
Subcomponents of units: &lt;identifier (ST)&gt; &amp; &lt;test (ST)&gt; &amp;
&lt;name of coding system (ST)&gt; &amp; &lt;alternate identifier (ST)&gt;
&amp; &lt;alternate text (ST)&gt; &amp; &lt;name of alternate coding system
(ST)&gt;</p>
<blockquote>Definition:  This field contains the shelf life of the product
expected by the manufacturer.  This will usually be in months or years.</blockquote>
<h4>
<A NAME="Heading282">7.11.5.14 Date First Marked  (TS)   01260</A></h4>

<blockquote>Definition:
 This field contains the date the product was first marketed in the country.</blockquote>
<h4>
<A NAME="Heading283">7.11.5.15 Date Last Marked  (TS)   01261</A></h4>

<blockquote>Definition:
 This field contains the date the product was last marketed in the country.
This field will be omitted if the product is still being marketed.</blockquote>
<h3>
<A NAME="Heading284">7.11.6 FAC - facility segment</A></h3>


<center>Figure 7-25.  FAC attributes
</center>
<TABLE BORDER><TR>
<TD >SEQ</TD>
<TD >LEN</TD>
<TD >DT</TD>
<TD >OPT</TD>
<TD >RP/ #####</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR>
<TD >1</TD>
<TD >20</TD>
<TD >EI</TD>
<TD >R</TD>
<TD ><BR></TD>
<TD ><BR></TD>
<TD >01262</TD>
<TD >Facility ID</TD></TR>

<TR>
<TD >2</TD>
<TD >1</TD>
<TD >ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0331</TD>
<TD >01263</TD>
<TD >Facility Type</TD></TR>

<TR>
<TD >3</TD>
<TD >200</TD>
<TD >XAD</TD>
<TD >R</p>
<BR></TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01264</TD>
<TD >Facility Address</TD></TR>

<TR>
<TD >4</TD>
<TD >44</TD>
<TD >XTN</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01265</TD>
<TD >Facility Telecommunication</TD></TR>

<TR>
<TD >5</TD>
<TD >60</TD>
<TD >XCN</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01266</TD>
<TD >Contact
Person</TD></TR>

<TR>
<TD >6</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01267</TD>
<TD >Contact Title</TD></TR>

<TR>
<TD >7</TD>
<TD >200</TD>
<TD >XAD</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01268</TD>
<TD >Contact Address</TD></TR>

<TR>
<TD >8</TD>
<TD >44</TD>
<TD >XTN</TD>
<TD >O</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >01269</TD>
<TD >Contact Telecommunication</TD></TR>

<TR>
<TD >9</TD>
<TD >60</TD>
<TD >XCN</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01270</TD>
<TD >Signature Authority</TD></TR>

<TR>
<TD >10</TD>
<TD >60</TD>
<TD >ST</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01271</TD>
<TD >Signature Authority Title</TD></TR>

<TR>
<TD >11</TD>
<TD >200</TD>
<TD >XAD</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01272</TD>
<TD >Signature Authority Address</TD></TR>

<TR>
<TD >12</TD>
<TD >44</TD>
<TD >XTN</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >01273</TD>
<TD >Signature Authority Telecommunication</TD></TR></TABLE>
<p>
7.11.6.0   PCR field definitions</p>

<h4>
<A NAME="Heading285">7.11.6.1 Facility ID  (EI)   01262</A></h4>

<p><tt>Components:
 &lt;entity identifier (ST)&gt; ^ &lt;namespace ID (IS)&gt; ^ &lt;universal ID
(ST)&gt; ^ &lt;universal ID type (ID)&gt; </tt></p>
<blockquote>Definition:  This field contains the facility identifier.</blockquote>
<h4>
<A NAME="Heading286">7.11.6.2 Facility type  (ID)   01263</A></h4>

<blockquote>Definition:
 This field contains the type of facility.  Refer to HL7 table 0331 - Facility
type for valid values.</blockquote>
<center>Table 0331 - Facility type
</center>
<TABLE BORDER><TR>
<TD >Value</TD>
<TD >Description</TD></TR>

<TR>
<TD >U</TD>
<TD >User</TD></TR>

<TR>
<TD >M</TD>
<TD >Manufacturer</TD></TR>

<TR>
<TD >D</TD>
<TD >Distributor</TD></TR>

<TR>
<TD >A</TD>
<TD >Agent for a foreign manufacturer</TD></TR></TABLE>

<h4>
<A NAME="Heading287">7.11.6.3 Facility address  (XAD)   01264</A></h4>

<p><tt>Components:
 &lt;street address (ST)&gt; ^ &lt;other designation (ST)&gt; ^ &lt;city
(ST)&gt; ^ &lt;state or province (ST)&gt; ^ &lt;zip or postal code(ST)&gt; ^
&lt;country (ID)&gt; ^ &lt; address type (ID)&gt;<b> </b>^ &lt;other geographic
designation (ST)&gt; ^<b> </b>&lt;county/parish code (IS)&gt; ^ &lt;census
tract (IS)&gt;</tt></p>
<blockquote>Definition:  This field contains the facility's address.</blockquote>
<h4>
<A NAME="Heading288">7.11.6.4 Facility telecommunication  (XTN)   01265</A></h4>

<p><tt>Components:
 [NNN] [(999)]999-9999 [X99999] [B99999] [C any text] ^ &lt;telecommunication
use code (ID)&gt; ^ &lt;telecommunication equipment type (ID)&gt; ^ &lt;email
address (ST)&gt; ^ &lt;country code (NM)&gt; ^ &lt;area/city code (NM)&gt; ^
phone number (NM)&gt; ^ &lt;extension (NM)&gt; ^ &lt;any text (ST)&gt;</tt></p>
<blockquote>Definition:  This field contains the facility's telecommunication
information.</blockquote>
<h4>
<A NAME="Heading289">7.11.6.5 Contact person  (XCN)   01266</A></h4>

<p><tt>Components:
&lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type code(ID)&gt;
^ &lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID )&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;</p>
<blockquote>Definition:  This field contains the primary contact person's name.</blockquote>
<h4>
<A NAME="Heading290">7.11.6.6 Contact title  (ST)   01267</A></h4>

<blockquote>Definition:
 This field contains the primary contact person's title.</blockquote>
<h4>
<A NAME="Heading291">7.11.6.7 Contact address  (XAD)   01268</A></h4>

<p><tt>Components:
 &lt;street address (ST)&gt; ^ &lt;other designation (ST)&gt; ^ &lt;city
(ST)&gt; ^ &lt;state or province (ST)&gt; ^ &lt;zip or postal code(ST)&gt; ^
&lt;country (ID)&gt; ^ &lt; address type (ID)&gt;<b> </b>^ &lt;other geographic
designation (ST)&gt; ^<b> </b>&lt;county/parish code (IS)&gt; ^ &lt;census
tract (IS)&gt;</tt></p>
<blockquote>Definition:  This field contains the primary contact person's
address.</blockquote>
<h4>
<A NAME="Heading292">7.11.6.8 Contact telecommunication  (XTN)   01269</A></h4>

<p><tt>Components:
 [NNN] [(999)]999-9999 [X99999] [B99999] [C any text] ^ &lt;telecommunication
use code (ID)&gt; ^ &lt;telecommunication equipment type (ID)&gt; ^ &lt;email
address (ST)&gt; ^ &lt;country code (NM)&gt; ^ &lt;area/city code (NM)&gt; ^
phone number (NM)&gt; ^ &lt;extension (NM)&gt; ^ &lt;any text (ST)&gt;</tt></p>
<blockquote>Definition:  This field contains the primary contact person's
telecommunication information.</blockquote>
<h4>
<A NAME="Heading293">7.11.6.9 Signature authority  (XCN)   01270</A></h4>

<p><tt>Components:
&lt;ID number (ST)&gt; ^ &lt;family name (ST)&gt; ^ &lt;given name (ST)&gt; ^
&lt;middle initial or name (ST)&gt; ^ &lt;suffix (e.g., JR or III) (ST)&gt; ^
&lt;prefix (e.g., DR) (ST)&gt; ^ &lt;degree (e.g., MD) (ST)&gt; ^ &lt;source
table (IS)&gt; ^ &lt;assigning authority (HD)&gt; ^ &lt;name type code(ID)&gt;
^&lt;identifier check digit (ST)&gt; ^ &lt;code identifying the check digit
scheme employed (ID )&gt; ^ &lt;identifier type code (IS)&gt; ^ &lt;assigning
facility (HD)&gt;</tt><br>
Subcomponents of assigning authority:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;<br>
Subcomponents of assigning facility ID:  &lt;namespace ID (IS)&gt; &amp;
&lt;universal ID (ST)&gt; &amp; &lt;universal ID type (ID)&gt;</p>
<blockquote>Definition:  This field contains the name of the individual with
signature authority or who is responsible for the report.</blockquote>
<h4>
<A NAME="Heading294">7.11.6.10 Signature authority title  (ST)   01271</A></h4>

<blockquote>Definition:
 This field contains the title of the individual with signature authority or
who is responsible for this report.</blockquote>
<h4>
<A NAME="Heading295">7.11.6.11 Signature authority address  (XAD)   01272</A></h4>

<p><tt>Components:
 &lt;street address (ST)&gt; ^ &lt;other designation (ST)&gt; ^ &lt;city
(ST)&gt; ^ &lt;state or province (ST)&gt; ^ &lt;zip or postal code(ST)&gt; ^
&lt;country (ID)&gt; ^ &lt; address type (ID)&gt;<b> </b>^ &lt;other geographic
designation (ST)&gt; ^<b> </b>&lt;county/parish code (IS)&gt; ^ &lt;census
tract (IS)&gt;</tt></p>
<blockquote>Definition:  This field contains the address of the individual with
signature authority or who is responsible for this report.</blockquote>
<h4>
<A NAME="Heading296">7.11.6.12 Signature authority telecommunication  (XTN)   01273</A></h4>

<p><tt>Components:
 [NNN] [(999)]999-9999 [X99999] [B99999] [C any text] ^ &lt;telecommunication
use code (ID)&gt; ^ &lt;telecommunication equipment type (ID)&gt; ^ &lt;email
address (ST)&gt; ^ &lt;country code (NM)&gt; ^ &lt;area/city code (NM)&gt; ^
phone number (NM)&gt; ^ &lt;extension (NM)&gt; ^ &lt;any text (ST)&gt;</tt></p>
<blockquote>Definition:  This field contains the telecommunication information
of the individual with signature authority of who is responsible for this report.</blockquote>
<h2>
<A NAME="Heading297">7.12 PRODUCT EXPERIENCE - EXAMPLE MESSAGES</A></h2>

<p>The
RXE segments in this message include a proposed change in RXE to include an
element to transmit the indication as a coded entity (CE).<br>
<u>MSH</u>|^-&amp;|...<br>
<u>EVN</u>|...<br>
<u>PID</u>|1|||A^A^A||19230616|F||||||||||||||||19950710|Y&lt;cr&gt;<br>
<u>PES</u>|^Eli Lilly and Company^||Lilly Corporate
Center^Indianapolis^IN^46285||
GB95070448A|0|||19950704|19950710|10D&lt;cr&gt;<br>
<u>PEO</u>||^Awaiting results of
autopsy^|19950704||||^^^^^GB||S|N|D^H^O||Patient admitted via casualty with
increased shortness of breath and left sided chest pain on 04 JUL 95 for
assessment.^11-JUL-95 Patient admitted 09-JUL-95 at 11:30 PM with an 18 hour
history of diarrhoea followed by collapse. On admission, patient was exhausted
and dehydrated.  She had a rash on both breasts and abdomen. Patient found to
have deteriorating renal function.  Patient commenced IV fluid, however patient
was found dead on 10-JUL-95 morning.  Query vomited and aspirated. Post mortem
requested. Events possibly related to study drug.&lt;cr&gt;<br>
<u>PCR</u>|xxxxx^Wonder Drug 1^ATC|N|antineoplastic|||||||^NON SMALL CELL LUNG
CANCER&lt;cr&gt;<br>
<u>RXE</u>|1^^^06/29/95^07/10/95|<i>xxxxx</i>^Wonder Drug
1^ATC||||||||||||||||||||M1|3||NON SMALL CELL LUNG CANCER&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1|NO2AA^DIHYDROCODEINE^ATC||||||||||||||||||||D1|120|MG^MG^L|PAIN&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1^^^06/27/95^|GO3AC^MEGESTROL^ATC||||||||||||||||||||D1|320|MG^MG^L|DECREASED
APPETITE&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1|AO2BC^OMEPRAZOLE^ATC||||||||||||||||||||D1|20|MG^MG^L|PAST
HX&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1|AO7EC^SULPHASALAZINE^ATC||||||||||||||||||||D1|1000|MG^MG^L|RHEUMAT&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1^^^06/27/95^|A11GA^ASCORBIC
ACID^ATC||||||||||||||||||||D1|1|TAB^TAB^L|DECREASED APPETITE&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1^^^06/27/95^|A11DA^THIAMINE^ATC||||||||||||||||||||D1|1|TAB^TAB^L|DECREASED
APPETITE&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1^^^06/29/95^|AO3FA^METOCLOPRAMIDE^ATC||||||||||||||||||||D1|60|MG^MG^L|NAUSEA&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>RXE</u>|1|BO3A^IRON^ATC||||||||||||||||||||D1|600|MG^MG^L|ANEMIA&lt;cr&gt;<br>
<u>RXR</u>|PO&lt;cr&gt;<br>
<u>PRB</u>|AD|19950704|705^DYSPNEA^MEDR&lt;cr&gt;<br>
<u>PRB</u>|AD|19950710|20143^DEATH^MEDR&lt;cr&gt;<br>
<u>PRB</u>|AD|19950704|18330^CHEST PAIN^MEDR&lt;cr&gt;<br>
<u>PRB</u>|AD|19950709|21197^DIARRHEA^MEDR&lt;cr&gt;<br>
<u>PRB</u>|AD|19950709|6432^SYNCOPE^MEDR&lt;cr&gt;<br>
<u>PRB</u>|AD|19950709|4966^DEHYDRATION^MEDR&lt;cr&gt;<br>
<u>PRB</u>|AD|19950709|20544^KIDNEY FUNCTION ABNORMAL^MEDR&lt;cr&gt;<br>
<u>OBX</u>|1|CE|804-5^lEUKOCYTES^LN||2300|10*3/ml||||||19940704&lt;cr&gt;<br>
<u>OBX</u>|2|CE|770-8^NEUTROPHILS/100
LEUKOCYTES^LN||1.9|%||||||19950704&lt;cr&gt;<br>
<u>OBX</u>|2|CE|6299-2^UREA NITROGEN^LN||22.3|mg%||||||19950709&lt;cr&gt;<br>
<u>OBX</u>|2|CE|2160-0^CREATININE^LN||247|mmole||||||19950709&lt;cr&gt;<br>
<u>NTE</u>|Additional details must be obtained from the affiliate in order to
assess causality. A three day alert phone call was made to the FDA on 12-JUL-95&lt;cr&gt;
</p>

<h2>
<A NAME="Heading298">7.13 PRODUCT EXPERIENCE - REFERENCES</A></h2>

<p>Gabrielli
ER. Standard specification for drug therapy documentation. ASTM Committee
E31.12 July (1993).<br>
Kessler DA.  Introducing MEDWatch.  JAMA 269: 2765-2768(1993).<br>
Kurata JH, Overhage JM, Gabrielli E, Jones JK.  International Data Standards
for Hospital-based Drug Surveillance.  M.D. Computing 12(1) 50-57 (1995).<br>
Moore N, Montera d, Coulson R, DeAbajo F, Kreft-Jais C, Biron A, Monteaugudo J.
The single case format: proposal for a structured message for the telematic
transmission of information on individual case reports in pharmacovigilance.
Pharmacoepidemiology and Drug Safety 3: 157-162 (1994)<br>
Thompson WL.  A modest proposal for enhancing the safety and effectiveness of
use of human drugs, biologics and devices and animal health products with human
health implications through cost-effective health informatics tools supporting
a global database of safety reports as a joint ICH E2, M1 and M2 initiative.
Private communication. March (1995)
</p>

<h2>
<A NAME="Heading299">7.14 WAVEFORM SUMMARY</A></h2>

<p>HL7
support for waveform data is intended to provide access to waveform data in a
variety of situations. Needs include remote access to waveform data, research,
and input to clinical decision making, as well as obtaining snippets of
waveform data to complete waveform data sets. In some cases, predominantly in
research oriented environments, a physician may want to manually interpret,
scale the raw data, and/or apply alternative algorithms to the raw data values.
In these environments, the review of waveform data includes the processing of
the raw data. The HL7 waveform data capabilities allow for these applications,
including data collection information such as skew between channels, in-band
with the waveform.<br>
Waveform observations, like other results, can be transmitted in solicited mode
(in response to a query) or in unsolicited mode - see Section 7.2, "MESSAGE
DEFINITIONS ," for discussion.  In either mode of transmission the timing
information, channel definition, annotations, and digital time series data in
the waveform recording are treated as individual "observations" within a result
"battery."  For a given "battery," each of the result fragments is transmitted
in a separate OBX segment, where the Observation ID suffix for the OBX is used
to identify the result fragment.  To reduce ambiguity, an explicit framework
for defining the structure of waveform result messages is provided.  The
elements of that framework include the following:<br>
*	Waveform specific data types which enable transmission of channel definition
and waveform data<br>
*	Waveform specific Observation ID suffixes (<i>OBX-3-observation
identifier</i>) which uniquely identify the category of waveform result in a
given OBX segment<br>
*	Fixed rules for combining OBX segments of each category in the waveform
response messages<br>
*	Explicit definition of which OBX fields may be populated for each category of
waveform result<br>
*	Unique trigger events which identify result messages which contain batteries
of waveform result OBX segments
</p>

<h2>
<A NAME="Heading300">7.15 WAVEFORM RESULT DATA TYPES</A></h2>

<p>Three
waveform specific data types have been defined to enable transmission of
waveform results.
</p>

<h3>
<A NAME="Heading301">7.15.1 NA - numeric array</A></h3>

<p><tt>&lt;value1&gt;
^ &lt;value2&gt; ^ &lt;value3&gt; ^ &lt;value4&gt; ^ ...</tt><br>
This data type is used to represent a series (array) of numeric values, each
one having a data type of NM.  A field of this type may contain a
one-dimensional array (vector or row) of numbers.  Also, by allowing the field
to repeat, a two-dimensional array (table) of numbers may be transmitted using
this format, with each row of the table represented as one repetition of the
field.  Arrays which have one or more values not present may be transmitted
using this data type.  "Not present" values are represented as two adjacent
component delimiters.  If the absent values occur at the end of a row, the
trailing component delimiters may be omitted.  If an entire row of a table has
no values, no component delimiters are necessary (in this case, there will be
two adjacent repetition delimiters).  The maximum number of values in one
repetition of an NA format field is determined by the maximum field length.<br>
Examples:<br>
|125^34^-22^-234^569^442^-212^6|				vector of 8 numbers<br>
|1.2^-3.5^5.2~2.0^3.1^-6.2~3.5^7.8^-1.3|		3 x 3 array of numbers<br>
|^2^3^4~5^^^8~9^10~~17^18^19^20|				5 x 4 array of numbers with<br>
 											the values in positions<br>
											(1,1), (2,2), (2,3), (3,3), <br>
											(3,4), (4,1), (4,2), (4,3), <br>
											and (4,4) not present
</p>

<h3>
<A NAME="Heading302">7.15.2 MA - multiplexed array</A></h3>

<p><tt>&lt;sample
1 from channel 1&gt;^&lt;sample 1 from channel 2&gt;^&lt;sample 1 from channel
3&gt; ...~</tt><br>
&lt;sample 2 from channel 1&gt;^&lt;sample 2 from channel 2&gt;^&lt;sample 2
from channel 3&gt; ...~<br>
 ...<br>
This data type is used to represent channel-multiplexed waveform data, (e.g.,
the digitized values from an analog-to-digital converter or other digital data
source).  Each value is of type NM, and represents a time sample from a
channel.  This segment may contain data from one or more channels.  The
waveform data is in channel-multiplexed format (that is, the values for all
channels for the first time sample are transmitted, then the values for the
next time sample, and so on until the requisite number of time samples have
been transmitted).  Time samples are separated by repeat delimiters (~), and
channels within a sample are separated by component delimiters (^).  The time
between samples (the sampling interval) is the reciprocal of the digitization
frequency as specified using the CD data type.<br>
Examples:<br>
|0^0^0~1^1^1~2^2^2~3^3^3~4^4^4~5^5^5|		3 channels (identical), 5
time-samples<br>
|0~1~2~3~4~5~6~7~8~9~10|						1 channel, 11 time-samples
</p>

<h3>
<A NAME="Heading303">7.15.3 CD - channel definition</A></h3>

<p><tt>Components:
 &lt;channel identifier&gt; ^ &lt;waveform source&gt; ^ &lt;channel
sensitivity/units&gt; ^ &lt;calibration parameters&gt; ^ &lt;sampling
frequency&gt; ^ &lt;minimum/maximum data values&gt; </tt><br>
This data type is used for labeling of digital waveform data.  It defines a
recording channel which is associated with one of the values in each time
sample of waveform data.  Each channel has a number (which generally defines
its position in a multichannel display) and an optional name or label (also
used in displays).  One or two named waveform sources may also be associated
with a channel (providing for the use of differential amplifiers with two
inputs).  The other components of the channel definition data type are
optional.  The individual components are defined as follows:</p>

<h4>
<A NAME="Heading304">7.15.3.1 Channel identifier </A></h4>

<p>Two
subcomponents separated by subcomponent delimiters (&amp;) which identify the
channel, consisting of a channel number (required, maximum 4 characters, data
type NM)and a channel name (optional, maximum 17 characters, data type ST).
The channel name is a text string used as a label in waveform data displays.
If this name is not present, the channel label displayed is
&lt;source1&gt;-&lt;source2&gt;, where &lt;source1&gt; and &lt;source2&gt; are
the names of the two waveform sources connected to this channel, or, if only
one waveform sources &lt;source1&gt; is specified, the channel label displayed
when the channel name is not given is &lt;source1&gt;.</p>

<h4>
<A NAME="Heading305">7.15.3.2 Waveform source</A></h4>

<p>Identifies
the source of the waveform connected to the channel.  Two names (each maximum
of 8 characters, data type ST) separated by a subcomponent delimiter (&amp;)
may be specified if it is necessary to individually identify the two inputs for
a waveform.  Only one name need be specified if the channel is connected to a
single input. For example, in EKG recordings typically only one name is used
(such as I or II); in electroencephalography, two names are typically used, one
for each input of the differential amplifier (such as F3 and C3)..<i>(NOTE:
Although the committee voted in Denver to make waveform source a coded entry,
this is not syntactically possible.  We do not have a sub-sub-component
delimiter available to separate the sub-fields of the proposed coded entry.
Therefore, waveform source remains a string data type.).</i></p>

<h4>
<A NAME="Heading306">7.15.3.3 Channel sensitivity and units (CM)</A></h4>

<p>This
CM data type defines the channel sensitivity (gain) and the units in which it
is measured.  This component consists of up to seven subcomponents, separated
from each other by subcomponent delimiters (&amp;).  The first subcomponent
specifies the sensitivity, while the remaining six subcomponents are used to
specify the units of the sensitivity, using a format similar to the components
of the coded entry (CE) data type.  The subcomponents of the channel
sensitivity and units are as follows:</p>

<h5>
<A NAME="Heading307">7.15.3.3.1 Sensitivity (NM)</A></h5>

<p>Defines
the nominal value (maximum 20 characters, data type NM) that corresponds to one
unit in the waveform data, that is, the effective resolution of the least
significant bit of the ADC, and the polarity of the channel.  The sensitivity
incorporates both the amplifier gain and the actual ADC resolution.  It does
not, however, relate to the vertical scaling of a waveform display (it is, for
example, a measure of voltage, not voltage per unit distance).  For channels
recording potential differences between two electrodes using a differential
amplifier, a positive sensitivity indicates that a number in the waveform data
which is greater than the channel baseline represents a potential at the first
electrode which is more positive than that at the second electrode.  A negative
sensitivity indicates that a number in the waveform data which is greater than
the channel baseline corresponds to a potential at the first electrode which is
more negative than that at the second electrode.</p>

<h5>
<A NAME="Heading308">7.15.3.3.2 Units </A></h5>

<p>A
units designation (for example, uv = microvolt, mv = millivolt, v = volt, pal =
pascal, or mm(hg) = millimeters of mercury) from a designated system of units,
such as the ISO+ extension of the standard SI single case unit abbreviations
presented as <i>Figure 7-13</i> in Section  7.3.2.6.1, "Identifying reporting
units," or the ANSI+ U.S. customary unit abbreviations, a superset of the ANSI
standard which appears in <i>Figure 7-10</i>. Other unit systems can be used as
well. </p>

<h4>
<A NAME="Heading309">7.15.3.4 Channel calibration parameters (NM)</A></h4>

<p>This
component consists of three optional subcomponents (each a maximum of 20
characters, data type NM), separated from each other by subcomponent delimiters
(&amp;), which define corrections to channel sensitivity, baseline, and channel
time skew which may be derived from a calibration procedure.  The three
subcomponents are as follows:</p>

<h5>
<A NAME="Heading310">7.15.3.4.1 Sensitivity correction factor</A></h5>

<p>Defines
a correction factor for channel sensitivity which may be derived from the last
calibration procedure performed.  The actual channel sensitivity is the nominal
channel sensitivity given in the previous component multiplied by the unitless
correction factor.</p>

<h5>
<A NAME="Heading311">7.15.3.4.2 Baseline</A></h5>

<p>Defines
the actual channel baseline (the data value which corresponds to a nominal
input signal of zero).  The actual baseline may differ from the ideal because
of a dc offset in the amplifier connected to the ADC.  The actual baseline
values for all channels (which need not be integers) may be determined at the
time of calibration as the average digitized values obtained when a zero input
signal is connected to each channel.</p>

<h5>
<A NAME="Heading312">7.15.3.4.3 Time skew </A></h5>

<p>Defines
the time difference between the nominal sampling (digitization) time (which
would be the same for all channels) and the actual sampling time of the
channel, in seconds (or fractions thereof).  This value will differ from zero
when all channels in the montage are not sampled simultaneously, as occurs in
systems which sample successive channels at regular time intervals.  This value
may be determined from a calibration procedure in which an identical
time-varying signal is applied to all channels and interchannel time
differences are estimated, or more commonly it may be taken from the
manufacturer's specifications for the digitizing system used.  For example, for
a system which samples successive channels at regular time intervals <i>t</i>,
the time skew of channel number <i>n</i> would be <i>(n-1)t</i>.  The actual
time of sampling (digitization) of sample number <i>m</i> of channel number
<i>n</i> in such a system would be <i>R + (m-1)/f + (n-1)t</i>, where <i>R</i>
is the reference time at the start of the epoch and <i>f</i> is the channel
sampling frequency (<i>t &lt; 1/f</i>).</p>

<h4>
<A NAME="Heading313">7.15.3.5 Channel sampling frequency </A></h4>

<p>Defines
the sampling frequency in hertz of the channel, that is, the reciprocal of the
time in seconds between successive samples (maximum 20 characters, data type
NM).  Note that this is the frequency of transmitted data, which may or may not
be the actual frequency at which the data was acquired by an analog-to-digital
converter or other digital data source (i.e. the data transmitted may be
subsampled, or interpolated, from the originally acquired data.)</p>

<h4>
<A NAME="Heading314">7.15.3.6 Minimum and maximum data values (NM)</A></h4>

<p>Defines
the minimum and maximum data values which can occur in this channel in the
digital waveform data, that is, the range of the ADC (each maximum of 20
characters, data type NM), and also specifies whether or not nonintegral data
values may occur in this channel in the waveform data.  If the minimum and
maximum values are both integers (or not present), only integral data values
may be used in this channel.  If either the minimum or the maximum value
contains a decimal point, then nonintegral as well as integral data values may
be used in this channel.  The minimum and maximum data values are separated by
a component delimiter (&amp;).  For an <i>n</i>-bit signed ADC, the nominal
baseline <i>B</i> = 0, and the minimum (<i>L</i>) and maximum (<i>H</i>) values
may be calculated as follows:<br>
<i>L</i> = -2<sup><i>n</i>-1</sup><br>
<i>H</i> = 2<sup><i>n</i>-1</sup> - 1<br>
For an unsigned <i>n</i>-bit ADC, the minimum value <i>L</i> = 0, and the
nominal baseline value (<i>B</i>) and maximum value (<i>H</i>) may be
calculated from the formulas,<br>
<i>B</i> = 2<sup><i>n</i>-1</sup><br>
<i>H</i> = 2<sup><i>n</i></sup> - 1<br>
The actual signal amplitude <i>A</i> (for differentially amplified potential
measurements, the potential at electrode number one minus that at electrode
number two) may be calculated from the value <i>D</i> (range <i>L</i> to
<i>H</i>) in the waveform data using the actual baseline value <i>B</i> and the
nominal sensitivity <i>S</i> and actual sensitivity correction factor <i>C</i>
by the formula,<br>
<i>A = SC(D-B)
</i></p>

<h2>
<A NAME="Heading315">7.16 WAVEFORM SPECIFIC OBSERVATION ID SUFFIXES</A></h2>

<p>Each
waveform channel in a recording contains timing, channel definition and digital
time series data.  The category of waveform result transmitted in a given OBX
segment is determined by the Observation ID Suffix contained in<i>
OBX-3-observation identifier</i>.  Four suffixes are provided for the different
categories of waveform result:<br>
</p>
<TABLE><TR>
<TH >Observation</TH>
<TH >Suffix</TH>
<TH >Data Type</TH></TR>

<TR align="left">
<TD align="left">Timing Information</TD>
<TD >TIM</TD>
<TD >TS</TD></TR>

<TR align="left">
<TD align="left">Channel Definition</TD>
<TD >CHN</TD>
<TD >CD</TD></TR>

<TR align="left">
<TD align="left">Waveform Data</TD>
<TD >WAV</TD>
<TD >NA
or MA</TD></TR>

<TR align="left">
<TD align="left">Waveform Annotation</TD>
<TD >ANO</TD>
<TD >CE</TD></TR></TABLE><p>The
Observation Sub-ID is used to associate the TIM, CHN, and subsequent WAV, and
ANO category result segments for a given channel or channels in a waveform
response message.
</p>

<h3>
<A NAME="Heading316">7.16.1 Timing information (TIM)</A></h3>

<p>The
TIM category OBX result segment establishes the date and time of the first data
point in a given Observation Sub-ID grouping of waveform channels.  If there is
a gap in the time sequence of waveform data, this should be indicated by the
transmission of a new TIM category result segment prior to subsequent WAV
category result segments with the same Observation Sub-ID.  The data type is TS.
</p>

<h3>
<A NAME="Heading317">7.16.2 Channel definition data (CHN)</A></h3>

<p>The
CHN category OBX result segment defines recording channels for digitally
sampled time-series waveforms.  Subsequent WAV category result segments carry
the actual waveform samples. Each CHN category result segment defines one or
more channels; the <i>OBX-5-Observation Value</i> field may repeat to define
additional channels.  Each instance or repetition is formatted as a CD data
type.<br>
Each channel has a number (which generally defines its position in a
multichannel display) and an optional name or label (also used in displays).
One or two named waveform sources may also be associated with a channel
(providing for the use of differential amplifiers with two inputs).  A channel
also has an associated sensitivity, calibration parameters (sensitivity
correction factor, baseline, and time skew), sampling frequency, and minimum
and maximum values.  The sampling frequency refers to the number of samples per
unit time for the data reported in the subsequent WAV category result
segments.<br>
When multiple channels are defined within a single CHN category result segment,
if the channel sensitivity/units (third component), sensitivity correction
factor (first subcomponent of component 4), baseline (second subcomponent),
time skew (third subcomponent), sampling frequency (fifth component), minimum
data value (first subcomponent of component 6), or maximum data value (second
subcomponent) is not present in any repetition of the <i>OBX-5-observation
value</i> field, the value given in the last repetition in which the item
<i>was</i> present may used by the receiver system.  This is referred to as a
"sticky default."  For example, if all channels have the same sensitivity,
sensitivity correction factor/baseline/time skew, sampling frequency, and
minimum/maximum data values, these may be specified for the first channel but
omitted in all subsequent channel definitions in the same CHN category result
segment, thus reducing the length of the segment.  If the sensitivity
correction factor, baseline, or time skew is not present in the first channel
being defined, values of 1, 0, and 0 (respectively) may be used. No other
default values are assumed for components which are not present.
</p>

<h3>
<A NAME="Heading318">7.16.3 Waveform digital data (WAV)</A></h3>

<p>The
WAV category OBX result segment is used to transmit the actual waveform data
(the time-series digitized values from an analog-to-digital converter (ADC) or
other source of sampled digital data).  WAV category result segments are
associated with their corresponding channel definitions (CHN category OBX
result segment) via the Observation Sub-ID.  The number of channels defined in
the CHN category result segment specifies the number of channels of multiplexed
data contained in the WAV category result segments associated with it.  For
example, if a CHN category result segment contains only a single channel
definition, then each WAV category result segment with the same Observation
Sub-ID contains only one channel of data.  However, if a CHN category result
segment contains three channel definitions then each WAV category result
segment with the same Observation Sub-ID must contain three channels of data.
A given set of waveform data for all channels and at multiple successive times
may be transmitted in a single WAV category result segment (provided that the
length of the observation value field does not exceed the maximum defined field
length for OBX segments, 65536), or in multiple successive WAV category result
segments, possibly with interspersed result segments of other types (for
example, containing annotations, or comments).<br>
The data type of the WAV category result segment can be NA (Numeric Array) or
MA (Multiplexed Array).  Using the NA data type, the data values are formatted
in  "channel-block", or "unmultiplexed" format.  The digital samples for each
channel are separated using component delimiters, and successive channels are
separated using the repeat delimiter.  Using the MA data type, the data values
are formatted in "channel multiplexed" format, i.e., the values for the first
time sample (all channels) are transmitted first, then the values for the
second time sample (all channels) are transmitted, and so on until all samples
have been transmitted.  The digital samples for each channel are separated by
the component delimiter, and successive samples are separated by the repeat
delimiter.  Channel multiplexed format can only be used if all of the
multiplexed channels have the same effective sampling frequency. 
</p>

<h3>
<A NAME="Heading319">7.16.4 Waveform annotation (ANO)</A></h3>

<p>The
ANO category OBX segment is used to transmit waveform annotations (coded entry
associated with a given point in time during the waveform recording).  The ANO
category result segments are referenced to their corresponding channel
definitions (CHN category OBX result segment ) via the Observation Sub-ID.  The
number of channels defined in the CHN category result segment specifies the
number of channels of annotation contained in any ANO category result segments
associated with it.  For example, if a CHN category result segment contains
only a single channel definition, then any ANO category result segments with
the same Observation Sub-ID will contain only one annotation coded entry.
However, if a CHN category result segment contains three channel definitions
then any ANO category result segments with the same Observation Sub-ID must
contain three separate annotation coded entries.<br>
The data type of the ANO category result segment is CE.<i>  </i>The annotation
coded entries for successive channels are separated using the repeat delimiter.
Adjacent repeat delimiters are used when there is no annotation coded entry for
a channel in a multichannel result segment.  Refer to<i> user defined table
0317 - Annotations</i> for suggested values.</p>

<center>User-defined table 0317 - Annotations
</center>
<TABLE><TR>
<TH >Value</TH>
<TH >Description</TH></TR>

<TR>
<TD >9900</TD>
<TD >Pace spike</TD></TR>

<TR>
<TD >9901</TD>
<TD >SAS marker</TD></TR>

<TR>
<TD >9902</TD>
<TD >Sense marker</TD></TR>

<TR>
<TD >9903</TD>
<TD >Beat marker</TD></TR>

<TR>
<TD >9904</TD>
<TD >etc.</TD></TR></TABLE>
<h2>
<A NAME="Heading320">7.17 COMBINING RULES FOR WAVEFORM OBX SEGMENTS</A></h2>

<p>A
waveform result "battery" may contain one or more channels of digital waveform
data.  The Observation Sub-ID is used to logically associate the TIM, CHN and
WAV category OBX segments which pertain to a given set of channels in the
result "battery."  Each Sub-ID group must contain at least one TIM, one CHN and
one WAV category segment and at least one of the TIM category result segments
must precede the first WAV category result segment in that group.
</p>

<h2>
<A NAME="Heading321">7.18 RESTRICTIONS ON VALUATION OF OBX SEGMENT FIELDS</A></h2>

<p>The
 result category for a given OBX segment determines how specific fields in that
segment are valued.  The following tables define field requirements for each
category of OBX segment.  The OPT/X column can take the values of R = Required,
O = Optional, or X = Ignored and not valued.  <b>OBX Fields marked with an X
should not be valued in Waveform response messages of specified Suffix type.
</b>Valuation of the fields must match the value provided in the associated
wave category OBX segments, i.e., OBX with the same sub-ID must share the same
result status.
</p>

<h3>
<A NAME="Heading322">7.18.1 OBX segment - TIM category</A></h3>

<p><center>Figure
7-26.  OBX attributes - TIM category</center><br>
</p>
<TABLE BORDER><TR align="left">
<TD align="left">SEQ</TD>
<TD align="left">LEN</TD>
<TD align="left">DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left"><strike>4</strike></TD>
<TD align="left">SI</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00569</TD>
<TD >Set ID - Observational Simple</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0125</TD>
<TD >00570</TD>
<TD >Value Type </TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00571</TD>
<TD >Observation Identifier </TD></TR>

<TR align="left">
<TD align="left">4</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00572</TD>
<TD >Observation Sub-ID</TD></TR>

<TR align="left">
<TD align="left">5</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00573</TD>
<TD >Observation Value</TD></TR>

<TR align="left">
<TD align="left">6</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00574</TD>
<TD >Units</TD></TR>

<TR align="left">
<TD align="left">7</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00575</TD>
<TD >References Range</TD></TR>

<TR align="left">
<TD align="left">8</TD>
<TD align="left">10</TD>
<TD align="left">ID</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >0078</TD>
<TD >00576</TD>
<TD >Abnormal Flags</TD></TR>

<TR align="left">
<TD align="left">9</TD>
<TD align="left">5</TD>
<TD align="left">NM</TD>
<TD >X</TD>
<TD >Y/5</TD>
<TD><BR></TD>
<TD >00577</TD>
<TD >Probability</TD></TR>

<TR align="left">
<TD align="left">10</TD>
<TD align="left">5</TD>
<TD align="left">ID</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >0080</TD>
<TD >00578</TD>
<TD >Nature of Abnormal Test</TD></TR>

<TR align="left">
<TD align="left">11</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0085</TD>
<TD >00579</TD>
<TD >Observ Result Status</TD></TR>

<TR align="left">
<TD align="left">12</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00580</TD>
<TD >Date Last Obs Normal Values</TD></TR>

<TR align="left">
<TD align="left">13</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00581</TD>
<TD >User Defined Access Checks</TD></TR>

<TR align="left">
<TD align="left">14</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00582</TD>
<TD >Date/Time of the Observation</TD></TR>

<TR align="left">
<TD align="left">15</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00583</TD>
<TD >Producer's ID</TD></TR>

<TR align="left">
<TD align="left">16</TD>
<TD align="left">60</TD>
<TD align="left">CN</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00584</TD>
<TD >Responsible Observer</TD></TR>

<TR align="left">
<TD align="left">17</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00936</TD>
<TD >Observation Method</TD></TR>
</TABLE>
<h3>
<A NAME="Heading323">7.18.2 OBX segment - CHN category</A></h3>

<p><center>Figure
7-27.  OBX attributes - CHN category</center><br>
</p>
<TABLE BORDER><TR align="left">
<TD align="left">SEQ</TD>
<TD align="left">LEN</TD>
<TD align="left">DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left"><strike>4</strike></TD>
<TD align="left">SI</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00569</TD>
<TD >Set ID - Observational Simple</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0125</TD>
<TD >00570</TD>
<TD >Value Type </TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00571</TD>
<TD >Observation Identifier </TD></TR>

<TR align="left">
<TD align="left">4</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00572</TD>
<TD >Observation Sub-ID</TD></TR>

<TR align="left">
<TD align="left">5</TD>
<TD align="left">65536</TD>
<TD align="left">CD</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00573</TD>
<TD >Observation Value</TD></TR>

<TR align="left">
<TD align="left">6</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00574</TD>
<TD >Units</TD></TR>

<TR align="left">
<TD align="left">7</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00575</TD>
<TD >References Range</TD></TR>

<TR align="left">
<TD align="left">8</TD>
<TD align="left">10</TD>
<TD align="left">ID</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >0078</TD>
<TD >00576</TD>
<TD >Abnormal Flags</TD></TR>

<TR align="left">
<TD align="left">9</TD>
<TD align="left">5</TD>
<TD align="left">NM</TD>
<TD >X</TD>
<TD >Y/5</TD>
<TD><BR></TD>
<TD >00577</TD>
<TD >Probability</TD></TR>

<TR align="left">
<TD align="left">10</TD>
<TD align="left">5</TD>
<TD align="left">ID</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >0080</TD>
<TD >00578</TD>
<TD >Nature of Abnormal Test</TD></TR>

<TR align="left">
<TD align="left">11</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0085</TD>
<TD >00579</TD>
<TD >Observ Result Status</TD></TR>

<TR align="left">
<TD align="left">12</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00580</TD>
<TD >Date Last Obs Normal Values</TD></TR>

<TR align="left">
<TD align="left">13</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00581</TD>
<TD >User Defined Access Checks</TD></TR>

<TR align="left">
<TD align="left">14</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00582</TD>
<TD >Date/Time of the Observation</TD></TR>

<TR align="left">
<TD align="left">15</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00583</TD>
<TD >Producer's ID</TD></TR>

<TR align="left">
<TD align="left">16</TD>
<TD align="left">60</TD>
<TD align="left">CN</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00584</TD>
<TD >Responsible Observer</TD></TR>

<TR align="left">
<TD align="left">17</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00936</TD>
<TD >Observation Method</TD>
</TR>
</TABLE>

<p>Note: The length of the observation value field is variable, depending upon number of
channels defined.
</p>

<h3>
<A NAME="Heading324">7.18.3 OBX segment - WAV category</A></h3>

<p><center>Figure
7-28.  OBX attributes - WAV category</center><br>
</p>
<TABLE BORDER><TR align="left">
<TD align="left">SEQ</TD>
<TD align="left">LEN</TD>
<TD align="left">DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left"><strike>4</strike></TD>
<TD align="left">SI</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00569</TD>
<TD >Set ID - Observational Simple</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0125</TD>
<TD >00570</TD>
<TD >Value Type </TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00571</TD>
<TD >Observation Identifier </TD></TR>

<TR align="left">
<TD align="left">4</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00572</TD>
<TD >Observation Sub-ID</TD></TR>

<TR align="left">
<TD align="left">5</TD>
<TD align="left">65536</TD>
<TD align="left">NA or MA</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00573</TD>
<TD >Observation Value</TD></TR>

<TR align="left">
<TD align="left">6</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00574</TD>
<TD >Units</TD></TR>

<TR align="left">
<TD align="left">7</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00575</TD>
<TD >References Range</TD></TR>

<TR align="left">
<TD align="left">8</TD>
<TD align="left">10</p>
<BR></TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD><BR></TD>
<TD >0078</TD>
<TD >00576</TD>
<TD >Abnormal Flags</TD></TR>

<TR align="left">
<TD align="left">9</TD>
<TD align="left">5</TD>
<TD align="left">NM</TD>
<TD >X</TD>
<TD >Y/5</TD>
<TD><BR></TD>
<TD >00577</TD>
<TD >Probability</TD></TR>

<TR align="left">
<TD align="left">10</TD>
<TD align="left">5</TD>
<TD align="left">ID</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >0080</TD>
<TD >00578</TD>
<TD >Nature of Abnormal Test</TD></TR>

<TR align="left">
<TD align="left">11</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0085</TD>
<TD >00579</TD>
<TD >Observ Result Status</TD></TR>

<TR align="left">
<TD align="left">12</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00580</TD>
<TD >Date
Last Obs Normal Values</TD></TR>

<TR align="left">
<TD align="left">13</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00581</TD>
<TD >User Defined Access Checks</TD></TR>

<TR align="left">
<TD align="left">14</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00582</TD>
<TD >Date/Time
of the Observation</TD></TR>

<TR align="left">
<TD align="left">15</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00583</TD>
<TD >Producer's ID</TD></TR>

<TR align="left">
<TD align="left">16</TD>
<TD align="left">60</TD>
<TD align="left">CN</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00584</TD>
<TD >Responsible Observer</TD></TR>

<TR align="left">
<TD align="left">17</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00936</TD>
<TD >Observation Method</TD></TR>
</TABLE>

<p>Notes:<br>
1.	The length of the observation value field is variable, depending upon number
of channels and number of data points sampled.<br>
2.	Fields 8, 11 and 16 apply exclusively to the set of data points in the OBX.
They do not map to a particular data point or channel.
</p>

<h3>
<A NAME="Heading325">7.18.4 ANO category OBX segment</A></h3>

<p><center>Figure
7-29.  OBX segment - ANO category
</center></p>
<TABLE BORDER><TR align="left">
<TD align="left">SEQ</TD>
<TD align="left">LEN</TD>
<TD align="left">DT</TD>
<TD >OPT</TD>
<TD >RP/#</TD>
<TD >TBL#</TD>
<TD >ITEM#</TD>
<TD >ELEMENT NAME</TD></TR>

<TR align="left">
<TD align="left">1</TD>
<TD align="left">4</TD>
<TD align="left">SI</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00569</TD>
<TD >Set ID - Observational Simple</TD></TR>

<TR align="left">
<TD align="left">2</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0125</TD>
<TD >00570</TD>
<TD >Value Type</TD></TR>

<TR align="left">
<TD align="left">3</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00571</TD>
<TD >Observation Identifier </TD></TR>

<TR align="left">
<TD align="left">4</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >R</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00572</TD>
<TD >Observation
Sub-ID</TD></TR>

<TR align="left">
<TD align="left">5</TD>
<TD align="left">65535</TD>
<TD align="left">CE</TD>
<TD >C</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00573</TD>
<TD >Observation Value</TD></TR>

<TR align="left">
<TD align="left">6</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00574</TD>
<TD >Units</TD></TR>

<TR align="left">
<TD align="left">7</TD>
<TD align="left">60</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00575</TD>
<TD >References Range</TD></TR>

<TR align="left">
<TD align="left">8</TD>
<TD align="left">10</TD>
<TD align="left">ID</TD>
<TD >O</TD>
<TD >Y/5</TD>
<TD >0078</TD>
<TD >00576</TD>
<TD >Abnormal Flags</TD></TR>

<TR align="left">
<TD align="left">9</TD>
<TD align="left">5</TD>
<TD align="left">NM</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00577</TD>
<TD >Probability</TD></TR>

<TR align="left">
<TD align="left">10</TD>
<TD align="left">5</TD>
<TD align="left">ID</TD>
<TD >X</TD>
<TD><BR></TD>
<TD >0080</TD>
<TD >00578</TD>
<TD >Nature of Abnormal Test</TD></TR>

<TR align="left">
<TD align="left">11</TD>
<TD align="left">2</TD>
<TD align="left">ID</TD>
<TD >R</TD>
<TD><BR></TD>
<TD >0085</TD>
<TD >00579</TD>
<TD >Observ
Result Status</TD></TR>

<TR align="left">
<TD align="left">12</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00580</TD>
<TD >Date Last Obs Normal Values</TD></TR>

<TR align="left">
<TD align="left">13</TD>
<TD align="left">20</TD>
<TD align="left">ST</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00581</TD>
<TD >User
Defined Access Checks</TD></TR>

<TR align="left">
<TD align="left">14</TD>
<TD align="left">26</TD>
<TD align="left">TS</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00582</TD>
<TD >Date/Time of the Observation</TD></TR>

<TR align="left">
<TD align="left">15</TD>
<TD align="left">60</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00583</TD>
<TD >Producer's
ID</TD></TR>

<TR align="left">
<TD align="left">16</TD>
<TD align="left">60</TD>
<TD align="left">CN</TD>
<TD >O</TD>
<TD><BR></TD>
<TD><BR></TD>
<TD >00584</TD>
<TD >Responsible Observer</TD></TR>

<TR align="left">
<TD align="left">17</TD>
<TD align="left">80</TD>
<TD align="left">CE</TD>
<TD >X</TD>
<TD >Y</TD>
<TD><BR></TD>
<TD >00936</TD>
<TD >Observation
Method</TD></TR></TABLE><p>Note:
The length of the observation value field is variable, depending upon number of
channels defined.
</p>

<h2>
<A NAME="Heading326">7.19 WAVEFORM RESPONSE TRIGGER EVENTS</A></h2>

<p>Response
messages containing waveform results are identified by the trigger event
provided in the message header segment (MSH-09, second component of message
type).  Separate trigger events have been defined to differentiate the
solicited and unsolicited modes of transmission.
</p>

<h3>
<A NAME="Heading327">7.19.1 W01 - waveform result, unsolicited transmission of requested information </A></h3>

<p>The
waveform response unsolicited trigger event identifies ORU messages used to
transmit waveform data which are results of an ordered test or series of
observations. The W01 trigger event may also be used to identify ORU messages
sent as the eventual response to a QRY message specifying a deferred mode query
for waveform results/observations with record-oriented format (similar to the
deferred response display mode DSR message type described in Chapter 2).  One
or more ORU messages with the W01 trigger event  may result from this type of
QRY message.  
</p>

<h3>
<A NAME="Heading328">7.19.2 W02 - waveform result, response to query</A></h3>

<p>The
W02 trigger event identifies QRF messages which are a response to a QRY message
specifying an immediate mode query for waveform results/observations with
record-oriented format.
</p>

<h2>
<A NAME="Heading329">7.20 EXAMPLE MESSAGES FOR GENERIC WAVEFORM DATA</A></h2>

<p>This
section gives four example messages of type ORU (unsolicited) that each contain
a three-channel waveform recording, with the same waveform in each channel.
These examples contain data for one patient.  In these example message
transmissions, <b>&lt;cr&gt;</b> indicates an ASCII carriage return character
(ASCII 13).<br>
The following is a detailed explanation of each of the segments contained in
the example messages:<br>
<b><i>Message Header (MSH) Segment</i></b> - This specifies the delimiters
(<b>|^~\&amp;</b>), sending application (<b>SVL,</b> meaning Sunnyville
Laboratory), receiving application (<b>SVC</b>, meaning Sunnyville Clinic),
date and time of transmission (March 24, 1990 at 10:12:15), message type
(<b>ORU</b>) and trigger event (<b>W01</b>), a message control ID that
identifies this message uniquely among all messages transmitted by this sender
(<b>19264</b>), processing ID (<b>P</b>, meaning production), and specification
version ID (<b>2.3</b>).<br>
<b><i>Patient ID (PID) Segment</i></b> - This contains a sequence number
(<b>1</b>), external and internal patient IDs (both <b>4567890</b>), and a
patient name (<b>Mr. John Q Doe, Jr</b>).<br>
<b><i>Order (OBR) Segment</i></b> - This contains a sequence number (<b>1</b>),
placer order number (<b>5678</b>) and placer ID (<b>SVC</b>, meaning Sunnyville
Clinic), filler order number (<b>1234</b>) and filler ID (<b>SVL</b>, meaning
Sunnyville Laboratory), and test/observation ID (<b>5</b>, using a local coding
system that is known to the intended receiver, meaning a three-channel waveform
recording).<br>
<b><i>CHN Category Result (OBX) Segments</i></b> - Using a value type of
<b>CD</b> (channel definition), these define each of the three data channels by
number and specify a label (waveform source) for each.  The channel sensitivity
(<b>0.5 mV</b>), sampling frequency (<b>200</b>), and minimum and maximum data
values (<b>-2048</b> to <b>2047</b>) are specified for each channel in examples
1 and 2 and 4. In example 3, these are specified only for channel 1, but apply
by default to all subsequent channels.  No baseline or calibration parameters
are specified, so defaults are used for all channels.<br>
<b><i>TIM Category Result (OBX) Segments</i></b> - Using the data type TS (time
stamp), these define the start of the waveform data at a time 525 ms past
8:12:37 on March 24, 1990.<br>
<b><i>WAV Category Result (OBX) Segments</i></b> - The data may be transmitted
in either "channel-block" (unmultiplexed) format using the NA data type, or in
"channel-multiplexed" format using the MA data type.  The three examples
demonstrate different ways of transmitting 3 waveform channels, with 25 samples
from each waveform channel.  Note that in these examples, each waveform channel
is identical.</p>
<p><b><i>ANO Category Result (OBX) Segments -</i></b> Annotation segments with
a single channel definition contain a single annotation string.  Annotation
segments with multiple channel definitions contain a separate annotation string
for each defined channel - successive annotation strings are separated from
each other by the repeat delimiter.  In the following examples, channel 1 has
been annotated at a time 565 ms past 8:12:37 on March 24, 1990; channel 3 has
been annotated at a time 605 ms past 8:12:37 on March 24, 1990.
</p>

<h3>
<A NAME="Heading330">7.20.1 Example 1: "channel-block" format, using  three separate sets of TIM, CHN, WAV and category OBX segments:</A></h3>

<p>MSH|^~\&amp;|SVL||SVC||19900324101215||ORU^W01|19264|P|2.3&lt;cr&gt;<br>
PID|1|4567890|4567890||Doe^John^Q^Jr^Mr&lt;cr&gt;<br>
OBR|1|5678^SVC|1234^SVL|5^three-channel waveform recording^L&lt;cr&gt;<br>
OBX|1|CD|5&amp;CHN^^L|1|1^ONE^0.5&amp;mv^^200^-2048&amp;2047||||||F&lt;cr&gt;<br>
OBX|2|TS|5&amp;TIM^^L|1|19900324081237.525||||||F&lt;cr&gt;<br>
OBX|3|NA|5&amp;WAV^^L|1|0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8||||||F&lt;cr&gt;<br>
OBX|4|CE|5&amp;ANO^^L|1|^Channel passing through
maxima||||||F||19900324081237.565&lt;cr&gt;<br>
OBX|5|CD|5&amp;CHN^^L|2|2^TWO^0.5&amp;mv^^200^-2048&amp;2047||||||F&lt;cr&gt;<br>
OBX|6|TS|5&amp;TIM^^L|2|19900324081237.525||||||F&lt;cr&gt;<br>
OBX|7|NA|5&amp;WAV^^L|2|0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8||||||F
&lt;cr&gt;<br>
OBX|8|CD|5&amp;CHN^^L|3|3^THREE^0.5&amp;mv^^200^-2048&amp;2047||||||F&lt;cr&gt;<br>
OBX|9|TS|5&amp;TIM^^L|3|19900324081237.525||||||F&lt;cr&gt;<br>
OBX|10|NA|5&amp;WAV^^L|3|0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8||||||F
&lt;cr&gt;<br>
OBX|11|CE|5&amp;ANO^^L|3|^Channel passing through
zero||||||F||19900324081237.605&lt;cr&gt;<br>
...
</p>

<h3>
<A NAME="Heading331">7.20.2 Example 2: "channel-block" format, using a single set of TIM, CHN, WAV and category OBX segments, with multiple channels within the one WAV category result segment:</A></h3>

<p>MSH|^~\&amp;|SVL||SVC||19900324101215||ORU^W01|19264|P|2.3&lt;cr&gt;<br>
PID|1|4567890|4567890||Doe^John^Q^Jr^Mr&lt;cr&gt;<br>
OBR|1|5678^SVC|1234^SVL|5^three-channel waveform recording^L&lt;cr&gt;<br>
OBX|1|CD|5&amp;CHN^^L|1|1^ONE^0.5&amp;mv^^200^-2048&amp;2047~2^TWO^0.5&amp;mv^^200^
2048&amp;2047~3^THREE^0.5&amp;mv^^200^-2048&amp;2047||||||F&lt;cr&gt;<br>
OBX|2|TS|5&amp;TIM^^L|1|19900324081237.525||||||F&lt;cr&gt;<br>
OBX|3|NA|5&amp;WAV^^L|1|<br>
0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8~<br>
0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8~<br>
0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8||||||F &lt;cr&gt;<br>
OBX|4|CE|5&amp;ANO^^L|1|^Channel passing through
maxima||||||F||19900324081237.565&lt;cr&gt;<br>
OBX|5|CE|5&amp;ANO^^L|1|~~^Channel passing through
zero||||||F||19900324081237.605&lt;cr&gt;<br>
...
</p>

<h3>
<A NAME="Heading332">7.20.3 Example 3: "channel-multiplexed" format, with multiple channels within the one WAV category result segment:</A></h3>

<p>MSH|^~\&amp;|SVL||SVC||19900324101215||ORU^W01|19264|P|2.3&lt;cr&gt;<br>
PID|1|4567890|4567890||Doe^John^Q^Jr^Mr&lt;cr&gt;<br>
OBR|1|5678^SVC|1234^SVL|5^three-channel waveform recording^L&lt;cr&gt;<br>
OBX|1|CD|5&amp;CHN^^L|1|1^ONE^0.5&amp;mv^^200^-2048&amp;2047~2^TWO^~3^THREE^||||||F&lt;cr&gt;<br>
OBX|2|TS|5&amp;TIM^^L|1|19900324081237.525||||||F&lt;cr&gt;<br>
OBX|3|MA|5&amp;WAV^^L|1|0^0^0~1^1^1~2^2^2~3^3^3~4^4^4~5^5^5~6^6^6~7^7^7~8^8^8~7^7^7~6^6^6~5^5^5~4^4^4~3^3^3~2^2^2~1^1^1~0^0^0~-1^-1^-1~-2^-2^-2~-3^-3^-3~-4^-4^-4~-5^-5^-5~-6^-6^-6~-7^-7^-7~-8^-8^-8||||||F
&lt;cr&gt;<br>
OBX|4|CE|5&amp;ANO^^L|1|^Channel passing through
maxima||||||F||19900324081237.565&lt;cr&gt;<br>
OBX|5|CE|5&amp;ANO^^L|1|~~^Channel passing through
zero||||||F||19900324081237.605&lt;cr&gt;<br>
...
</p>

<h3>
<A NAME="Heading333">7.20.4 Example 4: "channel-block" format, using  three separate sets of TIM, CHN, WAV and category OBX segments with a break in waveform data  used to pinpoint waveform annotations for channels one and three:</A></h3>

<p>MSH|^~\&amp;|SVL||SVC||19900324101215||ORU^W01|19264|P|2.3&lt;cr&gt;<br>
PID|1|4567890|4567890||Doe^John^Q^Jr^Mr&lt;cr&gt;<br>
OBR|1|5678^SVC|1234^SVL|5^three-channel waveform recording^L&lt;cr&gt;<br>
OBX|1|CD|5&amp;CHN^^L|1|1^ONE^0.5&amp;mv^^200^-2048&amp;2047||||F&lt;cr&gt;<br>
OBX|2|TS|5&amp;TIM^^L|1|19900324081237.525||||F&lt;cr&gt;<br>
OBX|3|NA|5&amp;WAV^^L|1|0^1^2^3^4^5^6^7^8||||||F&lt;cr&gt;<br>
OBX|4|CE|5&amp;ANO^^L|1|^Channel passing through
maxima||||||F||19900324081237.565&lt;cr&gt;<br>
OBX|5|NA|5&amp;WAV^^L|1|7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8||||||F&lt;cr&gt;<br>
OBX|6|CD|5&amp;CHN^^L|2|2^TWO^0.5&amp;mv^^200^-2048&amp;2047||||||F&lt;cr&gt;<br>
OBX|7|TS|5&amp;TIM^^L|2|19900324081237.525||||||F&lt;cr&gt;<br>
OBX|8|NA|5&amp;WAV^^L|2|0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0^-1^-2^-3^-4^-5^-6^-7^-8||||||F
&lt;cr&gt;<br>
OBX|9|CD|5&amp;CHN^^L|3|3^THREE^0.5&amp;mv^^200^-2048&amp;2047||||||F&lt;cr&gt;<br>
OBX|10|TS|5&amp;TIM^^L|3|19900324081237.525||||||F&lt;cr&gt;<br>
OBX|11|NA|5&amp;WAV^^L|3|0^1^2^3^4^5^6^7^8^7^6^5^4^3^2^1^0||||||F &lt;cr&gt;<br>
OBX|12|CE|5&amp;ANO^^L|3|^Channel passing through
zero||||||F||19900324081237.605&lt;cr&gt;<br>
OBX|13|NA|5&amp;WAV^^L|3|-1^-2^-3^-4^-5^-6^-7^-8||||||F &lt;cr&gt;<br>
...
</p>

<h2>
<A NAME="Heading334">7.21 OUTSTANDING ISSUES</A></h2>

<p>None.
 
</p>
<HR><a name="fn0" href="#fnB0">[     1.	These AS4 codes are taken directly from
ASTM 1238-91, and are printed/adopted with their permission.     2	The length
of the observation value field is variable, depending upon value type.  See
]</a><p><i>OBX-2-value type</i><a name="fn1" href="#fnB1">[.     3 	May repeat
for multipart, single answer results with appropriate data types, e.g., CE, TX,
and FT data types.<br>
4]</a> 	LOINC Committee. Logical Observation Identifier Names and Codes.
Indianapolis: Regenstrief Institute and LOINC Committee, 1995. c/o Kathy
Hutchins, 1001 West 10th Street RG-5, Indianapolis, IN  46202.  317/630-7433.
Available via FTP/Gopher (dumccss.mc.duke.edu/standards/HL7/ termcode/
loinclab) and World Wide Web (http://dumccss.mc.duke.edu/standards
HL7/termcode/ loinclab/).  The LOINC Code System is described in Forrey AW,
McDonald CJ, DeMoor G, Huff SM, Leavelle D, Leland D, et.al. Logical
Observation Identifier Names and Codes (LOINC) database: a public use set of
codes and names for electronic reporting of clinical laboratory test results.
Clinical Chemistry 1996;42:81-90
</p>

</body>
</html>
